Community Pharmacy Businesses and Community Pharmacists by Davies, JE
 
 
1 
 
 
Community Pharmacy Businesses and Community Pharmacists 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JAMES EDWARD DAVIES 
 
A thesis submitted to the UCL School of Pharmacy for the degree of Doctor of Philosophy in 
the Department of Practice and Policy 
JANUARY 2013 
UCL SCHOOL OF PHARMACY 
  
 
 
2 
 
PLAGARISM STATEMENT 
 
This thesis describes research conducted in the UCL School of Pharmacy between October 
2009 and November 2012 under the supervision of Professor David Taylor and Professor 
Nicholas Barber. I certify that the research described is original and that any parts of the 
work that have been conducted by collaboration are clearly indicated. I also certify that I 
have written all the text herein and have clearly indicated by suitable citation any part of 
this dissertation that has already appeared in publication.  
 
Signature: 
 
 
Date: 
 
  
 
 
3 
 
PUBLICATIONS FROM THIS RESEARCH 
 
Thum-Bonanno, S., J. Gill, J.E. Davies et al. (2012). “From making medicines to optimising 
outcomes: The evolution of a profession 1912-2012”, Federation Internationale 
Pharmaceutique. 
Davies, J.E, R.Hamilton et al (2012) “The imbalance between pre-registration training and 
undergraduate pharmacy student numbers”. A BPSA discussion paper, The British 
Pharmaceutical Students Association. London.  
Davies, J. E. and D. G. Taylor (2012). "Individualisation or standardisation: trends in National 
Health Service prescription durations in England 1998–2009." Primary Health Care 
Research & Development FirstView: 1-11. 
Davies, J. E., S. Neidle, et al. (2012). "Developing and paying for medicines for orphan 
indications in oncology: utilitarian regulation vs equitable care?" British Journal of Cancer 
106(1): 14-17. 
Forbes, A., J. Davies, et al. (2011). "Dispensing substitution: avoid the impression of 
therapeutic chaos." The Pharmaceutical Journal 286: 129. 
Davies, J. E. (2010). "Telepharmacy - Friend of Foe?" British Journal Clinical Pharmacy July 
2010. 
Davies, J. E. and D. Taylor (2010). “Making a difference”. London, The School of Pharmacy. 
Davies, J. E., K. Cottrell, et al. (2010). "Improving patient safety through electronic transfer 
of prescriptions and automation: an audit of near miss errors." International Journal of 
Pharmacy Practice 18(Supplement 2): R57. 
Davies, J. E. and D. Taylor (2010). "The Uncertain future: a pilot study if pharmacy student 
views." International Journal of Pharmacy Practice 18(Supplement 2): R78. 
  
 
 
4 
 
ABSTRACT 
The change in community pharmacists’ practice from compounding and effectively 
unregulated medicines supply through to the highly regulated and largely automated high-
volume dispensing process of today has been challenging. The economic and social 
standing of community pharmacy was transformed creating a need for further adaptation. 
This thesis explores ‘how business and professional practice models for community 
pharmacy in England in ten to twenty years are likely to be structured?’. It has six sections, 
plus an overarching discussion. 
A work sampling study of ten community pharmacies found that pharmacists continue to 
spend two-thirds of their time on dispensing related activities, compared to one tenth on 
counselling. The accompanying analysis links this to an increase in prescription volumes 
and payments that have incentivised pharmacy contractors to focus on medicines supply. A 
significant decrease in the average prescription duration for eight chronic disease 
medications over the past decade is revealed, and its desirability questioned.  
Using the Kingdon model of the policy process as an evaluative framework, 16 interviews 
with ‘policy leaders’ provided insight into how seven factors (identified from a structured 
thematic review of the implementation of Medicines Use Reviews) have influenced the 
implementation of the New Medicines Service. In addition, role theory-based thematic 
analysis involving 17 stakeholders in pharmacy policy highlighted the tensions between 
community pharmacists’ roles as shopkeepers, clinicians and businessmen, and the effects 
that new technologies will have on them. The analysis identifies a need for pharmacy to 
embrace a new strategic direction that enhances pharmacy’s contributions to health 
outcomes. 
In conclusion, community pharmacy in England should offer timelier and economically 
efficient ways of solving contemporary health problems. The evidence presented here 
suggests that without stronger internal leadership and robust external stakeholder support 
medicines supply will split from the provision of clinical pharmacy in the community 
setting, leaving community pharmacies as ‘commodity cost’, low return medicines 
suppliers. 
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Chapter 1. Introducing the Logics: The 
Development of Modern Community 
Pharmacy 
 
Chapter Introduction 
This chapter provides the background for - and an introduction to - the research question 
addressed in this thesis. How are business and professional practice models for 
community pharmacy in England in ten to twenty years time likely to be structured? 
Community pharmacy and community pharmacists are components of the complex social 
world within which we live. The practice of community pharmacists has been driven by the 
social forces and structures which contextualise their function in society. These social 
forces have shaped the evolution and development of the pharmacy profession and are 
therefore a subject worthy of investigation in this thesis. These different threads are then 
woven together to create a complex tapestry, which reveals the future avenues that 
community pharmacy businesses and community pharmacists, as professionals, may 
experience. 
Entwined within the literature about the modern development of community pharmacy is a 
narrative and accompanying debate relating to professionalism and the professional nature 
of pharmacy practice. Professionalism is a much discussed part of sociology and is the 
subject of a wide range of published literature. Interpretation of the professional character 
of community pharmacy practice requires a clear understanding of the literature in this 
field. For this reason, a significant part of this first chapter provides an overview of the 
theoretical frameworks and models used by sociologists to explore professions.  
Policy analysis also contributes a central role in the academic work that underpins this 
thesis. Policies express a general set of objectives or a desired state of affairs (i.e. they seek 
to realise intentions) and as such play an important role in defining future practice. Policy 
analysis is explored in greater depth in chapter 4. One key concept - path dependency- 
persists throughout this thesis and therefore deserves an early mention. Path dependency 
is neither a framework, nor a theory or model. Instead, it is an empirical category, an 
organising concept that can be used to label a certain type of temporal process (Kay, 2005). 
This theoretical concept posits that historical pathways are likely predictors of the future, 
insomuch as a process is path dependent if initial moves in one direction elicit further 
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moves in that same direction. Path dependency acts to unpack historical causality to 
explain how the set of decisions that one faces are limited by the decisions made in the 
past, even though previous circumstances may no longer be relevant. Therefore, the 
historical development of community pharmacy is described in this chapter to provide a 
firm foundation for the rest of this research.  
The conflict between pharmacist’s roles as businessmen and as clinicians is another thread 
that runs throughout this thesis. There is an asymmetry of knowledge between the 
consumer and the provider when a medicine is purchased or collected from a pharmacy. 
Knowledge asymmetry creates the environment for an imperfect market. The typical 
market solution to imperfect information exchange is for the consumer to appoint an 
agent, in this case a pharmacist, to combine information on the patient’s expressed 
preferences with their own information to make a decision for that patient. In the case of 
perfect agency, pharmacists make the choice that patients would have made if they had 
been informed. Yet in practice, pharmacists (and most healthcare professionals) are not 
perfect agents. The information asymmetry gives rise to the possibility of distortions and 
manipulations of the market.  
Society has sought to manage these possible market distortions with ethical codes of 
practice and professional self regulation to help to prevent the exploitation of the 
vulnerable. The need to effectively police and monitor these relationships has led to 
regulation and statute, the complexity of which has vexed governments. Although agency 
relationships exists in most healthcare interactions, pharmacies are unique in so much as 
they are often the only section of NHS healthcare in which there is a directly observable 
financial transaction that takes place alongside a clinical exchange1. This makes the 
opportunities for market manipulation more apparent to consumers even if they as likely 
to exist elsewhere in the health service.  
This agency role has allowed pharmacists to claim professional status, but has also 
provided them with economic rewards through the pharmacy business. However, the 
interaction between professional status and the economic viability of community pharmacy 
businesses remains strained. Given this background, the regulation of pharmacists is an 
important sub plot, which is described within the later part of this chapter.  
                                                          
1 While other areas such as dentistry and optometry do interact with patients financially, the healthcare provision takes place 
in a separate room from the financial exchange. England differs in this respect from other health systems around the world.  
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The final part of this chapter draws together these different perspectives and theoretical 
backgrounds to outline why the research question presented here is worthy of scholarly 
investigation.  
Therefore this chapter provides a background to the professionalism literature, describes 
the development of modern community pharmacy practice and explores the evolution and 
development of professional regulation, in order to establish base for the research 
question that this thesis seeks to address.    
Theory of Path Dependency 
Path dependency, as described above, is a concept used to describe how previous societal 
and human behaviour has a direct influence on the future, to put this in a Newtonian voice, 
‘everything has causes’ (David, 1985).  Although Page argues that the wider application of 
path dependency means that for many it has become a ‘trendy way to say that history 
matters’ (Page, 2006), he acknowledges that the lack of formal models to describe history-
dependent processes have led to a justified increase in its use. 
The broader literature on path dependency in health systems emphasises that critical 
events in history shape policy development and the marketplace. Individual decision 
making early on in a path may lead to a ‘lock in’2 (David, 1985).These events prove hard, if 
not impossible to reverse. Therefore actors within the policy field become ‘tied to previous 
decisions and existing institutions’ (Wilsford, 1994: p252) even when these decisions 
produce arguably sub-optimal solutions. Pierson (2000) suggests that such tendencies to 
follow previous decisions are exaggerated by the ‘increasing returns’ (Pierson, 2000: p251) 
that follow from adopting a particular policy course or strategy. 
Path dependency therefore builds upon a notion of incremental change, and therefore a 
path dependent process is clearly dominated by whatever the status quo happens to be, 
rather than the potential of big changes. However history tells of ‘conjunctures’ of events, 
which create windows of opportunity for actors to deviate from a given path (Wilsford, 
1994). It is these windows of opportunity that are the basis for the Kingdon model that is 
progressed in chapter 4. These ‘policy windows’ are highly unpredictable in their nature 
and timing, but crucially they possess the opportunity to overcome the ‘weight of history’ 
(Wilsford, 1994: p280).  
                                                          
2 An example of such a ‘lock in’ is the QWERTY keyboard, which was iniallity designed with typewriters in mind, and has since 
become the industry standard despite being an inefficient design.   
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In the context of this thesis, path dependency is applied to both the professional and 
economic development of pharmacy. Although several studies have applied the concept of 
path dependency in relation to embedded institutions in health service reform (Wilsford, 
1994), less attention has been applied to clinical professions (Kirkpatrick et al., 2009), and 
indeed none to community pharmacy in particular. This concept is applied here, by 
exploring the origins and subsequent development of community pharmacy in light of the 
theories of professionalism outlined below.  
Theories of Professionalism 
Occupations are a large part of social life, and therefore they have been of interest to 
sociologists who have created a wealth of literature and theories on professions, which 
have encountered several different stages of intellectual history. Beginning with the 
structural-functionalist trait theories from 1930 to the 1960s (e.g. Carr-Saunders and 
Wilson, 1933; e.g. Goode, 1957), the literature evolved into the market monopoly and 
power theories of the 1970s and 1980s (e.g. Johnson, 1972), followed by the third logic 
theories of the 1990s and the new millennium led by Eliot Freidson (Freidson, 2001). It is 
this intellectual history that will be used as the basis to understand professionalism 
amoungst community pharmacists.  
Structural-functional trait approach 
The early approaches to defining what constituted a profession were accrued from 
observation of the ‘learned professions’ of law, clergy and medicine. Early authors such as 
Carr-Saunders suggested that professions organise themselves into asymmetric expert-
client relations for client and social protection, and in doing so display a series of traits or 
qualities. Researchers began to develop lists of traits by analyzing the observable 
characteristics of groups believed to be professions (e.g. Goode, 1957). 
By definition these traits were outside the reach of the normal labour market, thereby 
placing the professions in an agency position. This agency status required the professionals 
to provide their skills in an altruistic manner for the good of the community. The early 
theorists believed that specialist skills and an ethic of altruism and service to the 
community legitimately rewarded professionals with autonomy, self-regulation, high social 
status and income. It was at the time thought that professions present themselves to 
society as a benefit, taking a functionalist stance, focussing on where professions exist 
within the social system, rather than analysing the need or desire for their existence. While 
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it was recognised within these theories that professions made money from their skills, it 
was understood that this was not their main aim (this position is challenged in the next 
section). 
The functionalist approach considered how professions form part of society, and how they 
fulfil their societal roles. While it offers a convenient fit, the approach has been criticised as 
overly simplistic and idealised, partly due to accepting the professions own definitions. It 
was from this base that the term professionalism developed, described as the 
characteristics displayed by professionals. Although some researchers continue to be 
absorbed with the problem of defining a ‘profession’, some more general descriptors, such 
as occupational control of work (Freidson, 2001); the sociology of middle-class occupations; 
or theories of occupations of expert labour (Evetts, 2003), have become the mainstay 
within this field. 
Although many examples of trait lists exist, most contain several essential features - 
showing technical expertise and judgment; rigorous academic screening and training 
programs; occupational licensing; value and service ideals and codes of ethics; workplace 
autonomy; and a self-governing occupational community.  
Goode suggested that there is in fact a ‘profession continuum’ (Goode, 1957), rather than 
accepting a dichotomous view  (professional or non-professional).  Against this observation 
an unskilled worker will posses none of the traits, whereas a traditional profession, such as 
medicine, will posses them all, implying a hierarchical view of professionals. Therefore, this 
removes the need to draw a hard line between professions and other occupations. Instead 
Goode’s perspective accepts that they are similar social forms that share many common 
characteristics. It is for this reason that some authors choose not to define professionalism, 
but instead to offer a list of relevant occupational groups (e.g. Abbott, 1988). Building on 
this Wilensky (1964) used the trait approach to develop a professional development model 
from ‘non professional’ to ‘fully-professional’ in stages, allowing professions to develop as 
‘semi-professional’3. 
Attempting to define the professions and understand the patterns of professional 
development bound these early structural-functional theories. It was only from the 1970s 
onwards, when the academic field of sociology embraced these areas further that groups 
began to question the value of professionalism as a social construct. The sociological field 
                                                          
3 As described later, this is a status applied to community pharmacy by some authors. 
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became dominated by critical theorists.  Parsons (1951) recognised (and then showed) that 
the capitalist economy and rational-legal social order were interrelated and mutually 
balanced by modern professionals who helped to maintain and stabilise the fragile 
normative social order (Evetts, 2003). As a result theorists became critical of the overly 
simplistic functionalist approach leading to the development of ‘market monopoly’ or 
‘power’ theories.  
Market monopoly/power models 
Implicit in professional encounters is a level of trust. The lay patient must place their trust 
in professionals and in doing so, professionals acquire a certain amount of knowledge that 
they can potentially exploit. In return for not exploiting this knowledge, professionals are 
rewarded with authority, privilege and higher status. Theorists became concerned with the 
power and control that professional groups had achieved, legitimised and maintained, 
suggesting that this trust may have been exploited. Indeed, some believed that the elitist 
monopolies created by professional groups allowed members to raise fees and increase 
their incomes in comparison to otherwise open markets, and in doing so restrict the 
interests of consumers (Freidson, 1970).  
Critical theorists began to argue that professional groups developed service ideals and 
codes of ethics that justified their privileged position in society; despite being superficially 
held and inconsistently followed. It was this that prompted attack of the medical profession 
by Eliot Freidson in the 1970s who argued that consumers would best be served by de-
regulation of entry and state regulation of practice (Freidson, 1970).  
To this point, professionalism had been regarded as a value system. This notion was 
rejected and replaced by a critical assessment of professional work concerned with 
whether professions deserved the influence they possessed over public affairs. It was 
argued that professionals used their specialist knowledge to create a social distance 
between themselves and ‘everybody else’ which helped them to protect their area of work 
(Macdonald, 1995). The culmination of these analyses was scepticism about all of the 
professions, although particularly medicine and law which were described in the literature 
as elite powerful occupational groups (e.g. Johnson, 1972). 
In order to legitimate their practice each profession had to gain state support for the 
exclusivity of their market shelter (e.g. Johnson, 1972; Freidson, 1970). Market monopoly 
(or power) theories began to argue that educational requirements and certified courses 
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required for licensing an occupation restricted the labour market and created market 
shelters for professionals. Freidson developed Johnson’s argument that through their 
training and identity professions create market shelters that set each occupation apart 
(Freidson, 1970). 
Larson also focused her attentions on how professions gain control of a marketplace to 
raise their social status (collective mobility) by tracing the historical development of a 
limited group of occupations into professions.  Larson demonstrated how economic 
advantage for occupations is achieved by restricting the supply of practitioners and striving 
for a special position of public respect and influence. The successful outcome for the 
collective was an occupational monopoly of competence, officially sanctioned expertise 
and a monopoly on credibility with the public (Larson, 1977). While Larson questioned the 
development of these monopolies, she importantly asked why and how the work practices 
of medicine and law became the rallying cry for a whole group of knowledge based 
professions despite their different employment conditions. This led some to conclude that 
it was for reasons of power and income – ‘a monopoly of practice’. 
“Third logic” approach 
According to power theories, all professions struggle to attain and maintain control and 
autonomy in a specific field. To protect their territory, professions must continually 
negotiate their position with the state. The re-stratification thesis first emerged in the mid 
1980s, in response to the growing recognition within sociology that something was 
happening to medical autonomy. This was supported by the thesis of de-professionalisation 
and proletarianisation.  
Haug (1973), the originator of the de-professionalisation thesis, argued that medical 
autonomy was being challenged due to a process of rationalisation and codification of 
medical knowledge and expertise into standardised rules and procedures. At the same time 
Oppenheimer (1973) argued that professional work was becoming subject to a process of 
rationalisation in the name of economy and efficacy. He contended that bureaucratic 
structures controlled by administrative elites were (through administrative routines, 
measures and targets) controlling the work of professionals effectively making them part of 
the proletariat. 
However, Friedson (Freidson, 1985) described the medical profession as ‘stratified’, 
whereby an administrative elite guide and evaluate the performance of those within the 
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profession. Freidson interpreted the rise of these control mechanisms in medicine as an 
essential part of re-stratification, rather than a sign of medical proletarianisation. He 
argued that re-stratification, which involves the medical elites exerting control over 
members of their profession helps them to maintain the continued dominance of the 
medical model4.  
Annandale’s (1989) work in obstetrics found re-stratification and hierarchy in the medical 
profession, which meant that some doctors, some midwives and some nurses were seen as 
more dominant, suggesting a disjuncture between obstetricians' inability to protect their 
interests as a corporate body and their relative ability to control the organization of 
everyday medical work. This re-stratification thesis coupled with the apparent ability of 
governments to successfully change the professions, undermined the monopoly position 
perpetuated by the power theorists. 
In the 1990s researchers began to reassess the significance of professionalism and its 
positive (as well as negative) contributions at the macro level to social systems and at the 
individual level to consumers, returning to a view of the professional from a value system 
perspective. It began to be argued that public interest and professional interest were not 
necessarily polar opposites (Saks, 1995). In general this led to a reinterpretation of the 
concept of professionalism. 
In light of these findings, Freidson, once a proponent of the market monopoly model 
(Freidson, 1970), began to shift his thinking. Freidson (2001) argued that the professional 
shelter from the market can be defended if –as well as increasing occupational income – it 
is seen as encouraging a higher quality of work, a greater commitment to the work, and 
more integrity in the conduct of that work than would be possible without the market 
shelter. As well as this, the service that a profession provides warrants protection if it has 
the capacity to produce a high minimum standard of benefit to consumers, and reduce the 
potential harm that would be caused by unqualified practitioners (Freidson, 2001). 
Translating this to pharmacists, it suggests that they must provide a service that can 
produce a quality of supply and standards above those that a market could achieve, if they 
are to maintain the market shelter currently afforded to them by professional status. In 
other words, to attract premium income pharmacy requires political and social recognition 
                                                          
4 This re-stratification is returned to later in this chapter when discussing the autonomy of the pharmacy profession. In 
particular building on the research of Armstrong (2002).  
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that medicines supply is a health protection and improvement function as opposed to a 
technical and logistic function.  
As a result of this change in perspective, Freidson argued that  
“a monopoly held by an occupation whose members are committed to maintaining 
the integrity of a craft that is of value to others is a more desirable and less 
destructive solution to an important social problem than is the free play of 
unbridled material interest or the reduction of all work to formally specified 
procedure proposed by critics” (Freidson, 1994).  
While he continued to accept that professional groups could exist to manipulate a market, 
he presented a defence of professions in the form of the social benefits that the market 
shelters professions operate under can offer. His beliefs moved away from criticism of the 
professional model as a force to manipulate markets, instead believing that these 
occupational groups are subject to stronger forces of labour control5.  
Freidson (2001) put forward the thesis that there exist three logics in society. The first is 
the idealised logic of the ‘perfect’ free market, as defined by Adam Smith, which by 
bringing increased competition and pressures for lower prices places consumers in 
command. The second logic, founded on the Weberian perspective of a rational-legal 
bureaucracy, portrays bureaucratic-managerial control as a logic that controls the market 
meaning that managers dominate. The final logic is that of professionalism, which Freidson 
develops into the ‘ideal type’ of professionalism, as a form of controlling work in which 
professional groups lead, bounded by an ideology of serving a transcendent value and 
asserting greater devotion to doing good work than to economic reward.  
Friedson’s argument is a powerful one because it builds on the accepted theories of the 
past, and builds a model for future practice in which professionalism is an important 
ingredient in the mix. Therefore this Freidsonian perspective acts as an underpinning part 
of the reasoning within this thesis, by comparing and contrasting the effects of the three 
logics on the community pharmacy profession over time. However, before progressing 
Freidson’s approach to community pharmacy, one must understand the origins and 
subsequent political struggles of community pharmacy in managing its relationship with 
                                                          
5 It is important to emphasise the distinction here between unions, which seek to further the interest of employees and 
professions that seek to further the interest of consumers (and in doing so, the interests of themselves). However the line 
between these two distinctions is being blurred. 
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the state, and its relationship with the logics of professionalism, managerialism and 
consumerism. It is this story to which this chapter now turns. 
Origins of the Modern Community Pharmacy 
By reviewing the literature in the policy field related to community pharmacy in England, it 
is possible to explore the evolution of community pharmacy and interpret pharmacy 
leaders’ claims of professional status, while considering the accompanying logics of 
managerialism and consumerism. In doing so, it is possible to explore how previous 
decisions have sought to influence subsequent practice.   
Materials and Methods 
The majority of the health policy documents identified in this section were reviewed and 
abstracted from the free web archives of the Department of Health. Key excerpts from 
documents that relate to pharmacy policy in England6 published after 1997 were 
highlighted and summarised before being ordered chronologically7. The interpretation of 
these documents was checked for reliability by Prof David Taylor. Disagreements in 
interpretation were resolved through discussion. The work of Rudolph Klein, who has 
chronicled the developments and changes in the National Health Service(Klein, 2006), 
supported this analysis through a wider healthcare policy perspective. Evidence of 
implementation of policy into pharmacy and context to the developments prior to 1997 
were provided through bibliographic references, in particular Making Medicines (Anderson, 
2005), Health Policy in Britain  (Ham, 2009) and Royal Pharmaceutical Society of Great 
Britain 1841 to 1991: A Political and Social History (Holloway, 1991). A summary timeline of 
these policies is presented in table 1.1.  
Early Development of Community Pharmacy 
The narrative relevant to modern community pharmacy practice in this research begins at 
the creation of the National Health Service in 19488. By contrast to the complex changes 
and consultations that took place with other professional groups at the development of the 
NHS, pharmacy negotiations proved relatively simple. The scheme introduced as part of the 
National Insurance Act in 1911 was working well. This was expanded to a wider population 
in 1948 with only relatively minor alterations to the fees that pharmacy contractors 
                                                          
6 There have been a wide range of changes in the devolved administrations, especially in Scotland. They do not feature in the 
policy analysis presented in this chapter. However, where relevant, these innovations are discussed in later chapters.  
7
 This year was chosen due to the ease of accessibility of web archives of policies from this date. 
8 Anderson (2008) and Holloway (1991) both provide a rich account of the development of community pharmacy practice 
prior to 1948. 
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received. For contractors, the main difference experienced was a significant growth in the 
number of prescriptions as a result of greater public access to free medicines. The rapid 
expansion of prescriptions significantly changed working practices. Within a year, the 
number of prescriptions dispensed by pharmacists almost quadrupled from 70 million a 
year to around 250 million (Anderson, 2005). Today in England alone, this figure stands at 
over 960 million (The NHS information Centre Prescribing Support Unit, 2012). This 
unprecedented growth fundamentally impacted upon the business model of pharmacy at 
the time, moving from an income of 10% or less from these in the 1920s to over 30% in the 
late 1940s (Anderson and Berridge, 2000). This proportion has grown steadily. At present 
over four fifths of the income generated in the average community pharmacy is derived 
from dispensing9. 
Prescription numbers continued to increase in the 1950s, in part driven by the discovery 
and marketing of new medicines by the pharmaceutical industry, which included 
antibiotics, major and minor tranquilisers, anti-depressants and cardiovascular disease 
treatments and also in part due to the reduction in the number of prescriptions that 
doctors dispensed themselves. For example, in the 1940s about half of all prescriptions 
were supplied by doctors, the equivalent figure for the 1950s is about 10% (Anderson, 
2008). Prescription item volumes fluctuated following the introduction in 1952 of 
prescription charges, their subsequent abolishment in 1965, and their reintroduction in 
1968. Exemption categories were introduced in 1968 and successively expanded in 1974 
and 1975. Yet despite a further rise in charges, overall prescription volumes continued to 
steadily increase. The increase in workload and income meant that dispensing assumed a 
dominating position in the role of the community pharmacist. 
At the same time, the nature of dispensing went through an equally radical change. The 
changes in mass scale manufacturing processes introduced at the beginning of the century 
led to a dramatic shift away from the use of extemporaneously prepared medicines in the 
dispensary. Instead mass scale factory manufactured medicines were re-packed in the 
pharmacy to individual patient requirements. The dispensing process became one of 
interpreting prescribers’ instructions, assembling and labelling medicines, and handing 
them to patients with necessary instructions, as opposed to one of medicines formulation 
and compounding.  Pharmacists, who were once the compounders of medicines, 
increasingly found their role dominated by checking what others had done. This was 
                                                          
9 This proportion is discussed in further detail in Chapter 3. 
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accompanied by a shift in dosage forms from mixtures and draughts, to solid tablets and 
capsules. Despite this change in the role, the increased volume of prescriptions created a 
relatively stable and ‘busy’, in terms of activity, business in the community. 
The normalisation of proprietary medicines as a retail commodity began to infiltrate 
community pharmacy practice in the UK. For example, in 1952, Boots introduced self 
selection methods in their shops, which had been pioneered in the USA. This was a 
significant change from the traditional shop where an assistant found the requested 
product (Anderson, 2005). A confrontation between Boots and the Pharmaceutical Society 
ensued, with the latter arguing that medicines were not ordinary commercial articles and 
therefore should not be self selected. After an appeal to the high court, Boots won the case 
(although they did not implement self selection of General Sales (GSL) medicines until the 
1980s). This judgement was the first of many challenges to the ways in which medicines 
were supplied to the public despite professional opposition. This led to continued clashes 
between ‘professional’ imperative to control supply and the commercially led managerial 
pressure to increase sales. 
Pharmacists became increasingly concerned about threats to their professional practice, 
particularly from the large commercial operators. A motion at the 1965 Annual General 
Meeting of the RPSGB called for new pharmacies to be in physically distinct premises and 
to confine their trading activities to pharmaceutical, professional and traditional chemists’ 
goods. This was prompted by a Pharmaceutical Society report into the general practice of 
pharmacy (Anon, 1963). It suggested that commercial activities outside healthcare were 
impacting upon their professional standards, although this could well be interpreted as 
protectionist behaviour to prevent supermarkets from entering the retail territory of 
existing pharmacy contractors. 
Despite overwhelming support from within the profession for this motion, a challenge by 
Boots in the court of appeal and the House of Lords, ruled that such as restriction would 
result in a ‘restraint of trade’. Therefore the profession remained powerless to prevent the 
expansion of pharmacies into supermarkets and other locations, and as a result large 
bureaucratic organisations began to exert greater control over pharmacists’ domain of 
work. 
Meanwhile secondary care pharmacists were confined to the dispensary, often hidden 
away in the basement of the hospital. In 1958, the Aitken report on dangerous drugs in 
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hospitals changed this by making pharmacists responsible for the safe and secure handling 
of medicines throughout secondary care organisations (Department of Health and Social 
Security, 1958). The regulations made it necessary for hospital pharmacists to work with 
multidisciplinary teams to ensure that medicines were handled safely on the wards and in 
doing so laid the early foundations for ward based ‘clinical pharmacists’ (Crooks and Calder, 
1966). This role was further progressed by the first MSc in clinical pharmacy in 1976. 
Throughout the 1970s the need for pharmacists on the ward was becoming more 
established, but a shortage of entrants into the hospital sector due to lower salaries 
compared to community colleagues, led to recruitment problems. A working party under 
Noel Hall – an economist, academic and member of the Oxford Regional Hospital Board - 
made specific recommendations about restructuring the service to improve career 
opportunities (Anon, 1978; Department of Health and social Security, 1970), but even with 
these recommendations (and salary changes as a result of the NHS reorganisation in 1974) 
salaries remained too low to attract junior staff (Brookes, 1998). As a result pharmacists 
began to delegate increasing amounts of work to occupational assistants, laying the 
foundations for ‘pharmacy technicians’.  
The Medicines Act of 1968 in the aftermath of the Thalidomide tragedy, which had caused 
10,000 or more babies to be born with physical impairments, led to an increase in 
pharmaceutical testing as well as an improvement in overall manufacturing standards. This 
effectively prevented the small scale manufacture of medicines in community pharmacies. 
While in many respects this helped to regulate the sale of proprietary medicines in 
pharmacies, it also severely curtailed their ability to make commercial gains from ‘quack’ 
medicines. The Act also made it explicit as to which medicines required prescriptions. 
Together these both further disempowered pharmacists as medicines manufacturers and 
increased their prescription dispensing workload. 
In the community, Boots continued to influence community practice pharmacy, and grow 
through mergers and acquisitions. Companies such as Timothy Whites and Taylors in 1968, 
and Underwoods in 1989, joined the Boots family, making it the largest retail chemist in 
Britain. More recently, in 1990 Boots acquired Moss Pharmacy, which had been owned by 
Unichem PLC. Unichem, a medicines wholesaler merged with Alliance Sante in 1997, 
forming Alliance Unichem, which subsequently merged into Boots forming Alliance Boots in 
2006. This company now trades globally with operations in Brazil and China. It is has grown 
to become one of the UK’s most recognisable retail companies and represent an important 
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part of the UK economy. Such a large enterprise has a strong focus on commercial trading, 
which some believe is eroding the ‘professional’ practice of pharmacists (Bush et al., 2009). 
The era of ‘new management’ 
Against this backdrop of developments in manufacturing standards and new ‘clinical’ roles 
for pharmacists in hospitals, far reaching economic changes were taking place across the 
political landscape, directly influencing the delivery of public services including healthcare. 
Several trade union strikes over pay, followed by other setbacks such as the 1973 oil crisis 
and the three day working week in 1973-74, led to economic uncertainty. This industrial 
strife, coupled with rising inflation and unemployment, left Britain in a difficult economic 
position at the end of the 1970s. In 1979 Margaret Thatcher was elected Prime minister, 
and her government set about redefining economic policy through deregulation, 
privatisation, restructure of industrial relations, changes to the tax system, and reform of 
public services. Such reform precipitated an increase in competition and market forces 
within healthcare.  
Policy developments, particularly around labour relations and privatisation began to have a 
direct impact on the provision of healthcare. At the creation of the NHS in 1948, the 
medical profession dominated every level of health service decision-making and had a 
major influence over health policy decisions (Anon, 1948)10. The medical profession had 
managed to establish an ‘underlying concordat’ with the state in respect to resource 
allocation. The state determined the level of overall resources devoted to medical care 
leaving the profession largely free to determine the use of resources under the rubric of 
clinical autonomy (Klein, 2006).  
For the next two decades, under the badge of professionalism, doctors continued to act 
with relative freedom and with little state interference. But by the sixties and seventies 
writing by sociologists such as Howard Becker (1962) and Eliot Freidson (1970), began to 
focus on the medical power that had become an entrenched feature of the healthcare 
system11. Reports about medical negligence and poor management within the health 
service began to appear, one of the most significant examples was in 1967 when 
allegations were made by a nursing assistant at Ely Hospital, Cardiff to the News of the 
World about negligent care. The investigation that followed showed that members of the 
                                                          
10 This is despite the widespread opposition of much of the medical community to the creation of the NHS. For example in 
February 1948 over 90% of the BMA said that they, as doctors, would not be a part of the NHS. Then, in July of the same year 
over 90% of GPs joined. 
11 See previous comment on Power Theories of professionals.  
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health authorities, who were primarily doctors, were not representing the views of 
consumers in the local community. Ministers, backed by public support and a desire to get 
a handle on public services, began to challenge medical dominance in the health service – 
their chosen weapon was management. 
In 1983 the government commissioned Roy Griffiths - the managing director of the 
supermarket chain Sainsbury’s - to analyse NHS management. His report identified 
‘institutional stagnation’ and prescribed general management at every level of the NHS as 
the solution. Medical and nursing representatives on committees lost power and new 
managers were given incentives through performance related pay to bring about change. 
Griffiths brought in a new managerial framework, tight budgets and justification 
requirements for costs. Service outputs of the NHS were no longer decided by the medical 
profession. Instead new non-medical managers began making the decisions, challenging 
the very nature of professional autonomy (Hampton, 1983). The power of health service 
managers slowly increased if not superseding that of the professionals (Freidson, 2001), 
arguably de-professionalising the clinicians. 
Proponents of the de-professionalization thesis have argued that this contributed to the 
general decline in the medical profession’s cultural authority and legitimacy12. Alongside 
these new managers other changes were de-stabilising medical power. The increase in the 
accessibility of medical knowledge driven by technology, the rise in complementary 
medicine, the fact that doctors became more reliant on new areas of knowledge outside 
their control, and the preparedness of patients to challenge doctor’s decisions (reflected in 
the steady rise in complaints about medical care), acted to limit doctors control over the 
health service (Salter, 2001).  
The layers of management introduced by Griffiths continued to increase, fundamentally 
changing the working environment of professionals through the introduction of quality 
measures such as league tables and rating systems. These tools, initially designed to help 
develop service improvement at the local level, became political tools to demonstrate the 
relative successes (or failings) of the NHS.  Although the main focus of these changes had 
been on the medical profession, its relative standing in relation to other professions, meant 
that all other paramedical professions were affected.  
                                                          
12 The full discussion on the de-professionalisation thesis is provided by Haug (1973).  
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‘Re-professionalising’ Pharmacy? 
By the 1980s pharmacists’ professional monopoly over the manufacture, preparation and 
supply of medicinal products had been completely undermined by the expansion of the 
pharmaceutical industry (Brehm et al., 2006). The 1968 Medicines Act, and subsequent 
European Legislation, resulted in patient ready packs becoming more commonplace, 
removing the need to compound medicines in the pharmacy. As the availability of 
pharmacological treatments increased, pharmacists improved their education, but arguably 
became ‘trapped’ as over-educated distributors of medicines (Eaton and Webb, 1979; 
Wardwell, 1979).  The future role of the professional pharmacist was highlighted by a Royal 
Commission into the National Health Service (Merrison, 1979), which identified for the first 
time that pharmacists in community were not fulfilling their potential (Taylor and Harding, 
2001). The literature began to describe pharmacy as an ‘incomplete’ or ‘marginal’ 
profession due to the conflict between their clinical responsibilities and their growing 
commercial responsibilities. The legitimacy of pharmacists role began to be brought into 
question as their previous monopoly over drug manufacture and supply was being eroded 
(Morgall and Almarsdóttir, 1999). The profession weakened by internal strife became prey 
to the government's cost cutting activities.  
In 1981 Gerard Vaughan, the Minister of Health, announced at the British Pharmaceutical 
Conference “One knew there was a future for hospital pharmacists, one knew there was a 
future for industrial pharmacists, but one was not sure that one knew the future for the 
general practice [community] pharmacist” (Anderson, 2007). 
This statement stirred the development of community pharmacy in an effort to prove its 
worth and to redefine the role of the profession. Elite groups, such as Royal colleges, 
academics and professional leaders, within a given occupation tend to be the key 
advocates of new roles in any re-professionalization project (Birenbaum, 1982), and 
pharmacy was no exception. In England, the Department of Health, supported by the RPS, 
NPA and CCA spearheaded a movement to extend community pharmacist’s roles. 
Pharmacists began working with others, such as the Family Planning Association to actively 
deliver contraceptive advice in pharmacies. In 1983 the Trustees of the Nuffield Foundation 
commissioned an inquiry into pharmacy and the subsequent report, Pharmacy: a report to 
the Nuffield Foundation was duly published in 1986 (The Nuffield Foundation, 1986). This 
important report made 96 recommendations, 26 of which were specific to community 
pharmacy. Overall, it was optimistic about the future of pharmacy, suggesting that 
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pharmacy makes a ‘distinctive and indispensable’ contribution to healthcare (The Nuffield 
Foundation, 1986). 
Campaigns to redefine the role of pharmacy within the primary health care arena followed. 
Pharmacy groups such as the RPSGB and the National Pharmacy Association (NPA), began 
to act on the Nuffield recommendations. Pharmacists were gifted a further role in minor 
ailments and self care when in April 1985 a ‘black list’ of medicines appeared in the drug 
tariff meaning that many commonly known household medicine brands were no longer 
allowed on NHS prescriptions, and in the main, could only be accessed from pharmacies. 
The administrative elite within the pharmacy profession, grouped around the universities 
and the professional bodies, began to realise that pharmacists could play a key role in 
healthcare addressing factors outside of medicines supply. The Health of the Nation White 
Paper, which had identified that social factors such as lifestyle and environment were 
important for health (making it explicit that health and illness issues were no longer solely 
the property of doctors), provided an opportunity for community pharmacists to supply 
health promotion advice. At the same time their hospital colleagues began to further 
expand their clinical roles on the wards, supported by the Department of Health (Health 
Circular, 1988). 
While pharmacists were seeking to redefine their practice, greater regulation and 
managerial control of the health service grew. It became evident, through a series of high 
profile scandals and almost ‘daily horror stories about the NHS’ (Klein, 2006), that the 
professional domination of the health service had a scant understanding of consumer 
needs within it. Up to the 1980s, UK healthcare was characterised by health consumer 
groups that were non-existent, passive or medically dominated. The policy network was 
instead an ‘iron triangle’ between the medical profession, ministers and officials (Salter, 
2003). Despite the conservative government’s rhetoric regarding the importance of 
patients, this had been constructed to mean that health consumers should not be part of 
the health community, but instead rely on the greater legitimacy afforded to managers 
(Salter, 2003), a shift from professionalism to managerialism. 
Margaret Thatcher, boosted by confidence of winning a third election victory, and 
concerned about funding and the widespread public dissatisfaction with the NHS, set out a 
manifesto for change in the publication of Working for patients (1989). The Patients charter 
(Department of Health, 1991) which followed began a new paradigm in health policy 
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transforming  patients into consumers, making their rights more explicit in the health 
service, bringing the logic of consumerism more explicitly to the fore. 
The medical profession were further challenged in 1994 when the Department of Health 
published performance against the Patients’ Charter. This performance measure was 
primarily a managerial tool but soon became a political tool by which politicians could 
demonstrate the work of the NHS (and their policies) to the public. Although the rhetoric of 
these policies at the time was concerned with empowering patients in the delivery of their 
healthcare, some commentators believed that this was simply political cover for combating 
the ingrained power of the professions (Klein, 2006). 
The rise in consumerism over this period is regarded as one of the fundamental 
developments shaping health service delivery within the UK13 (Hibbert et al., 2002). The 
sociological literature outlines the conceptual distinction between a patient, regarded as 
occupying a subject position, with implicit dependency and unquestioning compliance with 
medical expertise, and a consumer, regarded as a rational, dispassionate and calculating 
person who no longer accepts at face value the authority of science and medicine (Hibbert 
et al., 2002). The societal shift from patient to consumer in healthcare challenged (and 
continues to challenge) medical dominance. Indeed in pharmacy this shift was reflected 
with it becoming less acceptable to talk about compliance, and more appropriate to use 
concordance, implicit in which is a move towards a shared ‘concordant’ relationship (The 
Royal Pharmaceutical Society, 1997). 
Following Working for Patients, the pharmaceutical society spurred on by Nuffield began to 
work closely with the Department of Health to respond to changing consumer needs. In 
1992 they published a joint report (Department of Health and Royal Pharmaceutical Society 
of Great Britain, 1992) recommending  pharmacists participate in health promotion 
campaigns. The report also identified extended services for community pharmacy such as 
the provision of EHC, smoking advice, repeat dispensing, medicines management and 
medication delivery to GPs and housebound patients. Yet later the same year the 
government did not include the emerging role of the pharmacist in its 1992 public health 
White Paper (Secretary of State for Health, 1992) much to the disappointment of pharmacy 
leaders. Bond (2001) observed that the medical profession received the joint report with 
severe reservations,  echoing the longstanding conflicts between these groups. Many 
medics believed that community pharmacists were incapable of extending their role. The 
                                                          
13 It is worth noting that both the state and the professions claim to be the true representative of the consumer 
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interpretation of this can go several ways, either as a heartfelt view that pharmacists were 
not capable of their role or more likely, a protectionist stance to the threat of another 
group seeking to occupy their professional sphere of work.  
The joint report was followed up by the Pharmaceutical Society (RPSGB) with a series of 
consultative papers in 1995 called ‘Pharmacy in a new age’ to help highlight how 
pharmacists could contribute further to healthcare. A report, The New Horizon was 
published in 1996 followed in 1997 by Building the Future, which laid out a strategy for the 
future development of pharmacy. While it raised the profile of the profession and 
convinced people that the pharmacy profession wanted to make a contribution to the 
broader agenda, it failed to produce a consistent message. Despite the celebrated success 
of these projects within the profession, the full force of their recommendations is still to be 
seen14. 
The Labour Years 
Political support slowly grew for the extended clinical role that pharmacists could provide. 
The new labour government, under the leadership of Tony Blair, released a public health 
White Paper in 1999 setting out a health strategy for the next ten years (Department of 
Health, 1999). The strategy set specific targets for reducing cancer, coronary heart disease 
(CHD) and stroke, accidents, and mental health. Its stated aim was to improve the health of 
the population and reduce health inequalities. This heralded the development of 
pharmaceutical public health and provided a major impetus for health promotion by 
pharmacists.   
Support for the extended role of pharmacists was further boosted by developments across 
the Atlantic. Two American pharmacists, Hepler and Strand developed the concept of 
Pharmaceutical care.  
“Pharmaceutical care is the responsible provision of drug therapy for the purpose of 
achieving definite outcomes which improve a patient’s Quality of Life” (Hepler and 
Strand, 1990).  
Their work helped emphasize the shift in pharmacy practice from a product focus to a 
patient focus within the policy community. Pharmaceutical care has since received 
                                                          
14 PIANA made a contribution to shaping future policy, not least by creating a definition of what pharmacy was for.  
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endorsement from the World Health Organisation and the International Pharmaceutical 
Federation (2006) as a concept for developing the pharmacy profession.  
Britain’s economy recovered from recession in the early nineties leading to economic 
growth and stability, which translated into a sustained investment in the health service. On 
January 16th 2000, on the sofa of the BBC programme ‘Breakfast with Frost’ the labour 
White Paper pledge for greater investment in the NHS came to fruition (BBC News, 2000). 
The Prime minister announced an increase in spending to bring the NHS up to the 
European Union average. This was followed in the summer of 2000, by the launch of a 
challenging program of reforms for the NHS, described in the White Paper ‘The NHS Plan’ 
(Department of Health, 2000a). The NHS plan was founded on ten core principles including 
improving quality, helping to keep people healthy, reducing health inequalities, shaping 
care and services around the needs of the patient and making better use of the skills of the 
NHS staff. It was this last principle that was developed in the document ‘Pharmacy in the 
Future: implementing the NHS Plan’, (Department of Health, 2000b) published later the 
same year. This set out the government’s plans for greater use of pharmacy and 
pharmacists in the NHS recognising that  
“Pharmacists are highly qualified professionals, whose skills the NHS has been 
under-utilising for too long”(Department of Health, 2000b). 
For patients the strategy created a road map to help them use their medicines more 
effectively, through better access to pharmacy services. These services were to be created 
by improving the skill mix within pharmacies to free pharmacists from the dispensing 
process, by increasing the number of pharmacies as well as integrating existing ones into 
the NHS, by creating legislation changes to allow pharmacists to make minor alterations to 
prescriptions without contacting the prescriber, by  reclassifying medicines to P status,  and 
by developing Patient Group Directives (PGDs) to enable access to a wider range of 
medicines. Importantly for community pharmacists, the strategy recognised them as NHS 
healthcare professionals and made a commitment to the development of an Electronic 
Prescription Services (EPS) and a commitment to care record access in community 
pharmacy settings. 
Throughout the spring of 2002 the government began to develop the strategy for 
‘Delivering the NHS Plan’ (Department of Health, 2002a). Published in April, this document 
discussed the steps to be taken to reform funding flows. Its political foundations were 
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rooted in patient choice, providing greater plurality in the health service and increasing the 
power of front line clinical staff.  
At the same time the late Dereck Wanless – a former banker and adviser to the labour 
party - released his first ‘independent’ review of the resources requirements of UK health 
departments for the next twenty years (Wanless, 2002). His report described a vision for 
the Health Service in 2022, where quality, access and patient centred care were at the core. 
Securing Our Future Health: Taking a long term view, detailed the resources required and 
the investment needed to build capacity for the future and highlighted how levels of 
patient engagement in self care would proportionally influence future healthcare 
expenditure. His recommendations included improving the IT infrastructure, renewing the 
estate and investing in the promotion of good health and disease prevention. Wanless also 
promoted the concept of a ‘whole system’ response to future costs that shifts healthcare 
away from relatively expensive secondary care environments towards comparatively 
cheaper primary care settings. This concept began to feature prominently in labour health 
policy.  
In May 2002 the government endorsed the proposals of the Medicine Control Agency 
(MCA)15 to significantly shorten the process of medicines reclassification from one legal 
status to another, as part of its commitment to improved medication access (as detailed in 
the NHS plan). At the time it was anticipated that this strategy would enable community 
pharmacists to manage common minor ailments and some chronic conditions (Department 
of Health, 2002c). Yet in 2004, the reclassification of the first chronic disease medication, 
simvastatin, under the brand name Zocor, proved to be a commercial failure (Hansford et 
al., 2007). This was due to concerns about the efficacy of the 10mg dose, the lack of 
support from general practitioners and the limited associated pharmacy resources required 
(Paudyal et al., 2012). But also if the drug was needed then patients could acquire it on 
prescription at less or no cost.  
Despite this set back, the Department continued to push for a changed role, looking 
systematically at the barriers to new responsibilities for pharmacists. The Department of 
Health recognised that community pharmacy “must make much better use of all its staff if 
it is to meet developing patient and service needs”. A discussion paper on the pharmacy 
workforce was published in the winter of 2002(Department of Health, 2002b). This 
supported the expansion of the skill mix in community pharmacies. It described the 
                                                          
15 Now known as the Medicines and Healthcare Products Regulatory Agency (MHRA). 
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development of pharmacy technicians, drawing on examples of technicians in secondary 
care, and suggested piloting the dispensing and supply of medicines by qualified 
technicians without the personal supervision of the pharmacist. It was envisioned that this 
would allow community pharmacists to extend their roles in medicines management 
schemes, supplementary prescribing and Local pharmaceutical services (LPS). 
Although pharmacist prescribing had been supported in ‘Implementing the NHS plan’ in 
2000, (Department of Health, 2000b), it took until April 2003 for supplementary 
prescribing, under an agreed clinical management plan, to become legal (Department of 
Health, 2003b). By contrast, pharmacists were almost a decade behind nurses who were 
conferred some prescribing rights in 1992, following recommendations in the 1986 
Cumberledge report, which were subsequently reinforced three years later by the Crown 
report. To some extent this demonstrates the political weakness of the pharmacy lobby 
when compared to other health care professionals. But this may also be a reflection that 
such a role breaks the traditional - doctors prescribe, pharmacists supply - hierarchy in the 
health service and as such is a threat professional boundaries. 
The importance of community services was set out in ‘Tackling Health 
Inequalities’(Department of Health, 2003c) which further supported extending 
pharmacists’ roles to address health inequalities. Yet, little tangible difference was actually 
observed in pharmacy practice.  
The ‘under-utilised’ expertise of community pharmacists was again explicitly recognised in 
the document ‘A vision for pharmacy in the new NHS’ (Department of Health, 2003d), 
which documented the progress made in the first three years since ‘Pharmacy in the 
Future’ (Department of Health, 2000b). It stated: 
 “There is considerable scope to build on the current achievements in public health 
and pharmacists are probably the biggest untapped resource for health 
improvement”.  
A vision for pharmacy went on to set out a continuing programme of pharmaceutical 
service reform by attempting to identify specific roles that pharmacists could play in 
improving the health of the public. Examples included: supporting patients wishing to care 
for themselves; responding to the needs of patients; helping to deliver the aspirations 
outlined within National Service Frameworks (NSF); and helping to promote public health, 
tackling health inequalities and improving general health. These recommendations were 
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followed by a Department of Health commitment to ease restrictions on the opening of 
new pharmacies, to expand the range of medicines available without prescription and to 
promote minor ailment schemes for members of the public exempt from prescription 
charges (Department of Health, 2003a).  
Commitment to reducing health inequalities was reiterated in 2004 as Wanless produced 
his second report, which emphasized the cost effectiveness of prevention (Wanless, 2004). 
His report concluded that only with a public fully engaged in health could society meet the 
future challenges facing the NHS. Targets to achieve this were set in June 2004 with the 
publication of the ‘The NHS Improvement Plan’ (Department of Health, 2004f). These were 
for CHD, cancer, smoking, obesity, teenage contraception, health inequalities, long term 
conditions and health outcomes. To help achieve these goals the Government published a 
framework for health and social care standards (Department of Health, 2004e), followed 
later that year with the White Paper ‘Choosing health: making healthy choices easier’ 
(Department of Health, 2004a). This set out the government’s plans to encourage people to 
make healthier decisions about their lifestyle prioritising obesity, smoking, sexual health, 
mental health and alcohol abuse. Yet, pharmacist’s explicit contribution to these changes 
was relatively minor. Indeed, during this period, prescription volumes continued to grow, 
and pharmacists became further entrenched in their dispensing roles. 
During late 2003 and early 2004 the government negotiated with healthcare professionals 
over their contracts as outlined in the NHS plan(Department of Health, 2000a). In April 
2004 the new general medical services contract for GPs was implemented. This linked a 
significant proportion of GP income to Quality and Outcomes Framework targets (QOF) in a 
drive to improve the quality and consistency of primary care. Community pharmacy, 
through the Pharmaceutical Services Negotiating Committee (PSNC), negotiated a new 
national contract which came into force in April 2005 (PSNC, 2004).The new pharmacy 
contract was a bid to create a remuneration model that was less reliant on prescription 
volume almost two decades after the Nuffield report recognized this as being inappropriate 
(The Nuffield Foundation, 1986). This built upon the development of the local 
pharmaceutical services (LPS) and was intended to move contractors towards service 
delivery (the contents of the contractual framework are discussed in more detail in 
chapters three and six). An important innovation included in the framework was nationally 
advanced services, the first of which was the ‘medicines use review’ (MUR)16.   
                                                          
16 The significance of the MUR to the pharmacy profession is discussed further in chapter 4.  
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At the beginning of 2005 the Department of Health published “Self Care – A Real 
Choice”(Department of Health, 2005e) which developed policy ideas to empower the public 
to treat themselves. Again the report recognised community pharmacy as a source of 
advice for minor ailments. Indeed, pharmacists’ role in helping to manage long term 
conditions was also made more explicit in the same year with the publication of 
‘Supporting People with Long Term Conditions’ (Department of Health, 2005f). Yet, these 
recognitions in policy failed to translate into economically viable income streams. As a 
result community pharmacists continued to focus most of their attention on the fast and 
efficient supply of prescription medicines. 
The Department of Health developed its strategy for implementing the priorities outlined in 
Choosing Health, making healthy choices easier in the spring of 2004 (Department of 
Health, 2004a). This was followed by a detailed map for pharmacy (Department of Health, 
2005a), which recognised the contribution that pharmacists could play in improving the 
health of the public. The plan identified important service priorities for pharmacy such as 
signposting to other healthcare providers, obesity management, smoking cessation 
programs, sexual health advice, drug misuse schemes, and the management of long term 
conditions. While this represented a positive policy message for pharmacy, there remained 
concerns that the report’s ambitions were unachievable due to the current workforce 
arrangements.  
Once again, in response to a pharmacy workforce consultation, proposals were put forward 
to amend supervision requirements (Department of Health, 2005c) to allow pharmacists to 
take on these wider public health responsibilities. This recommendation to change 
supervision and personal control requirement in the pharmacy is still one that current 
legislators are yet to resolve, as pharmacists retain personal liability for the workings of a 
pharmacy.  
The extension of nurse and pharmacist prescribing was announced in the winter of 2005, 
allowing them to become independent prescribers (Department of Health, 2005d). 
Although prescribing was aimed at opening paths of opportunity for pharmacists, it is still 
only practiced by a relatively small number of pharmacists. A recent study suggests that 
difficulties in embedding prescribing by pharmacists into the structure of healthcare is 
making it hard to provide a sustainable service (Baqir et al., 2010a). The embedded 
structure of the healthcare system since 1948 has been that doctors write prescriptions 
and pharmacists dispense them. Pharmacist prescribing threatens to subvert this prescriber 
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dispenser separation. Therefore creating opportunities for these prescribers requires a re-
definition of pharmacists’ roles within healthcare. Indeed, the public have established 
expectations of health providers and tend to trust them to deliver familiar services, which 
in pharmacist’s case is medication supply (Gidman et al., 2012).  
Yet despite established expectations, a Department of Health consultation in 2005, which 
included over 40,000 people, identified that the public desired a wider range of healthcare 
professionals to be involved in disease prevention and health improvement. The 
government response was the White Paper Our health, our care, our say released in early 
2006 (Department of Health, 2006c). It outlined four aims for the NHS: better prevention 
services with earlier intervention, more patient choice and a louder voice for people, more 
on tackling inequalities and access to community services, and more support for people 
with long term conditions. Services based around people with long term conditions were 
identified as an area in which pharmacists could actively improve the patient experience. A 
guide to support people in self care followed and further emphasised the support role that 
pharmacists could provide (Department of Health, 2006d).  
Opportunity for specialist practice, developed out of the changing nature of pharmacists 
roles, culminated in the publication of a national framework for pharmacy in September 
2006 (Department of Health, 2006b). This guidance made suggestions about how extended 
pharmacy services could be developed in local areas through the expansion of the 
pharmacy workforce. It outlined national standards for pharmacists’ roles and for 
consultant posts in secondary care.   
Further development of specialist practice in primary care arose in 2007 with the 
publication of the White Paper ‘Our Health, Our Care, Our Say - a New Direction for 
Community Services’, which emphasised the role for specialist pharmacy practitioners to 
support primary care. The first two Pharmacists with Special Interests (PhwSI), both from 
Bradford, became accredited in May 2008. Even with these initiatives, many pharmacists 
working in community struggled to specialise in a meaningful way. Meanwhile many of 
their colleagues in secondary care settings began to create specialist clinical posts and 
consultant pharmacist positions. 
Despite a sustained policy effort to make better use of pharmacists skills, much of 
pharmacy practice remained unchanged, driven by dispensing (Blenkinsopp et al., 2009). 
The All Party Pharmacy Group (APPG) launched an inquiry into the Future of Pharmacy in 
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June 2007 due to concern that pharmacy was still an ‘underused resource’ and not 
sufficiently integrated into the NHS (All Party Pharmacy Group, 2007). 
“...across the country, community pharmacy is not being utilised as effectively as it 
could be as a primary care resource”(All Party Pharmacy Group, 2007). 
 The work of the APPG helped to create a driver for the subsequent Department of Health 
pharmacy White Paper, ‘Pharmacy in England: building on strengths - delivering the future’ 
published in April 2008. This set out the vision for pharmacy in the future and aimed to 
ensure the delivery of pharmaceutical services in the context of wider NHS strategy. This 
White Paper was heralded by the profession as the most significant document since 
Nuffield as it was believed to be a comprehensive map for the future of pharmacy in 
England. Yet, two years after its publication, a new government took office. It therefore 
remains unclear as to whether the aims of the pharmacy White Paper will continue to be 
implemented (Anon, 2010).  
Many pharmacists and pharmacy organisations felt that the legal framework limited the 
ability of pharmacists to enhance their clinical role. A regulatory change that came as a 
result of the White Paper was the responsible pharmacist legislation to support 
pharmacists in developing their clinical role and contribution to healthcare services. Passed 
in October 2009, it allows the ‘responsible pharmacist’ to be absent from the premises for 
up to two hours in order to extend the range of pharmacy services offered. This was 
originally suggested in the Nuffield report. 
“...it is a handicap for pharmacists that at present they are tied to their premises 
and, given modern methods of communication, we regard this as unnecessary. We 
think that the law should be relaxed to enable a pharmacist to leave the premises 
for a limited period to undertake professional activities elsewhere.” (The Nuffield 
Foundation, 1986) 
At the time this position was not accepted by the RPSGB who felt ‘every prescription for a 
medicine must be seen by a pharmacist’ effectively keeping pharmacists tied to the 
dispensing role (Anderson, 2005: p132).  This demonstrates an underlying tension between 
the argument put forward by those in policy circles that pharmacists are under-utilised and 
the desires of the professional body to maintain current practice.  
Although the Department of Health has indicated that it intends to develop ‘remote 
supervision’ (i.e. supply of prescriptions without the pharmacist physical presence in the 
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pharmacy) further, opposition has come from several pharmacy bodies, in particular the 
Pharmacists’ Defence Association. Many of the English pharmacy board members, elected 
in 2010, stood under a banner of ‘stop remote supervision’. Despite an intention to make 
community pharmacists work more clinical orientated, early indications on the effect of the 
responsible pharmacist legislation suggest that it has failed in this aim (TNS UK Limited, 
2011). Therefore the issue of supervision and personal control continues as a problem 
within pharmacy policy.  
Economic Downturn 
Despite a period of growth and investment for nearly a decade, the NHS like the whole 
public sector became subject to the global economic downturn in 2008. Following the 
collapse of several important banks, including Lehman Brothers in September 2008, the 
country  - and world economy - entered an economic recession. Against this backdrop of 
economic uncertainty, David Nicholson- the chief executive of the NHS - sent a letter in 
August 2009 to trust chief executives setting out a policy for Quality, Innovation, 
Productivity and Prevention (QIPP).   
This letter came on the back of several economic mandates written by David Nicholson 
which informed finance directors that the NHS needed to find £20 billion in ‘efficiency 
savings’ by 2015 as a result of ‘extremely challenging’ conditions caused by the economic 
downturn (Ball and Sawer, 2009).This was later dubbed by Stephen Dorrell - the health 
select committee chairman – as the ‘Nicholson challenge’. It was not long after this 
announcement that the media began to report ‘cuts’ to NHS front line services. Part of 
these efficiency savings were to be found through the QIPP program, which has was a 
follow up to Darzi’s next stage review that had set out to improve the quality and efficiency 
of the NHS. 
Ara Darzi – a leading surgeon – had been asked in 2006, by NHS London, to lead a review 
into healthcare provision across the capital. The report, Healthcare for London: A 
framework for action was published on 11 July 2007. Given his success in leading the 
project, Darzi was asked by the government to lead a review to determine the course of 
the NHS over the decade ahead, under a process known as the ‘NHS Next Stage Review’. 
The overall review set out a vision for future healthcare, which was to be embraced by the 
NHS (Darzi, 2008). The final report updated traditional notions of professionalism and 
described a new accountability in clinical practice under a mantra of putting quality back 
into the NHS. In particular, this championed pharmacies as providers of prevention services 
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building on the pharmacy White Paper. In many respects Darzi’s review outlined the 
boundaries for pharmacists by confining them to prevention and keeping people healthy, 
rather than treating disease. In doing so it re-iterated the medical hierarchy, keeping 
pharmacists from crossing professional boundaries.   
“Liberating the NHS” 
The coalition government came into power in 2010, ending the previous 13 years of a 
labour led NHS. Andrew Lansley, as Secretary of State for Health, introduced an ambitious 
program of change for the NHS, beginning in July 2010. Within months of becoming a 
minister he published the English NHS White Paper Equity and Excellence: Liberating the 
NHS. The aspiration contained within this White Paper was to create GP led commissioning 
groups, thereby disbanding Primary Care Trusts (PCT) and Strategic Health Authorities 
(SHAs). These proposals aimed to free the NHS from centralised bureaucratic input and 
remove the political micromanagement of the health service. However, the creation of a 
coalition government meant that the planned reforms for the NHS were not solely those 
that the Conservatives had created in opposition, but contained elements of Liberal 
Democrat policy. The result was far more wide reaching reform that had initially been 
anticipated (Timmins, 2012).    
To many these changes represented a radical restructure of the health service. Of the 
changes, David Nicholson said ‘It is the only change management system you can actually 
see from space-it is that large’. Yet, many of the proposals were continuations of the 
previous labour policies, such as a focus on outcomes and quality following Lord Darzi’s 
review, a drive towards competition and patient choice, foundation trust status for all 
hospitals, practice based commissioning, and the separation of provider arms for primary 
care trusts. Yet the pace of introductions and the scale of the changes all at once led these 
to be branded a revolution, rather than an evolution in policy terms, creating much 
opposition to the reforms (Timmins, 2012). 
So great was the resistance to the policies that the Government was forced to have an 
unprecedented pause in the passage of the legislation. Yet the pause failed to silence many 
critics who were (and remain) sceptical about GPs abilities to take on these new 
commissioning roles and the ability of the NHS to cope with such significant change in 
times of economic austerity.  
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From the perspective of community pharmacy, Liberating the NHS is sparse in its specific 
mention of this professional group, but it did indicate the continuing drive for pharmacist’s 
roles to move beyond the supply of medicines towards optimising their use: 
“The community pharmacy contract, through payment for performance, will 
incentivise and support high quality and efficient services, including better value in 
the use of medicines through better informed and more involved patients. 
Pharmacists, working with doctors and other health professionals, have an 
important and expanding role in optimising the use of medicines and in supporting 
better health. Pharmacy services will benefit from greater transparency in NHS 
pricing and payment for services” (Department of Health, 2010: para 3.22). 
The Health and Social Care Act 2012 that followed continues to support the shifting pattern 
of pharmacists’ role in its implementation. For example, the White Paper made patient 
access to electronic health care records a priority, which may in the future permit a 
pharmacist access to medical information. 
The impact of the reforms will depend on how they are implemented, as much as on the 
provisions within the Act. A detailed debate on their relative merit is beyond the scope of 
this thesis, although its influence in the collection of data throughout this project should 
not go unmentioned17.  
Section Summary and Thoughts 
The narrative presented here has shown how successive policy mandates have sought to 
change and control the way that healthcare is delivered. A summary of these policies is 
presented in table 1.1. Beginning with the Griffiths report in 1983, but seen more recently 
with the ‘Nicholson challenge’, managers have acted more extensively to control resource 
use in the NHS, often against professional desires.  
As Nye Bevan is famously quoted as saying at the inception of the NHS  
“We shall never have all we need. Expectations will always exceed capacity. The 
service must always be changing, growing and improving – it must always appear 
inadequate” (Bevan, 1948).’ 
                                                          
17 An excellent overview of the development of this policy is provided in Never Again (Timmins 2012) 
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Yet until recently the controllers of access, and the managers of resources, were the same 
people, creating a significant internal conflict. In this position, healthcare professionals can 
exploit these opportunities for personal profit, although the theoretical basis for not 
exploiting consumers is professionalism. As described previously, there are two other 
mechanisms used to cope with this situation. The first is the market based logic of 
consumerism, which has begun to increasingly contribute to healthcare policy. The second 
is the logic of managerialism, which since the advent of Griffiths has become a central form 
of controlling work. Indeed these represent the arguments of private sector versus public 
sector, and bureaucracy versus competition which have dominated healthcare policy for 
the last half century.  
From a policy perspective the government, through the Department of Health, have 
attempted to embrace all of these concepts. But arguably they have failed to push the 
profession down any path adequately. Despite their attempts at reform, there remain 
several professional barriers for pharmacists that have yet to be adequately resolved.  
First is the challenge of ‘under-utilisation’. In the middle part of the last century, driven by 
staff shortages and a growing need for ward based expertise, hospital pharmacists 
embraced new ways of working with doctors, nurses, and patients. Observing this the 
government recognised that community pharmacists were also equally capable of taking 
on greater roles. This led to community pharmacists being described repeatedly as an 
‘under-utilised’ resource in policy. That is as a group whose knowledge and expertise could 
be developed to enhance patient care. This view has been continually reasserted in areas 
from the support of common minor ailments to the management of long term conditions. 
However, this position is conflicted. Pharmacists are being encouraged to move away from 
the supply of prescription medicines. But there are an increasing number of prescription 
medicines that require safe and accurate supply, and yet no widely available services exist 
which embrace these ‘under-utilised’ skills. This is in contrast to the development in 
hospital pharmacy where clinical ward based services are commonplace.  
Secondly, the development of the community pharmacy workforce and how this aligns 
with the overall supervision of a community pharmacy has also received continuous 
attention. In particular, the extent to which pharmacists must oversee the supply process 
has been a contentious issue to which there is yet to be an adequate resolution. Repeated 
calls for better use of skill mix in community pharmacy have failed to be enacted. The 
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profession’s desire to maintain control of supply, which is arguably their defining role in the 
health service, has limited the ability of new models of practice to develop. 
Thirdly, motivated by a desire to deliver more health care in primary care settings, 
attempts have been made to integrate pharmacists with the rest of the NHS, again without 
adequate resolve, with many pharmacists practicing in isolation.  
Fourthly, the boundary of healthcare professionals has created tensions in the delivery of 
healthcare services. In particular, the relationship between general practitioners and 
pharmacists has been a constant source of strife that has been played out in policy 
documentation (Bryant et al., 2009). Defining and maintaining professional boundaries has 
been seen most acutely in the area of prescribing (Baqir et al., 2010a), but persists in other 
areas where the dominance and power of the medical profession has been changed (Eaton 
and Webb, 1979). 
Professional behaviour is itself subject to corrupting forces, due to the economic rewards 
that are given to professionals as a result of their work. For this reason the state has sought 
to regulate and control professionals in order to protect consumers and the wider public. 
This regulation is not without its drawbacks, not least the limitation it places of professional 
autonomy in practice. The dynamic relationship between the state, society and the 
professionals is the topic of discussion for the next section of this chapter. 
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Table 1.1 – Key Developments in Community Pharmacy History (1949-2010) 
Year National Health Service Policy Pharmacy Specific Policy Prescribing Healthcare Practitioner Regulation 
1948 Creation of the NHS    
1952  Boots Self Selection Case   
1958 Report on the Control of Dangerous Drugs and 
Poisons in Hospitals (Aitken Report). 
   
1965  RPS fail in call for restriction in pharmacy trading 
(Dickson Case) 
  
1966  Foundations of the ‘clinical pharmacist’ in 
Hospitals 
  
1970  Report of the working party on the Hospital 
Pharmaceutical Service (Noel Hall Report) 
  
1979 Margaret Thatcher elected prime minister Royal commission into the national health service 
(Merrison) highlights underused role of 
pharmacists. 
  
1981   Gerard Vaughan makes announcement at BPC   
1983 Griffiths report on NHS management    
1985  NHS announced ‘black list’ of drugs   
1986  Pharmacy: the report of a committee of inquiry 
appointed by the Nuffield Foundation; 
RPSGB and NPA begin public health campaigns 
Cumberledge Report recommends nurse 
prescribing 
 
1989 Working for patients  Crown report on recommends expansion of 
prescribing 
 
1990s  Hepler and Strand publish principles of 
pharmaceutical care 
 
  
1991  Patients Charter    
1992 The health of the nation: a strategy for health in 
England 
Joint RPSGB/DH report - Pharmaceutical Care: 
The future for community pharmacy. 
Nurse prescribing becomes legal  
1992 Trusts judged against performance to patients 
charter 
   
1995  Pharmacy in a New Age Consultative papers  
 
 
1996  The New Horizon (PIANA)   
1997  Building the Future (PIANA) 
 
 GMC hearing into Bristol Cardiac Surgery begins 
1999 Saving Lives: Our Healthier Nation   Medical Professionalism Project 
2000 Tony Blair pledges investment in the NHS; 
The NHS Plan: A plan for investment. A plan for 
Pharmacy in the future: implementing the NHS 
Plan. A programme for pharmacy in the National 
 Harold Shipman commits murders 
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reform; 
 
Health Service. 
 
2001    Kennedy Report on Bristol deaths; Redfern 
Report on Aldery Hey. 
2002 Delivering the NHS Plan. Next steps on 
investment. Next steps on reform; 
Wanless Report long term health trends; 
Wider access to medicines to allow patients to 
manage their own healthcare; 
 
Pharmacy workforce in the New NHS: Making the 
best use of staff to deliver the NHS Pharmacy 
Programme Pharmacy workforce in the New NHS: 
Making the best use of staff to deliver the NHS 
Pharmacy Programme 
 
  
2003  Building on the best: Choice, responsiveness and 
equity in the NHS; 
Tackling health inequalities: A Programme for 
Action Tackling Health Inequalities;  
A vision for pharmacy in the new NHS 
 
Pharmacists supplementary prescribing legal - 
Supplementary prescribing by nurses and 
pharmacists with the NHS in England a guide for 
implementation 
 
2004 Wanless - Securing good health for the whole 
population: Final report; 
The NHS Improvement Plan: Putting people at the 
heart of public services; 
National Standards, Local Action: Health and 
Social Care Standards and Planning Framework 
2005/06 – 2007/08; 
Choosing health making healthier choices; 
New GP contract 
 Shipman inquiry reports; 
On being a doctor medical professionalism for 
better patient care; 
 
 
Committee of Inquiry - independent investigation 
into how the NHS handled allegations about the 
conduct of Clifford Ayling; 
Committee of inquiry to investigate how the NHS 
handled allegations about the performance and 
conduct of Richard Neale, Department of Health; 
 
2005 Self Care - A Real Choice. Self Care Support - A 
Practical Option; 
Supporting People with Long Term Conditions. An 
NHS and Social Care Model to support local 
innovation and integration; 
 
New pharmacy contract; 
Choosing health through pharmacy. A 
programme for pharmaceutical public health 
2005-2015;  
Making the best use of the pharmacy workforce: 
Consultation outcome. 
Independent prescribing nurse and pharmacist 
prescribing powers extended; 
 
The Kerr/Haslam Inquiry full report. 
2006 Supporting people with long term conditions to 
Self Care. A guide to developing local strategies 
and good practice;  
 
WHO and FIP endorse pharmaceutical care; 
Our health our care our say;  
Implementing care closer to home – providing 
convenient quality care for patients: A national 
framework for Pharmacists with Special Interests 
 Foster Review;  
Good doctors, safer patients: Proposals to 
strengthen the system to assure and improve the 
performance of doctors and to protect the safety 
of patients; 
2007 Our Health, Our Care, Our Say - a New Direction 
for Community Services 
APPG Inquiry into Future of Pharmacy;  
RPSGB commissions Clarke Inquiry; 
 
 Trust, Assurance and Safety - The Regulation of 
Health Professionals in the 21st Century; 
Report of the working party on professional 
regulation and leadership in pharmacy; 
2008  Pharmacy in England : building on strengths 
delivering the future; 
First PwSI accredited 
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2009 Nicholson proposes QIPP agenda; 
“Nicholson Challenge” to save £20 billion 
announced 
Responsible pharmacists legislation enacted   
2010 Equity and Excellence: Liberating the NHS. Pharmacy Order;  
GPhC begins taking responsibility for regulation 
of pharmacists 
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Professional Regulation 
Successive governments have sought to assert their control over the regulation of 
professionals. This has happened in tandem with the developments previously described 
that have sought to extend community pharmacy practice. The political requirement to 
control the power of the medical profession came to head in October 1997 when the 
General Medical Council (GMC) began a hearing into the high mortality rate of 15 
paediatric cardiac surgery cases at the Bristol Royal Infirmary (Kennedy, 2001). The 
subsequent report, Learning from Bristol: the report of the public inquiry into children's 
heart surgery at the Bristol Royal Infirmary 1984 -1995 published under the chairmanship 
of Prof Ian Kennedy – an academic lawyer who specialises in health and ethics - made 
fundamental challenges to the regulation of healthcare professionals and the workings of 
teams within the NHS. This report made it clear that the previous self regulation models of 
the medical profession had failed to protect patients, and had resulted in avoidable deaths.  
To this point medicine, society and the state had interlocked to form a stable triangle of 
political forces based on a mutual exchange of benefits. The state provided healthcare to 
society through the NHS, delivered to an appropriate standard by medicine. In doing so, the 
state gained respect for its legitimacy from society whilst relying on the medical profession 
to covertly ration public healthcare expenditure. Through its fulfilment of obligations to 
both, medicine received the trust of society and the privilege of self-regulation. Yet, this 
triangle began to decline, mainly due to a weakening of public trust in the medical 
profession and wider public dissatisfaction with medical attitudes (Stacey, 1989; Stacey, 
1992; Rosenthal, 1995; Allsop and Mulcahey, 1996; Smith, 1989). 
Trust in the medical profession was further reduced by the high degree of media attention 
that followed the case. This resulted in a trial for the whole of the medical profession who 
were seen to be more concerned with protecting their members than the public. At the 
same time other alleged medical misdemeanours came to light, including a large store of 
human organs held at Alder Hey Children’s hospital without consent. A separate inquiry, 
chaired by Michael Redfren – a barrister who specialised in medical negligence - further 
increased public scrutiny of medical practice (Redfern, 2001). 
Despite the disquiet of the medical profession there was full public support for new radical 
measures to change medical regulation. These drew further momentum when it was 
revealed that Harold Shipman, a general practitioner from Hyde, had murdered 15 of his 
patients. His imprisonment in 2000 led to a series of public reports to safeguard patients 
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(The Shipman Inquiry  (Chairman: Dame Janet Smith), 2004).  This began with an overhaul 
of the GMC (General Medical Council, 2001), and led to a succession of regulatory and 
managerial bodies such as the Council for Healthcare Regulatory Excellence, the Healthcare 
Commission, the National Clinical Assessment Authority and the National Patient Safety 
Agency that all aimed to put ‘quality’ back into the NHS. Public distrust was further 
bolstered by investigations into malpractice by Clifford Ayling (Department of Health, 
2004b) an obstetrician and gynaecologist who worked in Kent; Richard Neale (Department 
of Health, 2004c), a consultant obstetrician and gynaecologist who worked in a number of 
hospitals in North Yorkshire; and William Kerr and Michael Haslam (Department of Health, 
2005b), two consultant psychiatrists who practiced in North Yorkshire. 
Commentators such as Salter (2001; 2003; 2004) believe these developments mark a 
watershed in the relationship between the state, health professionals and health service 
users18, disrupting the previous ‘iron triangle’. Not only did these medical failings provide 
justification for greater government intervention in previously professional realms, but 
they have also (whether intentionally or not) been used to impose greater managerial 
control over the healthcare system (Salter, 2001). While previous policies had disrupted 
this ‘iron triangle’, the change in tone created by these cases meant that for the first time 
these conflicts were visible to the public and therefore could be used to garner public 
support for change.  
These revelations brought the very notion of professionalism into the spot light. The launch 
of the Medical Professionalism Project in 1999, organized by the European Federation of 
Internal Medicine, the American College of Physicians, the American Society of Internal 
Medicine, and the American Board of Internal Medicine was a response to changed 
professional values. Doctors were: 
“experiencing frustration as changes in healthcare delivery systems in virtually all 
industrialised countries threaten the very nature and values of professionalism” 
(Medical Professionalism, 2002).  
This led to a raft of projects to redefine medical professionalism in modern society (Askham 
and Chisholm, 2006; Picker Institute Europe, 2008; Royal College of Physicians, 2005). 
Richard Horton, editor of the Lancet and the prime author of a report on medical 
                                                          
18
 These changes (although being seen globally) were seen particularly acutely in England due to the politicised role that the 
NHS plays. There is an imperative for the government to act when tragedies happen. In this sense England has become more 
overzealous in its professional regulation of these groups. 
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professionalism from a working party of the Royal College of Physicians made it clear that a 
partnership between government oversight and regulation and medical professionalism 
was needed. 
“The chaos that is modern health-care regulation has left the health care 
professions in disarray. The political consensus is that doctors do not set sufficiently 
high standards of practice; that even when they do, they fail to act when those 
standards are not met; and that the profession has shown itself to be insufficiently 
concerned about protecting patients. The result is inquiry after inquiry, law after 
law, to bring doctors to heel, to make them more ‘accountable’”(Horton, 2005). 
Yet these inquiries failed to resolve the debate on medical freedom and autonomy, but 
they did provide political legitimacy for the government to intervene. Following a review of 
the regulation of the medical profession (Department of Health, 2006a), the Department of 
Health called for a review of  the non-medical health professions including pharmacy, 
nursing, dentistry, optometry, chiropractice and osteopathy (The Foster Review, 2006). 
These inquiries culminated in the government White Paper, Trust, Assurance and Safety - 
The Regulation of Health Professionals in the 21st Century (Department of Health, 2007b), 
which led to a complete overhaul of the regulation of medical and allied professions, 
including pharmacy.   
A Department of Health working group chaired by Lord Carter of Coles examined the 
regulation of pharmacists in the wake of Trust Assurance and Safety.  This working group 
for pharmacy recognised the  
“transformation underway from a “product-focused service” to a truly clinical 
profession, directly caring for patients and the public” (Department of Health, 
2007a: p4) 
The group recommended the formation of a General Pharmaceutical Council to regulate 
pharmacists that was transparent to the public and the profession, and therefore 
suggested the separation of professional and regulatory functions from the current 
regulator, the RPSGB. Ministers accepted the working party’s recommendations and 
established the Pharmacy Regulation and Leadership Oversight Group (PRLOG). The 
primary purpose of this group was to oversee the establishment of a new regulator for 
pharmacy – the General Pharmaceutical Council (GPhC), advising Ministers accordingly. 
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In 2007 the RPSGB also commissioned an independent inquiry, chaired by Nigel Clarke (a 
public affairs consultant with a background in government relations, public policy and 
healthcare), into the possible options for a new professional body for pharmacy and the 
separation of the regulatory and professional roles. After nearly a year of deliberations a 
subsequent ‘transitional committee’ was then appointed and charged with implementing 
Clarke’s prospectus for pharmacy. The process to create a new professional body meant 
changing the Royal Charter of the RPSGB and lengthy consultations on how this new body 
should act. This created many internal debates within pharmacy, consuming much time and 
resource, and distracting the profession from the wider changes in the healthcare system. 
The foundations for a new regulator for pharmacy as described by PRLOG were set in 
motion. The Pharmacy Order 2010, which successfully completed its passage through 
parliament in February 2010, allowed the formal handover of regulatory powers from the 
RPSGB council to the GPhC in late 2010.  This created both a new regulator for pharmacy to 
ensure minimum standards of patient safety and care and a new professional body to lead, 
develop and nurture the pharmacy profession. 
The upheaval in the structures at the top of the profession should not be downplayed. To 
maintain their professional credibility, the profession’s elite exerted a significant amount of 
effort realigning the regulatory systems within pharmacy. Therefore on the one hand these 
regulatory changes gave the public greater influence and control over the pharmacists, 
helping to build public trust in pharmacists. Yet on the other hand they removed the 
professions self-regulation, a principle component of professional autonomy. It is this 
notion of professional autonomy that the next section seeks to address.  
Professionalism in Community Pharmacy 
The new professional body has set out to understand the constraints on current pharmacy 
practice and to work with the profession to develop future roles, in a function akin to that 
of a medical college. However, the new professional body will be mindful of the body of 
literature that has written the obituary of the pharmacy profession, with pharmacists 
described as an incomplete (Denzin and Mettlin, 1968), marginal (McCormack, 1956) or 
quasi profession (Birenbaum, 1982). 
Sociologists articulated the main difficulties facing pharmacy during the 1950s to 1970s. 
The sociological literature began to describe how pharmacy had failed to achieve and 
maintain professional status. In part, the replacement of smaller retail pharmacies by larger 
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multiple entities was seen as a problematic structural change, pressurizing pharmacists to 
concentrate on aspects of commercial endeavour rather than professional skills. Shaw 
(1972) argued that this reduced level of autonomy began to result in pharmacy being 
perceived less positively  by the public. 
The limited autonomy of the profession, coupled with the inability of pharmacy to have 
complete control over the social object that justifies its existence, led Denzin and Mettlin 
(1968) to brand pharmacy an ‘incomplete profession’. Their analysis influenced later 
sociologists, who continued to highlight the barriers to pharmacy achieving complete 
professional status. In particular they focused on the spread of technology in 
pharmaceutical manufacture, as previously noted, which has caused pharmacists to lose 
their main function as compounders of medicines.  
The response to this loss were new models of practice, advocated by the elite groups 
within the occupation (Birenbaum, 1982). Birenbaum (1982) in the USA contented that 
‘clinical pharmacy’ was needed to ‘re-professionalise’ pharmacy, suggesting the removal of 
technical tasks to free pharmacists to undertake more professional ones. While some, such 
as Holloway (1986) criticised Birenbaum’s concept as too simplistic for failing to addresses 
the dynamic nature of occupations, his overall concept for developing the profession 
gained credence.  
Dingwall and Wilson (1995) reanalyzed the previous claims of Denzin and Mettlin, which 
they argued lacked original data. Instead they believed that pharmacy did possess many 
professional traits and was deserving of professional status. Harding and Taylor (1997) on 
the whole agreed with Dingwall and Wilson’s analysis, recognising that pharmacy had 
increasingly striven to define and establish its role in the face of technological change. 
However, they argued that pharmacy has the knowledge to control the symbolic 
transformation of a pharmacological entity (a drug) into a social object (a medicine) and 
that that pharmacy had failed to capitalize on this when defining its professional role.  
In contrast to Birenbaum (1982), Harding and Taylor made a case suggesting that the 
extended clinical role could be damaging to the professional status of pharmacy. They 
argued that these activities take the pharmacist away from dispensing and therefore 
remove the focal point needed for transforming drugs into social objects. They contend 
that 
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...strategies which displace the activities associated with dispensed medicines, and 
emphasise those associated with technology and routinised advice giving, may have 
a de-professionalising effect, when drugs lose their centrality to pharmacists’ 
activities. 
Yet, Harding and Taylor’s argument appears to be in contrast to the ‘re-professionalisation’ 
strategies that followed at the turn of the millennium as has been described in the previous 
historical analysis reported in this chapter. They recognized that the simplification of the 
technical skills required in the dispensing of prescription medicines had been equated to a 
reduction in importance. But they felt that without professional input, presenting a 
prescription form for a drug would represent no more than a simple exchange, whereas 
with a professional involved, there is opportunity for symbolic transformation from ‘drug’ 
to ‘medicine’. Therefore, they argue that pharmacists should consolidate their skills and 
focus their knowledge on drugs and medicines, rather than spreading themselves too thinly 
with extended services. 
However, the corporatisation of community pharmacy is seen by some to be undermining 
re-professionalisation (Bush et al., 2009). Indeed, an increasing number of pharmacists are 
being recruited as employees of multiple corporations. These organisations are forced to 
adopt distinct working practices in order to operate economically, effectively and 
competitively. Yet in doing so, they also exert greater control over their workforce. As 
Harding and Taylor (1997) state  
“Successful large bureaucratic organisations require rational routinized procedures 
for maximizing efficiency, and this is reflected in their delivery of rationalized, 
standardized pharmaceutical services dictated by company policies. Thus the 
autonomy of pharmacist employed in such organisations to practice discretion in 
their occupation is precluded”  (Harding and Taylor, 1997: p556) 
These companies have used efficiency as a pseudonym for control and power over 
professional decision making. It has been argued that a future breed of “McPharmacists” 
may be subjected to de-skilling and ultimately perform solely routinized actives (Harding 
and Taylor, 2000). Bush et al (2009) contend that in divergence to patient interest, 
pharmacists working in a supermarket are unable to supply the emergency contraceptive 
pill to those under 16, even if an appropriate patient group direction is in place, due to 
nationwide standard procedures.  
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While some use the commercial imperatives of a community pharmacy as a stick with 
which to beat the profession, it is the same stick that helps to support the profession. Until 
the 19th Century, the public could purchase whatever medication they saw as fit. For 
Chemists and Druggists, their success depended on meeting customer needs. While this 
liberty, have since been eroded by medicines legislation, the underpinning principle of 
responding to the ‘sovereignty’ of the patient remains an abiding principle of pharmacists 
work today.  
Occupational groups have a dynamic relationship with society. They begin to become 
professions through professionalization, can then lose their professional status, ‘de-
professionalisation’, or indeed regain professional status through ‘re-professionalization’.  
In light of the historical development of community pharmacy outlined above, it is evident 
that community pharmacists have passed through these different stages and continue to 
drift between de-professionalisation and re-professionalisation. At the heart of this 
professionalism question lies ‘autonomy’ (Freidson, 2001).  
Autonomy of Practice 
Edmunds and Calnan (2001) (in contrast to Harding and Taylor) furthered the debate on the 
re-professionalisation of pharmacy by suggesting that the extended role of pharmacists’ 
provided an opportunity for the enhancement of pharmacists’ professional status.  Central 
to their argument was the notion of autonomy in practice, which Freidson argues is the 
distinguishing characteristic of a professional (Freidson, 2001).  
The concept of professional autonomy is often depicted in professional definitions as self-
governance and self regulation. As outlined above, regulations imposed since 1997 have 
removed the self-regulation governing many professionals, fundamentally reducing their 
autonomy. Rather than a single entity, Edmunds and Calnan (2001) suggest that autonomy 
can be contextualised in three ways, economic autonomy (control over remuneration); 
political autonomy (position to influence policy decisions); and clinical autonomy (ability to 
make clinical judgements). 
For community pharmacists, their position as retailers would suggest a high degree of 
economic autonomy. However, as discussed later in chapter 3, contractors accrue the 
majority of their income from the NHS, which is predominately governed by the 
negotiations of the PSNC and the occupations elite. Furthermore the majority of 
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community pharmacists are employed, and therefore their economic income is dependent 
on the terms of their employers limiting their economic autonomy19. 
Political autonomy has been difficult to achieve given the political complexities of 
pharmacy. The wide range of career prospects in a profession of a relatively small number 
(circa 40,000) from journalism, industry, academia to the more traditional community 
pharmacy on the high street where the vast majority of pharmacists now practice, limits 
the united identity of this profession creating fragmentation. Although the RPSGB has been 
a professional advocate for the pharmacy profession, its role as both a regulator and a 
professional body has hindered its ability to be a true political advocate. As with any 
political organisation, pharmacy needs a manifesto of which to act. But at present it lacks 
sufficient vision or purpose as to where it should progress. 
Clinical autonomy is limited because pharmacists in the community sit in the shadow of 
physician decision making. The ability to use their clinical autonomy to counter-prescribe is 
restricted by medicines legislation, within stringent product licenses. These licenses have 
enabled pharmacists to supply more medicines – increasing the collective autonomy- but 
under more restricted conditions – decreasing individual autonomy.  
Armstrong (2002), building on a debate raised by Freidson in the 1980s about professional 
organisation revealed the tension between the maintenance of autonomy of the profession 
as a collective and the autonomy of the individual practitioner. To this end, Freidson had 
suggested that an administrative elite, often grouped around the academy and professional 
colleges, was emerging to control the work of individual practitioners. Under this approach, 
the ‘freedom’ of the profession was justified politically by an elite and implemented 
through intra-professional controls over the content of everyday practice (Freidson, 1983). 
Armstrong (2002) observed that ‘evidence based medicine’ has acted in this was to enable 
medicine collectively to resist at least some of the challenges to ‘traditional autonomy’, yet 
in doing so it has limited the individual autonomy of practitioners (Armstrong, 2002).  
Parallel examples of this tension can also be drawn from community pharmacy. For 
example, in 1995 the Royal Pharmaceutical Society instructed all community pharmacists to 
implement protocols covering the procedures to be undertaken when a medicine is 
requested by a customer. This had two functions, on the one hand it formulised practice 
and re-established pharmacists professional role as the gatekeeper to non-prescription 
                                                          
19
 The PDA estimate that 90% of pharmacists are employees or locums.  
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medicines driving up the collective autonomy of the profession to supply proprietary 
medicines. On the other, it limited the individual autonomy of each pharmacist. The RPS 
has since introduced further overt regulation of practice through professional practice 
codes and the creation of independent regulatory bodies20. Indeed, this is in itself a 
‘managerial logic’ of standardising treatments for efficiency and effectiveness.  
However, individual clinical autonomy has also been subject to more covert labour control 
through commercial retail managers from within large multiple run pharmacy 
organisations. This has led to an employer versus employee contest for control. Some 
suggest that this conflict between labour controls exerted by commercial enterprise and 
clinical autonomy is at the heart of the profession’s marginality (McCormack, 1956), a 
dilemma that has been repeatedly observed (Benson et al., 2009). Shaw (1972),  
McCormack (1956), and more recently Bush et al (2009), have argued that an increase in 
multiple owned businesses has been detrimental to professions’ image because 
pharmacists have been pressurized to emphasize their business role at the expense of their 
professional role. Particularly in relation to advanced services, evidence is emerging that 
pharmacy companies are threatening disciplinary action to employee pharmacists who fail 
to meet targets for MURs (Bush et al., 2009). 
The message relayed from this evidence is that both internal and external pressures at the 
economic, political and clinical levels are assaulting the autonomy of individual 
pharmacists. This prevailing trend in pharmacists’ autonomy represents an important 
theme that is explored further in this thesis. 
The Three Logics in Community Pharmacy  
The argument within this chapter goes full circle to return to the arguments  of Freidson 
(2001) described in the early part of this chapter. He contended that there are three logics 
concerning work in society. The first is the well-known logic of the free ‘perfect’ market, 
defined by Adam Smith. It postulates an idealised world (or model) where consumers are 
fully informed about the quality and cost of goods and services and are able to choose 
them rationally, to their own best interest. In doing so, value is measured by cost. In this 
world competition of the free market between suppliers drives efficiency. Put simply, this is 
a world driven by consumerism and the ‘perfect’ exchange of trade. 
                                                          
20 This is an example of the re-stratification thesis. 
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The second of Freidson’s logics is that of managerial control based on the ‘Weberian’ 
perspective of rational legal order. In this world all goods and services are planned and 
controlled by the administration of large organisations. Each organisation, whether private 
or public, is governed by an elaborate set of rules that establish the qualifications of those 
who can be employed to perform different duties. The effective planning and supervision 
of jobs standardises production to assure consumers of reliable products at a reasonable 
cost. In this world managers control those producing goods. The aim is for predictability 
and efficiency. Put simply, this is a world driven by managerialism.  
Finally, the third logic is what Freidson defines as professionalism. In this world workers 
have specialised knowledge that allows them to provide important services with the power 
to organise and control their own work. It is enshrined in law that only these workers can 
offer particular services to consumers. Yet these workers do not abuse their exclusive rights 
because they are more dedicated to doing positive work for their own satisfaction and for 
the benefit of others than maximising their income. Therefore consumers and managers 
know that the work is of high quality at a reasonable cost. This world is driven by 
professionalism.  
As Freidson acknowledges, none of these worlds exist because virtues are accompanied by 
vices. In unregulated markets, consumers must contend with deception and collusion to 
inflate prices. In organisations, inflexibility and monopoly can lead to poor treatment of 
consumers. Occupations may put economic advantage ahead of the good of their clients. 
Nonetheless, the world that we live in experiences elements of all three of these logics, and 
Freidson argues that all of these logics are required to counteract the negative effects of 
the others. Therefore, the policy question is not which of these logics to follow, but instead 
the precise composition of their mix.  
However, we have seen the mix of these logics change over the last century. Consumerism 
and managerialism have both grown in their politically acceptability, meanwhile 
professionalism, which represents occupational rather than consumer or managerial 
control, has suffered a loss. Indeed, the free market ideals of ‘competition’ and ‘efficiency’ 
have become the driving forces within much of policy formation. Furthermore the benefits 
of the private sector and the skilled management of firms have also gained credence. In 
many respects the UK is unique in the extent to which the mix of these logics has changed, 
due to the highly politicised nature of the NHS. However, general trends in decreasing 
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professionalism and increasing consumerism have been experienced in many other 
western countries (Timmermans and Oh, 2010) .  
From this perspective, community pharmacists have also experienced the rise in both 
consumerism and managerialism. It is argued that these imposing logics have swung 
regulation from a position of protecting the interests of occupations to protecting the 
interests of the consumer. In doing so, the ‘market shelter’ afforded by professional status 
has been subject to greater regulation and bureaucratic control.  
So far this thesis has explored current professional models of community pharmacy in light 
of the dynamic mix of the three logics in community pharmacy. The question to be 
considered is how these logics will progress in the future, and which will become the 
dominant force for community pharmacy business and professional models in the future. 
Indeed central to this is whether pharmacy is deserving of the third logic, professionalism, 
at all.  
Defining the Research Question 
The traditional functions of NHS community pharmacists and pharmacies were eroded 
during the first half of the twentieth century because of a transfer of responsibility for 
medicines manufacture to the pharmaceutical industry. This affected the social standing of 
the profession, as in the second half of the century did factors such as the extension of the 
‘prescription only’ medicines category and increased (original pack) dispensing volumes. 
The latter decreased pharmacists’ contact with the public as prescription volumes 
increased, while the former almost certainly impacted negatively on pharmacists’ 
perceived authority in the UK. 
Since 1948 the rising tide of prescriptions also acted to financially support community 
pharmacy businesses. They were, and are, paid a premium for the skilled services of 
pharmacists in medication supply.  But recently even this source of security has been 
challenged. Computer and allied technological advances that have increased the level of 
automation in the supply process, and now even threaten to replace human labour in 
‘cognitive service’ contexts such as giving information and advice. 
Such trends may lead government and other service funders to question whether or not 
the premiums paid for the expertise of pharmacists in the supply of prescription medicines 
are required. In this country policy documents have from the early 1980s onwards 
repeatedly described pharmacists as being ‘under-utilised’. This suggests that the centrality 
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of pharmacists to medicines provision is decreasing and/or that activities such as 
dispensing alone are being questioned as an adequate core foundation for professional 
status. A possible implication is that a more direct health improvement role is increasingly 
being expected. 
Wider societal trends have also led to questioning of previously accepted ‘paternalist’ 
professional practices and opened the way to relatively assertive forms of consumerism in 
the health sectors of ‘developed’ societies. The extent to which this has as yet happened 
should not be overstated. But increasing ‘lay knowledge’ of medicines and the 
determinates of their appropriate use is arguably ‘de-mystifying’  pharmacists’ (and to an 
extent medical doctors’) roles through a weakening of their exclusive ownership of the 
knowledge base that defines their professional ‘territory’. Even ignoring the significance of 
issues such as those relating to the supply of drugs in non-pharmacy outlets such as 
supermarkets and petrol forecourts, the ‘normalisation’ of many medicines seen not long 
ago as being at the cutting edge of scientific advance means that step-by-step the power 
enjoyed by pharmacists by virtue of their ‘agency relationship’ is declining.   
Such trends point towards the ‘commoditisation’ of medicines supply. That is, the pushing 
down over time of unit dispensing fees to the lowest possible level consistent with public 
interests in safety and sustainability. Alongside – and possibly as a result of such pressures 
– the growing ‘corporatisation’ of pharmacy businesses in settings like that of the UK has 
led to an increasing number of pharmacists being recruited as employees. To promote 
efficiency and quality as defined in their terms, large bureaucratic pharmacy enterprises 
have implemented standardised practices and procedures, which act as a form of work 
control. Such procedures serve to limit individual professional ‘autonomy’ and arguably to 
weaken the traditionally defined professional status of pharmacists. 
Reforms across the health care sector have in addition led to a rebalancing of external 
power and dependency relationships.  Hence pharmacy is no longer self-regulated. Instead, 
the State has created the General Pharmaceutical Council, which is not answerable to the 
profession’s members but ultimately to the public being served. Together, these forces 
may be taken to be driving a ‘de-professionalisation’ of pharmacy, characterised by 
pharmacists’ power over their own working environment being systematically reduced. 
The political elite or leadership cadre of the profession has attempted to counteract this 
trend towards ‘de-professionalisation’ by re-branding pharmacists as ‘clinical’ practitioners, 
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and by building on the successes achieved by hospital pharmacists in the 1970s. Members 
of the leading elite have attempted to move community pharmacy on from its ‘traditional’ 
technical and logistic function towards a new health care focused paradigm. This has 
manifested itself under many names, including ‘medicines management’, ‘role extension’, 
‘pharmaceutical care’, ‘medicines optimisation’ and ‘public health pharmacy’. All these 
terms suggest that pharmacists should embrace roles that support patients (pharmacy 
service users) to take medicines and behave in ways that further enhance health outcomes. 
These approaches may be seen as ‘re-professionalisation’ strategies. But in seeking to 
introduce them there is an associated ‘re-stratification’ of professional responsibility. Seen 
from this perspective, the leaders of pharmacy in Britain (like those of medicine)  have 
acted to extend managerial control over individual pharmacists through putting in place 
standardised procedures and new forms of control in order to retain  more internal 
professional authority than would otherwise be possible. This has involved a subtle shift in 
the nature of professional, away from an emphasis on individual self-realisation towards 
collective discipline.  
There has been, and remains, much debate as to the details of the strategies the evolving 
profession should embrace.  Anderson (2002) has argued, for example, that a role in public 
health promotion should form a significant part of pharmacy ‘re-professionalisation’, albeit 
that he has subsequently stressed that placing too much emphasis on seeking effectively to 
change health behaviours could result in common failure (Anderson, 2012). Taylor and 
Harding (1997) suggested that pharmacy should consolidate its knowledge and focus on 
making medicines ‘meaningful social objects’, while Edmunds and Calnum (2001) 
contended that the most appropriate path towards ‘re-professionalisation’ runs via 
‘extended clinical roles’. 
There is disagreement both internally and externally as to the best way to progress. But 
what is clear is that any successful ‘re-professionalisation’ strategy will probably need to be 
cognisant of (or at least consistent with) both the commercial contexts within which 
pharmacists and pharmacies operate, and the profession’s wider social environment. With 
respect to the latter, powerful external influences like that of the medical profession as 
well as public and political  expectation may force (or require) pharmacy to develop down 
paths that are not necessarily the most rational or beneficial from an internal standpoint. In 
practice, no successful way forward can afford to ignore such realities. 
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Against this background and the current high degree of uncertainty regarding the part that 
(community) pharmacists will in future be able to play in health care this thesis seeks to 
understand and interpret data relating to the future business and professional 
development paths for pharmacy in England. It seeks to balance and explore the competing 
logics of commercialism, managerialism and professionalism, and address the central 
question: 
How are business and professional practice models for community pharmacy in England 
in ten to twenty years time likely to be structured? 
This was to be achieved through: 
 Investigating the current practice of community pharmacists in England through a 
work sampling study (Chapter 2); 
 Exploring the economic drivers behind current community pharmacy workload and 
practice (Chapters 3 and 6); 
 Exploring the facilitators and barriers to the implementation of services into 
community pharmacy (Chapter 4); 
 Mapping the development and implementation of policies in community pharmacy 
(Chapter 4 and 5);  
 Analysing stakeholder perception of the future of pharmacy practice (Chapter 5); 
and 
 Discussing future strategies for community pharmacy businesses (Chapter 7). 
Chapter Conclusion 
This chapter has sought to provide a thorough introductory grounding for the original 
research presented in the following chapters. Its main goals were to present a critical, 
comprehensive and structured overview of the literature relating to professional groups, to 
explore relevant aspects of the historical development of community pharmacy in England 
and to document the successive policy interventions that have sought to change the 
professional practice of community pharmacists.  
Arguably, professional progress in all fields in part reflects political and economic struggles 
to attain and maintain control and autonomy in specific areas of activity, and to protect 
territory in the labour market in order to secure income and favourable working conditions. 
Seen from this viewpoint pharmacy as a profession, and particularly pharmacists working in 
the community, have during the twentieth century struggled to assert their identity and 
protect their economic and related interests. Pharmacy can be said to have undergone a 
process of ‘de-professionalisation’.  
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This has led various academics, politicians and social commentators to write the obituary of 
the profession, arguing that pharmacy is no-longer deserving of such a special status in 
society. As noted above, the profession’s members’ place in their traditional domain of 
work, medicines manufacturing, has been lost to the pharmaceutical industry. Pharmacists’ 
working conditions and practices are now rarely controlled by pharmacists themselves, but 
rather by (public and private) bureaucratic managerial structures. These may be supported 
by the profession’s political leaders, who as in other professional contexts may seek to 
exert further control over ‘their membership’ in order to defend collective status. At the 
same time other social changes are placing more power in the hands of patients and 
consumers, and shifting the nature of the agency relationships between pharmacists and 
those they serve.  
Such factors, when looking ahead to what follows in this thesis, may mean that as the 
twenty first century unfolds community pharmacy will cease altogether to exist in its 
current form. However, the conclusion offered in this thesis is that (community) pharmacy 
could rebound from this situation by incrementally re-defining its role and purpose. In his 
later work Freidson offers a lifeline for all professional groups by arguing that they have a 
legitimate and vital place in societies as and when they provide a form of settlement that 
neither market forces nor managerial structures can alone achieve. Community 
pharmacists have an opportunity to justify their professional status by demonstrably 
providing benefits to society that require the continuation of market shelters to provide 
protection from both counter-productive competition and inadequately informed external 
managerialism. 
Seen from a financial perspective, pharmacists will only be able to attract premium 
incomes if they are able to show that their role in medicines supply and health care more 
broadly is more than simply a technical and logistic supply function, but instead a facet of 
health improvement to be achieved through the application of their unique abilities in 
areas such as risk management, safety, and service support. Such a justification of 
pharmacy could represent an effective ‘re-professionalisation’ strategy, provided that it is 
genuinely based on value-adding contributions to enhanced public welfare rather than 
rhetorical sectional claims. With this in mind the next chapter turns to the question ‘what 
do community pharmacists presently do?’ 
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Chapter 2. What do Community Pharmacists 
do? 
 
Chapter Introduction 
As described in the previous chapter, pharmacists who once occupied their time 
compounding drugs into medicines are instead preoccupied with the comparably simpler 
manipulative tasks of dispensing pre-packaged dosage forms.  This has moved pharmacists 
from being the creators of medicines from raw drugs, towards being the guardians of safe 
medicines supply. As this role change has taken place, successive policy documents have 
indicated the ‘under-utilised’ nature of community pharmacy, suggesting that pharmacists 
can use their scientific and clinical skills to greater effect (e.g. Department of Health, 
2008a). However, it is unclear as to whether pharmacists are really ‘under-utilised’ or 
whether this is simply the rhetoric of the political elite to mask a re-professionalisation 
strategy. Therefore this chapter sets out to interpret this claim by finding out what 
community pharmacists actually do, by conducting a work study (Emmerton and Jefferson, 
1996). 
This chapter describes and contextualises current community pharmacy practice in England 
and outlines the current path from which future activities in community must progress21. 
The second section of this chapter describes a work sampling study conducted in 
community pharmacies across London, which is compared to a structured review of 
previous work sampling literature to establish how policy developments have affected 
community pharmacy practice over the past few decades. This allows conclusions to be 
drawn about the effectiveness of current policies designed to change pharmacists’ patterns 
of work.  
However, there are many different methods of observational research used in pharmacy 
practice, each with their own relative advantages and disadvantages.  Therefore 
justification for the methodological approach adopted here provides the opening to this 
chapter. 
  
                                                          
21 This forms the basis for the exploring the path dependency of community pharmacy policy. 
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Methods of Observational Research in Pharmacy 
The arguments put forward for studying the work practices of individuals began in the early 
industrialisation. It became recognised that understanding and then manipulating work 
practices could lead to superior employee performance and in turn superior organisational 
productivity. The origin of these techniques are often attributed to the social reformer 
Robert Owen, who in the early 19th century introduced an allocation of time for rest in 
order to allow workers to recover from fatigue which in turn improved production.  
This work was furthered by Frank and Lillian Gilbreth. As a young building contractor, Frank 
discovered ways to make bricklaying a faster and more efficient process and sought to 
apply this efficiency elsewhere. The couple studied the work habits of manufacturing and 
clerical employees in all sorts of industries to find ways to increase output and make jobs 
easier. In doing so they reduced all of the movements of the hand to a basic set of 17 
motions, which they named the therbligs (a reversal of Gilbreth). The individual elements 
such as grasp, and assemble, were recorded against time, creating the first ‘time and 
motion’ studies (Gilbreth, 1911).  
These methods of work measurement were developed by industrial engineers and have 
since been applied across a range of settings, including healthcare. The popularity of work 
measurement rose in the last decade as a result of the development of ‘lean production’ 
and ‘total quality management techniques’ imported from Japanese car manufacturers. 
These approaches helped the Toyota car company to create successive gains over their 
competitors (Liker, 2004). As a result of the apparent advantage produced by these 
techniques, lean approaches were applied in many different settings, including an inpatient 
pharmacy (Hintzen et al., 2009). As a result the methodologies of work study have been 
subject to increased scrutiny from companies seeking to implement the lean principles of 
continual identification and elimination of waste. 
The benefits of work study as a management tool in pharmacies has not gone unnoticed. In 
the 1970s work study formed a feature in the Chemist and Druggist magazine (Downing, 
1970), and has since been used in both community and hospital environments around the 
world (Savage, 1999). Rutter et al, (1998b) and Rascanti et al (1986) both offer reviews of 
the work study techniques and methodologies used in assessing the work practices of 
pharmacists. 
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In their review of the methods (primarily based on hospital pharmacists in the USA), Rutter 
et al (1998b) categorised the work study techniques used in pharmacy practice research 
into seven categories (table 2.1): Subjective Evaluation; Self-Reporting; Productivity Data; 
Direct Time Study; Standard Time Study; Work Sampling; and Multidimensional Work 
Sampling. This review analyses each of these methodological approaches in turn with a 
view to justifying the technique chosen in this thesis.  
Table 2.1– Work Study Method in Pharmacy 
 
Method Description 
Subjective 
Evaluation 
Workers estimate at the end of the day how much time is spent on tasks 
Self Reporting  Use of worker time on various elemental tasks is recorded in log or diary.  
 
Direct Time Activity is separated into discrete tasks with observable beginning and end 
points. Observer times each elements as it is performed. Particularly 
effective for workload of repetitive tasks.   
Productivity Data Work is separated into “units” which can be compared with personnel 
time 
Standard Time Standard time is the average time for a fully trained operator to perform 
an activity at normal pace 
Standard data system – standard times for a job reported are collated and 
analysed to provide a standard time 
Pre-determined time systems – based on a detailed description of an 
activity, an observer assigns a time value to each hand and body 
movement. These are summed to provide the time necessary to perform 
a unit of work 
Work Sampling At random or fixed intervals, an observer or the worker, records the 
activities being performed. 
The proportion of observations for each activity relate to the total number 
of observations approximates to the percentage of time staff spend on 
each activity. 
Multi-dimensional 
work sampling 
Jobs are broken down into dimensions. These are measurable aspects of 
task and job related behaviour (activity, function and contact). At random 
intervals, staff self report the dimensions of an activity being undertaken.  
(based on Rutter et al., 1998b; Rascati et al., 1987; James et al., 2011) 
Subjective Evaluation 
This is a method of work measurement by which a subject estimates the amount of time 
spent on various activities based on personal judgement, past experience and tradition. In 
this approach jobs are first deconstructed into discrete tasks, and then participants are 
asked to estimate how much time is spent on each of the tasks, usually in the form of 
questionnaires.  These questionnaires are relatively easy to administer, interpret and are 
able to provide valuable cognitive information.  
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The method has been used in both hospital and community settings (Oddone et al., 1993; 
Roberts et al., 1982), but has been reported to be imprecise, due to overestimation biases 
created by recent events (Sittig, 1993); biases towards professional activities (Nickman et 
al., 1990) and social desirability (Laurier and Poston, 1992). Therefore, Robertsen (1982) 
suggests that estimates can deviate from measured standards by about 25% on average, 
and should not be used for obtaining labour standards. As a result its main utility lies in 
formulating hypothesis or indicating worker perceptions that highlight areas of future 
research interest (Rascati et al., 1986). One example of this from the United States 
(Schommer et al., 2006) highlighted the gap between the desired and actual time spent by 
pharmacists on various activities. However, Rutter et al. (1998a) validated a subjective 
evaluation of tasks performed by community pharmacists across a large multiple in England 
by using a work sampling technique (Rutter, 1999). The consistency of results found 
between the two methods may be due to the potential for inaccuracies being more 
appropriate to repetitive work of single activities as opposed to the varied tasks of 
community pharmacy (Nickman et al., 1990). Indeed, this technique has subsequently been 
used to assess different aspect of community pharmacy work. For example Humphries et 
al. (2008) evaluated the impact of an automated dispensing machine in an outpatient 
pharmacy, while Terry and colleagues (2011) used this approach to discover that hospital 
prescriptions took significantly longer to dispense in the community when compared to 
general practice prescriptions.  
Self Reporting 
Self reporting relies on workers documenting work units in a continuous diary or log. As 
with subjective evaluation this method allows for personal biases and data collection 
inaccuracy that can lead to imprecise results, although these biases can be minimised by 
clearly informing workers of the purpose and importance of the study (Roberts et al., 
1982). Although Rutter et al. (1998b) suggests that the potential for inaccurate results 
using this methodology are high, time standards derived from self reporting are said to be 
better than subjective evaluation estimates. As a technique it is relatively inexpensive. It 
allows for cognitive activities to be reported (Nickman et al., 1990) and can generate large 
amounts of data in a short period time. It is particularly useful for tasks that involve 
cognitive processing (e.g. prescription monitoring and clinical ward work; Barber et al., 
1993) or when participants are constantly on the move (e.g, nights shifts of junior doctors, 
McKee and Black, 1993).  
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Self reporting can be aided by data collection tools such as time-ladders, where one column 
lists the time in minutes, with an adjacent column left blank for participants to record the 
coded activity. A line is drawn across the column when one task starts and another stops. 
Mackewicz (1983) used this self reported approach to develop time standards for 
pharmacy personnel. More recently Robinson and Stump (1999) used this method as a 
management tool to help benchmark pharmacists time and track clinical pharmacists’ 
patterns of work.  
Productivity Data 
Although Rutter and colleagues (1998b) refer to these approaches as productivity data, it is 
often termed ‘statistical data’ in the literature. Productivity data requires the recording of a 
number of work units completed (e.g. prescriptions dispensed) by a subject compared to 
personnel time (Roberts et al., 1982). This can then be used to establish ratios of work units 
per unit time. This is of particular use in pharmacy workforce planning to create gearing 
ratios for prescription dispensing (John, 2008). In the hospital environment Cooper and 
Zaske (1988) compared pharmacy work tasks with hospital census data to show that 
decreasing the duration of stay in hospital led to nearly a threefold increase in pharmacy 
workload. More recently Rough and colleagues (2010) reasserted that this method can be 
used to create bench markers that help measure the  impact of pharmacists on patient 
care. The advantage of this method is that it can be used in situations where detailed 
studies are not required. This provides results that are approximate, but provide an overall 
picture of the activity being investigated. However, as this method focuses on complete 
‘units of work’, it fails to take into account factors such as clinical intervention or cognitive 
processes associated with each unit.  
Direct Time Study 
According to James and colleagues (2011) direct time study is the ‘gold standard’ method 
for measuring workload and has been shown to be a highly precise, accurate and consistent 
(Emmerton and Jefferson, 1996). This labour intensive method is sometimes known as the 
‘stop watch’ technique, as a one-to-one observer records exactly how much time is being 
devoted to each task over extended periods of time (Finkler et al., 1993). For this reason 
direct time study is most appropriately applied to highly repetitive technical tasks, where 
work is divided into short elements that have a logical sequence (Rascati et al., 1987). 
Therefore its application in the pharmacy literature has often been used to measure 
workloads associated with sterile manufacture. For example, this method has been used to 
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investigate different automated and manual processing techniques for chemotherapy 
(Patel et al., 2006), to form the basis for a full cost evaluation of the dispensing and 
administering of fluorouracil (Simon et al., 2010; Suh et al., 2010), to compare different 
infusion techniques (Florea et al., 2003; Sahni et al., 2007) and to compare outpatient and 
community chemotherapy preparations (Brixner et al., 2006).  
The technique has also been used outside of sterile products to: discover baseline data on 
prescription dispensing times (James et al., 2011); evaluate the effects before and after 
computerisation in an outpatient pharmacy (Moss and Pounders, 1985; Unertl et al., 1984); 
build model projections of a hospital dispensary (Reynolds et al., 2011); calculate standard 
time in Thailand for each element of outpatient and inpatient pharmacy services (Wisai et 
al., 2007); discover the feasibility of a robotic courier medication delivery system (Kirschling 
et al., 2009); assess the needs for clinical pharmacist staffing levels in Australian hospitals 
(O'Leary et al., 2010); and study the time taken to produce a label for individual patient 
medication (Ngo et al., 1992).  
Although this method has been used to evaluate the counselling practices of community 
pharmacists in Iran (Garjani et al., 2009) and the time taken to process repeat prescriptions 
in the UK (Ashcroft et al., 2006), its application in the community pharmacy setting has 
been limited (Rutter et al., 1998b). This may be because the varied nature of pharmacist’s 
work makes it difficult to use this method in practice, coupled with the expense of one to 
one observation.  
Standard time study 
Standard time study is a technique used to determine the average time for a fully qualified 
and trained operator to perform an activity when working at normal pace, previously 
determined by other work measurement techniques (Mobach, 2008a). These standards can 
then be used as targets to incentivise workers. Strictly speaking this is not a separate 
technique, instead relying on the other methods detailed in this section to develop 
standards.  
The approach can be categorised into two classes; standard time systems and pre-
determined systems (Rascati et al., 1987; Rutter et al., 1998b). Standard time systems 
commonly refer to large scale or macroscopic systems where studies of related tasks are 
collated to create a standard time from a particular task. By contrast, pre-determined time 
systems tend to be more microscopic in data where precise time values are assigned to 
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specific hand and body movements. Using this data the time required for a unit of work can 
be built up. The applicability of predetermined time studies in pharmacy practice is limited 
due to their complexity, although efforts have been made to use standard time systems in 
secondary care (e.g. Bartscht et al., 1965; Hammel et al., 1977; Buchanan, 2003). This 
approach has led to the creation of benchmarks and targets for specific pharmacy activities 
(Mitchell, 1996) and more recently to simulate how long clinical pharmacists should spend 
on the wards (Dean et al., 1999). 
Work Sampling 
Work sampling is the most common work study technique used in health services research 
and has been applied in pharmacy (e.g. Bell et al., 1999; McCann et al., 2010a), dentistry 
(e.g. Marklin and Cherney, 2005) and nursing (e.g. Upenieks, 1998). Work sampling studies 
collect a large number of observations recorded into pre-defined, mutually exclusive 
categories, taken at either fixed or random intervals of time. For example, data may be 
sampled randomly six times an hour, or precisely every 10 minutes, to determine exactly 
what a worker is doing. The data is often collected by a trained observer (Rutter et al., 
1999), but may be self reported by the study participants (e.g. Bell et al., 1999; McCann et 
al., 2010a). With sufficient sampling, the observed frequency of an activity can be said to 
reflect the proportion of time that is spent on that activity.  
One use of work sampling in pharmacy has been to document baseline work activities (e.g. 
Bell et al., 1999). However, the most common use of this technique in pharmacy is to 
assess changes in work patterns following the implementation of a technology ( e.g. 
Franklin et al., 2007; Lin et al., 2009b; Lin et al., 2007) or to compare activities following a 
change in work conditions (e.g. Schneider and Nickman, 1997; Schneider and Nickman, 
1998; Lin et al., 2003a).  
Savage (1999) presented a review of work sampling approaches in community pharmacy 
over the previous twenty years and showed that this technique had been used around the 
world. More recent examples of the techniques being used internationally include Thailand 
(Ploylearmsang et al., 2003), the US (Lin et al., 2003b) and South Korea (Ryu and Kim, 2003; 
Ryu et al., 2002). 
Multidimensional work sampling 
Although work sampling has been used extensively to observe technical tasks, the 
traditional technique lacks utility in measuring cognitive processes. Therefore the multi-
 
 
74 
dimensional work sampling technique was developed to measure problem solving and 
clinical thought in professional, executive or highly technical positions by analysing the 
different dimensions of the job as opposed to an individual’s activities. Using the self 
reporting techniques, participants record their own activities at randomly generated times 
using portable bleeper devices as a reminder. When a bleep is emitted, the participant 
chooses one item from each dimension. Although this approach can therefore be labour 
intensive, Robertsen (1982) suggests over a full day this only takes participants 
approximately ten additional minutes. As with other methods of self-reporting, concern has 
been expressed about the possible falsification of results (Hall and Rupp, 2001), although 
this may be limited by the large number of interrelated records that are collected (Ampt et 
al., 2007). 
The dimensions assigned to any job will vary according to the objectives of the study, 
although invariably three dimensions; activity, function and contact are used. Other 
dimensions, such as location, may be added where applicable. For example, activity is the 
context of the task, such as using a phone; the function relates to the purpose of that task, 
such as clarifying a dose; and the contact refers to the person, such as a junior doctor. 
Beech and Barber (1993) were the first to use this method to measure ward pharmacists’ 
work in the UK, which had previously been used in  the US (Ried et al., 1991) and has since 
been replicated in Japan (Hamai et al., 2001). Subsequently the method was used in 
community pharmacy settings by Dupclay et al. (1999) who analysed the work behaviours 
of grocery chain pharmacists in the USA, finding that 46.3% of time was spent on only 10 of 
a possible 1,760 activity-contact-function combinations. Further studies in Holland have 
successfully demonstrated the use of multi- dimensional work sampling in community 
pharmacy (e.g. Mobach, 2008a; Mobach, 2008b).  
Methods of Work study 
The techniques described above all represent different methodological approaches to work 
study in pharmacy settings. Each of these approaches has their own relative advantages 
and disadvantages, described in table 2.2 below.   
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Table 2.2 - Comparison of the different methods  
(based on Rutter et al., 1998b; Rascati et al., 1987; James et al., 2011) 
Method Advantages Disadvantages 
Subjective Evaluation Provides indicators of work patterns 
Useful for formulating hypothesis 
Can be used to assess worker perceptions 
Inexpensive 
Highly subjective and therefore can be 
imprecise 
Over or underestimation is possible 
 
 
Self Reporting  Creates large amounts of rich data quickly 
Self-reporting allows cognitive activities to be 
recorded 
Can be used for mobile subjects 
 
Relies on staff being highly motivated to 
record activities 
Time consuming and can be imprecise without 
observer training 
Direct Time If well designed it can accurately assess 
workload 
Often used to validate other techniques 
 
Hawthorne effect may influence the behaviour 
of staff 
Observers must be trained 
Reliability required if more than one observer 
used 
Productivity Data Easy application 
Output information only 
Units of work can be difficult to define for 
activities that cannot be easily timed  
Requires access to historical data 
Standard Time Enables comparison of productivity and 
staffing thereby facilitating manpower 
planning. 
Difficult to apply 
Time-consuming 
Resource intensive 
Requires review and refinement to ensure the 
unit of work remain accurate 
Work Sampling Allows simultaneous study of several workers 
Can be applied to repetitive and non repetitive 
tasks 
Easy to apply and inexpensive 
Sampling strategy can be used to reduce bias 
introduced by continuous workload 
measurement techniques. 
Observers require training and must be 
familiar with the tasks 
Data collection must be sufficiently long to 
ensure all activities are observed  
Production of a discrete, mutually exclusive 
categories can be challenging 
 
Multi-dimensional work 
sampling 
Accurate assessment of professional and non-
technical activities 
Relies on willingness of staff to report  
 
Designing a Work Study in Community Pharmacy 
Assessment of the relative advantages and disadvantages of the work study methods is 
described above (table 2.2). The purpose of this study was to discover what pharmacists 
spend their time doing. Of the methods, subjective evaluation, self reporting and work 
sampling are the most appropriate methodological approaches that allow for the 
proportion of time that pharmacists spend on different activities to be calculated. Yet the 
bias and additional workload for the participant created by subjective evaluation and self-
reporting makes observed work sampling the most preferable technique. The challenge 
with observed work sampling is the creation of discrete, mutually exclusive categories and 
the resource intensive nature of observed research. However these disadvantages are 
deemed to be smaller than the bias and workload created by the alternative techniques.  
On this basis a work sampling methodology was selected as the technique of choice. 
Central to the success of any work sampling study is the categorisation of work activity, and 
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the appropriate sampling of work to ensure reliable results. The process by which this was 
achieved is described in the method section below.  
Materials and Methods 
Coding Framework 
Work sampling relies on the activities of pharmacists being classified into mutually 
exclusive categories. Previous activity categories from published literature were reviewed 
(Rutter et al., 1998a; McCann et al., 2010b; Fisher et al., 1991; Bell et al., 1999; Savage, 
1997; Dupclay et al., 1999). These were collated, modified and altered to bring them up to 
date with current UK community pharmacy practice. A working draft of this framework was 
tested in two community pharmacies outside of the study area with a newly constructed 
data collection form. Following the pilot, the framework was revised and reviewed by three 
practicing community pharmacists to create 18 mutually exclusive categories (table 2.3). 
Activities were grouped into professional, semi-professional and non professional activities 
through interpretation of a previous frameworks (McCann et al., 2010b). 
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Table 2.3– Coding Framework 
Activity Classification 
1. Prescription monitoring and appropriateness  
Interpretation of the Rx including checking the correctness of the dispensed item. Includes 
checking the indication for drug, suitability for patient, e.g. interactions with other medicines. 
Appropriate dose of each medication. Contacting the prescriber if necessary. Includes ensuring 
that the product is dispensed as prescribed, e.g. checking any product assembled by dispensary 
technicians, as well as the legality of prescription. 
Professional 
2 Assembly and labelling of products  
Includes the assembly of the product requested on the prescription and generating labels for the 
container of that product. The process of assembling a prescription [Rx] item from receipt to the 
final assembly of the product, including the endorsement and filling of an individual prescription. 
Semi- Professional 
3  Endorsing prescriptions and clerical health related work  
Includes preparing the end of month returns to the Drug Pricing Authority, coding prescriptions 
etc., directly related to health provision. 
Professional 
4 Counselling patients on prescribed medicines 
 Includes personally giving out the medication to the patient and providing information on disease 
state, medicines supplied, side-effects, dose etc. 
Professional 
5 Non-prescription medicines counselling/responding to symptoms 
Includes listening to any problems, advising on problems either to patients or counter staff, 
recommending a non-prescription medicine or referring the patient to a GP. 
Professional 
6  Professional encounter with non-patients 
Discussing new drugs with company representatives, contacting the Pricing Authority etc. 
Professional 
7 Health Related Communication 
An activity or function that involves any aspect of health provision, written or verbal, that is not 
direct counselling to patient. Including advice to GPs.  
Professional 
8 Provision of Advanced Services 
This relates specifically to Medicines Use Reviews  
Professional 
9 Provision of Enhanced or other NHS Services 
Conducting any additional services that are provided by the pharmacy. e.g. Medicines supplied via 
PGD (EHC etc.). Smoking cessation advice via PGD 
Professional 
10 Provision of Private Enhanced Services 
Conducting any additional services that are provided by the pharmacy e.g. Medicines supplied via 
Private PGD or paid for vaccinations.  
Professional 
11  Provision of services to homes 
As 1 and 2 but directly related to residential and nursing homes. 
Professional 
12 Inventory and Stock Control 
Includes stock maintenance of prescription-only medicines (dispensary) and non-prescription 
medicines (counter) or of non-medicinal products (perfumes/baby products etc.). 
Non- Professional 
13  Staff training and Education 
Includes any training given to new and existing staff, work experience students, e.g. formal 
training for dispensary staff. 
Professional 
14 Housekeeping 
Includes General maintenance and cleaning of the work place including merchandising of 
dispensary or non-dispensary areas.  
Non- Professional 
15 Sales Transactions 
The selling of goods between vendor and purchaser, for non health related products, such as 
perfumes.  
Non- Professional 
16 Money and Managerial Administration 
Includes all clerical work such as dealing with mail, filing etc. An activity not involving any aspect 
of healthcare. Functions that the person in charge must do for the business to run effectively. 
Includes wages, tax returns, balancing cash at the end of the day etc. 
Semi- Professional 
17  Rest Waiting and Personal time 
Includes lunch and tea breaks, resting and toilet breaks etc or Time when the pharmacist is being 
unproductive. 
Non- Professional 
18 Non-professional encounters 
 Includes gossip and general chat with non-professionals, e.g. talking about the weather with a 
customer. Advising customers on non-healthcare related products e.g. perfumes  
Non- Professional 
 
Observational Approach 
Although Robersten (1982) argues that it is difficult to deliberately bias self reported data 
as one participant would not intentionally try to be out of step with others, self-reported 
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data is generally considered less reliable, as workers often do not record activities in a 
timely fashion, and may not be totally frank concerning what activities were being 
undertaken at the specified time resulting in bias. For this reason direct observation was 
the preferred method. However, this requires additional people as observers (Oddone and 
Simel, 1994), who can produce a Hawthorne effect (Savage, 1996), distract professionals 
who do not like being observed (Emmerton and Jefferson, 1996) and may bring bias into 
the study through their interaction with staff (Rascati et al., 1987). While it is recognised 
that some of these effects can be mitigated through the use of one way mirrors (Finkler et 
al., 1993) and video surveillance (Lin et al., 2009a), they are impractical in confined 
community pharmacies. Therefore discrete direct observation was deemed to be the most 
appropriate approach.  
Observer Training 
Nine third year pharmacy students and the study coordinator were trained to observe 
community pharmacists. Pharmacy students were chosen as they have been used as 
observers in previous studies (Rutter et al., 1999; Nelson et al., 1977), and are familiar with 
the work of pharmacists, an important aspect in work sampling (Rutter et al., 1999). 
Ensuring reliability between observers necessitated extensive training.   
Firstly, the observers were briefed on the method, introduced to the study and provided 
with background material to read. Secondly, they were given a written questionnaire to 
assign categories of practice to gain familiarity with the coding framework. Thirdly, the 
observers practiced observational techniques through coding a series of videos of 
community pharmacists in a training session using the pre-tested data collection forms. 
Discrepancies between observers were discussed until observers recoded in a consistent 
way. Previous studies have reported that observers must correctly assign 90% of 
observations to be deemed competent (Rascati et al., 1987; Rutter et al., 1999). Fourthly, 
consistency was tested with a new video in which all observers correctly assigned more 
than 90% of the observations. Fifthly, the study co-ordinator also coded with the students 
at different times throughout the observation period to ensure consistent coding whilst at 
study sites.  
The focus of data collection was on the time spent by the pharmacist. Only one pharmacist 
was observed at any one time. Where two pharmacists were present, the regular 
‘responsible pharmacist’, was the subject of observation. However, data about the number 
of other staff present during each time period was collected to allow for analysis of the 
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effects of staff on the allocation of roles, as well as the average number of prescriptions 
dispensed per month (table 2.4). In situations where the pharmacist was performing more 
than one activity simultaneously, the observers made a subjective decision about which 
activity predominated as practiced in previous studies (Summerfield et al., 1978).    
Sampling Approach 
Given that fixed interval sampling is comparable to random sampling in community 
pharmacy practice due to the non cyclical nature of community pharmacists’ work 
(Dickson, 1978) and that fixed interval is simpler and cheaper because specialised random 
generation devices are not required, a one minute fixed interval sampling approach was 
chosen.  
Sample Size 
Work sampling studies require a large number of observations over a sufficient period of 
time to allow confidence in inferences made from the results (Ampt et al., 2007).Previous 
studies have reported that between 5-10% of pharmacists time is spent counselling 
(Savage, 1997; Savage, 1999). As a result it was decided that 8% be used as an estimated 
percentage for calculating the one minute fixed interval sample size (McCann et al., 2010b). 
Equation 2. 1 – Sample Size Equation 
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p = fraction of time believed to be spent on the activity of greatest research interest. (0.08, 
i.e. anticipate 8% of time will be spent counselling). 
a = 1.96 (based on a 95% confidence interval) 
I = Width of the confidence interval (0.01) Confidence interval width, I is 0.01, meaning 
that the estimate of proportion will span from 0.08 + 0.005 to 0.08-0.005,ie. Half of the 
confidence interval  
N= minimum number of observation required 
 
  
 
 
80 
Equation 2.2 – Calculation of Sample Size 
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A total of 11,310 observations will measure an activity at this frequency with and accuracy 
of ± 5%. In order to obtain 11,310 observations a one minute sampling frame was tested 
during the pilot which was shown to be practical, equivalent to 118.5 hours of observation.  
Selection of Study Sites 
For purposes of practicality, ten community pharmacies were selected from across the 
London area. These were purposefully selected from a ‘convenience’ sample to represent 
the four different categories of community pharmacies, namely traditional, specialist, 
health and beauty led and supermarket pharmacies (Department of Health, 2008a). Of 
these, five pharmacies were from large multinational chains with the remainder from the 
independent sector (table 2.4).  
Due to the inclusion of ten pharmacies, this equated to 1,131 observations per pharmacy, 
or with one minute sampling, 18 hours and 51 minutes of observation per pharmacy. In 
order to ensure an even spread of data across the days of the week and the opening times 
of the pharmacy, 20 hours per pharmacy was set a target, equivalent to 12,000 
observations. The observers visited the pharmacists at different times of day across the 
opening hours of the pharmacies providing an even spread of data collection throughout 
the week. Pilot work demonstrated that collecting data for longer than four hours per day 
was unfeasible due to observer fatigue. 
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Table 2.4- Demographic Data 
Pharmacy No. of 
pharm
acists 
observ
ed 
Pharmacist 
status and 
code 
Pharmaci
st gender 
Pharm
acist 
estima
ted 
age/ye
ars 
Mean no. 
of: 
Technicians
; 
Dispensers; 
Counter 
assistants; 
Pre-reg. 
Students* 
Mean 
monthly 
prescripti
on 
volume 
/items 
Pharmacy 
type 
Opening 
hours 
 
A 
 
1 1a regular  Male 32 1.93 
0 
0.18 
0.95 
3500 
 
  
Specialist Mon-Fri: 
9am-7pm 
Sat: 10am-
3pm 
B 
 
2 2a Owner 
 
 Female 60 
 
0 
0 
2.5 
0 
4000 Health and 
Beauty  
Mon-Fri: 
8:30am-
6:30pm 
2b Locum  Female 
 
 32 Sat: 9am-
1pm 
 
C 
 
2 3a Regular Female  30 
 
0 
0 
1.81 
1 
4000 Specialist Mon-Fri: 
9am-6pm 
3b Locum Female 27 Sat: 10am-
4pm 
D 
 
4 4a Locum Female 32 0 
0.36 
1.17 
0 
4000 Supermark
et 
Mon-Fri: 
9am-6pm 
4b Locum Male 39 
4c Locum Male 58 Sat: 9am-
6pm 4d Locum Female 27 
E 
 
2 5a Regular Female 31 0 
0 
1.12 
0 
4500 Supermark
et 
 
Mon: 8am-
10:30pm 
Tues-Fri: 
6:30am-
10:30pm 
5b Locum Female 55 Sat: 
6:30am-
10pm 
Sun: 10am-
4pm 
F 
 
3 6a 
Manager 
Male 30 0.81 
0 
2.36 
0 
4000 Health and 
Beauty 
Mon-Fri: 
9am-7pm 
6b Locum Male 30 Sat: 9am-
7pm 
6c Locum Male  70 
G 
 
1 7a Owner Male 49 0 
1.6 
6 
1 
12000 Traditional Mon-Fri: 
9am-
7:30pm 
Sat: 9am-
7pm 
Sun: 10am-
2pm 
H 1 8a Regular Male 34 1 
0 
0.4 
1 
4000 Specialist Mon-Fri: 
9am-6pm 
Sat: 10am-
2pm 
 I 2 9a Regular Male 50 1 
1.82 
0 
1 
3500 Specialist  Mon-Fri: 
9am-
6.15pm 
 
9b Regular Male 29 Sat: 10am-
4pm 
J 3 10a 
Manager 
Female 
 
27 0 
0.38 
0.64 
0.74 
3500 Supermark
et 
Mon-Fri: 
9am-8pm 
 
Sat: 9am-
8pm 
10b 
Regular 
Female 27 
10c Locum Male 34 
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NB. *The data refers to the average/ number of staff observed during the observational study period and does not reflect the 
exact numbers of staff employed by a pharmacy.  
Data Analysis 
The data was entered into Microsoft Excel and analysed with PASW v18 (SPSS) where the 
number of observations for each activity was expressed as a proportion of the total 
number of observations. The proportion of time spent on activities was found to be non-
normally distributed. Because of this, median and inter-quartile range in addition to the 
mean is reported. Statistical analysis was carried out using non-parametric tests due to the 
sample size of ten pharmacies using the Mann-Whitney U test and ANOVA. In all cases 
significance was set at p<0.05.  
Ethics and Approval 
Institution ethical approval was received (REC/B/10/03) from the School of Pharmacy, 
University of London Ethics Committee.   
At the onset of the study, the pharmacy superintendents (and where applicable area and 
local pharmacy managers for the pharmacies) were supplied with detailed information 
about the study. The study co-ordinator also briefed all of the pharmacy managers on the 
study process. At data collection, pharmacists were provided with a study information 
sheet and explained the purpose of the study. At this point informed consent was received 
from the study participants.  
In order to reduce the Hawthorne effect participants were assured of their anonymity and 
it was explained that the collective, as opposed to individual results would be analysed. 
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Community Pharmacy Work Study Research 
An accompanying structured literature review of work sampling studies in community 
pharmacy was undertaken to establish if policy changes outlined in the previous chapter 
had influenced work practice.  
Electronic databases, MEDLINE, EMBASE, International Pharmaceutical Abstracts and 
CINAHL were searched. MEDLINE use of MeSH headings “Time and Motion Studies” OR 
“Work Capacity Evaluation” OR “Work” AND “Pharmacy” OR “Pharmacies” OR “Community 
Pharmacy Services” OR “Pharmacy Administration” OR “Pharmacists”. CINAL headings, 
“Pharmacy and Pharmacology” OR “Pharmacy, Retail” OR “Pharmacy administration” OR 
“Pharmacy service” AND “Work Assignments” OR “Work Sampling” OR “Work” OR” Work 
Measurement”. Additional searches were performed with the terms included  “work”, 
“work study”, “Pharmacy”, “Pharmacist”, “Time and Motion” as keywords. As several 
reviews of the use of work sampling methodology in community pharmacy were published 
prior to 1998 (Rutter et al., 1998b), the search was limited from 1997 to 2010. 
In addition the references of all selected articles were scrutinised, as were the contents lists 
of the International Journal of Pharmacy Practice and the Journal of American Health 
Systems Pharmacists between the defined dates. Initial inclusion criteria for articles 
reviewed by title and abstract and were assessed based on three questions.  
 Did the research take place in a community or retail pharmacy setting? 
 Does the study use, or appear to use, one of the seven methods (Table 2.1) (as defined by 
Rutter et al., 1998b)? 
 Does the data show the different activities that pharmacists perform?  
 
These selected articles were then assessed for their full eligibility. Inclusion criteria was any 
study that used work study techniques (Rutter et al., 1998b) in order to show the amount 
of time that community pharmacists spend on different activities and that met the research 
question of showing the amount of time that community pharmacists apportioned to 
different activities. This included ‘before and after’ studies investigating the 
implementation of a new process or technology. All original research studies and abstracts 
that met the criteria were included.  
Despite productivity data being a valid work-study technique, studies that only reported 
productivity data, such as the number of prescriptions processed per hour by a pharmacist, 
but that did not discuss how much time was spent on different activities, were excluded. 
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This is because such studies would not directly explore the activities of community 
pharmacists. Studies in outpatient, ambulatory care and hospital settings were excluded as 
their work practices were considered significantly different to those of community 
pharmacists. Review articles were also excluded. Studies that exclusively showed the work 
activities of pharmacy technicians were also excluded.  
Literature Review Results 
Sixty-six articles were initially identified (figure 2.1), and where possible full papers 
obtained. It was not possible to acquire five full text papers from the British Library, mainly 
due to these being local US pharmacy publications. Three conference abstracts were 
removed as duplicated by full publication. A further 35 papers were excluded. In most 
cases these were review papers and therefore excluded for not being original research. 
Other reasons for exclusion included reporting productivity data, being exclusively about 
pharmacy technician time, or reporting work in non-community pharmacy setting. This left 
23 papers and abstracts that were included in the qualitative analysis (table 2.5). Where 
definitions allowed comparable data was extracted from the papers. Due to differences in 
definitions statistical comparisons were not performed.  
  
 
 
85 
Figure 2-1– Data Flow Diagram 
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Table 2.5 – Studies included in the Analysis  
*this is the submission or publication year when not reported in the text 
First Author Year of 
Data 
Collecti
on 
Country Method Number Involved Nature of Study 
Anderson (Arthur 
Anderson LLP, 1999) 
1999 USA Direct Time Study 15 pharmacies Baseline 
Angelo (Angelo et 
al., 2005) 
2003* USA  Direct Time study Four pharmacies, 11 
pharmacists 
Before and After 
Angelo (Angelo and 
Ferreri, 2005) 
2003* USA Direct Time Study 1 pharmacy, 3 pharmacists Before and After 
Bell (Bell et al., 
1999) 
1998 Northern 
Ireland 
Work Sampling, 
Self Reported 
30 pharmacies Baseline 
Bond (Bond et al., 
2008) 
2008* UK Subjective 
Evaluation 
762 pharmacists Baseline 
Crealey (Crealey and 
McElnay, 2003) 
2003* UK- 
Northern 
Ireland 
Subjective 
Evaluation 
268 pharmacy staff at 49 
pharmacies 
Baseline 
Dupclay (Dupclay et 
al., 1999) 
1997 USA – 
Indianap
olis 
Multidimensional 
Work Sampling 
15 pharmacies, 25 
pharmacists 
Baseline 
Emmerton 
(Emmerton et al., 
1998) 
1996 New 
Zealand 
Multi dimensional 
Work Sampling, 
Self Reported 
One pharmacy Baseline 
Fleming (Fleming, 
1999) 
1999* USA Subjective 
Evaluation 
917 pharmacists Baseline 
Lin (Lin et al., 2007) 2002 USA, 
Michigan 
Work sampling, 
Fixed Interval 
One pharmacy Before and After 
Mobach (Mobach, 
2006) 
2004/5 Netherla
nds 
Work sampling, 
random self 
reported 
One pharmacy Before and After 
Mobach (Mobach, 
2008a) 
2004 Netherla
nds 
Multidimensional 
Work Sampling 
Three pharmacies Baseline 
Midwest Pharmacy 
Workforce Research 
(Midwest Pharmacy 
Workforce Research 
Consortium, 2010) 
2009 USA Subjective 
Evaluation 
464 Community pharmacist 
responses 
Baseline 
McCann (McCann et 
al., 2010a) 
2009 Northern 
Ireland 
Work Sampling, 
Self Reported 
30 pharmacies Baseline 
(Compared to 
Bell) 
Quinones (Quinones 
and Thompson, 
2009) 
2005 USA 
Illinois 
Subjective 
Evaluation 
496 pharmacists Baseline 
(compared shift 
and non-shift) 
Rutter (Rutter et al., 
1998a) 
1996 UK Subjective 
Evaluation 
1084 pharmacists Baseline 
Rutter (Rutter et al., 
1999) 
1996 UK Work sampling, 
fixed interval 
5 pharmacies Baseline 
Rutter (Rutter et al., 
2001) 
2001* UK Work sampling, 
Fixed Interval 
One pharmacy Before and After 
Rutter (Rutter, 
2002) 
2000 UK Work sampling, 
Fixed interval 
Four pharmacies, 11 
pharmacists 
Baseline 
Schommer 
(Schommer and 
Pedersen, 2001) 
1999 USA – 
Minnesot
a and 
Ohio 
Subjective 
Evaluation 
597 Pharmacists Baseline 
Schommer 
(Schommer et al., 
2002) 
2000 USA Subjective 
Evaluation 
832 pharmacists Baseline 
Schommer 
(Schommer et al., 
2006) 
2004 USA Subjective 
Evaluation 
1,564 pharmacists Baseline 
Scott (Scott, 2009) 2006 USA – 
North 
Dakota 
Subjective 
Evaluation 
689 pharmacists Baseline 
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The methods used in the studies can either be categorised as subjective evaluation, where 
pharmacists were asked to report the activities that they perform, direct time studies or 
work sampling, with several using the multi-dimensional work sampling technique.  
Previous analysis of work sampling in community pharmacy reported little published 
literature (Savage, 1999; Emmerton and Jefferson, 1996). Yet, the review reported here 
suggests that popularity of work study methods in community pharmacy has increased, 
although particularly in the US (Arthur Anderson LLP, 1999; Angelo et al., 2005; Angelo and 
Ferreri, 2005; Dupclay et al., 1999; Fleming, 1999; Lin et al., 2007; Midwest Pharmacy 
Workforce Research Consortium, 2010; Quinones and Thompson, 2009; Schommer and 
Pedersen, 2001; Schommer et al., 2002; Schommer et al., 2006; Scott, 2009) and UK (Bell et 
al., 1999; Bond et al., 2008; Crealey and McElnay, 2003; McCann et al., 2010a; Rutter et al., 
2001; Rutter et al., 1998a; Rutter, 2002; Rutter et al., 1999). Two studies were identified 
from the Netherlands (Mobach, 2008a; Mobach, 2006), and one from New Zealand 
(Emmerton et al., 1998). 
In these studies, the use of these techniques has been for two main applications, either to 
assess the implementation of a new process or technology, or to create a baseline of 
current activity. Five of the studies reviewed were ‘before and after’ studies, four of which 
investigated the impact of automation and one investigated the effect of changes in 
pharmacy design on work flow. A full discussion of this literature review is included in the 
discussion towards the end of this chapter.  
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Work Sampling Study Results 
A total of 12,306 observations were recorded in ten community pharmacies across London, 
labelled Pharmacy A-J (A=1252; B=1440; C-I=1200; and J=1214) over a two week period 
between the 21st March and 3rd April 2011. Data collection predominately took place 
Monday to Friday (n=11886, 96.6%). However some data were captured on Saturday 
(Pharmacy B, n=240, 1.95%) and Sunday (Pharmacy J, n=180, 1.46%). Data collection was 
spread across the opening hours of the pharmacies (Range: 7am-10.30pm) and across 
different days of the week. The mean opening hours per week for the pharmacies was 
61.38 hours per week (range 49-100), with all of the pharmacies being open at least 9am-
6pm Monday to Friday. One pharmacy (Pharmacy E) was open under a 100 hour contract 
and was located in a supermarket. As shown in figure 2.2, the box plot indicates that data 
captured within some of the activity codes is non-normally distributed, with a wide range 
of values.  
Figure 2-2 - Box Plot of Pharmacist Activities 
 
 
 
89 
Overall seven categories accounted for three quarters of all pharmacists time (table 2.6): 
assembling and labelling of products (mean 25.5%; median 25.2%; IQR 12.0%); prescription 
monitoring and appropriateness (mean 11.9%; median 10.6%; IQR 4.7%); Rest and Personal 
Time (mean 11.2%; median 8.6%; IQR 8.5%); Endorsing and Health related clerical work 
(mean 8.2%; median 8.7%; IQR 6.6%); Non-professional encounters (mean 7.0%; median 
4.1%; IQR 8.7%); Counselling non prescribed medicines (mean 6.6%; median 6.6%; IQR 
4.1%);  and counselling prescribed medicines (mean 4.2%; median 3.8%; IQR 2.9%).   
In these pharmacies, which are open on average 61.38 hours per week, on average over 25 
hours were spent each week on dispensing activities. The endorsement of prescriptions 
and health related clerical work, which accounted for about a twelfth of pharmacists time 
may have been increased by the fact that data collection was collected near the end of the 
month. Stock control activities accounted for 3.6% (median 3.4%; IQR 3.1%) of the 
pharmacists’ time. Often this was unpacking and checking the delivery on managing the 
stock within the pharmacy. In the two pharmacies that provided services to nursing homes, 
this accounted for 4.5% of their time.  
Activity codes were grouped together to facilitate further interpretation and comparison 
with the literature (table 2.6). The two categories for counselling accounted for a mean 
10.9% (median 10.3%) of the pharmacists’ time, equivalent to 7.4 hours per week. It 
appeared that the pharmacists spent a larger proportion of their time offering counter 
advice on non-prescription medicines than on prescription medicines (mean 6.6%; median 
6.6%; IQR 4.1). In total the provision of clinical services accounted for about a twentieth of 
pharmacists’ time although the range was between 0.2% and 15%.  
Table 2.6 – Combing Activities 
Activities (activity codes) Mean percentage of 
activities (%) 
Median of activities 
(quartiles) 
Prescription related matters (1+2) 37.3% 39.6% (35.5, 44.5) 
Non Counselling Communication 
(6+7+13+18)  
16.4% 15.1% (13.5, 18.2) 
Rest Waiting and Personal Time (17) 11.2% 8.6% (6.9, 15.3) 
Counselling (4+5) 10.9% 12.4% (7.5, 13.3) 
Premises (12+14+15+16) 10.8% 8.6% (6.9, 15.3) 
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Health Administration (3) 8.2% 8.7% (4.8, 11.4) 
Services (8+9+10+11) 5.1% 3.2% (0.8, 7.5) 
Using the framework defined by McCann and colleagues (2010a), the activities of the 
pharmacists were separated into professional; semi-professional; and non-professional 
activities (table 2.7).  
Table 2.7 – Activity Categorisations (McCann et al., 2010a) 
Activities (activity codes) Mean percentage of 
activities (%) 
Sum of median combined 
activities (%) 
Professional 
(1+3+4+5+6+7+8+9+10+11+13) 
45.5% 40.1% 
Semi Professional (2+16) 28.4% 17.3% 
Non-Professional (12+14+15+17+18) 26.1% 20.4% 
 
Statistical Testing 
A number of statistically significant relationships were found between the demographic 
characteristics of pharmacies (table 2.7) and the mean time apportioned to the different 
activities sampled during the course of the study. There was a statistically significant 
variation in the proportion of time spent of staff training (p=0.019) between those 
pharmacies with and without a preregistration student. These pharmacists also spent a 
statistically significant proportion of their time on sales transactions (p=0.011) when 
compared to those without students.  It was also found that pharmacies that dispensed 
more that 4000 prescriptions a month spent less time on advanced services (p=0.039). The 
validity of these findings is questionable given the limited sample size of ten. 
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Figure 2-3 - Mean time spent on each activity by the pharmacists at each pharmacy 
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Table 2.8 –Total time spent on each activity code across all ten pharmacies (A-J) 
 A B C D E F G H I J Mean Median IQR 
1. Prescription Monitoring and appropriateness 23.2% 23.6% 13.4% 1.5% 8.4% 11.8% 8.3% 11.8% 9.3% 7.2% 11.9% 10.6% 4.7% 
2. Assembly and Labelling of Products 17.3% 24.9% 24.2% 43.9% 37.5% 29.9% 9.3% 10.8% 25.5% 31.4% 25.5% 25.2% 12.0% 
3. Endorsing Prescriptions and Health related clerical 
work 10.6% 8.1% 7.2% 4.0% 2.4% 11.7% 2.2% 11.7% 9.4% 14.8% 8.2% 8.7% 6.6% 
4. Counselling Patients on Prescribed Medicines 5.7% 2.7% 5.6% 2.9% 2.9% 4.6% 1.6% 6.9% 7.6% 2.0% 4.2% 3.8% 2.9% 
5. Non prescription medicines counselling and responding 
to symptoms 3.3% 4.3% 6.8% 3.0% 9.9% 7.8% 1.3% 6.5% 6.7% 16.8% 6.6% 6.6% 4.1% 
6. Professional encounter with non-patients 3.4% 5.0% 2.8% 0.3% 4.2% 1.0% 6.2% 5.8% 5.3% 1.0% 3.5% 3.8% 3.8% 
7. Non Counselling Health related communication 5.8% 1.3% 2.5% 3.1% 3.1% 1.8% 4.3% 4.2% 4.6% 1.9% 3.2% 3.1% 2.2% 
8. Provision of Advanced Services 0.0% 0.3% 1.1% 0.3% 0.2% 0.3% 1.3% 2.8% 0.3% 0.0% 0.6% 0.3% 0.7% 
9. Provision of Enhanced or other NHS Services 6.8% 0.2% 2.3% 2.6% 0.0% 0.4% 0.8% 0.6% 11.5% 1.1% 2.6% 0.9% 2.0% 
10. Provision of Private Enhanced Services 0.8% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 7.8% 0.5% 0.0% 0.9% 0.0% 0.4% 
11. Provision of services to residential and nursing homes 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 5.1% 3.8% 0.0% 0.0% 0.9% 0.0% 0.0% 
12. Inventory and Stock Control 2.6% 3.1% 5.1% 6.3% 0.3% 2.0% 6.0% 1.3% 3.8% 5.3% 3.6% 3.4% 3.1% 
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13. Staff Training and Education 2.9% 1.7% 3.3% 0.0% 2.3% 1.3% 2.2% 6.9% 4.1% 2.5% 2.7% 2.4% 1.4% 
14. House Keeping 3.0% 4.1% 4.0% 1.6% 1.3% 1.4% 4.3% 1.4% 2.5% 3.8% 2.7% 2.7% 2.5% 
15. Sales Transactions 1.5% 0.3% 2.3% 0.0% 0.2% 0.8% 3.8% 2.4% 1.6% 2.7% 1.6% 1.6% 2.0% 
16. Money and Managerial 4.8% 7.8% 0.1% 1.9% 1.9% 0.9% 0.9% 6.1% 0.7% 4.3% 2.9% 1.9% 3.7% 
17. Rest, waiting and Personal Time 7.0% 6.8% 13.8% 15.8% 10.1% 21.3% 23.4% 7.1% 4.6% 2.5% 11.2% 8.6% 8.5% 
18.Non-professional Encounters 1.4% 5.8% 5.4% 12.9% 15.4% 2.8% 19.3% 1.9% 2.3% 2.8% 7.0% 4.1% 8.7% 
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Discussion of Results 
Many of the extended services provided in community pharmacies are believed to be part 
of a re-professionalisation strategy. However it has been recognised that “the benefit to the 
public of pharmacists services....is dependent on the proportion of time that is devoted to 
pharmaceutical tasks” (Fisher et al., 1991). The logic follows that pharmacists must have 
adequate time available to deliver these services if they are to achieve re-
professionalisation.  
Pharmacists Still Perform Traditional Roles 
The results from this work sampling study in London suggest that pharmacists spend the 
majority of their time on assembling and labelling of products (mean 25.5%; median 25.2%; 
IQR 12.0%) and prescription monitoring and appropriateness (mean 11.9%; median 10.6%; 
IQR 4.7%), together accounting for nearly two fifths of pharmacists’ time.  
When compared to previous studies from the UK, the results found here are similar. A 2003 
study from Northern Ireland found that the largest proportion of pharmacists time was 
spent on assembly and labelling of products (Crealey and McElnay, 2003). In England in the 
late nineties it was felt that time was disproportionately dedicated to dispensing and could 
be better utilised (Rutter et al., 1998a). It appears that although this lack of pharmacist 
utilisation has been a theme throughout policy (chapter 1), dispensing activities continue to 
dominate, (mean 37.35%; median 35.8%), which is comparable to the 40.3% found by 
Rutter and colleagues in 1996 (Rutter et al., 1999). The finding that the proportion of time 
dedicated to dispensing has not appreciably changed is supported by two work sampling 
studies conducted ten years apart in Belfast, Northern Ireland (McCann et al., 2010b; Bell 
et al., 1999), which found no statistical difference in the amount of time spent on 
dispensing activities over the period. 
The dominance of the dispensing role was confirmed by similar research in the US (Fleming, 
1999; Schommer et al., 2002; Schommer and Pedersen, 2001; Schommer et al., 2006). 
Although their findings in 2000 did show willingness in the profession to move towards 
more care based activities (Schommer et al., 2002), a follow up survey in 2004 using the 
same methods did not appear to show any changes. However, these authors found that 
pharmacists wanted to spend more time on consultation and drug use management 
activities, and less time on medication dispensing (Schommer et al., 2006). These 
sentiments were confirmed by studies in North Dakota in 2006 (Scott, 2009), and in Illinois 
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in 2005 (Quinones and Thompson, 2009), and nationwide in 2009 (Midwest Pharmacy 
Workforce Research Consortium, 2010) which also found that medication dispensing took 
over half of pharmacists’ time.  
Although there are some challenges in making direct comparisons between the different 
definitions of dispensing used across the studies, they all suggest that dispensing is a 
dominant activity. Table 2.9 shows the definitions and proportion of time dedicated to 
dispensing which across the board represents about half of a community pharmacist’s time 
(Table 2.8). Although policy has sought to drive towards ‘utilisation’ of pharmacists away 
from ‘traditional’ dispensing tasks towards those considered to be more cognitive in nature 
(Edmunds and Calnan, 2001a), the traditional dispensing still dominates.  
Table 2.9 – Percentage of time spent dispensing  
 Definition of Dispensing Average 
proportion of 
time spent of 
dispensing 
activities 
This Study  Interpretation of the Rx including checking the correctness of the dispensed 
item. Includes checking the indication for drug, suitability for patient, e.g. 
interactions with other medicines. Appropriate dose of each medication. 
Contacting the prescriber if necessary. Includes ensuring that the product is 
dispensed as prescribed, e.g. checking any product assembled by dispensary 
technicians, as well as the legality of prescription. 
Assembly and labelling of products - Includes the assembly of the product 
requested on the prescription and generating labels for the container of that 
product. The process of assembling a prescription [Rx] item from receipt to the 
final assembly of the product, including the endorsement and filling of an 
individual prescription. 
37.3% 
Arthur Anderson LLP 
(Arthur Anderson LLP, 
1999) 
1. Present the Prescription: Includes greeting patient, obtaining appropriate 
data, manually recording information from ID cards 2. Process the Prescription: 
Includes entering patient/ doctor/ drug profile into computer system, complying 
with 3rd party requirements, resolving conflicts with PBMs, correcting clinical 
conflicts. 3. Prepare the Order: Includes retrieving drug from storage, counting 
pills, filling container, preparing/ placing label, returning drug to storage, 
bagging prescriptions. 4. Deliver/Dispense the Order: Includes placing into will 
call, retrieving drug from will call, delivering prescription to patient, counselling 
patient, cashiering. 
71.8 % 
Bell (Bell et al., 1999)  Assembly and labelling of products: Includes the assembly of the product 
requested on the prescription and generating labels for the container of that 
product. Checking accuracy of the final product: Includes ensuring that the 
product is dispensed as prescribed, e.g. checking any product assembled by 
dispensary technicians. 
27.52% 
Bond (Bond et al., 
2008) 
Dispensing Prescriptions 51-75% 
Crealey(Crealey and 
McElnay, 2003) 
Assembly and Labelling of products 16.25% 
Dupclay(Dupclay et 
al., 1999) 
Drug Distribution: Non judgemental tasks related to the physical distribution of 
the medication; Prescription: Receiving or transferring a medication prescription 
34.1% 
Fleming (Fleming, 
1999) 
 Dispensing Prescriptions  50% 
Mobach(Mobach, 
2008a) 
Filling Work ; Computer Work ; Ex tempore preparations 40% 
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Midwest Pharmacy 
Workforce Research 
(Midwest Pharmacy 
Workforce Research 
Consortium, 2010) 
Medication Dispensing: preparing, distributing, and administering medication 
products, including associated consultation, interacting with patients about 
selection and use of over-the-counter products, and interactions with other 
professionals during the medication dispensing process. 
74.25% 
McCann (McCann et 
al., 2010a) 
Assembly and labelling of products: Includes the assembly of the product 
requested on the prescription and generating labels for the container of that 
product. Checking accuracy of the final product: Includes ensuring that the 
product is dispensed as prescribed, e.g. checking any product assembled by 
dispensary technicians. 
31.63% 
Quinones(Quinones 
and Thompson, 2009) 
Medication Dispensing: preparing, dispensing, distributing and administering 
medications (traditional dispensing and medication distribution activities). 
53.86% 
Rutter(Rutter et al., 
1998a) 
Dispensing: The process of assembling a prescription [Rx] item from receipt to 
the final assembly of the product. Interpretation of the Rx: including checking 
the correctness of the dispensed item. Provision of services to homes : As 1 and 
2 but directly related to residential and nursing homes. 
52.79% 
Rutter(Rutter et al., 
1999) 
Dispensing: The process of assembling a prescription [Rx] item from receipt to 
the final assembly of the product. Interpretation of the Rx: including checking 
the correctness of the dispensed item. Provision of services to homes :As 1 and 
2 but directly related to residential and nursing homes. 
40.45% 
Rutter(Rutter, 2002) Dispensing: The process of assembling a prescription [Rx] item from receipt to 
the final assembly of the product. Interpretation of the Rx: including checking 
the correctness of the dispensed item.  
35.25% 
Schommer(Schommer 
and Pedersen, 2001) 
 Medication Dispensing: preparing, dispensing, distributing and administering 
medications (traditional dispensing and medication distribution activities). 
 48% 
Schommer(Schommer 
et al., 2002) 
Medication Dispensing: preparing, dispensing, distributing and administering 
medications (traditional dispensing and medication distribution activities). 
56% 
Schommer(Schommer 
et al., 2006) 
Medication Dispensing: preparing, dispensing, distributing and administering 
medications (traditional dispensing and medication distribution activities). 
56.2% 
Scott (Scott, 2009) Medication Dispensing: preparing, dispensing, distributing and administering 
medications (traditional dispensing and medication distribution activities). 
53.75% 
 
The data from London reported here shows a wide range of time spent on the assembly 
and labelling of products (range 9.3% to 43.9%) which suggesting some considerable 
differences in the organisation and structure processes within the pharmacies observed. 
What this data clearly suggests is that the activities of pharmacists are not homogenous 
across the group, and therefore other factors are influencing their work practices. Indeed, 
it is worth drawing attention to the results of Pharmacy D, which was run by locums during 
the study period. No sales transaction, training or private services were undertaken by the 
pharmacists, instead over half their time was dedicated to assembly and labelling of 
products. 
A move towards counselling patients 
There is similarity between the 10.9% (median 10.3%) spent on consultation activities in 
this study and the 10.9% (Rutter et al., 1999) and 12.5% (Rutter et al., 1998a) spent from 
studies in England in the late nineties. By contrast, the Northern Ireland studies found a 
significant reduction in the amount of time spent handing out prescriptions and counselling 
(9.46%,1998; 4.84%,2009) over a decade. In a 2008 survey, pharmacists reported spending 
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10-25% of their time spent counselling patients (Bond et al., 2008), with the accompanying  
work-log study finding that that median proportion of time spent on patient counselling 
was 9% (Bond et al., 2008). Over the last decade the number of prescriptions have 
increased by over 300 million items (The NHS information Centre Prescribing Support Unit, 
2010) and therefore the fact that in this study a tenth of the pharmacists’ time is still  spent 
counselling patients could be seen as an encouraging. When compared across the studies 
about an eighth of pharmacists’ time is spent counselling patients (Table 2.10).  
The proportion of time attributed to counselling non-prescription medicines (mean 6.6%; 
median 6.6%; IQR 4.1%) and counselling prescribed medicines (mean 4.2%; median 3.8%; 
IQR 2.9%), is perhaps a reflection that more than 92 medicines have been reclassified from 
prescription only (POM) to pharmacists supply (P) status in the past 28 years requiring a 
greater need for pharmacist’s advice and intervention with these products. This suggests 
that the policies that encourage self care advice in community pharmacies may be to the 
detriment of prescription only medicines counselling. However, a preliminary pilot as part 
of this study found no difference in the counselling time between pharmacists and 
pharmacy counter staff.  
Despite the inter-pharmacy variation, there were also differences across the week. Sunday 
saw a large amount of time apportioned to non-prescription medicines counselling (21%), 
which may be due to the doctors surgeries being closed and therefore reducing 
prescription numbers at the weekend and where access to other healthcare settings is 
restricted. However, the Sunday results are only from one pharmacy (Pharmacy J), which 
was located in a busy supermarket, although previous studies reported that pharmacists 
spent more time counselling at the weekends (Rutter et al., 1998a).  
A US study suggested that the likelihood a patient would receive counselling was not 
related to staffing levels, automation or workload, but instead the public perception and 
practice habits of the pharmacists (Angelo et al., 2005). Some studies suggest that 
pharmacists prefer working alone (Emmerton et al., 1998; Dupclay et al., 1999), actively 
avoiding patient contact,  although this appears to contradict their apparent desire to 
spend more time on consultation activities reported elsewhere (Schommer et al., 2006). 
Further studies have endorsed public perception as a factor, suggesting that it would be 
easier to advise patients if they appreciated counselling (Schommer and Wiederholt, 1994). 
Research suggests that majority of counselling is performed by counter staff (Mobach, 
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2008a; Mobach, 2008b; Angelo et al., 2005). The researchers in the study reported here 
agreed that this was the case although this was not formally recorded. 
Table 2.10– Counselling Rates in Selected Papers 
Author 
 
Counselling Definition Average 
Percentage 
This Study Counselling patients on prescribed medicines:  Includes personally giving out the 
medication to the patient and providing information on disease state, medicines supplied, 
side-effects, dose etc. 
4.2% 
Non-prescription medicines counselling/responding to symptoms: Includes listening to 
any problems, advising on problems either to patients or counter staff, recommending a 
non-prescription medicine or referring the patient to a GP. 
6.6% 
Arthur 
Anderson LLP 
(Arthur 
Anderson LLP, 
1999) 
Deliver/ Dispense the Order: Includes placing into will call, retrieving drug from will call, 
delivering prescription to patient, counselling patient, cashiering.  
8.9% 
Bell (Bell et al., 
1999) 
Non Prescription Medicines: Responding to Symptoms: Includes listening to any problems, 
advising on problems, recommending a non-prescription medicine or referring the patient 
to a GP.  
7.22% ± 2.80% 
Handing out prescription products and counselling: Includes personally giving out the 
medication to the patient and providing information on disease state, medicines supplied, 
side-effects, dose etc. 
9.46% ± 7.15% 
Bond (Bond et 
al., 2008) 
Counselling Patients  10-25% 
(Median) 
Crealey(Creale
y and McElnay, 
2003) 
Handing out the product and counselling  14.86%±12.26% 
Dupclay(Dupcl
ay et al., 1999) 
Proportion of time was spent interacting with patients  17.9% 
Emmerton(Em
merton et al., 
1998) 
Time and in contact with patients in of instances.  14% 
Fleming 
(Fleming, 1999) 
Counselling patients 14% 
Mark (Mobach, 
2008a) 
Counter care  4% 
Counter Other 7% 
McCann 
(McCann et al., 
2010a) 
Non Prescription Medicines: Responding to Symptoms: Includes listening to any problems, 
advising on problems, recommending a non-prescription medicine or referring the patient 
to a GP.  
6.82%±5.41% 
Handing out prescription products and counselling: Includes personally giving out the 
medication to the patient and providing information on disease state, medicines supplied, 
side-effects, dose etc. 
4.84%± 4.37% 
Quinones 
(Quinones and 
Thompson, 
2009) 
Consultation: consulting and communicating with patients about prescription 
medications; interacting / communicating with other health professionals on patient’s 
behalf (via phone, face to-face, etc.); patient / provider education.  
Non Shift 
Workers 
18.86% 
Shift Workers 
18.81% 
Rutter(Rutter 
et al., 1998a) 
Counselling: Verbal advice or information given to the recipient of the dispensed medicine 6.71% 
Pharmacist Prescribed Drugs: Counter prescribing or responding to symptoms 5.81% 
Rutter(Rutter 
et al., 1999) 
Counselling: Verbal advice or information given to the recipient of the dispensed medicine 8.7% 
Pharmacist Prescribed Drugs: Counter prescribing or responding to symptoms  2.2% 
Rutter(Rutter, 
2002) 
Counselling: Verbal advice or information given to the recipient of the dispensed medicine 8.75% 
Schommer(Sch
ommer and 
Pedersen, 
2001) 
Consultation: consulting and communicating with patients about prescription 
medications; interacting / communicating with other health professionals on patient’s 
behalf (via phone, face to-face, etc.); patient / provider education. 
31%±15% 
Schommer(Sch
ommer et al., 
2002) 
Consultation: consulting and communicating with patients about prescription 
medications; interacting / communicating with other health professionals on patient’s 
behalf (via phone, face to-face, etc.); patient / provider education. 
20.75% 
Schommer(Sch
ommer et al., 
2006) 
Consultation: consulting and communicating with patients about prescription 
medications; interacting / communicating with other health professionals on patient’s 
behalf (via phone, face to-face, etc.); patient / provider education. 
19.6% 
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Scott (Scott, 
2009) 
Consultation: consulting and communicating with patients about prescription 
medications; interacting / communicating with other health professionals on patient’s 
behalf (via phone, face to-face, etc.); patient / provider education. 
18.1% 
 
This work study suggests little deviation in the work activities performed by community 
pharmacists compared to a literature from a decade ago (table 2.9, 2.10). The literature 
suggests that pharmacists are willing and able to provide more counselling but have not yet 
been afforded the full opportunity opportunities in practice to move this ambition forward.  
Unproductive Time 
Pharmacists spent 11.2% (mean 11.2%; median 8.6%; IQR 8.5%); of their time on rest, 
waiting and personal activities, comparable to the 14.1% observed by Rutter and 
colleagues (1999). Much of this time was waiting for others to complete tasks prior to being 
checked, or access computer terminals. This indicates that work processes within the 
pharmacy could be streamlined to reduce this wastage. It is debatable whether the 7% 
(median 4.1%; IQR 8.7%) spent on non-professional encounters is actually unproductive. 
This time was spent in conversation with patients on non-healthcare topics, such as the 
weather. However, these conversations did appear to contribute to the pharmacists’ ability 
to build rapport with patients and therefore assess their pharmaceutical needs. By 
comparison pharmacists in this study spent 26.1% (median 20.4%) of their time on non-
professional activities, which is similar to that observed in the Northern Ireland studies 
(20% in Bell et al., 1999 ; and 20% in McCann et al., 2010b).  
Education and Training 
Although not originally powered for in the study, there was a statistically significant 
variation in the proportion of time spent of staff training (p=0.019) between those 
pharmacies with and without a preregistration pharmacy student. When preregistration 
pharmacists are present the pharmacists apportion a greater amount of time to staff 
training. However these pharmacists also spent a significantly more time on sales 
transactions (p=0.011) which may be due to them allowing other staff to perform 
consultation activities. 
Type of Pharmacy 
Analysis of the ownership of the pharmacies did not reveal any statistical differences in 
practice. This is in contrast to studies from the US which found that pharmacists in 
independent pharmacies reported spending more time in consultation (Scott, 2009) and 
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that practice settings were found to consistently be the most influential variable in 
pharmacists’ work activities (Schommer et al., 2006). 
Delivering Pharmaceutical Services 
The results from this study and the literature review suggest that around the world 
pharmacists spend a substantial proportion of their time on the activities and functions 
associated with the distribution of products, which they are contracted to do (Crealey and 
McElnay, 2003). The 2005 contractual framework was heralded by professional leaders as 
an opportunity for the pharmacy profession to use its knowledge and skills more fully in the 
interests of better patient care. However this study suggests that pharmaceutical services 
occupy less than 5% of pharmacists’ time, with several pharmacies failing to complete a 
single MUR during the observation period. This suggests that the contractual framework 
has failed to achieve the desired change in roles from technical to cognitive (Bond et al., 
2008). The barriers and facilitators of service delivery in relation to Medicines Use Reviews 
are multi-factorial and are discussed in detail in chapter 4. It is worth noting that this 
research was conducted towards the end of the financial year, where some pharmacies had 
already reached their annual MUR target. Also some pharmacies did complete MURs 
during the study period, but these were not during observation times. 
Whatever the reasons, the contractual framework, which represented a theoretical 
increase in workload for community pharmacy (Bond et al., 2008) has failed to appreciably 
impact pharmacists’ work practices. Similarly in the US, changes made to enhance 
medication therapy management services under Medicare Part D have not delivered the 
intended shift to more patient care activities (Benner and Kocot, 2009). 
Implications for Policy 
The evidence presented here suggests that pharmacists’ time continues to be dominated 
by medicines supply, and that work practices have remained relatively unchanged (McCann 
et al., 2010a), despite policy aims to better ‘utilise’ pharmacists skills (chapter 1). Yet, few 
would argue that checking the appropriateness of prescription medicines, counselling 
patients, or providing enhanced services were an inappropriate use of pharmacists’ skills. It 
is the domination of assembling and labelling products, a task that could be done by other 
staff, that supports the ‘under-utilisation’ argument.  
Schommer and colleagues (2006) argue that “Pharmacists appear ready and willing to 
provide consultation and drug use management services in community settings”, but 
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suggest that pharmacists have not been provided with the “full opportunity to engage in 
these desired activities” (Schommer et al., 2006). However, within the British context policy 
statements mean that this opportunity has been created in political rhetoric, but this has 
not filtered to the activities of grass roots of the profession.  
Authors of work sampling studies in the late 1990s expressed concern over pharmacists’ 
ability to expand their role if practice remained the same (Emmerton and Jefferson, 1996). 
Dupclay and colleagues (1999) articulated unease that only 2.3% of pharmacist time in 
grocery chain pharmacies in the US was spent performing medication interventions and 
2.9% on health interventions. These concerns have been repeated more recently in the 
Netherlands. Mobach (2006) advises that automation and robots, task specialization and 
interior design will be required because these have been shown to decrease workload, 
waiting time and congestion and create an increase in counterwork and pharmaceutical 
care (Mobach, 2006). However, in England, stock issues actually increased the time spent 
dispensing when a robot was installed (Rutter et al., 2001). Comparison studies between 
automated and non-automated community pharmacies in the US found that although 
automation was associated with high prescription productivity, actual counselling rates 
were no different (Angelo et al., 2005; Lin et al., 2007). By contrast, work flow redesign was 
shown to increase the number of patients offered counselling from 5% to 85% (Angelo and 
Ferreri, 2005). Even though the offer to counsel significantly increased after the 
intervention, patients appeared to be accustomed to declining communication with the 
pharmacist, which the authors suggest is a function of the poor expectations patients have 
of pharmacists. New technology and re-designed pharmacies provide increasing 
opportunities for pharmacists to use their skills for patient centred roles, yet many 
continued to perform tasks that could be performed by technicians. Therefore the 
conclusion of these studies suggests that staffing adjustments were needed to optimise the 
efficiency gained.  
Staffing and skill mix have been themes which have appeared in successive policy 
documents (chapter 1). Currently a large proportion of pharmacists’ time is spent on 
activities that others could perform (Arthur Anderson LLP, 1999). However, redeployed 
staffing will only create opportunities if properly managed. Rutter (2002) found that the 
same basic functions of dispensing, communication, checking and rest and were not 
significantly affected by staffing and prescription workload. This lack of change was 
attributed to pharmacists’ lack confidence in their staff’s ability when delegating (McCann 
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et al., 2010a; Bell et al., 1999). Some have suggested that this may be due to issues of 
liability (Bond et al., 2008), whereby the profession has adopted defensive strategies in 
light of recent high profile cases22. Expressions of concern over the lack of sufficient 
training in pharmacy staff has been described as threatening the safety of medication 
dispensing (American Society of Hospital Pharmacists, 1989; American Society of Health-
System Pharmacists and the American Pharmaceutical Association, 1996). This suggests 
that deft human resource management skills and a new paradigm that emphasizes the 
allocation of pharmacist time to those aspects that cannot be delegated may be required to 
overcome the entrenchment of roles and responsibilities in community pharmacy (Dupclay 
et al., 1999). 
Hall and Johnson argue that processes (in modern process management) consist of two 
functions, ‘art’ and ‘science’. However, many processes work best if they are treated as 
artistic work as opposed rigidly controlled. Hall and Johnson argue that “If businesses 
employ both artistic and scientific processes (the rule rather than the exception), managers 
should work to separate them and then carefully manage the areas where they intersect” 
(Hall and Johnson, 2009: p62). In the case of pharmacy the science is the rigid dispensing 
process, which should therefore be separated from the artistic counselling process. 
Creating a separation between the rigid, protocol driven, ‘McDonald’ processes of 
dispensing, with the artistic processes of patient centred care offers one possible way for 
the pharmacy profession to progress. Yet, if this separation were the only barrier to 
‘utilisation’ of pharmacists skills, then undoubtedly it would have already been 
implemented. Therefore the findings here suggest that there are other drivers at play. It is 
these other barriers that are explored in the next chapter.  
Limitations 
It is important to acknowledge the limitations of the fixed interval work sampling approach 
used here. Information was not provided about the quality of consultations or services; 
only the proportion of time. The results provide descriptive statistics of what is observed, 
but this method will always be a statistical estimate. 
Despite the extensive training and supervision of coding undertaken by the observers, 
there was still opportunity for inter-observer variance in recording activities as well as the 
confounding factors of observer bias and the Hawthorne effect. Taking this into 
                                                          
22 In the UK the ‘Elizabeth Lee’ case is one example, which is described in more detail in chapter 3.  
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consideration, these results cannot be said to be generalisable beyond the London area. 
However the similarity of these results with those elsewhere support the conclusion that 
pharmacists continue to spend the majority of their time dispensing and checking 
prescriptions (McCann et al., 2010b; Bond et al., 2008). The sample of pharmacies selected 
had below average prescription volumes when compared to national figures which may 
have affected pharmacists’ work patterns. 
The literature included in the discussion is qualitative in nature. The differences between 
the countries, their national pharmacy practice and the data collection methods will all 
influence the results. One of the main challenges has been combining the definitions for 
the studies for analysis. For example, a review of 42 studies showed that there was no 
common definition for advice-giving, better lone other functions that are carried out in the 
community pharmacy setting (Tully et al., 1997).   
Chapter Conclusion 
Work sampling studies provide an effective way of showing the proportions of time 
community pharmacists spend on different activities. Studies from New Zealand, USA, 
Netherlands and the UK appear to imply that work practices are remarkably similar, and 
across the board community pharmacists spend the majority of their time on traditional 
prescription dispensing and supply activities. 
Policy efforts have called for better utilisation of the skills of community pharmacists 
(chapter 1) and yet only about an eighth of their time is spent directly counselling patients. 
These results suggest that overall the roles of pharmacists have remained fairly static over 
the course of the last decade, dominated by the supply of prescription medicines. Although 
pharmacists spend a proportion of their time of activities that no others could perform, the 
charge of ‘underutilisation’ of their skills hold weight.  
While accepting that practice change will be evolutionary, rather than revolutionary, at the 
current pace it will be many decades before pharmacy skills are properly utilised. There is 
still scope for pharmacists to use the opportunities offered by appropriate staffing to 
delegate tasks more effectively. However this movement of responsibility will require a 
new paradigm that emphasizes the allocation of pharmacist time to those aspects that 
cannot be delegated, in order to overcome the entrenchment of roles and responsibilities 
in community pharmacy.  
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Work flow improvement, automation and process standardisation can be used to improve 
the efficiency of the pharmacy environment. Extrapolation of evidence from process 
management (Hall and Johnson, 2009) postulates that the separation of science -the rigid 
dispensing process- from the art - the counselling processes - will provide efficiency and 
patient benefits. After all, if pharmacist really wish to enter the medical domain then they 
must accept that “If it were not for the great variability among individuals, medicine might 
as well be a science and not an art” (Sir William Osler, 1892) 
The evidence presented here suggests that the current policy direction has failed to deliver 
the anticipated utilisation of community pharmacy skills. Although the desire for this 
change is largely supported within the profession and current policy creates an opportunity 
for this path to be followed, the practical implementation of this policy is yet to be 
achieved. On this basis; further research is required to understand why the implementation 
of these policies have not been realised, and to discover why pharmacists have not moved 
beyond the traditional dispensing role. It is this research that forms the basis of the next 
chapter.  
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Chapter 3. The Community Pharmacy 
Income and Workload 
 
Chapter Introduction 
The work sampling study in the previous chapter demonstrated that pharmacists remain 
deeply rooted in the medicines supply process. This is despite policies which seek to propel 
community pharmacy towards extended clinical services and care based activities on the 
high street. 
It is not solely these findings that acknowledge the lack of change in community pharmacy 
activities. A review of the contribution of community pharmacy to health services in Wales 
by the National Assembly for Wales concluded that significant barriers still exist in realising 
the full potential of community pharmacy, and that community pharmacy can do more to 
contribute to health services in Wales (National Assembly for Wales Health and Social Care 
Committee, 2012).  
This thesis  explores why this has been the case, and why these policy ambitions are yet to 
be realised in practice. The answers to these questions are multi-factorial and will be 
explored in this chapter through an analysis of the business, by understanding the financial 
models that incentivise practice and drive commerce. 
The ‘underutilisation’ of community pharmacists may be attributed to the workload 
increases that pharmacists have experienced. However, this workload can only be 
understood in context, which necessitates analysis of the income streams that support 
community pharmacy businesses. Community pharmacy workload is explored in greater 
detail in appendix A. Through extrapolation, this chapter explores the trends in community 
pharmacy income and relates this to anticipated future workload. Based on this, 
predictions are made about future occupational workload. Finally, the chapter closes by 
turning to the trends in prescription supply volume and the factors associated with them as 
these have dominated professional pharmacy practice since the creation of the NHS.  
The evidence and case for a reform of the current workload and practice is presented at 
the end of the chapter. Using a range of evidence, including original research into the 
shortened durations of prescriptions, this chapter indicates that the current policy 
community pharmacy objectives are unsustainable given the current framework.  
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Income in the Community Pharmacy Market 
In simplistic terms, companies take inputs to which they apply a service or process that 
adds value in order to produce an output23. At the basic level the difference between the 
input and processing costs compared to the output costs represents the profit. 
Under this basic model community pharmacies produce several outputs: prescription 
medicines and associated advice; consumer goods (in particular OTC medicines); privately 
or NHS funded pharmaceutical services; and finally, and some would argue most 
importantly, a pharmacy business produces profit as an output - a return on capital 
investment, required for sustainability.  
Pharmacies have traditionally been associated with two types of process to achieve these 
outputs: the dispensing and supply of prescription medicines, and the provision of certain 
consumer goods sold in the pharmacy. More recent changes in the pharmacy contract 
coupled with certain drivers from the professional leaders within community pharmacy 
have led to a third type of process, broadly defined as ‘extended pharmaceutical services’. 
This section of chapter three explores the main income streams into a community 
pharmacy behind each of these processes and reflects on how the changing mix of the 
income streams influences the workload of pharmacists and pharmacy staff. Workload 
trends are identified from extrapolation of historical data. Such trends provide insight into 
future workloads, practice and incomes. This section begins by analysing the trends in 
medicines supply before looking at the other factors associated with the pharmacy 
business.  
Prescription Medicines Supply 
Community pharmacies in England received 877.2 million dispensing fees from the NHS in 
2010/11. These prescribed items had an average net ingredient cost of £9.04 each (The 
NHS Information Centre, 2011). This equates to £7.9bn being spent on prescription 
medicines in primary care supplied from pharmacies, out of a total spend of £8.81bn on 
drugs in primary care in 2011 (Adams, 2012). Therefore over 90% of NHS primary care 
drugs by value are supplied from community pharmacies (Adams, 2012). In addition to this, 
there is a small market for private primary care medications, estimated at the market level 
to be less than 1% by value.  
                                                          
23
 A discussion of the value added by community pharmacy business is provided in Appendix C.  
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The number of prescription items is expected to continue to grow driven by patient 
demographics, but the rate at which this growth continues is likely to decrease (figure 3.1). 
Based on previous trends the forecasts suggest that prescription items will continue to 
increase at about 3.7% each year.  
Figure 3-1 - Prescriptions Items dispensed in England (millions)  
 
Source: NHS Information Centre. Forecast estimations in green.  
While the volume in item terms (and therefore in workload terms) is increasing, the 
relative value of each item is decreasing. In previous years the expenditure on the drugs 
budget grew by around 3 – 4 % per annum to keep pace with volume increase. Yet despite 
a steady increase of between 4 and 5 % in prescription volume (figure 3.1), the relative 
budget for primary care prescribed items in the NHS dropped by 0.1% in 2011 from the 
£8.83 billion spent in 2010. This change has been due to several factors that are likely to 
persist in this market. 
Firstly, the Medicines Margin Survey led to adjustments in Category M for generic drug 
reimbursement prices. This forced community pharmacy contractors to negotiate for lower 
prices on generic medicines.  
Secondly, there has been an increase in generic prescribing rates, driven by initiatives such 
as ‘better care, better value’ indicators and the patent expiry of some high volume branded 
5.3% 
4.9% 
5.1% 
4.3% 
5.4% 
4.3% 
5.2% 
5.9% 
5.1% 
4.4% 
2.8% 
3.8% 
3.7% 
0.0% 
1.0% 
2.0% 
3.0% 
4.0% 
5.0% 
6.0% 
7.0% 
0 
100 
200 
300 
400 
500 
600 
700 
800 
900 
1000 
Y
e
ar
 o
n
 Y
e
ar
  G
ro
w
th
 (
%
) 
P
re
sc
ri
p
ti
o
n
 It
e
m
s 
D
is
p
e
n
se
d
 (
m
ill
io
n
s)
 
 
 
108 
medications. Notably, this has been observed in the cardiovascular disease arena, where 
spending decreased from £1.51 billon in 2010 to £1.35 billion in 2011. In part this reduction 
was aided by a cut in spending on clopidogrel which reduced from £46 million in 2010 to 
£12 million in 2011, due to generic entry, despite an overall volume terms increase in 
supply. Other high value drugs (table 3.2) have become or are about to become generic, 
and therefore likely to lead to further savings. Atorvastatin (Lipitor) was the second biggest 
spend of any drug in 2011, at £310.8million. However, its switch to generic will lead to a 
significant reduction in the cost of this commonly prescribed lipid lowering medicine.  
Table 3.1 – UK Patent Expires 2012-13 
Brand Name Generic Name Expiry Date 
NHS Primary Care Cost 2010 
(millions) 
Lipitor Atorvastatin May-12 £305.8 
Seroquel Qutiapine Mar-12 £92.8 
Aricept Donepezil Jan-12 £63.1 
Amias CandersartanCilexetil Apr-12 £85.7 
Aprovel Irbesartan Aug-12 £46.6 
Plavix Clopidrogrel* Aug-12 £46.4 
Serevent Salmeterol Sep-13 £45.1 
Singulair Montelukast Aug-12 £43 
Viagra Sildenafil Jun-13 £41.4 
Destrusitol Tolterodine Sep-12 £34 
Reminyl Galantamine Jan-12 £17 
Cymbalta Duloxetine Dec-12 £16.8 
Amanex MometasoneFuroate Feb-12 £16.5 
Source: (Adams, 2011). Cost data based on Prescription Cost Analysis report for England 2010 (only primary 
care). *Clopidogrel has been available as a generic since 2009 due to a patent loophole.   
Thirdly, the Pharmaceutical Price Regulation Scheme (PPRS) has resulted in a reduction in 
branded drug prices (with price cuts of 7.0 per cent in 2005, 3.9 per cent in 2009 and 1.9 
per cent in 2010) which have further reduced the cost of medicines in primary care. The 
combination of these factors since 2005, has contributed to a steady decrease in the net 
ingredient cost of each prescription item (figure 3.2).  
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Figure 3-2 - Value of Prescriptions  
 
Source: NHS Information Centre; forecasts in green.  
The average net ingredient cost per prescription item is forecast to continue to decrease by 
at least 2.5% per annum. Meanwhile the overall volume is expected to increase by 3.7% 
(figure 3.1).  
The decreasing trend in ingredient costs from 2005 onwards (figure 3.2) can be attributed 
to the new pharmacy contractual framework, which restricted the purchase profit available 
on generic medicines through the Category M mechanism. Contractors are reimbursed 
from the NHS at a price listed in the Drug Tariff (Department of Health and the Welsh 
Assembly Government, 2012), a monthly publication from the Department of Health. If 
pharmacies are able to purchase medicines from wholesalers at less than the listed Drug 
Tariff price, then they can retain the difference – the ‘purchase profit’. The contractual 
framework limits the amount of purchase profit that pharmacy contractors can retain to 
£500 million per annum. When the £500 million target was originally set in 2005, it was 
estimated that there was £800 million of retained profit in the system, but evidence 
showed that this was an underestimate (National Audit Office, 2010).  
Successive reductions in the list price of Category M medicines have continued to reduce 
pharmacy income. For example, in 2007 the list price of generic medicines was cut by £400 
million. In 2008, Category M was reduced by a further £32.5m per quarter, which equated 
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to a reduction of approximately 16 pence per item (Pharmaceutical Services Negotiating 
Committee, 2008) due to the £500m agreed purchase price being exceeded in the previous 
year.  
The reason for margin targets to be exceeded is principally because pharmacy contractors 
negotiate lower purchase prices for medicine, which in turn creates lower than expected 
prices in the medicines market. These reductions are then factored into the following 
year’s negotiations, incentivising pharmacies to keep driving down medicine prices year on 
year. This cycle has helped to reduce the cost of medicines, but cannot continue 
indefinitely. Eventually prices will reach a point where pharmacies are unable to gain 
£500m from the system.  
Invoices of independent pharmacy contractors govern this £500m limit, but delays in the 
system sometimes allow contractors to accrue more than £500m. The system fails to 
account for those pharmacies with vertical integrated supply models, that have been able 
to extract more that this figure from the overall supply chain. For example, a margin of 
£3.61bn was retained between 2005/06 and 2008/09 (National Audit Office, 2010). This 
represented a difference of £1.57bn from the agreed £2.03bn (although £0.46bn of this 
was recouped through reduced practice payments (National Audit Office, 2010)).  
About 90% of medicines are delivered to pharmacies by wholesalers (within which  
approximately 6% is by short line wholesalers). The remaining 10% are either self-supplied 
by the pharmacy, or supplied direct from the manufacturer (Office of Fair Trading, 2007). 
Wholesalers and distributors also need to acquire their income from the £8bn paid by the 
Department of Health for medicines. It was established in 2007 by the Office of Fair Trading 
that the vast majority of branded medicines (which represent three quarters of NHS 
primary care medicines spend) are sold at a 12.5% discount to wholesalers, who supply the 
medicines to pharmacies at around a 10.5% discount. The exceptions to this account for 
less than 3% of sales value (Office of Fair Trading, 2007). Wholesalers will take their share 
of the discount and then supply this onto pharmacies. Pharmacies then have a claw-back of 
around 10% (between 5.63% and 11.5%) applied to their monthly reimbursement to allow 
the DH to gain from these reductions (Office of Fair Trading, 2007). 
In conjunction, these two mechanisms (Category M and claw back) help limit the cost of 
medicines across England. However, the system can leave pharmacists in a position where 
they are dispensing items as a loss. Firstly, some manufactures and wholesalers change 
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their discount terms to remove or reduce discount from certain products. After claw-back 
is imposed these contractors are reimbursed less than the price they paid. This particularly 
affects those contractors who have an above average number of items for which discount 
is not available. Secondly, for generic medicines there have been cases where the time-lag 
between price setting and current market conditions have left contractors with a loss 
following the purchase of a product. This is because Category M is based on data from 
generic manufacturers that is provided quarterly (e.g. data for October to December will be 
provided to the Department of Health by February to set prices in April to June) creating a 
time lag between data collection and setting.  
The recent implementation of direct to pharmacy or limited wholesale arrangements by 
pharmaceutical manufacturers provides them with a strong platform to reduce the level of 
discount they offer, in order to increase their own profitability. Roughly a one percentage 
point reduction in the level of pharmacy discount could result in a £50 million loss to 
pharmacy. Pfizer, among others, have assured the Department of Health that this will not 
lead to increases in medicines costs, however this may not be the case in the future (Office 
of Fair Trading, 2007).  
Overall there is a total market for both private and NHS primary care prescription 
medicines in England of £8.9bn. Of this, about £8bn is turned over through community 
pharmacies. About a £1bn of ‘purchase profit’ is shared between the wholesalers and the 
pharmacies. Some of this is clawed back by the Department of Health. Yet, the overall 
amount of profit available to pharmacy contractors from this market is highly dependent 
on their ability to secure discounts on list price, and is likely to be highly variable in the 
future.  
National Contractual Framework 
Each year since 2005, the Pharmaceutical Services Negotiating Committee (PSNC), made up 
of representatives from the Company Chemists Association (CCA), independent 
contractors, and national representatives for pharmacists, has negotiated with the 
Department of Health and the NHS Employers24 (a group representing about 95% of NHS 
organisations) for pharmaceutical services in England and Wales. This nationally negotiated 
framework represents a significant source of income into community pharmacies. The 
negotiations agreed £2.562bn for contractors nationally for 2011/12 (Pharmaceutical 
                                                          
24
 As of March 2013 the National Commissioning Board will have the responsibility for deciding upon the national contractual 
framework for community pharmacy.  
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Services Negotiating Committee, 2011d). The total budget has increased year-on-year since 
2005. However, in absolute terms - taking inflation into account at composite price index at 
2011 prices - the trend ceases to remains positive after 2010, and has a far shallower 
gradient (figure 3.3.).  
Figure 3-3– Agreed total contractor funding in England 2005-2012 (with and 
without inflation) 
 
Taking into account the increase in volume, and the increase in total contractor funding, 
then the notional value of total contractor funding for each prescription item has in fact 
decreased since 2005 as shown in figure 3.4.  
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Figure 3-4 – Nominal Funding per item* 
 
*Nominal Item value is calculated from the total contract budget divided by prescription item volume. This is non-inflation 
adjusted.  
The effect of this decrease in overall nominal funding per item at 2011 prices is suggestive 
of a squeeze on overall margins for pharmacy contractors. This indicates a decrease of 1.9% 
in the nominal value of a prescription item each year. Overall national funding for 
community pharmacy as a proportion of NHS expenditure has remained fairly static, at just 
under 2.5% (table 3.3). 
Table 3.2– Pharmacy expenditure as proportion of net NHS spend 
Year 
NHS net expenditure 
in England (£m) 
Agreed pharmacy 
contract funding (£m) 
Percentage of 
Total 
Expenditure 
2005/06 73,203 1,770 2.42% 
2006/07 76,831 1,910 2.49% 
2007/08 83,223 1,950 2.34% 
2008/09 89,927 2,231 2.48% 
2009/10 97,130 2,318 2.39% 
Source: NHS Net expenditure in England from the Public Expenditure Statistical Analyses 2011.  
http://www.nhshistory.net/parlymoney.pdf 
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Within the national funding negotiations, there is a negotiated budget for advanced 
services. About 2.5 million MURs were conducted last year, equivalent to £70 million, and 
NMS has been budgeted at £55 million, (AUR and SAC represent a marginal additional 
income stream). Therefore advanced services represent about 5% of the national 
contractual framework. 
Enhanced services are negotiated locally, and represent £4,977 per pharmacy per annum 
(Hall, 2012), contributing about £0.05bn across the sector. However, this is not 
homogenous, in City and Hackney PCT nearly £2.5m was spent on enhanced services, 
compared to just £250 in South Gloucestershire PCT. For the average community pharmacy 
with a turnover of several hundred thousand pounds, enhanced services represent a 
negligible income stream.  
The current outlook for services is particularly uncertain. The trend in the number of 
services commissioned has increased by 45% since 2005. Yet the rate of growth is 
decreasing, possibly indicating that the capacity to deliver services has become saturated. 
On the one hand policy initiatives suggest that this sector will develop, but on the other 
reconfigurations within the NHS suggest that widespread commissioning of pharmacy 
services will not be actively purchased by clinical commissioning groups. Therefore the 
estimations of this area as a source of income suggest that it will decrease in the future 
(figure 3.5).  
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Figure 3-5– Number of Pharmacies commissioned to provide local enhanced 
services 
 
OTC Pharmaceuticals 
Over the counter pharmaceuticals (OTCs) are categorised into ‘P medicines’, which must be 
sold under the supervision of a pharmacist, and GSL medicines, which can be sold from any 
retail outlet. The sale of these products accounts for a significant proportion of turnover in 
community pharmacies. Until 2001, pharmacy profits in medicines sales were maintained 
by a resale price maintenance (RPM) scheme. When this scheme was removed the profits 
of many independent community pharmacies fell, but consumers enjoyed cheaper 
medicines and better access through supermarkets. 
Despite the reduction in pack prices, the UK market for non-prescription medicines 
supplied without a prescription, as shown in figure 3.6, has continued to grow by 2.8% over 
the five years between 2007 and 2011 (AESGP, 2011). The market is currently valued at 
about £2.4bn (The Proprietary Association of Great Britain, 2010; AESGP, 2011; Keynote 
Report, 2011a). Including those non prescription medicines supplied on a prescription 
increases this market to approximately £3.4bn (at retail selling prices25). This suggests that 
about £1bn of OTC medicines are supplied on prescription26 (AESGP, 2011).  
                                                          
25
 Note that supplied on prescriptions, these medicines are zero rated for VAT.  
26 Conversion based on 2010 average of 1.17 Euro equal to 1GBP. Based on x rates.com 
http://www.x-rates.com/d/EUR/GBP/hist2010.html  
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Figure 3-6 -UK OTC self medication sales  
 
Source: AESGP, author estimations. Trend line in red. Forecasts in green. 
In 2008, for the first time ever, globally the growth of sales of OTCs surged significantly 
ahead of growth of sales of prescription medicines. Now worth €73bn globally, the OTC 
market continues to outgrow the pharmaceutical sector by a clear and consistent margin 
(Keynote Report, 2011a).  
Yet independent community pharmacy is less likely to capitalise on this growth due to the 
large mass market sector. The United Kingdom is often considered the most developed OTC 
market in Europe, in light of its progressive regulatory system, its heavy advertising spend, 
its highly active POM to OTC switch environment and its large mass market sector. While 
the wide availability provides benefits in exposure, the existence of such a prominent non-
pharmacy sector has created a highly competitive pricing environment. Such competition 
has only intensified in the current economic environment, with community pharmacies 
suffering. According to estimates by Keynote the share of total sales in retail pharmacies 
declined from 17.1% in 2005 to 16.4% in 2010 (Keynote Report, 2011b). The increasing 
number of supermarket pharmacies has contributed to this trend, undermining the number 
of OTC pharmaceuticals that are sold on high street pharmacies (Keynote Report, 2011b). 
By volume, Tesco now represents the largest supplier of non-prescription medicines 
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(Chapman, 2011b) taking the title from Boots, who by value remain the largest supplier of 
OTC medicines to the public (Boots UK, 2012). 
One of the factors driving the shift of supply away from pharmacies is the increasing 
deregulation of medicines.  The switches are part of a national policy that drives 
collaborative care, whereby consumers rely heavily on the advice of pharmacists in making 
their OTC purchases. For manufacturers within this saturated market creating innovation 
by switching medicines from POM to OTC is the surest way to stimulate market growth. On 
this basis, many new products and indications are likely to become available OTC. A 
centralised procedure for POM to OTC switches has opened a gateway for switches to take 
place simultaneously across all 27 EU member states. The first two products to move 
through this process were orlistat 60mg (marketed as Alli) for weight loss and pantoprazole 
20mg for acid reflux. Although these were categorised as P medicines in the UK, the future 
outlook suggests more medicines will be deregulated to GSL status, where pharmacies will 
be competing with other mass market outlets for sales. The combination of these factors 
has resulted in 55% of OTC medicine sales being made in community pharmacies down 
from closer to 70% a decade ago (IMS Health and Tisman, 2011). Therefore the remaining 
medicines that are supplied tend to be ‘P’ (pharmacy only) medicines which require more 
advice and time to be spent with the consumer. Indeed, increasingly complex sales 
protocols for new POM to P medicines, such as lengthy questionnaires, are being blamed as 
one of the most common factors in the ‘failure’ of a switch (PAGB, 2012).   
In 2011, the estimated total OTC market in England at retail selling price was £2.77bn27, of 
which £2.01bn was supplied without a prescription. Community pharmacy represents 55% 
of this market, therefore approximately £1.1bn OTC medicines are supplied without a 
prescription by community pharmacies28. 
While the overall market will grow the extent to which community pharmacy will benefit 
from this growth is limited. Nowhere else in Europe is there such a breadth of product 
types available for self service selection though supermarkets and impulse outlets. Grocery 
and discount stores have been increasing their market share, and therefore the growth in 
sales will likely benefit these alternative providers. Therefore the anticipated 0.5% growth 
expected in this market is unlikely to be realised by community pharmacy contractors. 
                                                          
27 Includes VAT payable on OTC medicines of 20%.  
28 There is an additional £0.7bn in OTC medicines supplied on prescriptions in England, however these are accounted for in 
the NHS prescription figures. 
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Private Income 
Pharmacies offer services that provide them with additional income, such as travel clinics 
or nurse led clinics. Taken as a whole the market for private healthcare is expanding with 
approximately 15% of the population in possession of some form of private healthcare 
insurance (Office of Fair Trading, 2012). The total market for acute private healthcare in the 
UK was approximately £5bn in 2010 (Laing & Buisson, 2012). The penetration of community 
pharmacy into this market is limited, with the main income arising from the supply of 
private prescriptions. Some pharmacies have embraced private travel clinics or fee based 
services, such as hair retention or weight loss. The estimated total revenue from this source 
is less than £0.2bn per annum across the pharmacy sector. 
The income from private sources is likely to remain relatively static. Some contractors may 
partner with other private healthcare providers, such as Virgin Activ or BUPA to expand 
into this sector. Although currently, the degree to which it influences the overall viability of 
the market is marginal.  
Health and Beauty Retail Sales 
The total health and beauty market in the UK in 2010 was £17.9bn and is estimated to have 
increased to £18.5bn in 2011 (Verdict Retail Futures, 2012). Despite an economic 
downturn, this market has expanded, driven by the need for small luxuries in everyday life, 
especially at a time of reduced spending. The bounce back seen in 2011 led this sector to 
become one of the fastest growth channels in store based retailing, with health and beauty 
specialist retailers increasing by about  4% in current value terms going into 2011 (Verdict 
Retail Futures, 2012).  
The health and beauty market is likely to remain resilient and continue to grow, especially 
as providers continue to push into underserved markets such as male health and beauty 
products. Between 2002 and 2007 sales by health and beauty specialists collectively 
increased by 18.5%, showing the beginning of a slow down on the 29.5% growth seen 
across the previous five years (Verdict Retail Futures, 2012). This slow down was 
exacerbated by the economic recession, leading to a predicted growth from 2008 to 2013 
of 16.8%. However these still represent an overall per annum growth of 2.7%. 
Boots lead health and beauty retailing, with annual health and beauty sales of over £3.984 
billon, representing 62% of their revenue in 2010/11 (Alliance Boots, 2011).  Recently there 
has been a loss in their market share due to strong competition from Superdrug, which 
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launched a beauty card scheme, and the major grocers, which are becoming a popular 
channel for health and beauty products. 
The changes in pharmacy market entry have led to a significant shift in focus from retailers 
placing attention on dispensing as a driver of footfall. Therefore Boots and Superdrug have 
continued to expand their pharmacy networks at the expense of their para-pharmacies29. 
Companies, such as Savers, a discount health and beauty supplier, have experienced a big 
decline in sales, largely as a result of its parent company Hutchinson Whampoa diverting 
resources to its sister brand, Superdrug (Verdict Retail Futures, 2012).  
Skincare has continued to expand as a component of the health and beauty market. The 
aging population and the higher proportion of women with disposable income is driving 
this growth, meaning that skincare may overtake OTC as the largest component of the 
market. Although the sector will see growth, pharmacies and specialist health and beauty 
retailers will continue to see loss of market share (figure 3.7) because supermarkets are 
continuing to aggressively develop their offering. 
Figure 3-7 – Changes in UK Health and Beauty Market Share 
 
Source: Keynote Market report 2011 
Supermarket chains have also expanded their pharmacy offering as well as creating in the 
region of half a million sq ft of additional health and beauty retail space in 2011. These 
rapidly growing pharmacy portfolios, and highly promotional pricing, including round 
pound and multi-buy deals in the grocery sector add pressure to stretched health and 
beauty specialists. Grocers represent approximately 44% of all health and beauty products 
                                                          
29
 Those operating as drug stores, sometimes without a pharmacy/pharmacist.  
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sold in 2011 (Verdict Retail Futures, 2012), taking market share from specialist health and 
beauty retailers. As a result the market leader, Boots, continues to lose market share down 
to 22.1%. Boots have attempted to react to this by cutting costs and raising margins, which 
has ultimately improved their profitability (Alliance Boots, 2011). These tactics have driven 
down prices in the sector and consequently the margins available to smaller pharmacies 
are likely to decline. 
Overall growth in health and beauty specialist retailers outside of pharmacy is likely to be 
minimal as a result of saturation and increasing competition. Budget retailers such as B&M 
Bargains, Poundland, 99p stores and Wilkinson are also competing with community 
pharmacies for market share and are opening more stores as high street properties 
becomes vacant. These retailers are changing their image to attract mid market shoppers 
who, in times of economic recession, are trading down.  
Particular aspects of community pharmacy sales are being hit. The fragrance market, which 
once showed significant profitability for pharmacies, is suffering from competition by The 
Perfume Shop and The Fragrance Shop. These providers are rapidly expanding by offering 
discounted designer label fragrances to price conscious consumers.  
In total the English market for health and beauty products is about £16bn. Of this, health 
and beauty specialists, which include pharmacies, represent about two fifths of market 
share. Excluding the other health and beauty specialists and the £1.1bn spent on OTC 
Medicines in community pharmacies. This suggests that health and beauty sales in 
community pharmacies in England are worth approximately £5bn.  
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Figure 3-8 - Value of the UK Market for Health and Beauty specialist retailers and 
Supermarkets 
 
Source: Verdict Health and Beauty Retailers 2011.  
The dashed line in figure 3.8 shows the forecast growth in the UK market. The year-on-year 
increase from 2012 onwards is forecast to be 2% growth. This figure relates to all health 
and beauty specialists, including pharmacies, and is UK wide. In reality, the real terms 
increase in market value for independent community pharmacies is likely to be minimal.  
Overall Community Pharmacy Market in England 
Considering the four different income streams identified above, the community pharmacy 
market can be represented as shown in figure 3.9 below, where the size of the circle is 
proportional to the value of the market. It is evident from this diagram that the main 
income streams are prescription supply and health and beauty products. Services provision 
represents a small fraction of overall income in the community pharmacy market in 
England. Overall, these six revenue streams combined to represent an estimated total 
market income available to community pharmacies in England of £16.3bn in 2011.   
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Figure 3-9  - Market Size for Community Pharmacy by Area  
 
While accepting that there are a variety of business models that operate across pharmacy, 
in general terms independent pharmacies operate in an environment where the majority of 
their income is derived from the NHS. It was suggested in 2003 that approximately 80% of 
the average independent community pharmacy’s turnover is generated by NHS business 
(Office of Fair Trading, 2003), a figure which has more recently been estimated to be closer 
to 90% (South East Local Pharmaceutical Committee Forum, 2005). Therefore typically 
prescription dispensing accounts for about 80-90% of revenue, retail sales accounts for 10-
20% of revenue and pharmacy services represent about 5%. 
In a business environment, workload will inevitably be focused towards those activities that 
secure the greatest income. In the case of pharmacy this is the supply of prescriptions and 
the sale of health and beauty products (including OTC medicines). The provision of 
community pharmacy services provides a minimal income, and although a possible income 
stream, it is not the main priority of the businesses. To some extent this explains the 
observation that pharmacists continue to spend the majority of their time on supply of 
prescription medicines (chapter 2).  
Average ‘Ideal Type’ pharmacy? – a simplistic model. 
Against these trends, the average community pharmacy: supplies 6,300 prescription per 
month; provides 192 MURs per year30; completes 54 NMS per year31; and receives £4997 
for enhanced services.  At £9.04 per prescription item, NHS revenue is £683,424. Including 
fees, total NHS revenue per annum is £896,591. The average pharmacy is independent, 
                                                          
30 Based on 2011 data: 203,628 MURs divided by 10, 951 pharmacies.  
31 Extrapolated based on limited March 2012 data 
Prescriptions Health and Beauty Sales NHS Supply Income OTC Sales  Private Services 
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therefore total non NHS revenue is 20% of this total, or £179,318. Removing purchase 
costs, gross Non NHS income is £17,931.Therefore average pharmacy income32 is £231,098 
For an independent the average property costs are £26,058, depreciation is £13,000, other 
costs, £17,767, head office Costs £2,600 and cost of capital is £39,983. The staff costs are 
£152,660. This totals a cost of £252,069. 
A full explanation of this model and the relative figures for each of these averages is 
provided in the appendix B. As with any model there are several simplifications and 
assumptions, based on the readily available data.  
Therefore, by the average of averages, the average pharmacy is not profitable, making a 
loss each year. It is evident from reality that the average pharmacy does not make a loss. In 
fact far from it, the vast majority of pharmacies operate a profitable business. What this 
suggests is that the data is either falsely increasing the costs, or there is additional income 
that is not accounted for in this model.  
The model of the average ‘ideal type’ pharmacy is one that is fictitious in its existence as 
the numbers provided are averages across a range of variables. As already described, there 
is no such thing as the average pharmacy, with pharmacies adopting different business 
models. However, what this exercise shows is that the national data sets used and the 
actually income streams into community pharmacy are not transparent. It is likely that 
retained buying profit and wage transfers exist which are not accounted for in this model.   
Section Conclusion 
The main income stream into a community pharmacy business is generated from the 
supply of prescription medicines. The margins for these medicines and the relative values 
of each prescription have decreased over the past decade. This is a trend which, under 
times of economic recession, looks set to continue.  
Sales of OTC medicines and allied health and beauty products from independent 
community pharmacies have suffered as a result of the expansion of supermarkets into this 
sector. While the large health and beauty retailers have been able to compete, smaller 
independent pharmacies have suffered a considerable loss in their market share. 
                                                          
32 This makes the Pharmacy Income = £201,444 + (£5376 + £1350 + £4997) + £17,931. 
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Further revenue can be generated by extended pharmaceutical services. Yet at present the 
scale of funding for these services is erratic and unpredictable.  At present such services do 
not represent a viable business opportunity for pharmacies. Without sufficient assurances 
of returns there is unlikely to be future investment by businesses in these services. 
Against this, it is unsurprising that pharmacists have focused their attention on prescription 
supply, and spend a large proportion of their time assembling and labelling products. 
Despite the workload challenges created by the growth in prescription items and the 
decrease in relative margins, dispensing continues to represent a guaranteed income 
stream. 
The rest of this chapter seeks to understand why there has been such an increase in 
prescribing volume, and to explore strategies that can be taken to address this workload by 
focusing on the relationship between prescription durations and volumes. 
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The Increases in Prescription Volume 
[The data report reported in the section formed the substantive part of a paper published in 
Primary Health Care Research and Development under the title “Individualisation or 
standardisation: trends in National Health Service prescription durations in England 1998–
2009”.(Davies and Taylor, 2012)]  
The increase in prescriptions seen over the last decade is a reflection of the changing 
mantra of the health service as it moves from acute healthcare towards preventative 
health and the management of chronic disease. The literature suggests that the increasing 
age of the population; the increased use of secondary preventative technique (as well as an 
increase in the prescribing of preventative medicines, such as low cost statins, for 
cardiovascular diseases); the dominance of the unhealthy lifestyle which have driven up 
prescription use (obesity, etc); and finally the increase in evidenced based medicine driving 
national guidelines for prescribing (e.g. NICE guidelines), are all factors that have led to 
rising prescription volumes (Davies and Taylor, 2010a).  
Undoubtedly, the Quality and Outcomes Framework (QOF), introduced in 2004 as a reward 
programme for GP practices, has led to the increase in prescription volume through its 
incentivisation of prescribing for primary prevention, particularly in cardiovascular disease. 
As the background prevalence of chronic disease increases, this (and other national 
prescribing frameworks such as NICE guidance and National Service Frameworks) has led to 
an increase in prescription items for other prevalent chronic diseases, such as asthma and 
diabetes. 
All of the reasons provided above suggest that prescription volumes are a factor of health, 
and are driven by  health targets. However, other subtle factors may be at play. Some have 
hypothesised that the duration of each prescription has also influenced the observed 
increase in prescription items (York Health Economics Consortium and School of Pharmacy 
University of London, 2010). The authors suggest that pharmacists have actively 
encouraged shorter prescription durations, using evidence that longer prescription 
durations result in increased medicines waste to artificially increase their income. However, 
there is little published evidence to prove whether this is the case.  
In order to strategise ways for pharmacists to manage the increasing number of 
prescriptions, as well as to understand processes that led to the increase in prescription 
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volume, an evaluation of the NHS prescribing data was undertaken to discover the extent 
to which the shortening of prescription durations has affected prescription volumes.  
Background to Prescription Duration 
During the 1990s, several studies explored the opportunities available for reducing the drug 
stocks held by patients at any one time, and where possible aimed to prevent the 
potentially hazardous and wasteful stockpiling of medicines. Reducing the duration of the 
average prescription emerged as a possible means of achieving this end. For example, an 
influential investigation published in 1996 of unused medicine returns made to thirty 
community pharmacies over a one month period (Hawksworth, 1996) found a positive 
correlation between prescription lengths and the volume prescribed, with the cost of the 
drugs brought back to pharmacies. The authors of this research claimed that if all 
prescription supplies could be limited to 28 days then wastage would be reduced by a third, 
albeit that they did not offset the financial savings implied by the possible cost increases 
involved in the associated fees to pharmacies. 
It is worth noting at this point that several initiatives were taking place in community 
pharmacy. The Nuffield report on community pharmacy had been published less than a 
decade before and was still very much in the minds of policy leaders in pharmacy. Those 
within the policy elite in the profession could see that the increasing genericisation of 
medicines and developments associated with reducing the supply costs of pharmaceuticals 
were likely to impact upon the future income of community pharmacies. Therefore they 
began to think strategically about how pharmacy could look elsewhere to gain both 
professional support and alternative income streams (chapter 1). 
One of the leading actors involved in these studies was Gillian Hawksworth, who was a 
member of the RPSGB council between 1992 and 1998. As an independent pharmacy 
contractor, Hawksworth began to realise the economic and business constraints likely to 
affect the future of community pharmacy, and as such sought to demonstrate the positive 
effects of community pharmacy through research. Her work promoting the idea of large 
scale medicines waste suggested short prescriptions and community pharmacy as the 
solution.  
Following such research, a significant proportion of prescribers were advised to reduce the 
length of their prescriptions in order to curb medicines wastage. This practice was 
supported by the Pharmaceutical Services Negotiating Committee (Pharmaceutical Services 
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Negotiating Committee, 2007), the Department of Health (Department of Health, 2004d) 
and the National Prescribing Centre (National Prescribing Centre, Undated). Since their 
formation in 2002, many PCTs have sought to restrict prescription lengths while also 
investing in awareness raising activities such as DUMP (dispose of unused medicines 
properly) campaigns. Even if the latter did little directly to curb ongoing waste, they may 
encourage and/or legitimate other interventions (York Health Economics Consortium and 
School of Pharmacy University of London, 2010). 
Certain medicines, most notably the combined oral contraceptive pill, have been excluded 
from such restrictions on the grounds that they are relatively inexpensive long term use 
products that normally require limited follow up care. As well as the fact that healthy 
young women wishing to use ‘the pill’ might be expected to oppose robustly the 
inconvenient imposition of unduly short supply durations. 
The provision of levothyroxine for conditions associated with thyroid deficiency offers 
another example of a medication that might rationally be expected to be supplied via long 
duration prescriptions. Yet research conducted by the British Thyroid foundation (Mitchell 
et al., 2009a; Mitchell et al., 2009b) found that in 2008/09 about a third of Primary Care 
Trusts were seeking to apply a 28 day limit on all levothyroxine prescriptions. In other parts 
of the country PCTs were ‘allowing’ 2, 3, or even 6 month prescriptions. But in more 
restrictive areas it appears that many GPs accepted that 28 day prescribing rules should 
apply to all medicines being taken for long term conditions (White, 2010).  
The extent to which this policy has in fact reduced the cost of medicines waste and other 
problems is difficult to estimate, not least because of the growing use of relatively low cost 
generic medications (The NHS information Centre Prescribing Support Unit, 2010). The 
latter has likely been partly responsible for a fall in the (non-inflation adjusted) net 
ingredient cost33 per prescription item to £9.04 in 2011, from £9.99 in 1999 (The NHS 
Information Centre, 2011). It is important to note that while drug reimbursement costs are 
based on the actual quantity of medicine supplied, the professional fees paid to pharmacy 
contractors are on a per item basis, meaning that contractors receive the same 
professional fees for supplying 28, 56 or 84 tablets. Therefore, an active reduction is 
prescription length will increase the number of prescriptions and the remuneration 
associated with them. 
                                                          
33 The net ingredient cost refers to the cost of the drug before discounts and does not include dispensing costs or fees.  
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A number of studies conducted outside the UK environment highlight the potential 
importance of such observations. For example, in 2004, US researchers investigating 
medicines supply via Medicaid concluded that restricting prescriptions to less than 100 
days would not be cost effective, as the savings made via wastage prevention would be 
outweighed by increased pharmacy service costs (Domino et al., 2004). Similarly, a New 
Zealand project which increased the length of prescriptions from around 30 days to 90 days 
indicated a saving in excess of NZ$100m. This occurred because the resultant pharmacy 
cost reductions were greater than the increase in medication wastage observed.  
It should not be assumed that such conclusions necessarily apply to the British setting. 
However, there is a clear case for believing that such a possibility might exist. Furthermore, 
the British Thyroid Foundation8 revealed that nearly two thirds of patients were dissatisfied 
with 28 day prescriptions for levothyroxine. This calls into significant question the 
desirability of trends observed in this context (White, 2010).  
A recent Department of Health funded review of medicines waste found that in England 
alone in 2008/09 some £300 million worth of NHS community supplied medicines were 
disposed of unused, and that up to £150 million of this inefficiency is cost effectively 
avoidable. This last figure is equivalent to about 2 per cent of the cost of all medicines 
supplied, and a little under 10 per cent of the cost to the NHS of community pharmacy 
services. This study also presented evidence that the inappropriate imposition of 
restrictions like 28 day prescribing in some circumstances reduces adherence in medicines 
taking and can lead to other forms of perverse consumer reaction.  At the same time some 
of the GPs and pharmacists interviewed expressed concerns about the quality of personal 
care being provided to vulnerable NHS patients living in the community. They noted that 
the amount of time being spent on activities such as dispensing by pharmacists, as opposed 
to understanding and meeting patients needs in a flexible and individually tailored manner, 
was to the detriment of patient care.   
Against this background a brief analysis was undertaken to see if nationally collected data 
showed any changes to prescribing lengths as a result of the original research 
(Hawksworth, 1996) and the policy suggestions that developed from it.  
Methodological Approach 
Each year the Department of Health (DoH) publishes a set of Prescription Cost Analysis 
(PCA) statistics. These data provide details of the number, content and costs of all the 
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prescription items dispensed in the community in England. This data are based on 
information systems at NHS Prescription Services, part of the NHS Business Services 
Authority. The data are collected as part of the process of reimbursing for medicines 
supplied34. 
The analysis offered here relates to the period of January 1998 to December 2009 inclusive. 
The numbers used includes all relevant items supplied in the community. The vast majority 
of prescriptions included are written by General Medical Practitioners in England, but the 
analysis includes prescription written by dentists and hospital doctors that were dispensed 
in the community, as well as prescriptions written in Wales, Scotland and Northern Ireland, 
but dispensed in England.  
The information available allows for the calculation of the average quantity of dosage units 
(tablets or capsules) supplied per prescription item in each year, which serves here as a 
proxy for prescription duration. Liquid and injectable formulations of these medications 
were excluded, as comparable volume data is not easily accessible. In total eleven drugs, 
available as 34 different dosage and strength presentations and in over 60 forms (i.e. 
different brand and generic items) were included in the sample analysed. They were 
selected due to featuring in the ‘top twenty’ most frequently prescribed agents in 2009 for 
which dosage units could be considered an appropriate proxy for prescription length.   Nine 
long-term medications used in chronic conditions (simvastatin, levothyroxine, ramipril, 
bendroflumethiazide, amlodipine, atenolol, atorvastatin, aspirin and citalopram) were 
selected, in part because of the high volume of these products dispensed. Other selection 
criteria included the characteristic of being taken via a specified dosing schedule (i.e. they 
are not PRN or ‘take as required’ medications) and their availability in countable dosage 
forms and data being available for the period analysed.  
Due to the fact that prior investigations indicated that PCT prescribing advisers usually 
accept that contraceptive products should be exempted from 28 day supply requirements, 
Microgynon – the most commonly prescribed combined oral contraceptive was also 
included for comparative purposes. Finally, antibiotics are subject to different prescribing 
restrictions compared to chronic medications as they are usually prescribed for a short 
defined period of time. Therefore, amoxicillin capsule supply duration was interrogated as 
a comparator to the chronic medications because it is the most commonly prescribed 
                                                          
34
 Due to the complex automated and manual processes involved in capturing this data, inaccuracies may occur. Currently 
internal audit suggests the data is 97.5% accurate.  
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antibiotic in the community setting35. This would aid the assessment of the a priori 
hypothesis that prescription durations had decreased in the past decade. A full list of the 
presentations analysed is shown in table 3.4. In combination they accounted for 194 million 
of the prescription items dispensed in 2009, representing approximately 20% of the 
prescription items supplied.  
Data were extracted from the Department of Health published tables. For each drug, all 
data relating to branded and generic formulations was extracted from the published 
Prescription Cost Analysis (PCA) tables. Data extraction was checked manually to ensure 
accurate extraction and formatting. Preparation data was then collated to provide values 
for each drug. This was subsequently analysed using Microsoft Excel 2010 and SPSS V16. 
Trends in the average number of unit doses (tablets or capsules) supplied per prescription 
were analysed using Pearson r and linear regression analysis. The complete data set is 
summarised in Table 3.5. 
Table 3.3 – Presentations Analysed 
Drug Presentations analysed (Generic and Branded) 
Simvastatin 10mg tablet, 20mg tablet, 40mg tablet, 80mg tablet. 
Levothyroxine 25mcg tablet , 50mcg tablet, 100mcg tablet 
Ramipril 1.25mg tablet, 2.5mg tablet, 5mg tablet, 10mg tablet, 1.25mg 
capsule, 2.5mg capsule, 5mg capsule, 10mg capsule 
Bendroflumethiazide 2.5mg tablet, 5mg tablet 
Amlodipine 5mg tablet, 10mg tablet 
Atenolol 25mg tablet, 50mg tablet, 100mg tablet 
Atorvastatin,  10mg tablet, 20mg tablet, 40mg tablet, 80mg tablet 
Citalopram 10mg tablet, 20mg tablet, 40mg tablet 
Aspirin  75mg tablet, 75mg E/C tablet 
Combined Ethinylestradiol Microgynon 30mcg tablet 
Amoxicillin 250mg capsule, 500mg capsule 
                                                          
35 In the strictest sense amoxicillin could not be used as a control, but it offers some insight into the differences between 
acute and chronic medication supply.  
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Table 3.4– Prescription Length Comparison 
 A B C  D E F  G H     
 
Prescription 
items 
dispensed in 
1999 
(thousands*) 
 
Total volume 
of doses 
(e.gtablets,  
capsules) 
supplied in 
1999 
(thousands*) 
Mean 
number of 
doses per 
prescription 
in 1999 
(B/A) 
 
Prescription 
items 
dispensed in 
2009 
(thousands*) 
Total 
volume of 
doses 
(e.gtablets,  
capsules) 
supplied in 
2009 
(thousands*) 
Mean 
number of 
doses per 
prescription 
in 2009 
(E/D) 
 
Number of 
additional 
Prescriptions 
items created by 
change in mean 
number of doses 
(D – (E/C) 
Percentage 
change in 
mean 
number of 
doses per 
prescription 
((C-F)/C) 
 
Pearson r 
(YEAR/ 
AVERAGE 
LENGTH) 
R Squared 
(YEAR/ 
AVERAGE 
LENGTH) 
P 
(YEAR/ 
AVERAGE 
LENGTH) 
Amoxicillin 250mg 
Capsules 
6496 126825 19.52  3508 70549 20.11  -105.8 2.9% 
 
0.862 0.743 <0.001 
Amoxicillin 500mg 
capsules 
2791 55122 19.75  6175 127102 20.58  -260.4 4.1% 
 
0.929 0.863 <0.001 
Atorvastatin 10mg 
Tablet 
1201 48566 40.43  2856 104097 36.45  281.5 -10.9% 
 
0.991 0.983 <0.001 
Atorvastatin 20mg 
Tablet 
392 16396 41.8  3396 123570 36.39  440.2 -14.9% 
 
0.998 0.996 <0.001 
Atorvastatin 40mg 
Tablet 
111 5007 45.31  3560 125580 35.27  788.4 -28.4% 
 
0.986 0.972 <0.001 
Atorvastatin 80mg 
Tablet 
x x x  1037 33842 32.64  x x 
 
0.999 0.997 <0.001 
Simvastatin 10mg 
Tablet 
2195 94164 42.89  2834 103806 36.63  413.7 -17.1% 
 
0.999 0.998 <0.001 
Simvastatin 20mg 
Tablet 
1289 54870 42.55  11010 405262 36.81  1487.1 -15.6% 
 
0.988 0.976 <0.001 
Simvastatin 40mg 
Tablet 
103 4298 41.65  22981 829109 36.08  3073.3 -15.4% 
 
0.955 0.912 <0.001 
Levothyroxine 
25mcg Tablet 
1842 122439 66.49  6706 295111 44.01  2267.3 -51.1% 
 
0.933 0.986 <0.001 
Levothyroxine 
50mcg Tablet 
3099 228595 73.76  7066 306141 43.32  2915.9 -70.3% 
 
0.991 0.982 <0.001 
Levothyroxine 
100mcg Tablet 
3290 192292 58.44  8129 352648 43.38  2095.0 -34.7% 
 
0.994 0.989 <0.001 
Atenolol 25mg 
Tablet 
1981 89185 45.02  4436 182561 37.85  380.9 -9.4% 
 
0.998 0.995 <0.001 
Atenolol 50mg 
Tablet 
5467 248842 45.52  9707 408695 38.69  728.0 -8.1% 
 
0.998 0.996 <0.001 
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Atenolol 100mg 
Tablet 
2571 116759 45.42  3167 132944 38.35  239.8 -8.2% 
 
0.998 0.996 <0.001 
Citalopram 10mg 
Tablet 
199 6646 33.4  2681 85273 31.80  128.1 -5.0% 
 
0.945 0.893 <0.001 
Citalopram 20mg 
Tablet 
959 32958 34.36  6344 213459 33.65  132.0 -2.1% 
 
0.849 0.721 <0.001 
Citalopram 40mg 
Tablet 
56 1766 31.71  1421 44294 31.18  24.0 -1.7% 
 
0.631 0.399 0.28 
Ramipril 1.25mg 
capsule 
269 11175 41.6  1613 53114 32.93  336.5 -26.4% 
 
0.999 0.998 <0.001 
Ramipril 2.5mg 
capsule 
515 23605 45.85  4313 154869 35.91  935.5 -27.7% 
 
0.988 0.975 <0.001 
Ramipril 5mg 
capsule 
725 38950 53.75  5154 203288 39.45  1371.8 -36.3% 
 
0.955 0.912 <0.001 
Ramipril 10mg 
capsule 
31 1292 41.16  7477 277020 37.05  746.1 -11.1% 
 
0.957 0.916 <0.001 
Ramipril 1.25mg 
Tablet 
x x x  71 2353 33.34  x x 
 
0.966 0.933 <0.001 
Ramipril 2.5mg 
Tablet 
x x x  161 5714 35.40  x x 
 
0.962 0.925 0.001 
Ramipril 5mg Tablet x x x  188 7396 39.33  x x  0.916 0.839 0.004 
Ramipril 10 mg 
Tablet 
x x x  272 9757 35.92  x x 
 
0.546 0.298 0.205 
Bendroflumethiazide 
2.5mg Tablet 
7850 363738 46.34  18206 698946 38.39  3122.4 -20.7% 
 
0.992 0.983 <0.001 
Bendroflumethiazide 
5mg Tablet 
1760 78668 44.71  632 24386 38.56  86.9 -15.9% 
 
0.991 0.982 <0.001 
Microgynon 
Combined 
Ethinylestradiol 
30mcg 
2554 253331 99.2  2238 220466 98.51  15.4 -0.7% 
 
0.647 0.419 0.023 
Amlodipine 5mg 
Tablet 
3260 139585 42.82  10122 377313 37.28  1309.5 -14.9% 
 
0.995 0.99 <0.001 
Amlodipine 10mg 
Tablet 
1607 67950 42.28  6320 235311 37.23  755.5 -13.6% 
 
0.998 0.997 <0.001 
Aspirin 75mg tablet 11618 646766 55.67  26647 951342 35.70  9558.2 -55.9%  0.99 0.981 <0.001 
Aspirin 75mg E/C 
Tablet 
2227 114854 51.58  6748 230794 34.20  2273.4 -50.8% 
 
0.999 0.997 <0.001 
*rounded to the nearest thousand X – product not available in 1999.  
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Results 
All of the long term use medications analysed showed a clear trend over time towards a 
reduced number of doses being supplied per prescription. Typically, on average, the mean 
quantity supplied fell by five doses on each prescription over a ten year period (table 3.5). 
To illustrate the nature of the calculations made, the PCA data showed that in 2009 
7,066,184 prescriptions were written for levothyroxine 50mcg tablets (Figure 3.10), and 
that overall 306,141,376 tablets were supplied in that year. This equates to an average of 
43.32 tablets per prescription.  By contrast, in 1999 3,099,000 prescriptions were written 
for Levothyroxine 50mcg tablets, and 228,594,600 tablets were supplied. This equates to 
an average of 73.76 tablets per prescription. If all the tablets supplied in 2009 had been 
supplied via prescriptions written to the 1999 mean, this would have resulted in 4,150,282 
prescription items, rather than the 7,066,184 actually dispensed. The close to three million 
item discrepancy between these totals is indicative of the scale of the dispensing workload 
that could have been avoided if the number of tablets per prescription had not been 
reduced. 
Other than in the case of amoxicillin where the correlation was positive, the majority of the 
drugs included showed a strong, statistically significant (p<0.001), negative correlation 
between the year of prescribing and the mean number of doses per prescription item. The 
exceptions to this were citalopram 40mg tablets (r =0.631, p=0.28), ramipril 10mg tablets 
(r=0.546 and p= 0.205) and the combined oral contraceptive, Microgynon (r=0.647, 
p=0.023, see figure 3.11). The mean number of doses per prescription decreased by 
approximately seven tablets over the last decade for atenolol, bendroflumethiazide and 
amlodipine (Figure 3.12), which are commonly used to treat hypertension in primary care. 
However, ramipril tablets were not widely available until 2003, which may well explain the 
non-significant trend observed in this context. The ramipril capsules show an average 
decrease of nine capsules against a typical initial volume of 50 across all the different 
strengths in the period assessed. 
The mean number of statin doses per prescription reduced by about six tablets against a 
starting total of just over 40 in the period concerned (Figure 3.13). The 80mg atorvastatin 
presentation did not enter the market until 2000, and is only featured in the data available 
from 2001. Similarly simvastatin 80mg does not feature in the data until 2000.  
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It was anticipated that there would be no significant change in the mean number of doses 
for amoxicillin capsules. However, these capsules showed a shift towards increased 
prescription duration. In overall (population level) volume use terms the number of 250mg 
capsules supplied has also decreased, while the volume of 500mg capsules prescribed has 
markedly increased (table 3.5). 
The reduction in prescription item volumes observed in the decade 1999-2009 varies 
considerably between the different medicines analysed. The observed range was from an 
increase of 4.2% in the case of amoxicillin 500mg capsules to a fall of 41.3% in that of 
levothyroxine 50mcg tablets. The prescribing of aspirin 75mg tablets also reduced markedly 
(circa 35% in volume per item terms). 
The results shown suggest that overall, if the average prescription length had been kept the 
same as in 1999 then some 35 million fewer prescription items would have been dispensed 
in 2009 than was actually the case for the preparations included in this sample.  
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Figure 3-10 - Average Levothyroxine prescription durations (1998-2009) 
 
Figure 3-11- Microgynon Combined Ethinylestradiol 30mcg, prescription duration 
(1998-2009)  
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Figure 3-12– Anti-hypertensive prescription durations (1998-2009) 
  
Figure 3-13– Statin prescription durations (1998-2009) 
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Towards shorter prescriptions? A Discussion 
This shift across a range of medications suggests a generalised change in prescribing 
behaviour, associated with both local and national policies and interventions. Amoxicillin 
showed an opposite trend to the chronic medications, with longer prescription durations 
and a greater volume of higher strength capsules. This could in part be explained by 
concerted national and international campaigns over the last decade to change prescribing 
behaviour for antibiotics to optimal doses, however it is unclear from this data as to why 
prescription durations for amoxicillin have increased.  
One of the most striking differences is observed in aspirin, which may in part be related to 
changes in the pack sizes available.  Aspirin was once commonly supplied in 100 tablet 
bottles. It is now more often presented in boxes of 28 tablets.  The trend shown here may 
also have been affected by a shift away from 150mg (2x75mg) daily dosing to 75mg daily 
dosing. The move towards the common supply of original pack dispensing, as seen with 
Aspirin, was partly the result of a European Community Directive (92/27/EEC) which 
requires all dispensed drugs to be accompanied by a Patient information leaflet (PIL). 
Therefore, it has been law since 1998 for all UK medicinal products to be supplied with an 
authorized PIL. The requirement for a PIL to be provided spurred the development of 
patient ready packs leading to an increased number of products being packed and supplied 
in a patient ready format. This suggests one of the limitations to the analysis performed 
above. In most cases, and certainly for the preparations analysed, items are supplied in 
patient ready packs. This would suggest that prescription length is not a continuous 
variable, but instead a dichotomous one (i.e. 28 days or 56 days) as dictated by patient 
pack size. However, evidence from pharmacists suggests that prescribers are often 
unaware of pack sizes and therefore supply quantities of 28, 30 or 32 days, which causes 
pharmacists to ‘snip’ packs. This results in additional time consuming processing steps 
(Pharmaceutical Services Negotiating Committee, 2007)36. Therefore, a limitation of this 
data it that it does not allow for the evaluation of the spread of data behind each mean. A 
further limitation is that the drugs and formulations selected may not be fully 
representative of prescribing as a whole, despite their high prescribing volumes.  
The combined oral contraceptive was one of the first products to be supplied in patient 
ready packs, and yet the view that contraceptives such as Microgynon should be excluded 
                                                          
36
 Consider the RPSGB Snipping campaign, or for example evidence presented to the APPG. 
http://faculty.ksu.edu.sa/hisham/Documents/StudentsAll4/1/2/1a%20%2833%29.pdf or more recently  
http://www.pharmacy-life.co.uk/news/news/6/medicines-packaging-campaign-launched.aspx 
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from prescribing length restrictions is supported by the data presented. No statistically 
significant change in prescription length could be observed.  
For products where a significant decrease was not observed, several other factors may be 
important. For example, the discrepancy seen in Citalopram may be due to the supply of 
short term prescriptions due to the nature of the indications to which this is being used and 
the associated risk of suicide, coupled with possible prescriber concerns regarding self 
harm attempts.  
However, despite the limitations acknowledged above and the limited number of 
medicines studied, there has been a general trend towards shorter prescription lengths.  As 
prescription durations have reduced, the number of items dispensed has increased. It is not 
possible to extrapolate with full confidence the findings offered here to the entire range of 
medicines supplied in the community setting in England. Yet it is probable that if 
prescription lengths had not decreased over the course of the last decade the total number 
of items being dispensed via community pharmacies and other outlets would be about 10 
per cent lower than is currently the case. A simple extrapolation would suggest a 175 
million prescription item variation between 1999 and 2009, but long term use items subject 
to prescription volume declines were probably over-represented in the sample selected. If 
it were assumed that the total number of potentially avoidable items were only 50 per cent 
of the total implied by simple extrapolation, then it would stand at just under 90 million. 
Considering pharmacy fees, and all other things remaining constant, the increase in 
prescription numbers due to duration declines, cost the NHS in the region of £150 million in 
2009. This is approximately 10% of the cost of the 2009 community pharmacy budget for 
medicines supply.   
As previously noted, the overall increase in NHS prescription item numbers observed in 
England during the decade from 1999 to 2009 was over 300 million, a nearly 70% rise. The 
significance of prescription volume reductions alone should not therefore be overstated. 
The calculation of pharmacy fees is also linked to fixed, rather than variable, business cost 
assumptions, and should consequently over time take into account the marginal, rather 
than average, costs of activity rate increases. This implies that although community 
pharmacists will (unlike non-dispensing GPs) in the short term gain financially through 
supplying additional prescription items, their longer term returns will be ratcheted down.  
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In considering the public policy implications of growing prescription item numbers and 
their ongoing health and health care impacts, two initial points deserve emphasis. First, as 
already highlighted, growth in the overall volume of generic and other medicines being 
supplied to the population is a multifaceted phenomenon. It is taking place worldwide as 
relatively rich societies age and relatively poor ones benefit from globalisation and their 
populations gradually get better access to health care.  
One particularly important driver in the last ten to twenty years has been the mass use of 
medicines to reduce the risk of, and to treat, vascular diseases. For example, a recent 
Canadian study showed a 165% increase in the total number of prescriptions for such drugs 
in the decade 1996-2006 (Jackevicius et al., 2009).  There is substantive evidence that such 
changes in medical and pharmaceutical care have significantly benefited the communities 
being served, and have been encouraged by governments as well as by commercial 
interests. In Britain, for instance, the current general medical services (GMS) contract 
incorporates a points based Quality and Outcomes Framework (QOF) which incentivises 
improved chronic disease management (Alabbadi et al., 2010). One of its effects has been 
to encourage an increased use of medicines such as statins and anti-hypertensives. 
Second, with regard to the reductions in prescription durations reported here, the 
arguments in favour of this strategy in England have related primarily to medicines waste 
prevention. In addition to evidence such as that published by Hawksworth et al in the 
1990s, there are more recent studies that confirm that restricting periods of chronic/long 
term medicines supply to a period of 28 days should reduce the volume of NHS medicines 
that eventually have to be discarded. For example, a widely cited Bradford University study 
investigated two groups of 20 elderly patients receiving regular prescriptions for more than 
3 medications. The first had 28-day prescriptions and the second 56-day supplies. It was 
found that the 56-day group had greater home stocks, and reported disposing of unwanted 
medicines more often than the 28 day group (Gatley et al., 1995). Suggesting that the 
rational application of 28 day prescribing polices appears to reduce medicines waste. 
It would therefore be wrong to assume that the growing volume of NHS prescription items 
supplied by community pharmacies has been a negative trend in public health terms, 
and/or that reducing the length of the average prescription has during the past decade 
increased dispensing costs without conferring any counterbalancing benefit. 
 
 
140 
However, the possibility that therapeutic gain has been lost as a result of policies ostensibly 
aimed at medicine waste reduction should not be ignored. For example, evidence from 
Italy suggests that shortening prescription durations for patients being treated for 
hypertension reduced adherence rates in people who had previously been taking their 
medicines appropriately (Atella et al., 2006). In the American context Domino et al. (2004) 
recognised reducing duration decreased waste but this was not justified due to increases in 
dispensing outlays. Notwithstanding the dissatisfaction and inconvenience that these 
prescribing policies have for patients (Mitchell et al., 2009a; Mitchell et al., 2009b).   
Such research suggests that the supply of medicines to people should be facilitated in ways 
which maximise customer satisfaction and minimise professional workloads, even if longer 
average prescriptions durations are associated with an increased risk of physical waste. The 
latter’s cost might be successfully offset via greater concentration on identifying and 
effectively supporting patients at unusually high risk of experiencing problems with 
medicines taking. Lack of harmonisation when managing repeat pharmaceutical supply has 
been suggested to contribute to waste, highlighting perverse provider side incentives that 
produce system failings (Jesson et al., 2005). In this instance a balance should be struck 
between standardised prescribing terms and patient desires for individualised care, albeit 
that in situations where there are unusually high treatment costs or risks of non-
consumption, safeguards should be instituted. 
The findings reported here do not in themselves define the extent of avoidable waste or 
the effects of 28 day policies on clinical outcomes. But they do indicate a need for further 
evaluations. It is possible that a more flexible approach to regulating prescription lengths 
could increase service efficiency and effectiveness while also creating a more convenient 
system for some patients. International experience suggests that median community 
prescription duration periods of up to three months (that is, of around twice the current 
estimated length) may prove desirable (Domino et al., 2004) especially if community 
pharmacy and other resources released can be cost effectively re-deployed towards areas 
of higher gain. 
Section Conclusion 
The data presented in this analysis indicates that in the context of longer term medicines 
use, the last decade has seen a significant reduction in the duration of prescriptions 
supplied by the NHS. This may have been due to the encouragement of ‘28 day prescribing’ 
which has been applied rigidly in some localities. While such policies may have brought 
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advantages in some contexts, they may nevertheless have imposed additional 
disadvantages elsewhere.   
This study does not provide a definitive answer in favour of prescription duration 
individualisation as opposed to standardisation. Yet it does suggest that this is an area in 
need of further exploration aimed at discovering if the intelligent, ‘customer needs’ 
focused application of informed professional judgement to prescription duration 
determination should be preferred to blanket prescribing policies. As such there are 
potential opportunities for the community pharmacy profession to advocate increasing the 
duration of prescriptions. In doing so this would release some of the pharmacists’ time, and 
would allow them to carry out therapeutics based interventions.     
Chapter Conclusion 
The productivity of pharmacists has increased over the last decade to manage the swell in 
prescription items created as a result of the new and innovative ways of using 
pharmaceutical therapies to treat diseases, particularly as preventative treatments for 
diseases associated with a western lifestyle. This trend looks only set to increase. Further 
administrative and regulatory changes, coupled with an increasingly competitive market, 
have all added to the workload pressures that pharmacists experience. 
The main income stream into a community pharmacy business is generated from the 
supply of prescription medicines through the pharmacy contractual framework, and as a 
result it is understandable why this activity dominates so much of pharmacists’ time. Yet 
the benefits of pharmacists supporting and overseeing the safe and effective supply of 
nearly a billion prescription items each year should not be underestimated. 
Meanwhile the economic reward for each unit of work has decreased. This is a trend which, 
under times of economic recession, looks set to continue. This has been positively 
reinforced by the restrictions on dispensing income and retained buying profit imposed by 
the Department of Health as well as by the increase in prescription volume observed over 
the last decade. Such changes have added to the pressure that community pharmacists 
experience in their day-to-day working practice.  
The evidence presented in this chapter suggests that the supply of medicines to people 
should be facilitated in ways which maximise customer satisfaction and minimise 
professional workloads, even if longer average prescriptions durations are associated with 
an increased risk of physical waste. The latter’s cost might be successfully offset via greater 
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concentration on identifying and effectively supporting patients at unusually high risk of 
experiencing problems with medicines taking, a role that pharmacists are well placed to 
support. Indeed, such activities would make better use of their skills. Professional efforts 
ought also to focus on situations where unusually high treatment costs are involved, and/or 
where failures to take medicines as recommended are most likely to lead to lost health 
gains. 
Additional commercial pressures have been generated by competitive practices in the sales 
of OTC medicines and allied health and beauty products, which have shifted custom away 
from high street locations towards large scale grocers. Retail led health and beauty retailers 
have robustly competed, but all the signals indicate that smaller independent pharmacies 
will continue to suffer a considerable loss in their retail market share. 
At present the current structure of the pharmacy business is pulling the workforce in 
several different directions. Pharmacists are struggling to decide what their core purpose 
and responsibility should be within the health service under challenging economic 
conditions. The economic and practical viability of extended ‘clinical’ roles appears 
doubtful. At present the scale of the funding for community pharmacy based services is 
erratic and unpredictable, which in turn prevents future investment and innovation. The 
combination of these factors has led to several obstacles to the further development of for 
the pharmacy profession, including stress, workload fatigue and general disillusionment. 
Unless the underlying issues of workload are suitably managed or resolved, community 
pharmacy practice is unlikely to be able to embrace the clinical mantle that government 
policies are suggesting it take37. 
Given this background, the next chapter goes on to explore the development and 
implementation of policies related to advanced community pharmacy services, to establish 
if there are strategies that both pharmacists and policy makers can adopt to help manage 
these workload issues.  
 
 
  
                                                          
37 Further discussion of this is provided in Appendix A 
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Chapter 4. Implementing Policy in 
Community Pharmacy 
 
Chapter Introduction 
The previous chapters have established that community pharmacists spend the majority of 
their time on activities related to the dispensing and supply of medicines (chapter 2). One 
of the main drivers of this trend was the therapeutic revolution of the second half of the 
twentieth century which provided doctors with a wider range of medicines to prescribe. 
Coupled to this, the increase in the occurrence of unhealthy lifestyles as a result of the 
‘western’ diet has driven up prescription use in chronic diseases, such as obesity and type II 
diabetes. The ageing population has also given rise to the better use of secondary 
preventative medicines, supported by national evidenced based guidelines for prescribing 
(Davies and Taylor, 2010a). This has led to an increase in the number of prescription items, 
which have been further exacerbated by a reduction in the average duration of each 
prescription (chapter 3).  
Guaranteed income streams from dispensing have also helped to ensure that medicines 
supply has come to dominate pharmacists’ work even if it is at the cost of reduced 
professional contact with medicine users (chapter 3). Yet despite the dominance of the 
supply of prescription medicines, community pharmacy policy (as described in chapter 1) 
has shown a desire for pharmacists to be ‘utilised to greater effect’ through ‘clinically’ 
focused services. 
The evidence gathered so far in this thesis proposes that the implementation of services 
into community pharmacies has been slow. On this basis, the aim of this chapter is to 
understand and interpret the process of service implementation into community pharmacy 
through two case studies, and discover if any lessons can be learnt for future pharmacy, 
and wider healthcare policy, implementation. 
A structured overview of the barriers and facilitators to implementation from the 
Medicines Use Review and prescription intervention (MUR) literature is described here. 
This is succeeded by an analysis of the most recent service to be implemented in 
community pharmacy - the New Medicine service (NMS). Through the use of the Kingdon 
model of the policy process (Kingdon, 1984), the development and implementation of a 
community pharmacy service is recorded and captured by analysis of qualitative interviews 
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with key stakeholders involved in the services’ implementation. This provides insight into 
the challenges and complexity associated with bringing community pharmacy policy to 
fruition. This chapter concludes by comparing MUR and NMS implementation with an 
interpretation of the challenges that future services in community pharmacy are likely to 
face. 
The implementation of Medicines Use Reviews 
The Medicines Use Review (MUR), implemented through the 2005 pharmacy contractual 
framework, is a documented, face-to-face consultation between a patient and a 
community pharmacist that takes place in a pharmacy consultation room. The aim of this 
advanced service is to improve a patient’s knowledge, adherence and use of medicines by 
ascertaining their understanding and experience of medicines taking (Pharmaceutical 
Services Negotiating Committee, 2012).  
During this documented consultation the pharmacist may identify ineffectual or poor 
medicines use, side effects, or therapeutic drug interactions, which are then resolved 
through discussion with the patient and, where applicable documented feedback, which 
highlights any medication related problems, is supplied to the patients’ GP on an approved 
form. Beyond clinical governance requirements, any community pharmacy in England and 
Wales can offer this service as long as the pharmacist wishing to provide the service has 
completed a nationally accredited training program, and the premises has a private 
consultation area deemed fit for purpose by the contracting local primary care 
organisation.  
Although this was the first nationally advanced service to be offered free to patients in 
community pharmacy, pharmacists are not obliged to offer MURs. They can claim 
reimbursement (currently £28) from the NHS, subject to a maximum of 400 MURs per 
pharmacy per year (Department of Health and the Welsh Assembly Government, 2012) 
which can provide an addition £11,200 in income per annum. 
Despite this service being heralded by the profession at its conception as a positive 
development, the widespread implementation of the MUR delivery was limited in the early 
years. The uptake was initially slow (figure 4.1), with only 7% of the available funding spent 
in the first year and only 38% of pharmacies claiming payment for MURs (Blenkinsopp et 
al., 2007a). However, recent data shows that nearly nine out of every ten community 
pharmacies in England have provided and been paid for providing an MUR (The NHS 
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Information Centre, 2011), with a peak of 249,986 MURs completed in England during May 
2012 (equivalent to about 20 MURS in a month per pharmacy). Figure 4.1 shows the steady 
increase in MUR numbers since 2005. There are observable drops in the number of MURs 
completed in December, attributed to the effect of the festive period which limits the 
number of working days in which MURs can be provided coupled with attention being 
focused on retail sales, and observable peaks in March as contractors aim to reach their 
target of 400 MURs before the end of the financial year.  
Figure 4-1– Number of MURs completed in England per month (2005 –2012) 
 
Source: NHS Prescription Services 
The uptake and delivery of MURs from community pharmacies across England has been far 
slower than originally anticipated and is believed to be a result of implementation 
problems. Given the importance placed on pharmacy services by the government 
(Department of Health, 2008a), it is vital for their future delivery that the factors that have 
limited implementation are understood. 
The overview provided here offers a structured review of the published literature relating 
to the implementation of MURs by community pharmacists in England and Wales. The aim 
of this was to discover the barriers recorded during the implementation of MURs to see if 
these can be learnt for subsequent policy implementation.  
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Methodological Approach 
PubMed, International Pharmaceutical Abstracts and CINAHL were searched for the term 
“Medicines Use Review” or “Medicines Use Reviews”, between 2004 and 2012. Studies 
were limited to English language and based in the United Kingdom. This revealed 33 
abstracts, of which only 22 were deemed relevant from analysis of the title.  
In addition the abstracts of the British Pharmaceutical Conference (BPC - now known as the 
RPS conference) and the Health Services Research in Pharmacy Practice Conferences 
(HSRPP) databases were interrogated for articles relating to Medicines Use reviews 
between 2004 and 2011. This revealed 44 abstracts that contained the words “Medicines 
Use Review” or “MUR”.  
In conjunction to this, all of the references of the papers identified were interrogated for 
relevant research articles relating to Medicines Use reviews. This strategy helped to 
highlight research that had been published in the Pharmaceutical Journal. The majority of 
the references identified were conference abstracts, but where applicable full copies of 
these papers were sourced.  
These abstracts and full papers were assessed against three criteria: 
 Does the study describe its methods clearly? 
 Does the study describe or investigate perceived or real barriers or facilitators to 
the implementation of MURs? 
 Was the study conducted in the United Kingdom? 
Against these criteria, papers were only included if they made a mention of barriers or 
motivators that support the implementation of Medicines Use Reviews in community 
pharmacy in the United Kingdom. Most of the excluded papers lacked a description of a 
method, often due to being editorial in nature. Several of the excluded articles looked at 
patient perceptions or disease outcomes from MURs in specific disease groups and 
therefore did not describe or explain barriers or facilitators to implementation. Two papers 
were excluded which related to Medicines Use Reviews in New Zealand.  
This left 41 abstracts, articles and papers to be included in the review (figure 4.2). Each of 
these was thematically analysed and cross-examined for barriers and facilitators to the 
implementation of MURs. The findings of which were tabulated for analysis.  
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Figure 4-2– Flow Chart of Literature review 
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Results and Discussion 
Thematic analysis of the literature, which is a qualitative method used to analyse 
classification and present themes, revealed seven overarching themes (figure 4.3) that 
affected the implementation of medicines use reviews, namely: Work Environment; 
Financial Drivers; Accreditation and Training; Patient Recruitment; External Support; 
Documentation; and Individual Practitioner. 
Figure 4-3– Barriers and Driver to MUR implementation 
 
 
Work Environment 
The work environment of community pharmacy was commonly reported to be a barrier to 
the implementation of MURs. In particular time pressures, additional workload and lack of 
sufficient staff prevented MURs from being delivered. The reforms to the pharmacy 
contractual framework effectively represented an increase in workload without additional 
resource (Blenkinsopp et al., 2009; Cowley et al., 2010). Although the majority of 
pharmacists absorbed Medicines Use Reviews into their daily practice without additional 
pharmacist cover (Boardman et al., 2011; Blenkinsopp et al., 2007b), over half of 
pharmacists in a survey reported lack of sufficient staff as a barrier (Ewen et al., 2006), 
which resonates with findings elsewhere (Blenkinsopp et al., 2007b; Latif and Boardman, 
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2007; Rosenbloom et al., 2005). However, staffing is not solely a factor of the number of 
staff present, but also the ability of pharmacists to delegate their work effectively to those 
staff present (see chapter 2). It was suggested that other environmental factors are 
important, with the initial low volumes of MURs performed also reflecting resource 
pressures on space in small dispensaries (McDonald et al., 2010b). 
Pharmacists have reported that the reduction in the reimbursement of drugs has increased 
the pressure to focus on dispensing volumes (McDonald et al., 2010b; Rosenbloom et al., 
2005). Many expressed difficulty in managing time spent between the dispensary areas and 
the consultation room (McDonald et al., 2010b) making it difficult to maintain normal 
pharmacy services at the same time as an MUR service (Hilton et al., 2007), with 
opportunities for activities such as patient counselling at the last stage of the dispensing 
process being reduced (McDonald et al., 2010b). Many pharmacists felt that MURs only 
increased the pressures on their time (McDonald et al., 2010b) and therefore lack of time 
was a commonly reported barrier to providing the MUR service (Ewen et al., 2006; Latif and 
Boardman, 2007).  
As a result the importance attached to performing MURs appears significantly lower than 
routine activities. The pressure to manage patients who either wished to speak to a 
pharmacist or have their medicine checked, compared to providing an MUR, resulted in 
reviews being abandoned when the pharmacy became busy (Boardman et al., 2011). In 
some cases time management issues were such a challenge that they led several 
pharmacies to cease providing the service (Rosenbloom and Graham, 2008). 
Such pressures are understandable when the mean time to complete an MUR is 51 
minutes, of which just under a half (22 mins) is spent with the patient, the rest spent on 
paperwork (Blenkinsopp et al., 2007b). As a result pharmacists were observed doing MURs 
at times that were convenient to them and the workload in the pharmacy (Boardman et al., 
2011), which may not necessarily be the most convenient time for the patient.  
While some strategies, such as a support tool developed by the NPA and the PCPA are 
reported to improve pharmacists time management skills (Kaulbach et al., 2010), other 
strategies such as formalised appointment based system have been implemented. 
Although appointments allow pharmacists to regulate their work, they reflect a more 
formal approach to accessing pharmacists advice, which encourages the view that 
 
 
150 
pharmacists’ time is more valuable that patients (McDonald et al., 2010b) and changes 
public perception of pharmacists as an accessible healthcare provider. 
Financial Pressures 
Across any business, finance is a motivator of practice. MUR delivery remains financially 
driven with quantitative rewards based on number performed as opposed to their quality 
(Latif and Boardman, 2008). The remuneration system has resulted in what some argue is a 
prioritisation of income targets over patients (Bassi and Wood, 2009; McDonald et al., 
2010b) and therefore requires reform (Cowley et al., 2010). For example,  financially driven 
company policies were cited by two-fifths of pharmacists as a key driver for providing the 
MUR service (Blenkinsopp et al., 2007b) rather than patient need. Many pharmacists, 
particularly those working in multiples, have reported being under pressure from head 
office to deliver target volumes of MURs (McDonald et al., 2010b; Rosenbloom and 
Graham, 2008) regardless of whether patients require the service, leading these 
organisations to be depicted as large, impersonal and solely driven by profit (McDonald et 
al., 2010a; McDonald et al., 2010b). 
It is these motives that are argued to have increased MUR provision from multiples 
(Blenkinsopp et al., 2009; Latif and Boardman, 2007; Bradley et al., 2008; Elvey et al., 2007). 
On one hand, it is believed that this observed pattern was due to organisational pressure 
within multiple pharmacies and the forceful implementation of targets. On the other hand, 
independents suffer from a relative lack of staff capacity (Bradley et al., 2008). This  creates 
a challenge in fitting MURs into their daily activities, coupled with the additional costs 
associated with employing locums to increase capacity (Elvey et al., 2007). This is in 
contrast to the predictions made over a decade ago that extended roles for community 
pharmacists would be of greater benefit to independently owned pharmacies (Edmunds 
and Calnan, 2001a). Indeed, the demands of contract implementation reportedly fall more 
heavily on independents. In contrast to multiples they do not have well established 
management systems to streamline paperwork which reduce the effort required at an 
individual pharmacist level (Blenkinsopp et al., 2007a).  
While organisational pressures and company policies may have indeed led to an observed 
increase in the number of MUR completed, they have also shaped what has been described 
as the “McDonaldisation” of MURs (Latif et al., 2011c). These pressures have been 
implemented in undermining MUR quality (Elvey et al., 2007) and have forced pharmacists 
to compromise their professional judgement and autonomy (Harding and Wilcock, 2010; 
 
 
151 
Wilcock and Harding, 2008). For example, pharmacists reported performing MURs that 
they felt to be less resource intensive, of limited benefit and cursory in nature in order to 
reach their targets (McDonald et al., 2010b). Indeed, some reported gaming the system by 
choosing patients with fewer medications, despite acknowledging that those taking more 
drugs would benefit most from the service (Latif et al., 2011b). Even though the 
pharmacists acknowledged that this was likely to have a detrimental effect on the public’s 
perception of MURs and the pharmacy profession, they persisted in targeting the least 
complex patients (McDonald et al., 2010b).  
Training and Accreditation 
MUR training itself is believed to be a motivating factor for implementation (Elvey et al., 
2006). The small number of pharmacists accredited in the early stages of service 
implementation contributed to the initial slow delivery of MURs (Blenkinsopp et al., 2007a). 
The Department of Health insisted MUR accreditation be conducted by higher education 
institutions that were required to assess the competence of pharmacists against a national 
framework. Ideally, professional competence should be assessed through observation. 
However, the practicalities of achieving this in a cohort of 12,000 pharmacists meant that 
questioning and portfolio work were used as the assessment of choice, which some argue 
contributed to questionable MUR quality (Alexander, 2006).  
On one hand, time and financial pressures are forcing some pharmacists to game the 
system are implicated in decreasing the quality of MURs. On the other hand, such 
decreased quality may instead be a manifestation of poor training and implementation. 
Indeed, there is evidence of deficiencies in the training of pharmacists, particularly around 
communication (Kaulbach et al., 2010). Such deficiencies are exemplified by accredited 
pharmacists who reported not feeling confident enough to perform MURs after training 
(Rosenbloom et al., 2005; Davies and Pugsley, 2006; Khideja, 2009) and therefore wanted 
further assurance of their own competence (Davies and Pugsley, 2006; James et al., 2009). 
However, this may be a manifestation of the cultural change that MURs created. Some 
pharmacists expressed trepidation and uncertainty providing MURs, despite being 
perceived as a core feature of their professional activity now and in the future (Harding and 
Wilcock, 2010; Wilcock and Harding, 2008). Other pharmacists revealed that they had an 
aversion to speaking to people who took psychiatric medication because they were anxious 
about prying into ‘sensitive’ issues (Latif et al., 2011b), although there was also an 
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assumption that these patients were under specialist care and so were perceived to be in 
less need of an MUR (Latif et al., 2011b). 
Various education focused strategies have been suggested to improve service 
implementation. These include training opportunities provided by PCTs (Bradley et al., 
2006), providing direction and ongoing training with respect to the content of the MUR 
(Khideja, 2009), using supported peer review of MURs (Harding and Wilcock, 2010; 
Kaulbach et al., 2010), providing opportunities for pharmacists to practice MURs with 
constructive feedback on performance (Kaulbach et al., 2010), demonstrating good practice 
(Davies and Pugsley, 2006) and adopting key quality indicators of MUR action points 
(Harding and Wilcock, 2010). Yet despite this evidence few of these have since been 
incorporated into MUR accreditation.  
However, it is not solely the accreditation of the pharmacists, but also the accreditation of 
premises that has been shown to be a barrier to fast service rollout (Latif and Boardman, 
2007; Elvey et al., 2006; Blenkinsopp et al., 2007b). Two years after implementation, a fifth 
of community pharmacies did not have a private or semi-private consultation area 
(Blenkinsopp et al., 2007b), of those that did, some patients reported them being too small 
or claustrophobic for practical use (Iqbal and Wood, 2010).  
A further barrier to implementation was created by a misunderstanding of the intended 
purpose of MURs. Initially it was designed to improve patients’ concordance and 
understanding of medicines. Yet pharmacists have interpreted the MUR to be an extension 
of their role by including advice giving and knowledge of drug interactions in the 
consultations (McDonald et al., 2010a; McDonald et al., 2010b). While some have taken 
this further and conducted a full clinical medication review. The lack of uniform service 
objective has resulted in MURs of differing detail and quality. Given this ambiguity it 
unsurprising that  many patients and health care professionals are unaware of the purpose 
of an MUR (Iqbal and Wood, 2010).  
Patient Recruitment and Education 
Many papers have reported patient uptake and interest as a barrier to implementation 
(Elvey et al., 2006; News Team, 2006; Hall et al., 2006). Although strategies, such as a 
dedicated MUR facilitator in the pharmacy, can help to improve patient recruitment 
problems (Rosenbloom and Graham, 2008), nearly half of a randomly selected sample of 
community pharmacies in England and Wales believed that poor recruitment was due to a 
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lack of patient knowledge of the service (Ewen et al., 2006; Thomas et al., 2007b). Patients 
seldom asked for MURs themselves, instead being selected and persuaded by the 
pharmacy staff (Latif et al., 2011b). Indeed, poor service uptake can be compounded by 
patients who initially accepted an MUR but failed to attend the subsequent appointment 
(Blenkinsopp et al., 2007b).  
Some attribute the poor uptake of patients to the language that has been used in the 
recruitment materials which describe the process inconsistently, with interchangeable use 
of formal, (review meeting), and informal ‘friendly’ terminology (Van den Berg and Donyai, 
2007). One small explanatory study suggested that native language may also play a role in 
patient engagement, as the MUR form is only available in English (Hughes et al., 2009). 
However, interviews with patients declining MURs suggest that their reasons for lack of 
uptake are often more complex (Urban et al., 2008). It was found that patients main reason 
for accepting the offer of an MUR was simply because they had been asked, but only 
agreed if they had time (Latif et al., 2010). Latif et al (2010) suggest that some patients felt 
obligated to have an MUR to help the pharmacist. Such reasons do not suggest that 
patients are strongly motivated by self interest or the prospect of personal benefit to have 
the service (Latif et al., 2010), instead acting because of a moral obligation.   
It has been suggested that improving patients’ understanding of the service could be a key 
facilitator to future service delivery (Rosenbloom et al., 2005; Bassi and Wood, 2009; 
Davies and Pugsley, 2006). Suggested strategies to achieve this are national advertising 
campaigns and clearer explanations from individual pharmacists (Iqbal and Wood, 2010).  
External Support 
External support, either from Primary Care organisations (PCOs) or General Practitioners, 
was seen as a core factor in the effective implementation of MURs. In a telephone 
interview survey most pharmacists felt they did not receive sufficient support from PCOs 
(Hall et al., 2006) which limited their ability to provide the service. Blenkinsopp et al (2007) 
found that just under half of all primary care organisations had no strategy for MUR service 
delivery (Blenkinsopp et al., 2007a). This suggests that in the early years, PCOs may not 
have been able to think strategically about MURs for local healthcare needs (Blenkinsopp 
et al., 2007a). 
In England PCT leads blamed the lack of support from General Practitioners as the number 
one barrier to implementation of MURs (Elvey et al., 2006). They believed that MURs had 
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done little to improve integration (Elvey et al., 2006). The lack of effective working between 
GPs and community pharmacists has been reported elsewhere as a factor for the poor 
uptake of MURs (Ali et al., 2011; Latif and Boardman, 2007; Blenkinsopp et al., 2007a; Ewen 
et al., 2006).  
Although some PCOs reported creative ways to incentivise GP participation through the 
GMS Quality and Outcomes framework (Blenkinsopp et al., 2007a), most were 
unsuccessful. This may be because GPs view MURs negatively (Wilcock and Harding, 2007), 
by and large, describing MURs as a waste of time and money (McDonald et al., 2010b). This 
general lack of support may be a product of a limited understanding of the service itself 
(Davies and Pugsley, 2006). Hilton et al (2007) found that inadequate information had been 
provided to general practitioners and other health professionals about the purpose of 
MURs (Hilton et al., 2007). James et al (2007) reported that GP were unaware of their role 
in MURs. Indeed a lack of central guidance may have contributed to this (Thomas et al., 
2007b).  
As a result of this misunderstanding of purpose, community pharmacists, pharmaceutical 
advisors, and local pharmaceutical committees have expressed concern that MURs are 
making clinical recommendations when this was not their primary intent (Hilton et al., 
2007). This ambiguity of purpose has led some pharmacists to call for clarification about 
the extent of their clinical input and responsibilities following an MUR (Latif and Boardman, 
2008). This has not been aided by the low levels of communication between local 
pharmaceutical and medical committees (Blenkinsopp et al., 2007a) and the lack of general 
communication between community pharmacists, GPs and primary care organisations 
(Davies and Pugsley, 2006). This suggests that inter-professional dialogue is limited in 
primary care and may act as a barrier to the effective implementation of future services 
(Kaulbach et al., 2010). 
Documentation  
The presentation and transfer of information from pharmacies to other primary care 
providers contributed to the lack of external support for MURs. The documentation format 
has partly been blamed for this because it was confusing, complex, of poor design and 
difficult for GPs to use (Blenkinsopp et al., 2007a; Hilton et al., 2007; Thomas et al., 2007a).  
A redesign of the MUR paperwork was conducted after the initial implementation in an 
effort to address some of the documentation problems (Latif and Boardman, 2008). This 
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new design was found to be more user friendly and time saving (Bassi and Wood, 2009), 
making it clear when GP action is required. Yet despite the changes the form is still 
considered unnecessarily bureaucratic (Cowley et al., 2010). The structured format, which, 
when coupled with standardised procedures and routines, is seen to limit professional 
autonomy of pharmacists and their decision making abilities (Latif et al., 2011a). Some 
argue that a review of the formulaic approach to the MUR is required so that the complex 
ways patients take their medicines can be understood (Latif et al., 2011a). At present the 
model of MUR delivery treats individuals as passive recipients of expert knowledge, which 
appears to be an inappropriate response to inspire confidence to meet the changing needs 
of patients. However, without such standardisation, the resulting output from MURs 
around the country would be even more diverse. 
The documentation of the MUR consultation was found to be incompatible with computer 
systems and therefore regarded as a barrier to effective inter-professional communication 
(Rosenbloom and Graham, 2008). Changes have since been introduced which link MURs to 
patients records on the pharmacy computer, although some suggest this could be 
improved further by sharing across NHS IT systems (Thomas et al., 2007b). However, even 
with these innovations the variable quality of pharmacists’ written communication remains 
a problem (Kaulbach et al., 2010). 
Furthermore patients are required to sign MUR forms that are subsequently submitted for 
payment. This act creates a visible link between payment and service, which some argue 
alters patient perceptions of this being altruistically motivated as opposed to a financially 
driven (McDonald et al., 2010a). Such acts are believed to be a barrier to future 
recruitment of patients to pharmaceutical services. 
Individual Pharmacists  
The individual motivation of pharmacists was seen as one of the main drivers that enabled 
the implementation of MURs to progress in a locality (Elvey et al., 2006). The literature 
suggests that the vast majority of pharmacists welcomed the intention of the new contract 
to encourage a move away from dispensing towards other cognitive based roles (McDonald 
et al., 2010b; McDonald et al., 2010a; Bradley et al., 2008). In general, MURs were viewed 
positively by community pharmacists who perceive this service as an opportunity through 
which the profession can evolve (Ewen et al., 2006; Latif and Boardman, 2007; Hughes et 
al., 2009) and enhance its relationship with patients (Cowley et al., 2010). 
 
 
156 
Yet despite this optimism, the delivery of advanced services is not homogenous across the 
profession. In general terms owners struggle to conduct MURs while maintaining an 
economically viable dispensing volume, locums reported little desire or motivation to 
conduct MURs, whereas salaried pharmacists experienced varying degrees of pressure and 
motivation to deliver this advanced service (McDonald et al., 2010b). Coupled with this, 
those pharmacists working ‘full time’ performed significantly more MURs than part time 
pharmacists, and store based pharmacists performed significantly more that ‘relief’ 
pharmacists (Ewen et al., 2006; Latif and Boardman, 2008; Latif and Boardman, 2007), 
which some suggest is a reflection of their dedication to the profession.  
For locums, factors of familiarity, such as working with staff who were strangers and 
unfamiliar settings, procedures, policies and equipment were reported to be the main 
factors limiting the number of MURs that they are able to deliver (McDonald et al., 2010b). 
This literature suggests that individual professional priorities influence the extent to which 
advanced services are provided. In turn, these priorities are influenced by all of the other 
factors outlined above.  
Policy Lessons 
This literature review has exposed the main barriers and motivators to the implementation 
of the Medicines Use Review and prescription intervention service into community 
pharmacies, which have been grouped together into seven broad themes: Work 
Environment; Financial Drivers; Accreditation and Training; Patient Recruitment; External 
Support; Documentation; and Individual Practitioner Motivation.  
Policy leaders working from the ‘top down’ can manipulate the macro, contextual 
environment, of the organisational system within which individual pharmacists operate. 
However, ultimately, implementation relies on the practice habits of the individual 
pharmacists at the local level.  
Encompassed within these individual practice habits is the organisational culture of the 
pharmacy, which is commonly understood to be integral to the way in which organisations 
function, as an influence of behaviour. It has been broadly described as “the way we do 
things around here” as well as the way things are judged, valued and understood (Schien, 
2004). Pharmacists as the individual leaders of a pharmacy at the micro level have a key 
role to play in re-defining the culture of each pharmacy. Yet despite its importance, cultural 
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leadership has been largely ignored in pharmacy practice research (Roberts et al., 2003; 
Clark and Mount, 2006).  
Understanding the thoughts, actions, beliefs and values that drive behaviour and the 
everyday assumptions that influence how an organisation functions can provide a powerful 
insight into service implementation. Under an organisational paradigm the values and 
beliefs that people hold individually as members of the organisation are thought to 
collectively influence how they act, and therefore influence the behaviour and function of 
the place in which they work (this is explored further in chapter 5). What this review 
suggests is that while the six contextual factors identified are important for manipulating 
the environment, it is ultimately the individual pharmacist’s professional cultural identity in 
the pharmacy that drives service implementation. It is argued here that future service 
implementation needs to empower change in the professional cultural identity of 
pharmacists if it is to succeed (Roberts et al., 2003; Roberts et al., 2006; Roberts et al., 
2008; Scahill, 2008; Scahill et al., 2009). As leaders of the premises they will then influence 
the culture of the community pharmacy, and eventually the profession. In many respects 
this is an argument in favour of professional empowerment and a ‘bottom up’ approach to 
policy implementation.   
The individual interpretation and professional empowerment of service delivery at the local 
level has been recognised within the policy arena under the framework of  ‘street level 
bureaucrats’ (Lipsky, 2010). Lipsky contests that individual autonomy at the consumer 
facing level influences who benefits from policy initiatives (Lipsky, 2010). Kelly (1994) 
suggests that due to their responsibility as the final implementers of policy, street level 
bureaucrats find their jobs inherently discretionary. This is exacerbated by a knowledge 
asymmetry between street level bureaucrats and the public (Hupe and Hill, 2007)38. 
Pharmacists display the characteristics of a ‘street level bureaucrat’ through their agency 
status which allows them to decide who is offered the service; for example pharmacists 
excluded those with mental health medications (Latif et al., 2010). Some might argue that 
this is a manifestation of professional autonomy, yet this discretion results in a gap 
between the objectives of policy and the observed outcomes39. As demonstrated by the 
literature review, pharmacists, like all street level bureaucrats, have incentives to pursue 
their own ends that are at odds with the interests of management (Riccucci, 2005). Moore 
                                                          
38 This is a manifestation of the agency relationship outlined in chapter one. 
39 Note the conflict here between professionalism and managerialism/bureaucracy.  
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(1987) suggests that in negotiating ambiguous work settings, street level bureaucrats 
create conflict between themselves and management - something that was observed in 
community pharmacy settings (Latif and Boardman, 2008) -  in order to exert their own 
autonomy and identity. 
Citing Hill (1997), Walker and Gilson (2004) argue that there is often a disjuncture between 
what senior level management prescribes and what actually happens at the ‘street level’. In 
their analysis of nurses they argue that this ‘bottom up’ approach subverts the ‘top down’ 
discourse that rationalists believe is central to policy formulation (Walker and Gilson, 
2004). They argue that this bottom up perspective, “emphasises the need to understand 
implementation systems and the actors responsible for implementation” (Walker and 
Gilson, 2004: p1215). Such arguments suggest that implementing services and policies into 
community pharmacy require a clear understanding of individual pharmacist’s culture as 
they are the actors responsible for implementation.  
 Walker and Gilson (2004) suggest that policies should be created in ways that are inclusive 
of the street level bureaucrats discretion, which in the case of pharmacy should take into 
account the individual pharmacists’ professional cultural identify. What this literature 
review reveals is that the process of MUR implementation relied heavily on the decisions 
made in the planning and delivery of a service, as a ‘top down’ approach, as opposed to a 
flexible ‘bottom up’ approach required by pharmacists. While the objectives may be clear 
at the early stages of the service, it is only when the pharmacists act as street level 
implementers of the service is it possible to assess the outcomes. 
Section Conclusion 
The analysis presented in this section revealed seven broad themes about service 
implementation. These are: Work Environment; Financial Drivers; Accreditation and 
Training; Patient Recruitment; External Support; Documentation; and Individual 
Practitioner Motivation. The last of these was the most influential in deciding on the 
implementation of services locally. 
The literature in chapter 2 describes the general willingness of pharmacists to provide 
extended services. Yet despite this, the results here suggest that individual practitioner 
willingness is the biggest driver of service implementation.  Individual resistance to change 
is not a new phenomenon and a well reported in the wider implementation literature. But 
clearly overcoming the barriers described here requires more than and motivating 
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individual pharmacists to change, or remunerating them to provide a service. Wider 
external and organisational factors are important.  
Change is always a difficult process. And while this literature identifies the barriers to 
successful change, its focus has been limited to the individual pharmacist as the unit of 
analysis. Indeed, the facilitators of change suggested in this section mainly relate to the 
behaviours of individual pharmacists. This ‘bottom up’ interpretation of policy 
implementation negates the ‘top down’ effects of these polices. Few studies have 
considered the ‘top down’ effects of MUR implementation with the whole profession as 
the unit of analysis. Less focus has been placed on the collective profession (the 
organisation) that influences implementation at the local level.  
It is for this reason that the next section of this chapter considers the ‘top down’ 
implementation of the New Medicines Service in England.  Such research will help to 
discover if the lessons of MUR implementation have been learnt and whether the same 
barriers persist.   
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Implementing the New Medicines Service 
The literature review of MUR implementation revealed that the organisational culture of 
the community pharmacy is an important element in service implementation. Involving 
street level operators early in the planning and development of the process is hypothesised 
to increase the effectiveness of the service when implemented at the local level. This builds 
upon the differences between ‘top down’ and ‘bottom up’ approaches to policy 
implementation. In this section the development and implementation of the most recent 
advanced service – the New Medicines Service- is explored as a case study to assess if 
‘grass roots’ pharmacists were involved in the initial development of this service and to 
discover if lessons have been learnt following the implementation of MURs. These were 
analysed to provide a background to future policy implementation.  
The New Medicines Service (NMS) 
Consider a consumer buying a new piece of technology, a camera for example. They take it 
home, they experiment with using it, and in some cases they attempt to read the 
information manual provided. However, after a few weeks, the consumer may have 
developed problems that the manual fails to address. They may require some additional 
expert advice to obtain the full potential of a technology. This consumer follow up is the 
underlying concept behind the New Medicines Service (NMS), which was rolled out in 
England on 1st October 2011. 
The way that patients interact with medicines, another technology, is no different.  Patients 
experiment with their medications. They get used to taking them and fitting them into their 
daily routine. In some cases patients read the patient information leaflet (the instruction 
manual) provided. After a few weeks some patients may experience side effects or 
problems, which they want to discuss with an expert. In the case of medicines this ‘expert’ 
is the community pharmacist whose body of knowledge is centred on medicines and their 
use40. Although pharmacists have always offered advice, they have historically recouped 
the economic cost of advice from healthcare products and prescriptions supplied. This new 
nationally advanced service allows pharmacy contractors to be directly remunerated for 
providing expert advice, either face to face or via the phone, to help patients get the full 
potential benefits out of their newly prescribed medicines.  
                                                          
40 However this expert can often be other health care professionals, particularly the GP or the practice nurse.  
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On initiation of a new medicine for one of four therapeutic areas (Asthma and COPD, 
Hypertension, Type II Diabetes, and anti-platelet or anticoagulation therapy) patients are 
enrolled to the service by their pharmacist or by GP referral. After two weeks, patients 
return to the pharmacy where problems with medications are discussed. A follow up 
consultation typically two to four weeks later is made to ensure no further medication 
problems persist. It is suggested that this service will help patients with their medicines, 
reduce waste, improve adherence and increase pharmacovigilience (Pharmaceutical 
Services Negotiating Committee, 2011b). The case study described here explores the 
political process that led to the development of this new advanced service.  
Theoretical Framework 
In the social sciences theorists seek to develop models and theories that explain the world 
around them. All theories and concepts are contestable, meaning that they are part of an 
ongoing controversy. There are some concepts that are contestable but for which we have 
no way of resolving competing arguments. Therefore we can note the rival positions, but 
we cannot evaluate them in terms of principles that command general agreement. This is 
the very nature of politics, in that all political concepts are inherently contestable. 
Deciding on a framework that can be used to analyse a policy problem is itself a 
contestable argument and therefore a decision that requires explanation. A multitude of 
theoretical models exist to describe the policy process (Sabatier, 2006), each with their 
own merits and drawbacks. Models, by their very nature, involve degrees of abstraction 
and idealisation that act as both their strengths and weakness. On the one hand these 
theories abstract certain features of reality, that is, they pick up aspects of reality and 
ignore others in order to simplify the focus. On the other hand, models add to our 
perception of reality by repressing the complex and entangled nature of the world being 
studied. 
Until the mid-1980s the Stage Heuristic Model was the most influential framework for 
understanding the policy process. The model comes under the rationalist school of 
thought. It suggests that policymaking is a rational linear process separated into agenda 
setting, policy formation and legitimation, implementation, and finally evaluation (Sabatier 
and Jenkins Smith, 1993). 
This ‘stages’ model describes ‘implementation’ as a separate stage in a rational sequential 
approach. In reality, policy formation is often non-sequential and may develop during 
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implementation. Therefore such an approach underestimates (and fails to capture) the 
importance of non-formal processes such as the disagreements between different 
advocacy positions or groups. It also ignores the ‘bottom up’ effects and conflicts involved 
in policy implementation, the links between several policies, and ignores the fact that 
policies are not created in isolation (see MURs above). As such rational models of policy 
development were deemed inappropriate for this study.  
John Kingdon (1984) developed the multiple stream model, which is primarily concerned 
with the timing and flow of policy action as opposed to its components steps. As a model it 
fits closely with the narratives approach adopted here and therefore was used as the 
‘theoretical framework’ for this section41. 
The starting point for Kingdon’s work was the ‘garbage can model’ developed by Cohen and 
colleagues (1972), which attempted to describe the ambiguous behaviours that contradict 
the classical rational behaviour perspectives (e.g. stages approach). The model was 
influenced by the observation that under great uncertainty, responses from decision 
makers would appear, when viewed from a distance, to be irrational. The ‘garbage can 
model’ was formulated in the context of universities where interdepartmental 
communication problems helped to support the model. This conjecture separates 
problems, solutions and decision makers from each other. It suggests that problems require 
attention, solutions are answers looking for a question, and choice opportunities are where 
organisations are expected (or they think they are expected) to produce a decision. In this 
model participants vary between problem and solutions. It was named the ‘garbage can 
model’ because it was believed that organisations produce many solutions that are 
discarded due to lack of appropriate problems. However, problems may eventually arise 
that have a solution in the ‘garbage can’.  
Kingdon (1984) attempted to reflect the complexities and realities of the policy making 
process by focussing on policy entrepreneurs who take advantage of agenda setting 
opportunities – named policy windows. The changing nature of the flow and timing of 
polices can lead to the opening and closing of windows of opportunity that allow policies to 
reach the agenda. Building on the garbage can approach, this model suggested that three 
streams or processes exist – the problems stream, the policy (solutions) stream and the 
                                                          
41 In the strictest sense of the word this is not a theoretical framework. However it is a model around which the narrative 
presented here can be explained.  
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politics (political will) stream (figure 4.4). All three streams must meet at a policy window 
for a policy to progress.  
Problems stream consists of various conditions that citizens and policy makers want 
addressed. These may come from indicators, (such as nationally collected statistics or 
specific studies), focusing events (such as riots or earthquakes), feedback (evaluation of 
previous policies) and load (the extent that other events preoccupy the minds of policy 
makers). 
The Policy (or solution) stream is generally an output of mid level government officials, 
policy advocates, think tanks and academics. These ideas compete to win acceptance in 
policy networks. Ideas are considered in policy circles through papers, hearings and 
conversations. Some ideas survive, yet others are combined and still more disappear. As 
such, these policy solutions are subject to sensitive development of sequence, content, 
timing and translation to become action. It is worth emphasising that Kingdon’s model does 
not suggest that solutions are built to resolve given problems, but instead that they float in 
search of problems to which they can be tied.  
The Politics (or political will) stream explains changes in national mood as to what is 
acceptable, pressure group campaigns to change events and the turnover of the 
government, which all influence the desire of politicians to act on any given problem. 
Figure 4-4 - Multiple Stream model of agenda setting and policy process ( adapted 
from Buse et al., 2005) 
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The model suggests that while each of these streams move and ‘flow’ independently, it is 
only when they run together at critical moments in time that the policy is taken seriously. 
These opportunities are known as policy windows. Policy entrepreneurs may be individuals 
or corporate actors who attempt to couple the three streams together. The relative skill 
they have in doing this increases the chances of a policy being adopted.  
This model differs from the other frameworks because it adopts the logic of political 
manipulation, whereby policy entrepreneurs couple the streams together. The power of 
this model is that it accepts that the policy process is non-linear and involves a numerous 
actors and forces. 
Other lenses, such as rationality, fail to address this political manipulation. Rationalists 
assume individuals adopt the utility maximising concept of Homo economicus, they suggest 
that every individual has a clear and consistent way of arriving at a final decision. While this 
may often be the case, the multiple streams approach reveals rationality as opposed to 
assuming it exists.  On the other hand constructivists see policy making a driven by 
persuasion and social construction. In reality it is more than just persuasion, it involves 
generating facts that can change people’s minds. Constructivist approaches specify how 
identities are constructed but fail to sufficiently explain the fluctuations seen in policy over 
time.  
The New Medicines Service has come into practice as a result of themes being coupled 
within the policy process. This case study uses the multiple streams model of policy 
development (Kingdon, 1984) to analyse the expansion of what some within the pharmacy 
profession see as a major stepping-stone for community pharmacist development and a 
path to pharmacy’s clinical future (Richardson, 2011). 
Method – Case Study Approach 
This study applied a mixed method single case study approach. Despite the beliefs of some 
that case study research is the ‘weak sibling among social science methods’ (Yin, 2009: p 
xiii), case studies continue to be used extensively in a variety of academic disciplines, 
including political science and public policy research. The case study approach allows for an 
explanatory as well as a descriptive approach to understand complex problems and social 
developments (Yin, 2009: p5).  
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This case study used a purposive sampling methodology to identify policy entrepreneurs 
who were involved in the development and implementation of the new medicines service. 
A ‘snowball technique’ was used with an initial core of interviewees to identify other 
relevant people to be interviewed. All those interviewed were directly involved in the 
policy negotiations and had intimate knowledge of the service. Sampling ceased once no 
new streams were identified from the narratives. A semi-structured qualitative research 
instrument was piloted and developed to support a series of interviews with stakeholders 
who were known to have played a key role in the development of the NMS.  
The interviewees were from the following groups: Academics (2); Pharmacy Voice (1); PSNC 
(2); Department of Health (1); CPPE (1); NHS Employers (3); Royal Pharmaceutical Society 
(3); GPhC (1); PCT Representatives (2). 
The average interview duration was just under an hour. Participants were guaranteed 
confidentiality. In most cases the interviews were digitally recorded alongside summary 
notes that were made during the interview. The interviews were subsequently transcribed. 
Where recording equipment was not used, or where it failed, a summary of the researchers 
notes was formally written up.  The transcriptions or notes from the interviews were 
shared with the interviewees for confirmation and clarity, as well as to ensure that their 
views were not misrepresented. The researcher was satisfied that he had sampled to 
saturation, in as much as later stage interviews did not reveal new streams, albeit that they 
added to his understanding. The interviews were analysed using a descriptive framework 
that allowed this case study of NMS implementation to be understood.  
 
A descriptive strategy may be considered less preferential than a theoretical proposition, 
but serves the purpose required here. The technique is not guided by any preconceptions, 
but instead by the content that is recorded. Therefore this method allowed for the 
extraction of the descriptive narrative that underlay the development of this service. Due 
to the nature of this research institutional ethical approval was applied for and received 
from the School of Pharmacy Ethics Committee (Ref B-10-12).  
The interviews were supported by a wealth of information about the service from academic 
literature as well as grey literature sources, such a trade magazines, community pharmacy 
blogs and internet discussion boards. 
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Systematic searching of the Pharmaceutical Journal for all mentions of the New Medicines 
Service (NMS) was performed, as were searches of the Chemist & Druggist Magazine. 
Websites of key pharmacy bodies, including the NPA, PSNC and RPS were also analysed 
alongside key documents and reports. 
 
Interview transcripts were compared to the NMS implementation documents provided on 
the Pharmaceutical Service Negotiating Committee (PSNC) website (www.psnc.org.uk). 
Where decisions about the implementation of the NMS were not clear from the available 
documents and transcripts, employees from the PSNC, Department of Health and NHS 
Employers were contacted and invited to provide additional clarity.  
 
All statements and observations made below are qualitative in nature. As far as possible 
dates, times and the sequence of events were confirmed by triangulation with the 
literature and the interview responses. However, in some cases discussions and 
conversations as part of the policy development process were not written down or formally 
recorded. These cases therefore rely solely on the memory of the interviewees. Although 
efforts were made to access minutes of significant meetings, confidentiality and 
commercial sensitivity restricted access to these documents. 
Results - Narrative Findings 
The results of this case study are organised in a narrative approach that adopts the multiple 
stream model of the policy process. Each of the streams is analysed in turn. Areas where 
these streams overlap are narrated, before being analysed. For ease of understanding 
these results have been summarised in the timeline shown in figure 4.5.  
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Figure 4-5 – Timeline of the NMS Development 
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The Problem Stream – Adherence to Medicines 
The challenge of getting patients to use and take medicines as prescribed by their doctors 
has been described in the literature for centuries. However, it was not until the 
development of modern mass scale factory produced pharmaceuticals in the Western 
world, that the problems of non-adherence to medications became contextualised as a 
problem. This was particularly brought to the fore from 1987 onwards by the introduction 
of statins to prevent chronic heart disease. Despite statin use increasing rapidly across 
Europe during the 1990s, the anticipated benefits of the drugs to prevent and manage 
cardiovascular diseases was not being observed in the population. It was postulated that 
compliance with medication regimes was the reason for this. Trials in the early 1990s, such 
as the West of Scotland Coronary Prevention Study (WOSCOPS) confirmed this belief by 
finding that adherence to statins of over 75% reduced the risk of death from any cause by 
one third (Shepherd et al., 1995).  
Pharmaceutical companies began to recognise the importance of considering what 
happened to their medications after they had been dispensed. In early 1996, a working 
party of the Royal Pharmaceutical Society, with financial support from Merck Sharpe and 
Dohme Ltd (MSD), who at the time were the biggest supplier of branded medicines to the 
NHS, began to investigate the potential challenges associated with getting patients to take 
their medicines as prescribed. The group, which included doctors, pharmacists, nurses and 
social science researchers, produced a literature review that developed the terminology of 
‘concordance’. This assembly recognised that the culture of society had moved away from 
medical paternalism that defined ‘compliance’ in the 1940s, towards a more proactive 
patient centric system (The Royal Pharmaceutical Society, 1997). Not only were issues of 
medical paternalism (and patient non-adherence) highlighted in this report, but also the 
pharmaceutical waste and lost therapeutic outcomes that result from poor medicines 
adherence. This captured political attention, and on 13th November 1997, the newly 
elected Secretary of State for Health, attended a conference at the RPSGB to discuss how 
best to develop the concept of ‘concordance’ into the health service (News, 1997).  
The next decade of research, mainly supported or sponsored by the pharmaceutical 
industry, analysed the issues, approaches and challenges related to taking medicines as 
advised. This issue was brought to the international stage in 2003 when the World Health 
Organisation (WHO) reported that action was needed to address the costs and safety 
aspects of poor medicines adherence (World Health Organisation, 2003). Such a report 
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failed to significant impact in primary care, with pharmaceutical waste and shared 
prescribing decisions remaining a problem (National Audit Office, 2007).   
On 5th April 2005 the government formally asked the National Institute of Clinical 
Excellence to prepare clinical guidance on Medicines Concordance. The groups remit was 
“to prepare clinical guidelines for the NHS in England on involving patients in decisions 
about prescribed medicines”. These guidelines  were published in January 2009, under a 
changed title - Medicines Adherence (NICE, 2009). This report described the ‘under-
utilisation’ of pharmacists (see chapter 1) and pharmacy resources in combating poor 
adherence (Department of Health, 2008a). They suggested that pharmacists should be 
empowered to help create ‘behavioural change’ in medicines taking.    
Poor adherence continued to feature in government sponsored research. A 2010 
Department of Health funded report further showed the costs associated with non-
adherence in primary care (York Health Economics Consortium and School of Pharmacy 
University of London, 2010). It suggested that non-adherence was costing in the region of 
£100 million per year. The government was keen to act partly because such significant 
sums of money at a time of economic recession and constrained spending are politically 
unpalatable. The stage had been set for the problem stream.  
The Policy (Solutions Stream) 
The documented loss of therapeutic benefit in the 1990s from non-adherence prompted 
both the pharmaceutical industry and Department of Health to fund further research to 
understand the problem. At the same time health services research, and in particular 
pharmacy practice research, was beginning to be accepted as an academic discipline. A 
pharmacist, Nicholas Barber, sought to establish and develop the concept of pharmacy 
practice research from a base within the School of Pharmacy, University of London. He built 
links with those in the developing field of health services research. There was an increasing 
recognition that understanding systems and processes within healthcare could help 
improve patient care, but also politically this could be used as a tool to influence service 
developments and assist managers within the NHS. From this base Barber became part of a 
Department of Health Prescribing Research initiative. The group investigated the dynamics 
of communication between doctors and their patients (Stevenson et al., 2000). They 
discovered that shared decision making and medicines information were poorly tackled 
during general practice consultations. Barber realised the potential benefits that 
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pharmacists could offer in assisting patients in the understanding of their medicines. He set 
about trying to establish whether this potential could become a reality.  
Rob Darracott, who had been the Principal Pharmaceutical officer at the Department of 
Health since 1991, left in 1995 to join Moss Chemists, which at the time had in the region 
of 350 outlets. Darracott become the Professional Services Manager with a remit to expand 
the services component of the community pharmacy business. Darracott recognised that 
the chain had the potential to be used as a research network. He capitalised on such a 
network by exploring the factors influencing consumer choices into OTC medicines with 
academics from Manchester University (Payne et al., 1997; Payne et al., 1998).  
During this period Darracott had been aware of Barber’s work on shared decision making 
because of mutual professional and social friends. This precipitated discussions into how 
they could work together to utilise the Moss pharmacies as a potential research network. 
Barber developed their idea into a research proposal in the late 1990s. However, finding a 
sponsor for a project, which aimed to investigate the effects of community pharmacists’ 
advice on medicines adherence, proved difficult.  
At the time the Directorate for Health and Social care (DHSC) London had a research 
budget set aside to support innovative practice.  Yet the DHSC, when presented with this 
research proposal, were reluctant to acknowledge the existence of non adherence as a 
problem in primary care. It was believed that acknowledging the existence of non-
adherence in primary care would undermine the perceived effectiveness of medical 
interventions. Eventually, at the turn of the millennium, Barber received financial support 
from DHSC, but only to investigate if such an adherence problem existed.  
Sarah Clifford - a health psychologist - was recruited to the School of Pharmacy to replace 
Jim Parsons (who for the first twelve months had been the main research assistant 
supporting this project). Clifford set about supporting and developing a research program 
that would identify non-adherence in primary care. After an initial slow engagement from 
community pharmacies, 258 patients who were aged over 75 and beginning a new 
medicine for a chronic condition were recruited to interview. Sixty-seven (30%) of the 226 
people still taking their medicine at 10 days and 43 (25%) of the 171 people still taking their 
medicine at four weeks were found to be non-adherent. The research team, which included 
Rob Horne - a pharmacist and health psychologist from Brighton - found that 61% of 
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patients reported a substantial and sustained need for information ten days after starting a 
new medication (Barber et al., 2004).  
On the back of this evidence the DHSC funded a subsequent intervention study to evaluate 
if a community pharmacy based intervention could improve adherence. At the time this 
represented the largest ever grant given by the Department of Health to community 
pharmacy research.  
A randomised controlled trial of a pharmacist-delivered intervention to improve adherence 
using a centralised telephone service to patients at home was developed. The methodology 
was progressed to incorporate an economic evaluation with the assistance of Rachel Elliot, 
a health economist from Manchester University42.  
In the wider society public acceptability of health services via the telephone was increasing 
(e.g. Hallam, 1993). In 1998 NHS Direct, a national nurse led telephone advice service, was 
created to help manage the demand for out of hours primary care in the UK (Munro et al., 
2005). This service built upon the use of telephone technology in this way.  
The pharmacists in the study were trained in 2000, with an initial pilot from October 2000 
to May 2001. The main study, conducted between June 2001 and October 2002, found that 
the telephone intervention improved adherence. Their results won the runner up prize in 
the Pharmaceutical Care Awards 200243 (PJ, 2003) under the title of “Hello, it’s the 
pharmacists calling” – how telephoning patients improves adherence. The research team 
were also highly commended in the 2003 Primary Care Report best practice award. The 
research was formerly submitted for publication in 2005 and printed in 2006 (Clifford, 
Barber et al. 2006), with the economic evaluation following in 2008 (Elliott et al., 2008). 
Despite the awards and media coverage of this research, the service received limited 
attention outside the profession, and failed to gain political attention. Moss business 
managers experimented with a telephone service targeting osteoporosis patients in 
collaboration with the pharmaceutical industry and tried selling a redesigned service to 
Primary Care Trusts. However, these small private schemes had limited commercial success 
and were quickly scrapped.   
                                                          
42 In late 2000, Elaine Hartley assumed the lead for this project at Moss Pharmacy. Darracott- who had previously been the 
key liaison - moved internally as result of a takeover of Moss by Alliance UniChem. 
43 This was presented in July 2003. 
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The problem stream of non-adherence received political attention in the middle of the 
decade, but this solution failed to be coupled with the problem until 2008. Even the 
National Co-ordinating Centre for NHS service Delivery and Organisation R&D (NCCSDO) 
commissioned research, Concordance, adherence and compliance in medicines taking 
(Horne et al., 2005), failed to effectively couple the telephone based study and the problem 
stream together despite a crossover of authors between the projects. It is postulated by 
some of those interviewed that the lack of political penetration of this study was part of a 
wider inability of pharmacists to effectively lobby and influence public policy. 
Political Will  
In May 1997, Tony Blair became the new labour Prime Minister. He took office with a large 
majority, popular support and a manifesto pledge to ‘save and modernise the NHS’ (The 
Labour Party, 1997). This pledge was implemented through a 1997 White Paper 
(Department of Health, 1997). Such investment was announced on January 16th 2000 (BBC 
News, 2000). This financial support provided a platform on which Alan Milburn - the 
secretary of state for health (previously Frank Dobson’s deputy) – could bring about 
reform. The July 2000 publication of the NHS plan: a plan for investment, a plan for reform 
(Department of Health, 2000a) set out the government’s modernisation program for the 
NHS. This aimed to move away from the paternalism of professionals towards greater 
active patient involvement through a quasi-market and greater patient choice in healthcare 
decisions. Revelations from the public inquiry into children’s heart surgery (Kennedy, 2001) 
highlighted the lack of information provided to patients and carers by overbearing 
paternalistic doctors. This helped to spur public support for change.  
The government publications (analysed in chapter 1) show a ‘political will’ to ‘utilise’ 
community pharmacists to help patients get the best out of their medicines. Such 
documents acknowledged the previous work of the Royal Pharmaceutical Society advisory 
committee on ‘concordance’. A commitment of more than one million pounds over two 
years was provided by the government to support a national strategy for integrating 
partnership in medicines taking. This investment led to the foundation of the Medicines 
Partnership Program, which was established in 2002 to promote the concept of shared 
decision making and concordance. 
Given the new investment and political rhetoric towards greater patient choice, the 
government was keen to develop “modern contracts for both GPs and hospital doctors” 
(Department of Health, 2000a: p15) to make best use of the new investment in the health 
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service. A new contract for community pharmacists followed in April 2005, a year after the 
successful implementation of the new GP contract. This contract attempted to address the 
‘under-utilised’ of pharmacists by shifting “away from being paid mainly for the dispensing 
of individual prescriptions towards rewarding overall service” (Department of Health, 
2000a: Para 9.8). Although previously there had been services provided in community 
pharmacies, this new contractual framework created a system for services to be 
commissioned nationally. The first of these was the Medicines Use Review (MUR) 
implemented with political support from Patricia Hewitt, the Secretary of State for Health.   
Some of those involved in the negotiations at the time have implied that they regret not 
being radical enough in using the contractual negotiations to create a seed change in 
pharmacy practice. They believe that opportunities were missed. For example, the 
chairman of the PSNC, Barry Andrews, was at the time working for Moss Pharmacy. In this 
role he had oversight of the telephone intervention service, but failed to suggest it as a 
possible service during contract negotiations.  
The lack of seed change created by the new contractual framework was reported in a 
Department of Health commissioned review of the new pharmacy contractual framework 
(Galbraith, 2007). This spurred pharmacy organisation to create ‘political will’ for further 
change. In June 2007, the All-Party Pharmacy Group (APPG) published a report that made a 
series of recommendations about the future development of community pharmacy (All 
Party Pharmacy Group, 2007).  
Despite investment and improvements, reports that patient services across the NHS 
appeared fragmented and designed ‘more to suit the needs of those delivering them than 
using them’ (The Healthcare commission, 2005: p9) persisted. The government 
commissioned Ara Darzi - a world leading cancer surgeon and confidant of Tony Blair - to 
undertake a systematic review of the NHS. His review presented an opportunity for 
pharmacy organisations to emphasise the role that community pharmacists could play in 
aiding patient care.  
The combination of the 2007 AAPG report, the Galbraith review of the contractual 
framework, and Darzi’s review of the health service, persuaded ministers to write a White 
Paper for pharmacy. The evidence gathering for this pharmacy White Paper was conducted 
alongside events to inform Ara Darzi’s review. 
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In wider politics, Alan Johnson had taken the helm as Secretary of State for Health, and 
there had been a change of leadership at the top of the labour party, with Gordon Brown 
the prime minister. 
The separate problem stream of pseudoephedrine misuse enters the narrative. In 2007, the 
Medicines Healthcare and Regulatory Agency (MHRA) was consulting on proposals to 
restrict pseudoephedrine to a prescription only medicine. This was due to concerns over 
the availability of pseudoephedrine, which can be converted into methylamphatamine - a 
drug of misuse. The Company Chemists Association (CCA) - a trade body representing the 
interests of nine large pharmacy chains44 -  had recently instated their new chief executive, 
Rob Darracott in January 2007.  The CCA developed a concerted communication campaign, 
in conjunction with the RPSGB, to make pharmacists aware of the potential risks associated 
with pseudoephedrine misuse. 
The CCA gained positive support for their campaign from the Department of Health for the 
effectiveness of this intervention. This helped the CCA to get a ‘foot in the door’. They were 
subsequently encouraged by Mark Britnell, the then Director General for commissioning 
and service management, to feed into Darzi’s review of the NHS. They were invited to hold 
a meeting in which they could present the contribution that pharmacy could play to future 
the development of the NHS. Various stakeholders from across Pharmacy, including 
hospital pharmacists and notably Professor Barber, were invited by the CCA to this meeting 
in March 2008. Mark Britnell was only in attendance for the final few minutes of the 
meeting and therefore Dr Keith Ridge – the chief pharmaceutical officer - chaired the 
meeting. 
A literature review on pharmacy services commissioned by the Department of Health for 
the upcoming pharmacy White Paper had not been captured this pharmacy based 
telephone intervention study. Therefore this meeting allowed the telephone adherence 
service to be raised formally as part of the policy process. Britnell was impressed with the 
evidence and the potential value of this service as it appeared to meet policy objectives 
regarding adherence, waste medicines, and also supported clinical roles for community 
pharmacists. Officials were asked to explore this service in more detail.  
The publication of a pharmacy White Paper was due in a matter of weeks. Therefore 
officials quickly began to investigate if this service could be set into the context of the 
                                                          
44 equal to about half of all pharmacies in the country 
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‘Darzi reforms’ and if it could be included in the pharmacy White Paper. Several 
conversations (facilitated by the fact that Ridge and Barber had previously worked closely 
together during Ridge’s time as an MSc and PhD student at Manchester University in 1998) 
between Ridge, Darracott and Barber followed in both formal and informal settings. The 
reaction was positive given the strong evidence. This quickly resulted in the service being 
drafted into the pharmacy White Paper.   
The Streams Coalesce 
In April 2008 the three streams (policy, politics and problem) coalesced with the 
publication of the Pharmacy White Paper (Department of Health, 2008a). This linked non-
adherence – the problem stream, research – the policy stream, and the political will stream 
together by making a commitment to help patients with newly prescribed medicines. 
“The Government will therefore discuss with the PSNC and NHS Employers how such 
a support service may best be introduced within the community pharmacy 
contractual work” (Department of Health, 2008a: Para 4.56).  
Barber’s initial research into non-adherence in primary care was described in this White 
Paper. Yet there was no direct reference made to the successful telephone intervention 
service. The incorrect reference citation was used in the internal partial impact assessment. 
It referred to the problem of non-adherence rather than the telephone intervention. This is 
possibly a reflection of the rush to include this service in the White Paper. 
Despite the streams coalescing, the pharmacy led service to help patients with newly 
prescribed medicines was only a White Paper recommendation, which would require 
funding, further negotiation and implementation to become a reality. 
In the summer of 2008 Ara Darzi published the findings and recommendations of his review 
of the NHS. In this he described a role for pharmacists in public health. This was interpreted 
by some as a signal to pharmacists that they should stop trespassing in to general practice 
territory. 
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The 2008 pharmacy White Paper made NHS Employers (NHSE)45  the lead for negotiating 
service developments in community pharmacy. Yet their negotiations were bounded by a 
‘mandate’ from ministers provided to them by officials in the Department of Health.  
The NHSE mandate 2008/09 instructed them to negotiate with the Pharmaceutical Services 
Negotiating Committee (PSNC - a membership group that represents NHS pharmacy 
contractors) over MUR service developments, relationships between pharmacists and GPs, 
and aspects of service quality. It was funding reasons that prevented the inclusion of a 
service for patients on newly prescribed medicines in this mandate.  Although the partial 
impact assessment had indicated a positive economic benefit, initial implementation funds 
were required to commission any new service.  
Barber, whose research included aspects of medicines safety and service quality, was 
invited to discuss the service quality aspects of community pharmacy in early 2009. By 
chance one of the lead pharmacy negotiators for NHS Employers struck up a conversation 
with him about his research. This conversation helped to bring their attention to the 
telephone based intervention, which they had previously been unaware of.  
Ministers could either fund the service with a new budget form elsewhere or source the 
funds directly from savings made within the pharmacy contractual framework. It was the 
latter of these options that prevailed. The medicines margin of 2008/09 allowed the service 
to be included in the 2009/10 mandate. 
Throughout the autumn of 2009, NHSE and PSNC met on four occasions to negotiate the 
development of a service to support patients taking new medicines. It was only after the 
second of these meetings that PSNC representatives became fully aware of Barber’s 
research that underpinned the service. Towards the beginning of winter of 2009 Barber 
was invited to present to the negotiating teams and explain his research. Eventually at the 
end of 2009, after much negotiation, these discussions culminated in a mutually designed 
‘heads of agreement’ document46. This described a ‘first prescription service’ which was to 
be implemented into practice in the financial year 2010/11. 
On 15th September 2008 the collapse of the Lehman Brothers signalled the beginning of a 
global economic downturn. In August 2009, to help manage this situation in the NHS, David 
                                                          
45 A group representing over 90% employers in the NHS. NHS Employers is part of the NHS Confederation. Their vision is to be 
the authoritative voice of workforce leaders, experts in HR, negotiating fairly to get the best deal for patients.  
46 The ‘heads of agreement’ is the outcome of the negations between the NHSE and the PSNC. This document is passed to the 
officials within the Department of Health to receive government ratification.  
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Nicholson - the chief executive of the NHS - sent a letter to chief executives setting out a 
policy for Quality, Innovation, Productivity and Prevention to help improve the NHS in 
times of financial austerity. This called for wide spread ‘efficiency savings’ to be made 
across the health service.  
In wider politics it was rumoured that a general election would be called in May 2010. 
Consensus was leaning towards a likely change of government following significant losses 
for the labour party in local and European elections in the summer of 2009. Gordon Brown 
reshuffled his cabinet in June 2009 replacing Alan Johnson with Andy Burnham as secretary 
of state for health. This reshuffle made Mike O’Brien the minister responsible for 
pharmacy, a post previously held by Ben Bradshaw. In doing so, Mike O’Brien assumed the 
responsibility for signing off the ‘heads of agreement’ document. This policy window was 
open and the streams of ‘problem’ and ‘policy’ were aligned. All that was required was 
‘political will’ to provide ministerial agreement for this service. 
The Streams Come Apart 
In January 2010, the All Party Pharmacy Group brought adherence to medicines back into 
the spotlight, calling for a universally designed service to support adherence. This was an 
attempt to create some consensus surrounding a pharmacy based adherence service.  
The proposal for the ‘first prescription service’ sat with O’Brien until the early spring of 
2010 awaiting ministerial assent.  When the minister spoke at the PSNC conference on 1st 
March 2010, it became apparent that a ministerial decision had been made not to pursue 
the service – The ‘political will’ had departed.  
Those interviewed postulated several possibilities for this verdict. Firstly, considering that 
there was likely to be an election in May, the commitment to this service was unlikely to 
provide the labour party with any political gain. Secondly, the responsibility for pharmacy 
funding negotiations was spread between several ministers, increasing the complexity of 
the decision. Thirdly, being new to the role, O’Brien may not have truly understood the 
complex nature of community pharmacy funding. Under pressure to make financial cut 
backs in the wake of wider external events it could be speculated that he did not believe 
community pharmacy required this funding.  Further it may have been a more fundamental 
ideological position that he believed pharmacists should focus on medicines supply. These 
postulations all represent conjecture and the real reasons may never be publically known. 
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However advocates of this service persisted in keeping the service on the agenda. 
Following the announcement of the election, the APPG produced a ‘policy action plan’ that 
called on any new government to launch “a national First Prescription Service” in 
community pharmacies (All Party Pharmacy Group, 2010).  
A new government formed in May 2010, but unusually for British politics this was a 
coalition between the conservatives and the liberal democrats. As widely predicted Andrew 
Lansley became Secretary of State for health47. However, as a result of the coalition 
agreement Mark Simmonds, who had been expected to take forward the mantle for 
pharmacy services, failed to gain a ministerial position. The responsibility for pharmacy was 
passed to Earl Howe.  
At the time of its publication the 2008 pharmacy White Paper had received cross party 
support. Yet with a new government the previous pledges were no longer policy creating a 
blank sheet in terms of policy. Therefore there was no guarantee that this new government 
would support a pharmacy service.  
The ‘first prescription service’ heads of agreement that had been presented to Mike 
O’Brien was passed to the ministerial office of Earl Howe where it remained unsigned. 
Those interviewed suggested that this was because it had been gifted from the previous 
government, and because large scale reforms were planned for the NHS. Indeed, two 
months after being elected, the new government issued Liberating the NHS, a wide ranging 
White Paper that proposed large scale reform of the health service (Department of Health, 
2010: Para 3.22). 
The Streams Realign  
On 21st July 2010, the same month that Liberating the NHS was published, Earl Howe 
announced at the APPG summer reception that he would be asking negotiations on the 
‘first prescription service’ to restart. This was a positive sign for the service, but the 
financial climate had resulted in a reduced funding envelope.  
NHS Employers received a new mandate in August 2010. Using the previous heads of 
agreement document as a base, the negotiators set about realigning the service in light of 
the financial climate and the polices of the new government. 
                                                          
47 Lansely has been the shadow health secretary for the last 12 years.  
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Between September and early November 2010, the groups negotiated to form a new 
‘heads of agreement’. It was during these discussions that the name of the service formally 
changed from ‘first prescription service’ to ‘my new medicine’, and then to ‘New Medicine 
Service’.  The latter was believed to be less antagonistic to the medical profession and to 
sound both professional and descriptive. Also, it was postulated that this created a visible 
separation between this service and the name used by the previous government.  
Positive ministerial support came later that year, when Earl Howe spoke at the PSNC dinner 
on 17th November. He made a public commitment to the introduction of a New Medicine 
Service. 
“I am an advocate of the new medicine service being mainstreamed within 
community pharmacy” (Howe, 2010).  
However, in this speech he alluded to the challenges of the economic climate and the need 
for appropriate funding.  
The economic evaluation carried out by Rachel Elliot as part of the original research (Elliott 
et al., 2008) provided a solid grounding for the impact assessment and helped to persuade 
officials of the economic benefits that this service provides. Pharmacy contractors waited 
four months for internal Department of Health scrutiny, and a revised impact assessment 
before the agreement could receive ministerial support. 
 However, on 15th March 2011 NHS Employers and PSNC were able to announce that a 
new medicine service (NMS) would be introduced. A funding letter from Bob Alexander - 
the Director of NHS finance – confirmed this to PCTs on the 17th March. It described how 
the service would be supported by a maximum investment of £55 million per annum in 
2011/12 and 2012/13 recovered from medicines margin adjustments. The trade press 
viewed the service development as a significant event for the profession, despite the 
associated reduction in category M funding. 
The challenges of getting from ministerial approval and commitment to a service on the 
ground should not be underestimated. While at this point all of the streams were aligned 
there were many rocks on which the service implementation could become snagged.  
The Path to Implementation 
The NHS employers and PSNC (with oversight from the Department of Health) set about 
developing the service specifications. These discussions were held confidentially, and 
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therefore the main source information as to what the service might entail came from the 
gesticulations of the pharmacy press. 
On 4th April 2011, in advance of the specification’s release, representatives of Pharmacy 
Voice48 met to discuss the implementation of this service. Barber was invited to present the 
research underpinning this service. Pharmacy contractors began planning what they could 
ahead of the release of the service specification. Some argue that early transparency in the 
design of the service specification would have helped improve implementation – an 
argument in favour of ‘bottom up’ policy design. They believed that the only way that this 
service could be implemented effectively was through a cultural shift in the hearts and 
minds of contractors. Such a shift would require a lengthy process and therefore early 
engagement was needed. 
However this engagement did not materialise until 11th May 2011, two months after the 
initial announcement. NHS Employers and the PSNC released an outline specification of the 
new medicines service at a large stakeholder meeting. Department of Health 
representatives urged for a structured implementation process in order to achieve the 
planned -1st October- service delivery date. NHS Employers, on behalf of DH were given the 
responsibility for service implementation, working with the PSNC (News Team, 2011).  
Following the stakeholder meeting, a New Medicines Service Requirements and 
Development group was convened. Its remit was to confirm the knowledge and skills that 
pharmacists require to deliver the NMS. The first meeting of this group, on the 1st June, 
discussed topics such as self-accreditation, outcome measures, training and the interview 
schedule for this service. Several tensions were exposed when the group began to discuss 
the delivery of the service. The choice of membership of this group may have contributed 
to those tensions. NHS Employers acknowledged that they do not necessarily know the 
best way to deliver any service, and therefore rely on expert groups to develop service 
specifications.  
The first tension was finding a suitable compromise between the professional opportunities 
of individual pharmacists and the commercial needs of the pharmacy business. The second 
tension concerned the extent of training and expertise that might be required to deliver 
the service. The third tension can be described broadly as theoretical differences of opinion 
                                                          
48 Pharmacy voice is a group that comprises of the three largest community pharmacy associations. The members of 
Pharmacy Voice are the Association of Independent Multiple Pharmacies (AIMp), the Company Chemists’ Association (CCA) 
and the National Pharmacy Association (NPA).  
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in tackling non-adherence. The fourth relates to outcome measures and implementation 
and the fifth to the funding model. The final tension was the short timescale in which 
decision had to be made and the service implemented. 
Education and Training 
Tensions pertained to the service training requirements were exposed early in the 
discussions. Publically the PSNC had suggested the service would have an accredited 
training requirement (Chapman, 2011a), but there was no indication what this would 
entail. There were concerns that a formal assessment of knowledge followed by 
certification could not be feasible achieved for 20,000 pharmacists in the time available. 
After much discussion, a decision was made that pharmacists should be allowed to self-
assess their competence, as long as they had already completed MUR accreditation. The 
Centre for Pharmacy Postgraduate Education49 (CPPE) and the regulators of pharmacy 
championed this focus on outcomes as opposed to tick box criteria. Yet several in the group 
were uncomfortable with this move to self declaration. They preferred some external 
assurance of the pharmacists’ ability to provide the service50. 
The role of training coordinators became important because educational materials were 
developed alongside service negotiations. CPPE given their close links with the DH, were 
both influential and pivotal in the development of training materials for pharmacists 
seeking to deliver this service. They had been given a green light to start developing 
training in early June ahead of a formal service announcement on 16th June at a 
Stakeholder engagement event at the Ambassadors Hotel in Bloomsbury. They worked as 
part of the review group to help develop training materials for national dissemination. 
However, they could only prepare the finer details of training materials once they had 
received decisions and approvals from NHS Employers and PSNC, often at the last minute. 
Pharmacy or Pharmacist 
The accreditation process was complicated by a need to separate the responsibilities of 
individual pharmacists from those of pharmacy contractors. For example it was initially 
stated that it was the responsibility of the pharmacists to ensure that a consultation room 
was present, when this is actually the responsibility of the contractor. As a result it took 
until the end of June for the content of the self-assessment accreditation forms to be 
                                                          
49 CPPE are a not-for-profit, Department of Health funded group who provide continuing professional development training 
materials and support for pharmacists and pharmacy technicians providing NHS services in England 
50 Indeed, many pharmacists wanted this themselves. The CPPE reported that after the service was launched they received 
phone calls asking them to formally accredit people to offer the service. 
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finalised. It was eventually release publically on 2nd August alongside the funding structure 
(Chapman, 2011c). 
Theoretical Approach 
Equally contentious was the development of the interview schedule. One of the principles 
of the service is that it is patient led, allowing patients to raise and discuss issues regarding 
their new medicines that they feel are important, necessitating a free flowing, semi-
structured approach. Pharmacists’ traditional responsibilities concern supply, following 
standard operating procedures, and protocols. As such, an unpredictable free flowing 
service was perceived by some to be both difficult and a potential threat. Therefore the 
interview schedule went through several iterations based on both theoretical and academic 
viewpoints as well as preliminary pilot work, before a degree of consensus was reached in 
early July. However, the schedule still required ratification by DH, PSNC and NHS 
Employers.  
Outcome measures and Documentation 
This group had to determine the records and outcome data that pharmacists would be 
required to collect. They also had to decide how this should be transferred to primary care 
organisations. This was an urgent issue because outcome measures required a full impact 
assessment and secondary legislation. Liberating the NHS was in a process of being 
developed into the Health and Social care bill. Because of this, operational responsibility for 
community pharmacy was being shifted between primary care employees. This operational 
turmoil in primary care allowed the service to develop without overbearing opposition 
from primary care representatives.  Several PCT representatives contributed to the 
stakeholder engagement. However, their offerings were easily side stepped (or as some 
claim ignored) in the development process. As a result some of those interviewed believe 
that the incorrect outcome measures were chosen for this service.  
The PSNC developed a electronic platform to make the outcome measures operational and 
to support documentation and recording of this service. This platform was named 
Pharmabase. The tight budget for this service meant that the content, organisation and 
structure of this database took time to develop. As a result the system was only 
implemented as the service was launched.  
Timescales  
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The final impact assessment was finished in early September. The secondary legislation 
that was required for this service to progress was only signed into law a week on 
September 22nd, a week before the service started nationally. Many contractors raised 
concerns about the tight turnaround of the service, which the PSNC blamed on the 
governments wider NHS reforms (Hunt, 2011).  
Funding Model 
The funding model was subject to much criticism when it was released. These arrangement 
were (to a large extent) decided in the negotiations that took place prior to wider 
stakeholder engagement. Given the previous experience of MURs (Latif et al., 2011b), 
concern had been expressed that this service may be used by contractors as a purely 
revenue generating activity. Early negotiations included such concerns by applying a “scum 
bag” approach to the service development specification to limit the ability of less 
professionally (more commercially) orientated contractors from producing low quality, 
poorly delivered services. This necessitated a movement away from a fee-per-service 
model towards a payment matrix that was intended to make NMS integral to daily practice.  
As experienced in MURs, there was concern that this service may encourage employers to 
exert undue pressure on pharmacists.  The introduction of written (as opposed to verbal) 
patient consent was also introduced to address quality, because it was believed that this 
would encourage pharmacists to explain the service to patients and would help reduce 
fraud51.  
Collaboration 
Learning from criticisms of MUR feedback, led the PSNC and NHSE to collaborate with the 
General Practitioners committee of the BMA to publish a standard feedback form for GPs, 
released jointly in August 2011. This communication to primary care and general 
practitioners was supported by a series of national road shows and engagement events in 
September that showcased the service.  
It was on the 1st October 2011 that the service was finally implemented into community 
pharmacy, despite the final service specifications and data recording requirements not 
being published until November 2011. The importance of this service to pharmacy should 
not be underestimated, so much so that the Department of Health have funded an 
evaluation of this service to support future service negotiations.  
                                                          
51 This intent is reflected in the consent form that was published without piloting. 
 
 
184 
Purpose of the Service 
The eventual NMS implementation was only possible due to the interlinking of multiple 
streams. Throughout, numerous justifications for this service have been used to rationalize 
its development. Indeed, the interviewees offered divergent opinions of which were most 
important. Some argued that the aim was:s to assist people with their medicines; to 
improve adherence; to utilise pharmacists; to reduce waste; to empower patients; to 
preserve pharmacists’ status; and to maintain contractors’ income. Whatever the driver, 
their combined effects led to this service, which has been described as a turning point for 
the pharmacists.   
The purpose of the multiple streams framework was to model the process that led to the 
implementation of the New Medicine Service. The streams that underpin the development 
of this service are extracted in figure 4.6 below to provide an overview to the descriptive 
narrative. 
Limitations of the Multiple Stream Model 
The multiple stream ‘model’ has been used extensively across the public policy literature. 
Models are expressions of the real world and as such contain assumptions and 
simplifications that make that the subject of denigration. Critics have attacked it for making 
a number of unrealistic assumptions because as a ‘model’ it has fails to generate enough 
clear, falsifiable hypotheses. However this case study approach did not begin with an a 
priori hypothesis, instead it aimed to observe the process of policy development. This 
framework was used for its narrative as opposed to hypothesis generating qualities.  
Such criticisms are often aimed at the origin of the model - the ‘garbage can approach’. 
While the criticisms of the ‘garbage can model’ are valid, in so much that it works on the 
basis of fortune, it should be remembered that the Kingdon’s model takes a different 
starting point and suggests that the coupling of streams is purposeful performed by policy 
entrepreneurs, rather than relying on chance.  
Some critics legitimately suggest that the ‘model’ is invalid as the streams are not actually 
independent. It is argued here that the streams do not have to be independent in reality, 
but only need but they only need to flow as if they are independent. This is a subtle but 
important distinction. Therefore accepting that models are a simplification of reality and 
provide a tool for understanding the complex social world should be acknowledged as both 
a strength and a limitation.   
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Figure 4-6– Streams of NMS Implementation 
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Section Conclusion 
This section has demonstrated that implementing a service into community pharmacy is a 
complex challenge. Political processes, when viewed from a distance, often appear 
confused an illogical. As such rational models of policy implementation fail to capture the 
subtleties involved in the development of real world policies. It is only when different 
streams are coupled together that ‘policy windows’ of opportunity are created. It is difficult 
to couple the stream together, but by contrast all too easy for them to come apart. 
In this case, political will and political support for a service has been the hardest stream to 
maintain control over. On more than one occasion the development of the new medicine 
service was halted due to a lack of political support. This set back the development and 
implementation of this pharmacy service by several years. In the future pharmacy will need 
to be far more attuned to politicians if they hope to have further services implemented.   
Even after ministerial support had been received internal tensions persisted. The 
profession failed to reach a consensus on various issues related to the service. The lack of 
unity and collaboration across the community pharmacy sector acts to hamper future 
service implementation. The service managed to be delivered on time because of several 
hard working people who sought to create unity.  
Innovations in practice therefore take many years to achieve wide roll out. The origins of 
the New Medicine Service are in the late nineties, yet the service was not implemented 
into practice until two decades later. At this pace the research innovations being piloted in 
community pharmacy at present are unlikely to feature in practice before 2030.  
Different groups have used different reasons to justify and explain the development of the 
NMS. The problem stream of adherence has been the most predominant, although issues 
of pharmacist ‘utilisation’, medicines waste and patient empowerment have all featured in 
the discussions and debates that led to this service being implemented. Such justifications 
create confusion as to the purpose of the service, but also allow the service to gain wider 
political support. 
The service also had to contend with the challenged that the previous advanced service, 
MURs, had created. The next section of this chapter considers if any of the problems 
identified in the implementation of MURs were addressed in the development of NMS 
policy.  
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Were Implementation Lessons Learnt? 
By the first of October 2011 the policy process had successfully managed to create a new 
advanced service for community pharmacy. Based on the MUR implementation literature 
there are seven main areas that need to be addressed in order for implementation to be 
successful, namely: Work Environment; Financial Drivers; Accreditation and Training; 
Patient Recruitment; External Support; Documentation; and the Individual Practitioner. The 
remainder of this chapter uses the policy documentation, news reports and interviews to 
analyse the implementation of NMS in relation to these seven barriers and discusses 
whether these challenges persist.  
Work Environment and NMS 
NMS arrived in October 2011 at the same time as a decrease in category M funding52, 
which further reduced the overall value of the average prescription and further raised the 
pressure on pharmacy contractors to increase prescription volume to counter a real terms 
loss in income (Pharmaceutical Services Negotiating Committee, 2011d). Therefore, an 
increase in additional staff to support the service was unlikely to be financially viable. As a 
result it is expected that (similar to MURs) time management challenges will continue, and 
indeed increase, as a barrier to service implementation. However, the NMS service 
intervention is generally a pre-booked appointment, thus allowing pharmacists the ability 
to regulate work responsibilities. The initial research that led to the NMS suggested that 
the median consultation time was about 12 minutes (Clifford et al., 2006), in contrast to 
the 51 minutes recorded for MURs (Blenkinsopp et al., 2009). By comparison NMS should 
be comparatively easier to fit into the working day. Also, follow up consultations can be 
completed by phone, which allows for greater flexibility in terms of timing and location. 
The lack of consultation rooms that plagued MUR implementation has been addressed as 
over 90% of community pharmacies in England now have one (The NHS Information 
Centre, 2011). Initial feedback suggests that these factors assisted in the completion of 
over ten thousand of NMS interventions in the first month of service role out compared to 
only 373 MURs after launch (NHS Prescription Services, 2012). 
The challenge of integrating the service into the workflow of the pharmacy persists. A 
reallocation of work responsibilities that allows the dispensing work to be carried out by 
non-pharmacists is yet to be resolved. Although legal barriers persist, the service may be 
                                                          
52 See Chapter 3. 
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used as a driver to relinquish pharmacists’ control of the dispensary and delegate their 
responsibilities more effectively to support staff. But this is still to be seen in practice.   
Financial Pressures and NMS 
Pharmacists are paid a fee per service for MURs, whereas NMS is rewarded according to a 
payment matrix.  The funding arrangements within the matrix are organised relative to a 
contractor’s dispensing volume in banded prescription volumes. A target number of NMS 
cycles to be completed each month (Pharmaceutical Services Negotiating Committee, 
2011a)is assigned based on the prescription volume (Pharmaceutical Services Negotiating 
Committee, 2011d). Feedback about inappropriate MURs, driven by organisational 
pressures precipitated this funding design. Negotiators conceded that this was designed 
specifically to prevent the cherry picking of ‘easy’ NMS patients at opportune moments. 
Instead pharmacists would be required to engage with all NMS opportunities, incorporating 
NMS into their working day.  
The target band constantly changes for each contractor as dispensing volumes in the 
pharmacy fluctuate from month to month. Therefore, contractors may deliver the same 
number of NMS services in two consecutive months, but receive different levels of 
payments, or in some cases receive no income. Anecdotal evidence suggests that the 
unpredictability of the revenue prevented some contractors from offering the service. 
Instead they concentrated on aspects of the business where there was a greater certainty 
of economic return, such as dispensing.  
However, policy implementation does not cease at service launch. After six months of 
complaints from contractors (Weinbren, 2012; PSNC News, 2011c), the negotiators 
produced a revised funding matrix which assured contractors a minimum income per 
service, but retained the banded matrix design. This was implemented in May 2012.  
Extrapolation of the evidence from MURs suggests that NMS implementation is likely to be 
more prolific in multiples. Independents continue to suffer from a relative lack of time and 
staff capacity to implement services. Although several pharmacy organisations, including 
the National Pharmaceutical Association (NPA, 2011) and the Royal Pharmaceutical Society 
(RPS, 2011) have developed support materials designed specifically to help independents 
implement the service. The ‘McDonaldisation’ of service by multiples was raised as a 
concern in NMS negotiations, with fear that it would become a tick box exercise (Latif et al., 
2011c). Therefore the training materials and interview schedule were designed to be open 
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and free flowing, with an emphasis on communication in the consultation - as opposed to 
following a rigid protocol (CPPE, 2011) -  to try to overcome the weakness of a protocol 
based approach. 
Financial rewards inevitably drive behaviour. The matrix design and the training materials 
have attempted to create a ‘culture’ that integrates the service into practice. However, 
while uncertainty persists contractors are likely to continue to focus on services that offer 
guaranteed income. 
Patient Recruitment in NMS 
The initial service design estimated that 0.5% of prescriptions would be eligible for NMS –
the reality appears to be far lower53. Therefore, contractors are not being afforded the 
anticipated opportunities to complete these services meaning they must recruit every 
eligible patient to meet the funding band requirements. However, patients are required to 
complete a consent form, which was designed with fraud prevention in mind. Completing 
an official form that was not properly piloted, instils a sense of formality and bureaucracy 
to which the service is explicitly designed to avoid. Therefore early indications suggest that 
the consent form is acting as a barrier to recruitment (Smith, 2011b). Explaining the 
empowerment and information benefits of the service to patient may improve service 
recruitment. Despite a national media promotion by the RPS in the early weeks of October 
2011, general patient awareness of pharmacy services remains low (Coombs, 2011). 
External Support for NMS 
As shown in MURs, recruitment can be improved with external support. The service was 
cautiously welcomed by the Royal College of General Practice (RCGP) with their chair 
quoted as saying  
“Patients do sometimes experience problems with their medicines and, through the 
New Medicine Service, GPs and pharmacists will work in partnership to ensure 
those that need support receive it”(PSNC, 2011).  
Beyond this, a professional relationships working group, formed from the PSNC, NHS 
Employers and the General Practitioners Committee (GPC) of the British Medical 
Association, wrote to local medical (LMC) and pharmaceutical (LPC) committees to 
                                                          
53 The exact proportion of prescriptions is still to be determined, but the national evaluation of the NMS should help to 
identify the true value of this figure.  
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encourage and facilitate local conversations about the New Medicine Service, with a focus 
on the immediate need for communication processes to be set up locally between 
pharmacists and GPs (PSNC News, 2011b). This working group published a guide for GP 
practices outlining the changes to the pharmacy contract recognising that service 
implementation relies on effective communication across primary care. Engagement with 
GPs was also incorporated into the self-assessment form for contractors in an attempt to 
improve dialogue. Despite well-intentioned support from the top, anecdotal evidence 
suggests that this has not been sufficient to drive referrals because GPs lack enough 
understanding and confidence to endorse NMS (Flynn, 2011). Indeed, during a busy clinic 
how many GPs will have the NMS in mind when issuing a prescription (De Simoni et al., 
2012)? Primary care organisations were found to significantly influence MUR 
implementation (Ali et al., 2011; Latif and Boardman, 2007; Blenkinsopp et al., 2007a; Ewen 
et al., 2006). Their wider support is likely to be an important factor in the future 
commissioning of the service. Yet the current reorganisations in primary healthcare have 
acted to prevent their engagement with this service. As such its longevity is being brought 
into question. 
Documentation and NMS 
Some of the documentation problems observed with MURs have been addressed in NMS. 
For example, PSNC, NHSE and GPC produced a simplified one-page NMS feedback form. 
This form had active GP involvement and aimed to ensure that communication between 
GPs and pharmacy was standardised and simplistic. The MUR forms had been criticised for 
not clearly specifying where GP intervention was required. Therefore it was re-designed so 
that problems, which requires resolution, could be easily identified by GPs (Pharmaceutical 
Services Negotiating Committee, 2011c).  
However, the biggest documentation development has been the creation of an information 
technology platform. Learning from MUR documentation, which was found to be time 
consuming to complete and incompatible with IT (Rosenbloom and Graham, 2008), the 
PSNC created Pharmabase, a web-based platform to support community pharmacy 
contractors in the delivery of their services. It provides an electronic storage format for 
entering and recording NMS interventions. It also produces reports for PCT audit purposes.  
While the intent is laudable, Pharmabase has been criticised for not integrating with 
Patient Medication Record (PMR) systems (Smeaton, 2011) and for lacking sufficient 
usability (Smith, 2011a).  
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Pharmacy software suppliers believe this could have been prevented if the PSNC had 
engaged them early. They believe that information was deliberately withheld from them to 
reduce competition in the market. Yet these suppliers began creating alternative recording 
systems, which has led to a loss of standardisation across the sector.  
Training and Accreditation in NMS 
Training coordinators were important in service implementation because they developed 
the educational materials alongside service negotiations. In doing so they were able to 
identify problems with the service specifications and feed these back into the discussions. 
Some believed that this led to a collaborative implementation process. 
Negotiators chose a self-accreditation solution, learning that formal accreditation of 12,000 
pharmacists created a barrier to service delivery. This approach was also adopted for 
premises. It allowed contractors to inform local primary care organisations that they 
proposed to offer the service, as opposed to waiting for an inspection visit. The result has 
been a rapid accreditation of pharmacies, with about of 70% of pharmacies able to offer 
NMS after the first month (PSNC News, 2011a). 
Pharmacists who were accredited to deliver MURs have sufficient clinical knowledge to 
provide NMS. Therefore, the CPPE training materials that were sent to every pharmacist in 
England (regardless of sector of practice) focused mainly on the theoretical framework and 
evidence base underpinning the service as well as on communication skills. However, 
facilitating training with in a short timescale from service announcement to 
implementation proved difficult. Multiples that employ thousands of pharmacists had to 
begin training in early August prior to the full service specifications being released. Much of 
the support and training materials were only released a few week prior to launch. This gave 
contractors little time to prepare.  
In contrast to MURs, alternative educational packages such as video training were also 
provided, but supported peer-to-peer review and simulations of consultations were not, 
despite these being called for in MUR training (Harding and Wilcock, 2010; Kaulbach et al., 
2010). 
Individual Pharmacists – NMS 
As with other services, there will inevitably be variation between individual practitioners. 
The thoughts, actions, beliefs and values that drive individual implementation behaviour 
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have not yet been investigated in the context of NMS. Employment characteristics that 
influenced MUR delivery are unlikely to be different in NMS. Owners will seek to maintain 
an economically viable dispensing volume, locums have little desire or motivation to 
conduct services and salaried pharmacists will experience pressure to deliver services, 
unless the organisational culture of pharmacy changes (McDonald et al., 2010a). 
Section Conclusion 
Despite the criticisms of the PSNC, it should be recognised that many of the practical issues 
associated with MUR implementation were addressed in NMS. For example, 
documentation provided to GPs had a positive effect on service implementation. However, 
by not identifying and rectifying implementation problems early on, new problems were 
created. For example, the funding matrix, which sought to mitigate some of the negative 
behaviours observed in the implementation of MURs created further implementation 
problems. This, and the challenges of the timescale, dissuaded some contractors from 
providing the service.  
Whilst it is evident that some lessons have been learnt, the cultural environment that 
underpins pharmacy continues to persist as a barrier to implementation.  Organisational 
policies motivated by financial returns continue to place pressure on pharmacists’ time. 
The widespread reallocation of responsibilities within pharmacy seems to be the most 
plausible solution.  Changing this culture was something that pharmacy bodies called for 
prior to NMS implementation. They suggested early engagement as a solution. This was not 
realised and therefore cultural barriers to change persist.   
The complexity of service implementation, evidenced by the two decades that it took for 
this service to develop (even without significant political opposition) tends to suggest that 
future services are unlikely to be implemented quickly. The policy commitment to full 
‘utilisation’ of community pharmacy as primary care based clinical professionals seems 
unlikely to be fulfilled in the short term. Indeed, while funding structures fail to offer stable 
and predictable alternative income streams, it is unlikely that pharmacists will be able to 
relinquish their control of the dispensing process.   
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Chapter Conclusion 
It is not solely good evidence that ensures that a ‘problem’ and its subsequent ‘solutions’ 
reach the policy agenda, but a subtle combination of factors. Policy entrepreneurs play an 
important role in helping to create policy windows of opportunity.  This requires the 
alignment of multiple streams, which is achieved by contextualising the ‘problem’ and 
‘policy’ and then engaging the required ‘political will’. However, even after the streams 
have been aligned there is no guarantee that they will remain coupled or that the service 
development will not get smashed by the rocks of implementation.  
Medicines Use Reviews suffered from several implementation difficulties. These can be 
described by seven overarching themes (Work Environment; Financial Drivers; 
Accreditation and Training; Patient Recruitment; External Support; Documentation; and the 
Individual Practitioner). Despite lessons being learnt, half a decade after MUR 
implementation the New Medicines Service (NMS) suffered from similar organisational 
challenges. It took over two decades to develop the service from initial inception and 
evidence gathering to full national roll out. Given this pace of change it is unlikely that the 
utilisation of community pharmacists described in policy (chapter 1) will be achieved in the 
short term.  
While the six contextual factors identified above are important for manipulating the 
environment, it is ultimately the seventh, individual practitioner motivation that drives 
local service implementation. Encompassed within this motivation is the organisational 
culture of the pharmacy, understood as “the way we do things around here” which 
influences role assignment in service delivery. However, organisational culture has been 
largely ignored in pharmacy practice research (Roberts et al., 2003; Clark and Mount, 
2006). Therefore understanding the future professional cultural identity motivating 
pharmacists forms the basis of the next chapter. 
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Chapter 5. Stakeholder beliefs on the Future 
of the Pharmacy 
 
Chapter Introduction 
In policy direction terms NHS community pharmacy appears to be going through a 
transformation which can be characterised as a shifting of its focus from medicines supply 
to ‘clinical’ service provision (chapter 1). This change in practice does not have a single 
clearly described goal, or policy aim. It  instead relates to a philosophical approach which is 
arguably centred around the ‘pharmaceutical care’ concept (Hepler and Strand, 1990) and 
the development of ‘cognitive pharmaceutical services’. These were defined by Cipolle et al 
as “the use of specialised knowledge by pharmacists for the patient or healthcare 
professionals for the purpose of promoting effective and safe drug therapy”(Cipolle et al., 
1998).  
This trend has the potential to fundamentally change the nature of pharmacy practice in 
England (and other UK nations) and with it community pharmacists’ functional roles and 
professional standing within healthcare. Such policy objectives were implicitly if not 
explicitly embodied in the 2008 White Paper ‘Pharmacy in England: building on strengths - 
delivering the future’ (Department of Health, 2008a). However, this document is only one 
of many that together can be taken to represent a global policy direction in not only the UK 
(Community Pharmacy Scotland, 2010; Community Pharmacy Wales, 2011) but many other 
OECD nations, including not only English speaking nations like New Zealand and Australia  
but also in European States such as (and arguably most notably) the Netherlands (New 
Zealand Ministry of Health, 2007; Australian Goverment & The Pharmacy Guild of Australia, 
2010; Bouvy et al., 2011). 
Yet the path ahead for community pharmacy is unlikely to be a smooth one, for a variety of 
reasons. The previous chapter provided evidence indicating that there are seven main 
factors that influence policy implementation in the community pharmacy context. While 
the majority of these lie outside the direct control of individual community pharmacists, 
their collective preferences and linked behaviours inevitably play a key part in determining 
the rate and nature of practice and service changes. The organisational culture of the 
pharmacy and the wider professional community – which may be understood as ‘the way 
we do things around here’ – is a powerful determinant of not only current roles, but also 
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their future evolution.  However, organisational culture has often been ignored in 
pharmacy practice research (Roberts et al., 2003; Clark and Mount, 2006). One of the aims 
of the research reported in this chapter was to contribute to knowledge the shared 
underlying identity of community pharmacists in England, and evaluate the views of 
stakeholders in primary care as to the future for community pharmacy within this social 
context. 
From a role theory perspective (see below) the shifting objectives of community pharmacy 
(and wider health policy) reflect a change process in which both the external identity of 
pharmacists and the internal ‘self’ of group members must adapt.  During periods of 
change ambiguity surrounding role identities can logically be expected to increase. New 
behaviours, skills and attitudes are required to enable actors to address new tasks and 
abandon redundant activities, and during major role adaptation processes there are almost 
certain to be conflicts within not only individuals but also between different factions within 
given communities. 
In England the traditional function of community pharmacy as compounders of medicines 
for ‘society’ (and in certain instances a direct health care provider) was in the main lost in 
the first half of the twentieth century (Thum-Bonanno et al., 2012). It was replaced by a 
finished product supply function. Because this function has been delegated and partially 
mechanised, a mix of new professional services delivered via community pharmacy, 
broadly aimed at improving medicines use and ‘improving’ health related behaviours has 
risen to take its place. Yet there have been difficulties related to adopting new practices 
and demonstrating their value (as discussed in appendix C). As such there remain questions 
as to what the ‘true’ roles of community pharmacists are now and could and should be in 
the future. As already indicated, the goal of the observations and analysis provided in this 
chapter is to cast new light onto pharmacists’ and other pharmacy sector stakeholders’ 
beliefs about relevant issues.   
Theoretical Framework 
The research presented below is based on constructivist theory (and in particular social 
constructivism) and on role theory. The former in essence postulates that subjects from 
different social backgrounds have, because of their varying experiences of being, different 
notions of reality and that knowledge and truth are created, not discovered, via the mental 
states and processes of observers. Researchers working in this area have focussed a great 
deal of their effort developing understandings about the ways in which actors and groups 
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of actors participate, within their overall social context, in the construction of their 
perceived social reality. 
This approach has been applied in the Danish context to the perceptions and future role of 
community pharmacists (Nørgaard et al., 2001). This work adopted the Social Construction 
of Technology (SCOT) theory to describe the development of Danish community 
pharmacists’ professional role(s). SCOT theory requires the identification of a ‘relevant 
social group’ comprised of people involved in the development of an artefact, which is in 
this case the pharmacists’ (clinical) role in the community setting. Examples of its 
membership include not only medicine users (patients) and pharmacists themselves but in 
addition medically qualified prescribers and other stakeholders such as politicians, 
journalists and consumer advocates. These sub-groups can be distinguished by their 
diverging interpretations of the role in question.  
Over and above this, the classical definition of role theory is that it is centred on ‘ a triad of 
concepts: patterned and characteristic social behaviours, parts or identities that are 
assumed by social participants and scripts or expectations for behaviour that are 
understood by all and adhered to by the performed” (Biddle, 1986).  Role theory has 
underpinned a wide range of work on social identities, behaviours and expectations as they 
influence human interactions. Perceived roles can be taken to be key elements of any social 
structure because they define social identities. For example, it can be argued that most 
people hold preconceived ideas about the work and characteristics of secretaries as 
opposed to, say, plumbers or dentists. It is in this sense that the ‘role’ of pharmacists is 
explored below. 
Role theory was developed from a theatrical metaphor, in which actors play their parts in 
social situations and follow relatively precise scripts (expectations). The extent to which 
such assumptions are realistic and defined in today’s circumstances is questionable. 
However, for the purposes of this research it is accepted that expectations learned through 
life experiences generate perceived roles, and that these in turn can influence beliefs and 
attitudes. It is also accepted that changing perceived roles is normally a necessary 
requirement for behavioural and wider social change.  
Broadly speaking role theory based research has in the past created five different 
perspectives: functional, structural, symbolic inter-actionist, organisational, and cognitive 
(Biddle, 1986). Each of these is described briefly below, although it should be noted that 
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terminological ambiguities may to a degree serve to exaggerate differences and conceal 
overlapping concepts. 
The functional perspective presents roles as sets of expectations that given societies in 
effect place on the individuals within them. Certain behaviours are deemed appropriate for 
a given ‘role’ as a result of normative expectations about the function of a given category 
of person in society. For example, it is appropriate for a doctor to ask personal health 
questions, but not an electrician. The functionalist conception believes that roles create 
regular patterns and thus a measure of predictability. Functionalist approaches struggle to 
account for variability in roles and find it difficult to accommodate the fact that individuals 
conceive given roles in differing ways.  For this reason the functionalist approach has been 
criticised for its static, relatively rigid, bias.  
Research undertaken from a functionalist perspective has attempted to categorise the 
‘roles’ of pharmacists in terms of their being business, clinically or professionally focused 
(Guirguis and Chewning, 2005). McCormack (1956) took a functionalist stance where 
discussing problems experienced by  pharmacy students who displayed both a business and 
professional orientation. So did Kronus (1975), who found that regardless of their role 
orientation, pharmacists were motivated by both service and income values. Using this 
functionalist stance it was found that key actors in healthcare policy in Denmark had 
differing expectations for the role of Danish pharmacists (Nørgaard et al., 2001). It was 
concluded that such differences would limit the development of the profession.   
Structural role theory gives cursory attention to the individual. It has been centrally 
concerned with the social environments and wider contexts in which actors play out their 
lives, and on social structures and institutions conceived as stable phenomena at any one 
point in time. In the case of pharmacy today this approach is likely to be of only limited 
value in casting light on how the profession can best adapt to social change, although it 
might be of more utility in understanding barriers to change within sections of the 
pharmacy community. 
Symbolic Interactionist perspectives are by contrast more fluid in their approach. They 
suggest that a role is a conception that is constantly negotiated between individuals 
operating within determining social contexts. This approach lays emphasis on the creation 
and re-creation of roles via social interactions and through cognitive processes that are 
influenced by norms, attitudes and contextual cues. As such it may be of more value in 
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describing evolutionary role developments, albeit that this approach may be limited by, for 
instance, a tendency to under-estimate the significance of structural constraints.  
Organisational role theory has typically been applied to understanding the social systems 
that exist in planned, hierarchically structured and task orientated organisations. Within 
these, formal roles are associated with identified social positions and strong normative 
expectations. However, individuals may question the values and ‘official’ demands of the 
organisations in which they work and also be subject to informal pressures from within the 
workforce they are part of, or through their membership of other communities that are 
important in their lives.   
Research in this area has shown that individuals are often subjected to ‘role conflicts’. In 
the pharmacy context ‘role conflict’ (see below) and ‘ambiguity’ have been found to relate 
to the professional orientation and expectations of pharmacists as compared to the day-to-
day demands placed on them (Guirguis and Chewning, 2005). Mott et al (2004) also used 
this approach to elucidate the role stressors affecting job satisfaction in pharmacies. More 
recent work in this area has described how changing aims and expectations can cause ‘role 
strain’, and the importance of the strategies that individuals and groups adopt to resolve or 
at least contain such tensions.   
Finally, cognitive role theory investigates the connection between personal level 
expectations and behaviour. Role expectations can be embodied in norms, preferences or 
beliefs. Research in this area has considered the potentially beneficial effects of role 
playing and developing anticipatory role expectations in relation to behavioural change. An 
example of pharmacy practice research conducted in this context was provided by  
Pendergast and colleagues (1995). They linked perceived role related factors to 
participation in research. 
In addition to the above it is important in relation to the findings reported later in this 
chapter to define terms such as role confusion, role conflict, role strain, role distance and 
role embracement. Key points to be made in these contexts include: 
 Role confusion (or ambiguity) describes a situation where individuals struggle to 
determine which role to assume. For example, if a student were to attend a 
celebration at a professor’s house, should they assume a student role, showing 
deference and respect, or a role as a friend, displaying familiarity, equality and 
reduced social distance?  
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 Role conflict results when tension is encountered between incompatible roles. This 
has in the past been said to affect women conflicted between their roles as 
mothers and as employed workers. It might in the context of pharmacy today exist 
in the case of an individual wishing on the one hand to act as a clinician and 
recommend a relatively unproven and/or costly treatment, and on the other as 
medicines manager committed to therapeutic risk and cost minimisation.  
 Role strain can be used to refer to difficulties experienced in meeting all the 
obligations of a single role with multiple dimensions. An academic may, for 
instance, struggle to conduct ‘high level’ research and at the same time deliver 
quality undergraduate teaching. 
 Role distance exists in situations in which an individual attempts to separate or 
distance themselves from the role they are playing. It may be reflective of an inner 
conflict between personal values and aspirations and those associated with a given 
formal role or task, and/or of social situations such as disciplinary interventions in 
which it is valuable to emphasise the impersonality of an action.  
As noted above, role theory has been applied in a variety of setting in pharmacy practice 
research (Guirguis and Chewning, 2005). Research from the symbolic inter-actionist and 
functionalist schools has drawn attention to the multiple roles of pharmacists, whereas 
organisationally oriented research has described instances of role overload, conflict and 
ambiguity (as discussed in the appendix). The work presented here relates to the future 
roles that pharmacists might pursue in the NHS, and the extent to which social constructs 
could help or hinder progress towards enhanced primary health care provision. 
Research Objectives 
In summary, the brief theoretical analysis above indicates that understanding roles and role 
change is a complex challenge, not least because although they may be formally delineated 
by statutory provisions and written job statements, roles are also defined by individual and 
group beliefs and informal human interactions. They are in part constructed by the social 
environment within which those who act them exist, and in part serve to form it. Changing 
‘objective’ demands and the introduction of new technologies often serve further to 
increase such complexities.  For example, while the incumbents of an established role may 
not wish it to change, the users and/or funders of their services may have differing 
expectations. Such phenomena lead to confusion, conflict and strain. 
 
 
200 
On the one hand, the functions of community pharmacy and pharmacists are well 
established. Their collective identity as medicine suppliers and advisors are generally well 
recognised and their activities are, from a role theory perspective, highly ritualised. A 
typical patient/pharmacist interaction follows a set ‘script’ through the application of which 
a pharmacist identifies a patient, provides information on medications and how to take 
then, and asks if the medicines recipient has any questions. The patient’s ‘role’ is to 
respond to the pharmacist, ask clarifying questions and pay (where applicable) for the 
prescription. Local contextual cues may influence the application of the script, but its 
content is in the main universal. In some respects it is so ritualised that patients can pre-
empt interactional stages with phrases such as “I have had this before”. Much of what 
takes place in such interactions is defined legally, and/or within standard operating 
procedures or pharmacy regulations.  
On the other hand there are significant ambiguities between pharmacy policies and 
pharmacy practices. Pharmacists are recognised by others or aspire themselves to be 
‘shopkeepers with degrees’, business people, guardians of drug safety, clinicians and/or 
‘scientists on the high street’. Government policies and wider literature suggest a transition 
in the pharmacists’ role from a product focus to a patient focus (as described in chapter 1), 
albeit that all but a few per cent of the typical community pharmacy’s NHS revenue is 
derived from dispensing and associated fees (chapter 3). There is much evidence that this 
uncertain situation is linked to considerable levels of ambiguity and uncertainty concerning 
the status of community pharmacists and their role as health care professionals. Both 
internal and external forces are working to change the profession of pharmacy, against an 
incumbent population of community pharmacists whose current roles and identities are in 
the main defined by established practice behaviours (chapter 2).  
Against this background social groups relevant to the future of community pharmacy 
include not only pharmacists themselves and their immediate representatives but the 
reforming political cadre (or informal leadership group) within the profession that has from 
the 1980s been attempting to introduce an extended role for community pharmacists, 
along with patients and consumer representatives, general medical practitioners and non-
pharmacy political actors. Each has a perception about the role that community pharmacy 
practitioners should perform in health care. 
 The research reported in this chapter was designed to generate qualitative insights into 
both the current perceptions and future vision for the pharmacists’ role that these actors 
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have. It was intended to promote understanding of not only conflicts and the problems 
facing community pharmacy as it seeks to adapt the business and professional practice 
models of the period 1950-2000 to meet the demands of the 21st century environment, but 
also of the opportunities and areas of agreement that may provide bridgeheads to change. 
Methodology 
A semi-structured interview guide was developed and employed as a research tool to 
facilitate increased understanding of the culture and beliefs underpinning community 
pharmacy practice, and the likely success of the current service focused strategy. Flexibly 
conducted semi-formal interviews permit, using a core set of open-ended questions as a 
basic template, the exploration of perceptions, meanings, attitudes and past experiences 
and allow people to offer their constructions of reality in a ways which other methods, such 
as structured questionnaires, are not able to emulate (Pope and Mays, 2006; Kvale, 1996). 
A key aim of such interviews is to reveal and support the evaluation of new concepts and 
ideas proposed by the interviewees: interviewers must therefore be open-minded to the 
views expressed (Patton, 2002). To allow sufficient discourse flexibility, not all the 
questions can be predefined before the interviewing commences, and question order and 
style should be adjusted to reflect the direction that an interview takes (Silverman, 2010).  
In this case the interviews were directed by a generic guide that covered some predefined 
areas based around the themes developed through the policy literature review (chapter 1) 
and earlier work that had investigated student perceptions of community pharmacy 
(Davies and Taylor, 2010b). This acted as a framework that allowed the interviewees to 
develop the conversation in a direction that they felt appropriate. As and when it was 
judged desirable questions were adapted to fit the expertise base of respondents. In 
addition the order of the questions asked was changed to meet circumstantial 
requirements and in some cases questions were omitted, due to the nature of the initial 
responses given by certain respondents. As the research project itself progressed 
interviews were also varied to accommodate the responses of previous interviewees. This 
allowed emergent issues and themes to be pursued in greater depth than would otherwise 
have been possible. 
All the interviews opened with a general question about the role that community 
pharmacist’s play. This was used to help establish interviewees’ beliefs and attitudes prior 
to confirmatory interrogation and subsequent questions that explored their views and 
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feelings in the context of the aims and barriers to and facilitators of future pharmacy 
practice developments.  
Seventeen purposively selected leaders of both the pharmacy and general practice 
communities were interviewed between November 2010 and February 2011 (see sampling 
strategy below). The interviews were normally conducted face-to-face and in a variety of 
locations, but most often in the interviewee’s office. In two cases the interviews were 
performed in public places. It was anticipated that all interviews would have been 
completed by early January, but due to the weather being particularly bad during 
December 2010, a number of the interviews were postponed or conducted via the 
telephone. This last tended to limit discussions and did not permit observations of 
emotional expression via, for instance, body language.  
The recorded interviews lasted between 30 and 65 minutes, with the average being 42 
minutes. In most cases the interviewee had allocated 60 minutes for discussion with the 
researcher, and therefore when possible further data was captured manually before and 
after the digital recorder was turned off. When appropriate these notes were also included 
in the analysis. During these interviews the interviewees were asked to express their 
personal views, rather than speaking on behalf of the groups that they represented. 
However, it appeared that the positions of respondents as group representatives tended to 
influence responses.  
In addition to a study explanation sheet all participants were given a preliminary 
introduction to the research before the interviews began. When face-to-face meetings took 
place the participants were asked to complete a consent form. In the case of telephone 
interviews verbal consent was given. All the interviews were digitally recorded with the 
interviewees’ consent, either written or verbal. One interviewee asked for the recorder to 
be turned off at one point to discuss some personal information, but it was subsequently 
restarted. During all interviews written notes were also made, in part to help guide 
discussion and also to help capture important phrases and ideas in case of recorder failure. 
No recording failures in fact occurred.  
After each interview the recording was checked and the process of the interview was 
reviewed to enable changes to be made in future interviews.   With the exception of three 
interviews, these recordings were sent to a professional transcriptionist to be transcribed 
in a specified format. Three interviews were personally transcribed for various reasons. 
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Two were due to background noise, which the professional transcriptionist found to be 
excessive, and the third was because the interviewee specifically requested a section be 
removed that contained potentially sensitive information. All transcriptions were verified 
and in some cases this was done on two or three occasions as part of the familiarisation 
process.  
Sampling Strategy 
The sampling methodology used in this case was purposive. Building on the principles of 
the SCOT theory described above, the techniques of ‘follow-the-actors’ and ‘snowballing’ 
were used to identify additional interviewees. In accordance with ‘snowballing’ 
methodology, all interviewees were asked to provide names of other potential actors. The 
sampling continued until saturation: that is, until no new themes emerged in new 
interviews.  
Interviewees were selected on the basis of their identification by other actors, their 
acknowledged influence and familiarity with the development of English community 
pharmacy and relevant policy issues and processes, as well as their observed standing in 
the primary healthcare domain. The sample included pharmacists and general medical 
practitioners, patient group representatives and individuals from the Department of Health 
and allied agencies. Overall, six of the respondents were pharmacists and or employees of 
pharmacy bodies, five worked within the Department of Health or in the wider public 
sector, four were general practitioners and two represented patient views. A brief 
summary of their roles is described in table 5.1 below. However, only limited detail is given 
in order to preserve anonymity. 
In many cases, due to the variety of ‘roles’ that these stakeholders performed, there was 
overlap between categories. For example one pharmacist was also a representative of a 
patient advocacy group. Likewise one general practitioner was still involved in direct care 
provision but also served in a national policy related role. These overlaps helped to 
promote the exploration of emergent themes through different lenses. As shown in table 
5.1 PH is used to denote pharmacists, DH represents Department of Health or public body 
representatives, GP denotes General Practitioners and PT indicates a patient 
representative.  Although several of the interviewees could have been included in more 
than one group, only the role taking most of their time was used in the descriptor.  The 
number that follows them serves as a personal identifier. 
 
 
204 
Table 5.1 – Brief overview of Participants’ Roles. 
Identification Number Role 
DH1 Department of Health pharmacy official  
PH1 Pharmacy body representative 
PH2 Pharmacy body representative 
PH3 Pharmacy body representative 
DH2 Department of Health pharmacy official 
DH3 Department of Health primary care policy  
DH4 Senior manager of a public sector body with health responsibilities 
PH4 Pharmacist primary care adviser working in general practice 
GP1 GP and Department of Health role holder 
GP2 Professor of general practice with primary care interests 
GP3 Professor of general practice with primary care interests 
GP4 General medical practitioner body representative 
PH5 Pharmacy body representative  
PT1 Patient group representative 
PT2 Pharmacist working with a patient group 
GP5 General medical practitioner body representative 
PH6 Pharmacy body representative 
 
Data Analysis 
In much qualitative research the data analysis begins during its collection to allow early and 
emergent findings to help shape ongoing data collection. This study incorporated such an 
approach. The data was constantly analysed through a process of deduction and induction 
to search for apparent regularities and anomalies. Given the author’s identity as both the 
data collector and analyser it was impossible to separate these two processes and 
therefore data analysis and collection existed simultaneously.  The identification of 
emergent themes was also in part guided by the previous literature review. 
The use of interim analysis (Miles and Huberman, 1994) has the advantage of allowing 
emerging avenues of inquiry to be explored in greater depth than would otherwise have 
been the case, and for questions to be refined and hypotheses to be developed and tested. 
It may be useful to note that the underlying approach adopted in the research presented 
here is based on a rejection of the so-called ‘realist’ view that qualitative research simply 
‘gives voice’ to the views of the responding participants. Rather, it is assumed that giving 
voice, even at the most basic level, inevitably involves identifying and crafting ‘pieces of 
evidence’ which are then edited and deployed in order to project a coherent argument and 
to generate hypotheses which can only be verified via subsequent quantitative analysis. 
What is arguably most important in the qualitative research context is that the methods 
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used and the theoretical frameworks employed are both consistent with the questions 
being asked. This decision process necessitates that value decisions and associated 
elements of prior knowledge are added to the observed data. It is argued here that this is 
an appropriate research approach which adds to the meaning of data gathered, provided 
that it is clearly documented and acknowledged. This explains why in the results section 
below references are made to literature search based findings, alongside the original 
observations reported.  
Approaches to analysing interviews 
Following on from the above, for the sake of linearity data management and data analysis 
are normally identified as separate, distinct ‘items’ in theses such as this. But in reality they 
are not normally neatly sequential in nature. There is rather an iterative process between 
the stages of data management, description and explanation (Ritchie and Spencer, 1994). 
The choice of method of analysis of qualitative data lies on a continuum from inductive to 
deductive analysis (Pope and Mays, 2006). Inductive analysis, also known as ‘coding up’, 
identifies themes from the data. Deductive analysis, also known as ‘coding down’, draws 
from predefined or anticipated themes identified in the published literature or from 
elsewhere to structure the analysis. In combination both approaches allow new ideas, 
theories and hypothesis to be formed, as themes are formed from the research findings.  
Methods of qualitative analysis are described in table 5.2 below. They can broadly be 
categorised into two different types. The first is tied to a particular method or theoretical 
position. Illustrations include conversational analysis (CA) or interpretative 
phenomenological analysis (IPA). Grounded theory and discourse (DA) or narrative analysis 
also lie within this camp. They are all methods which can be said to sit within a broad 
theoretical framework.  
The second methodological type includes approaches which are essentially independent of 
theory or epistemology. Therefore they can be applied across a range of theoretical 
positions. Framework analysis and thematic analysis are located within this second group.  
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Table 5.2 – Methods of Qualitative Analysis 
 Description Suitability for this study 
Content Analysis A review of documents, newspapers, reports 
or narratives. Occurrences of words or themes 
are counted and subjected to statistical 
analysis. 
This approach requires an a priori knowledge. 
However, this study began with as few 
preconceptions as possible and requires a 
deeper level of analysis of views and beliefs.  
Discourse Analysis This refers to a number of approaches to 
analysing speech series, propositions or 
sentences (discourses).  
These approaches emphasise different aspects 
of language use, by viewing language as a 
social interaction, and are concerned with the 
social contexts in which discourse is 
embedded. This is not the central aim of this 
study.  
Conversational Analysis This technique is a distinct form of discourse 
analysis and seeks to uncover and explain the 
structure of communication in natural 
dialogue. It explores naturally occurring 
language use to examine the way questions, 
answers and statements are made in social 
interactions. 
This is a method predominantly used by 
cognitive psychologists for detailed 
interactional analysis, which is again not the 
central aim of this research. 
Narrative Analysis This method focuses on the ways in which 
people make and use stories to interpret the 
world. It is not concerned with the specific 
stories per se, but with the social products 
that they help to generate. 
The aim of this research is not to investigate 
the way people describe the social world, but 
the beliefs about future pharmacy practice.  
Interpretative 
Phenomenological 
Analysis (IPA) 
This method was developed within 
psychology. It is concerned with individuals’ 
perceptions of events and experiences (hence 
the term phenomenological) and 
acknowledges the researchers’ role in making 
sense of those experiences (interpretative). 
This study does not seek to offer an 
interpretation or perception of particular 
experiences, but rather an in depth analysis of 
stakeholders beliefs’ across a general sphere.  
Grounded Theory This aims to generate, develop and verify 
theory from the data gathered. Grounded 
theory is an inductive thematic analysis where 
the data emerges from the analysis and is 
described as a cyclical process involving the 
continuous analysis of the raw data in light of 
the themes generated by constant 
comparison. Although it may, due to its 
inductive nature, be described as the ‘purest’ 
qualitative research method, it is time 
consuming and challenging to perform.  It may 
also fail to take adequately into account 
existing knowledge in complex and/or  already 
relatively well researched areas.  
The primary aim of this study was to describe 
the views and opinions of stakeholders in the 
light of a wide range of pre-existing 
knowledge sources, as opposed to generating 
new specific theory.  
Framework Analysis  Developed for the purposes of applied policy 
research. Although grounded in the original 
data it is best suited to addressing specific 
research questions via repeated systematic 
analyses that allow comparison between and 
within cases.  
This method requires a priori ideas that can be 
used to form the thematic framework. The 
present study sought to takes a more 
grounded approach, while also drawing on a 
priori knowledge. 
Thematic Analysis This is a relatively weakly demarcated 
method, which is widely used in qualitative 
analytic work to identify, analyse and report 
patterns within data. Typically, themes that 
are judged important to broad research 
questions are pulled from the original data 
and then considered and re-considered in the 
light of both the immediate research 
observations and other relevant knowledge 
sources. 
Although some commentators argue that this 
is not strictly an analytical method in its own 
right, it offers an accessible form of inquiry 
that was considered appropriate for use in the 
context of this study. 
 
In the field of pharmacy practice research the three most commonly used approaches are 
thematic content analysis; grounded theory and framework methodology. They share a 
common initial stage of reading and re-reading interview based data to achieve familiarity 
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with it, which is often called immersal in the data. This allows for the identification of and 
assigning of codes to key and associate themes, using exerts from the data/transcripts. It is 
beyond that point that the differences between these approaches become apparent.  
Thematic Analysis 
Thematic analysis was chosen for this data set because it allows both inductive and 
deductive reasoning. Thematic analysis involves qualitative research data being categorised 
into themes by reviewing the transcripts and identifying, comparing and coding recurrent 
sets of linked concepts. By using the thematic content approach, interview records are 
distilled into a list of common themes that express the communality of views across the 
interviewees. The reported themes should be grouped in such a way as to reflect the text 
as a whole. Although interpretation is required to sort and name the themes, deep 
interpretation is reserved for the discussion of the data. This method is widely used. There 
is a lack of agreement across the academic community about precisely what it involves and 
how best it should be undertaken. Nevertheless, table 5.3 seeks to provide an outline of 
thematic analysis described in structured linear process terms.  
Table 5.3 – Process of Thematic Analysis 
Phase Description of the process 
1. Data Familiarisation Transcribing data, reading and re-reading the data, noting down initial ideas. 
2. Generating initial codes: Coding interesting features of the data in a systematic fashion across the entire 
data set, collating data relevant to each code. 
3. Searching for themes: Collating codes into potential themes, gathering all data relevant to each potential 
theme. 
4. Reviewing themes: Checking in the themes work in relation to the coded extracts (Level 1) and the 
entire data set (Level 2), generating a thematic ‘map’ of the analysis. 
5. Defining and naming themes: Ongoing analysis to refine the specifics of each theme, and the overall story the 
analysis tells; generating clear definitions and names for each theme. 
6. Producing the report: The final opportunity for analysis. Selection of vivid, compelling extract examples, 
final analysis of selected extracts, relating back of the analysis to the research 
question and the available literature, and producing a scholarly and well reasoned 
report of the overall analysis. 
 
Stage 1 – Data Familiarisation 
During this study the initial familiarisation stage was achieved in the first instance via the 
interviewing process itself, followed by the transcription of some of the interviews and the 
verification of the accuracy of the audio file transcriptions. These were read and initial 
ideas and thoughts were noted.  
Stage 2 – Generating Initial codes 
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All interviews were listened to again to allow full immersal in the data and an extended list 
of initial ideas was developed. All of the transcripts were then read through in a hard copy 
format and important quotes were highlighted in the text to allow a preliminary list of 
codes to be drawn up. This was an iterative process that involved a series of refinements 
based on intuition, logical conceptualisation, understanding and prioritisation.  
The complete data set was then systematically analysed. Each of the interviews undertaken 
was organised into different codes. In some cases statements were given more than one 
code. The data extracts relating to each code were then mapped manually into different 
files using the cut and paste function in Microsoft Word. Where relevant a little of the 
surrounding data was copied in order to maintain the context of the data.  
Stage 3 – Searching for themes  
The long lists of codes were re-focused into broader level themes. It quickly became 
apparent that some of the codes naturally grouped themselves under similar overarching 
ideas. These were grouped together and placed under a preliminary thematic framework.  
During this process it became clear that several subthemes would need to be added to the 
framework. In some cases, several of the codes were combined. The full set of themes was 
drafted into a preliminary mind map that described all of the codes. While the 
representation here shows a clear linear structure, the reality of the process involved the 
movement of numerous post-it notes over a large table. During this process some aspects 
of the data gathered attracted increased attention. They tended to be linked to contrasts 
and conflicts of belief and attitude between different interviewees. 
Stage 4 – Reviewing the themes  
At this stage the current thematic structure and the coded data was discussed with this 
project’s primary supervisor (DGT) 54. It became apparent during this phase that some 
candidate themes did not qualify as free standing categories (e.g. because there was not 
enough data to support them, or it was too disparate) and that in other cases two or more 
themes could be collapsed into one. The proposed final categories were then re-evaluated 
in relation to their coherence and meaningfulness.  
Once again, problematic candidate themes were either reworked into already existing 
themes, made into new themes or discarded. This lengthy process went through several 
                                                          
54 Professor David Taylor 
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iterations. The process of re-reading the whole data set and reshaping the thematic 
structure was only ended when satisfaction that the resultant integrated thematic 
framework accurately represented the data and communicated its overall ‘story’ was 
reached.  
Phase 5 – Defining and renaming themes  
The finally identified themes were then re-organised into a satisfactory thematic map and 
the essence of each of themes was defined. A detailed account of each theme was written, 
showing how it fits within the overall narrative of the data set. At this stage interactions 
between the themes were considered, as was the existence of valid subthemes (themes 
within themes). By the end of this phase the themes were clearly articulated and defined, 
and the titles of the themes had been changed to reflect their meaning.    
Phase 6 – Reporting the Findings 
The final stage of the process described above involved reporting the main themes 
accompanied by relevant detail from within the data, together with other evidence as and 
when relevant. For the purposes of this thesis only the most relevant quotations have been 
included, followed by their coding notations (table 5.1).  
Ethical considerations 
This study was granted ethical approval in 2010 by the then School of Pharmacy, University 
of London, ethics committee. All participants were sent electronically an explanation of the 
purpose and method of the study as well as their rights and requested contributions. 
Where interviews took place in a face-to-face basis survey participants were in addition 
provided with a hard copy of this information sheet, the contents of which was also re-
iterated verbally at all relevant points. Informed consent was gained from all participants, 
and recorded either via signing or verbally for the digital recording of the interviews. 
Participants were assured that their anonymity would be protected and that no directly 
identifiable quotations would be used. Participants were not offered any honorarium and it 
was emphasised that they were all free to leave the study at any time. All the interviews 
were conducted at a mutually agreed location and time, often out of normal working hours 
to fit in with schedules of those involved.  
 
 
210 
Validity and Reliability 
Validity and reliability in qualitative research is a suitable topic for a thesis in its own right. 
Some social science researchers reject the concept of validity in qualitative research. 
However, a perhaps more realist approach would be to accept that there are measures that 
can be taken to reduce the risk and enhance the quality and credibility of the findings.  
Mays and Pope (1995) discuss how poor qualitative research is anecdotal, unreflective, 
descriptive and does not follow a coherent line of inquiry. To overcome this criticism this 
work has used several methods to help ensure the integrity of the data and to manage the 
inductive leaps made from the data collected. 
Methodological considerations were explored from a variety of angles to ensure that the 
interviews were valid and reliable for information gathering purposes. Questions were first 
piloted with a number of politically active pharmacy students to ensure that they were 
clear and appropriately understood. Their open nature was intended to allow respondents 
to raise issues that they personally believed are important. Digital recording of interviews 
enabled them to be reviewed and verified. Consistency was assessed by a third party 
(Professor David Taylor) who acted as an auditor for the coding for the first few transcripts, 
which, as described above, were re-coded several times and between the cycles.   
Demonstrating validity is a challenge, not least because it is not normally possible to apply 
statistical testing methods directly to qualitative research findings. However, other 
methods can be used. For example, third party audit can counteract interpretational bias, 
and help ensure consistency in coding and conclusions. Reliability was also improved 
through triangulation of the results with published literature and time points. Analytic 
process transparency should enable readers to trace explanations and conclusions through 
the way the data is recorded, referenced and charted. The inclusion of quotations within 
the results helps to demonstrate where induction was made from the interviewees’ 
responses. The combination of these processes provides a governance structure that helps 
to limit unsubstantiated inductive leaps from the data collected, albeit that in the final 
analysis all qualitative research findings may be thought to require quantitative validation 
before being translated into actions that might affect human wellbeing.  
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Results 
Organisation of the data 
The data below is organised into four central themes (Table 5.4).  They suggest that 
respondents believed that community pharmacy will need to move in the direction 
indicated in recent policy (see chapter 1). That is towards providing more cognitive services 
that utilise pharmacist’s skills in order to contribute actively to improved health outcomes, 
while maintaining a safe and cost containing medicines supply. Although some respondents 
appeared to believe that promoting development in this direction will prove relatively 
straightforward, there was amongst others significant evidence of ambiguity and 
uncertainty about how such progress will be achieved in practice.  
Table 5.4 – Central Themes  
Theme Summary Statement 
Professional Identity Pharmacists have a conflicted professional identity. They currently tend to operate as a risk 
averse, rule based, professional group, in contrast to expectations of their perceived future 
roles as clinicians who may be required to accept higher levels of risk and ambiguity.  
Status and value The contribution that pharmacists make to healthcare was felt by themselves and others to be 
under-recognised. This was perceived to act as a barrier to pharmacists changing and 
developing new contributions. At the same time their skills are commonly seen as under-
utilised, even though they may also be constantly busy. This may be taken to imply that the 
supply role they play is not valued, and may not be thought to justify the status to which they 
aspire. 
Business Imperative The business imperative of community pharmacy is a vital aspect of its identity. It is reflected 
in the fact that pharmacists are overtly involved in cash transactions with service users.  The 
recorded responses suggested that the ‘business’ image of pharmacy is  something that 
pharmacists seek to preserve despite fears that it undermines their perceived standing as 
altruistically motivated health care/clinical professionals. 
Technology development Developments in information, dispensing and other technologies are seen as inevitably driving 
forward changes in the organisation of the community pharmacy business and as threatening 
to current pharmacy practice in the supply context. But they may also open the way to new 
clinical care provision opportunities.  
 
The past, present and future identity of community pharmacists 
One of the most striking themes derived from the interviews was the ambiguity of 
community pharmacists’ identity in healthcare.  The core contribution of the pharmacist as 
described by the majority of interviewees relates to safe medicine supply, which some 
respondents implicitly linked back to the profession’s past medicines making role. The 
centrality of the safe supply of medicines to community pharmacy was regarded as 
valuable, although it is not without negative connotations. 
I think as far as patients are concerned, the primary thing they expect from 
pharmacy is an efficient dispensing service, so it’s a supply function. [PH1]  
 
In a way, I’m saying if supply is the future, there is no future. [PH2]  
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Medicines supply is at the core of the pharmacist’s traditional role.  In his seminal study 
entitled ‘Reprofessionalization in Pharmacy’ Birenbaum (1982) argued that compounding 
was pharmacy’s specialist area of knowledge and skill, and that it was lost as a result of the 
development of the modern pharmaceutical industry. Respondents to this study did not 
spontaneously mention this early nineteenth loss of core function (they talked rather of 
pharmacy taking on an extended set of functions in the modern setting) although an 
awareness of it may in part underlie comments made to the effect that pharmacists are 
‘under-utilised’.  
I have long believed that community pharmacy is an under-utilised source of patient 
care David Colin Thome (Department of Health, 2008a: p21).  
The latter can be taken to be indicative of an acceptance that greater contributions could 
and should be expected, and/or that the current role of pharmacists as suppliers of 
medicines is not in itself enough to justify the costs of the pharmacy system. Reflecting 
such observations, Waterfield (2010) also argued that pharmacy is an ‘under-utilised’ 
knowledge based profession. Yet he also maintained that community pharmacists have a 
potential ability to make a ‘massive impact on society’. The responses of some interviewees 
endorsed this perspective. But others said that the future of NHS community pharmacy is 
threatened by the activities of other groups, such as nurses, that are encroaching upon its 
perceived professional boundaries, as well as by developments in dispensing and other 
technologies (Edmunds and Calnan, 2001a). This can be regarded as indicative of high 
levels of role insecurity, and perhaps also of role conflict. 
In this last context the medicines at the heart of the profession’s expertise were also 
described in both positive and negative terms. On the one hand they were said to be a 
source of improved health and longevity. Seen from this standpoint their consumption is 
inherently desirable. On the other hand their perceived effectiveness was also associated 
with unwanted hazards: medicines are in this respect often regarded as a source of risk 
that needs to be minimised. Pharmacist interviewees tended to see risk management in 
terms of restricting medicines supply and to argue that they (pharmacists) are the only 
people who have a sufficient knowledge and motivation to balance the risk/burden of harm 
associated with medicines use against its possible benefits.  
We have got something, something about our roles that the managers of medicines 
recognise, whether that is the procurement of them, the supply of them, the 
sourcing of them, making sure they are safe. Making sure that somebody who has 
been prescribed five to 10 medicines takes them, or that they are not being wasted, 
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or that when they are being administered in environments where there isn’t a 
expert, that they are supported in doing so. [PH6] 
 
Such responses imply a conflict with the simple goal of optimising convenient access to 
medicines. A more complicated concept of facilitating the appropriate use of medicines 
was suggested, through a focus on safety, process control, risk avoidance, prescription 
checking and cost control. This research suggests a picture of pharmacists as (public health 
related) rule enforcers rather than rule makers or flexible (clinician) rule interpreters. To 
the extent that this is a valid observation, the primary role of pharmacists may encourage 
them to become, and be regarded by others as, inherently risk averse (Rosenthal and 
Tsuyuki, 2010). Respondents’ comments to the effect that pharmacists are ‘ideally placed’ 
to reduce waste, increase adherence and improve prescribing may be also linked to the 
social positioning of modern pharmacists as a group that seeks to police the risks taken by 
medical prescribers and the behaviour of medicines users.  
Pharmacists’ professional socialisation plays a part in inculcating such views. Pharmacy 
students are taught to be ‘scientists’ in the sense of being careful observers and actors who 
behave in an orderly and verifiably systematic manner. The 2008 pharmacy White Paper 
talked of the ‘science of pharmacy’ (Department of Health, 2008a). There is research 
indicating that the public tend to believe pharmacists have high academic ability but 
relatively limited social skills (Hean et al., 2006). At the extreme this can be linked to the 
stereotype of ‘a scientist’ as a socially inept workaholic (Losh, 2010). Rosenthal and Tsuyuki 
(2010) characterised the personality traits of pharmacists, at least as they are reflected in 
their approach to patient care, as encompassing a lack of confidence; fear of new 
responsibility; paralysis in the face of ambiguity; a need for approval; and risk aversion.  
While the ‘feminisation’ of the profession may have served to counteract part of the 
science stereotype (Seston and Hassell, 2009b), some sources still appear to promulgate 
this view of the profession. Indeed, it can be argued that the pharmacists’ main knowledge 
base rests on precise and systematic scientific observations made in areas such as 
pharmaceutical chemistry, rather than hypothesis generation or broad interpretational 
skills. At the same time activities such as dispensing require caution and a focus on avoiding 
mistakes (Harding, 2007), which may in turn promote or favour mindsets  that are relatively 
rigid and oriented towards imposing an order based on set rules and procedures (Rosenthal 
and Tsuyuki, 2010).  
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As respondents in all groups suggested, this ‘safety net’ has a utility for prescribers and 
medicine takers alike. However, it appears that many pharmacists are consequently 
reluctant to depart from or extend their oversight role in the supply of medicines in the 
direction of becoming autonomous clinical practitioners who are supported by rules as 
opposed to being bound by them. This is in part reflected in attitudes towards the 
management of the dispensing process: 
I think that pharmacist involvement is still essential for clinical checking, to make 
sure a prescription is safe and appropriate. [PH5]  
 
Although Birenbaum (1982) assumed the traditional compounder role was no longer 
valuable, other pharmacy commentators and entrepreneurs have suggested the benefits of 
pharmacists formulating bespoke medicines to meet an individual’s request. This idea is 
receiving a renaissance in Australia, USA and elsewhere, where increasing numbers of 
pharmacies are offering patients opportunities to purchase medicines compounded to their 
individual requirements. The desirability or otherwise of such developments is not explored 
here. But it is of note that some respondents suggested that patients will in future require 
a greater level of personalisation of their drug therapy as pharmacogenetics evolves and 
that ‘only pharmacists’ are/will be skilled enough to provide such a service. 
If you think about medicines optimisation, as was spelt out loud and clear in the 
coalition government’s White Paper, then pharmacy is well positioned to optimise 
medicines and that I would have thought would be in accordance to someone’s 
genetic make-up as much as anything else [DH2]. 
Such comments indicate that NHS and/or other policy makers may in future seek to 
encourage pharmacists to play a greater role in diagnostic and allied processes. There is a 
logical case in favour of this. But the observations provided here raise questions as to the 
capacity of existing role based pharmacy identities to accept such an adaptation. That is, 
there are substantive barriers to change located within the roles played within pharmacy 
itself. 
The research reported here has highlighted potential conflicts between the supplier of 
medicines role (which might naturally focused on volume maximisation) and the controller 
role (focused on risk and cost minimisation). Such tensions resonated throughout many of 
the views expressed. The situation of other health care professionals differs significantly. 
Doctors’ responses, for example, implied their own uni-dimensional and un-conflicted role 
that relates to the maximisation of the health of their patients and the populations they 
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serve. Put at its simplest, it is always appropriate to ‘sell more health’, whereas it is not 
always right to ‘sell more medicines.’ This links to the conflict between business and 
professional identity issues discussed below. 
Moving on from this, community pharmacies and pharmacists have always been directly 
involved in the support of self care and advising on, as well as supplying, treatments for 
common illnesses, defined in terms of minor and self limiting acute conditions (Dingwall 
and Wilson, 1995). By contrast, taking responsibility for making ‘serious’ diagnoses and 
disease treatment decisions (a category which has traditionally included the routine 
management of long term conditions and/or risk states) has been, and still normally is, 
perceived to involve levels of risk taking that lie outside the pharmacist’s role boundaries. 
Therefore responsibility must be transferred to general or even specialist medical practice.  
Limited though the current minor illness role may be in autonomy terms and current 
practice, it is of considerable importance to many pharmacists: 
If you’re looking at minor ailments then, I think minor ailments are so bread-and-
butter for community pharmacy that they are in a very natural position.[PH1] 
 
You’re talking about just dispensing and supply, then you’ve got enough trained 
people to be able to dispense. But if you’re talking about actually counter sales and 
actually prescribing over the counter, then you need a pharmacist. That’s what our 
skill is.[PH4] 
Interviewees raised a number of issues relating to the extent to which in future community 
pharmacists could play an extended ‘public health’ role, which will involve them accepting 
increased responsibilities relating to the provision of long term drug therapies as forms of 
primary, secondary and tertiary prevention. Depending on the therapeutic and service user 
support approach taken,  one possible interpretation of such a ‘pharmaceutical public 
health’ role is that it represents an extension of ‘healthy living’ and ‘compliant medicines 
use’ rule enforcement, rather than a significant change in occupation outlook. As such, 
progress in this direction will not necessarily conflict with a ‘risk minimisation’ oriented 
pharmacist mindset. 
Advocates of an extended community pharmacy role suggest that the profession should 
become more centrally involved in caring for and advising people with both acute and part 
stable chronic conditions. Others believe that pharmacists do not have the necessary 
diagnostic and clinical skills to manage such conditions appropriately (Richardson and 
Pollock, 2010), albeit that to date the development of minor ailment treatment schemes 
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suggests that pharmaceutical care can be cost effective and may in appropriate 
circumstances be preferred by patients (Baqir et al., 2010a; Baqir et al., 2011; Baqir et al., 
2010b).  
Some respondents to this survey were relatively cautious as to the extent to which 
community pharmacists’ clinical role extensions will prove possible and desirable: 
If you’re expecting people to come along and say ‘I’ve got this rash what do you 
recommend’, the more clinical side of things, then you would need somebody with 
more clinical training. [DH4]  
 
Embracing wider pharmaceutical care roles implies a greater level of uncertainty in 
practice. The qualitative observations offered here indicate that policies that encourage 
pharmacists to accept increased levels of clinical risk may often be interpreted as 
threatening to their fundamental identity and professional domain, as it is currently 
understood. This implies that if change is judged desirable it is likely to take time, and will 
require new approaches to pharmacy education. With regard to the latter, respondents 
implied that it presently succeeds in establishing a core set of knowledge but does not 
provide the over-arching competencies required for future role development, either 
individually or collectively.  
The bottom line conclusion drawn here is that although most community pharmacists may 
feel comfortable treating patients within the limited constraints of the traditional 
‘symptomatic relief of minor acute illness’ model, they are not commonly seen by 
themselves or other stakeholders as being ready to embrace clinical situations that involve 
higher levels of risk and uncertainty. Effectively presented role change proposals will need 
to build on this present reality, rather than ignoring it or attempting to bypass it. 
The future status and perceived value of pharmacy as a profession 
Pharmacists have historically enjoyed the privilege of professional status (Anderson, 2007). 
Those interviewed articulated being loyal and proud of their profession and of their 
personal status as regulated professionals. The pharmacist contributors to this research 
appeared to believe that only registered professionals can safely carry out or manage the 
medicines supply function. They expressed a sense of possessing a ‘special knowledge’ of 
medicines at the fundamental level that they believe is of value and that no other actor in 
health care possesses.  
 
 
217 
Over a decade ago Harding and Taylor found that extemporaneous dispensing represents ‘a 
potent symbol of the pharmacist’s status and value to the community’ (Harding and Taylor, 
1999). Although in practical reality terms little extemporaneous dispensing takes place in 
countries such as the UK, the profession’s sense of its unique value seems to live on in 
relation to its members’ shared belief in their special knowledge of medicines. Arguably 
knowledge asymmetries between service providers and users lie at the heart of traditional 
professionalism. Through the latter the practitioners of certain trades gain financial and 
other privileges, including a degree of protection from competition, in return for a 
collective commitment to consumer protection and ‘altruistic’ standards of behaviour (see 
chapter 1). 
However, respondents’ of all types also acknowledged that evidence indicative of the 
practically relevant, cost effective, use of community pharmacists’ pharmaceutical 
knowledge to improve health outcomes  is at best limited. This lack of role verification, and 
the incursion of other professions into the ‘drug’ knowledge domain, is potentially 
threatening to community pharmacists’ and their perceptions of their role defined identity. 
Pharmacist respondents argued and appeared to sincerely believe that they have an 
essential role in the supply function that is important for protecting the public’s health. Yet 
other interviewees believed the supply process normally involves little more than ‘handing 
out packets’ of medicines. This represents a significant vulnerability: 
If it were simply a matter of dispensing and handing out routine advice that was 
available from the packet, even for the prescription medicines, then you probably 
don’t [need a pharmacist in a pharmacy. [DH4] 
 
Some argue that the ‘mystery’ that once surrounded the compounding of medicines and 
mixing of potions has merely been replaced by the de-mystified functionality of pill 
counting and bottle labelling  (Hornosty, 1990). Yet at the same time pharmacist 
interviewees clearly thought that the profession and its members are often treated unfairly 
by other health care practitioners and misunderstood by policy makers. This is consistent 
with other research derived reports. There is robust evidence that pharmacists widely 
perceive that they are not treated as full professionals and are viewed by some as ‘non-
professionals’ (Hassell et al., 1999; Hassell et al., 1998). 
Pharmacists taking part in this research said that their professional role and value is not 
respected as much as it should be, with several describing themselves as an ‘underused’ 
resource: 
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I would argue community pharmacy has already been incredibly efficient and 
gained efficiency savings for the last 15-20 years. We haven’t got a lot left to 
squeeze. I think that’s not a point that is well understood by the policy makers. 
[PH1] 
 
This sense of injustice is likely to be the result of a variety of factors. In addition to 
questions relating to the possible under- or over- estimation of the safety related and allied 
value of community pharmacists in dispensing process management (in contexts such as, 
say, preventing low probability catastrophic consequence events as well as every day 
moderate consequence errors) their sense of unfairness may to a degree be an artefact of 
community pharmacists not having access to clinical records. This last helps to ensure that 
‘important’ medicines use decisions are, or are at least seen as being, under medical 
control. Hence some respondents argued that community pharmacist access to electronic 
patient records would help raise the perceived status of community pharmacy as a whole, 
as well as objectively opening the way to playing a more pro-active clinical care provider 
role. 
 
A scientific knowledge of medicines composition and actions can be seen as providing 
pharmacists with the credentials needed  for professional status (Brint, 2006). Some 
interviewees described themselves as being ‘the expert in medicines’. This knowledge can 
be translated into providing valued information to others, whether they are patients or 
other health care professionals. Issues of cost effectiveness aside, it is this knowledge of 
drugs that Harding and Taylor – along with a number of those interviewed here – suggested 
that pharmacists should capitalise upon (Harding and Taylor, 1997).  
Yet general practitioner respondents argued that an understanding drugs alone is not 
enough to justify pharmacists intervening in patient care over and above the basic supply 
process. As some interviewees’ responses indicated, this poses fundamental questions as 
to the utility of the pharmacist’s traditional knowledge base and skill set in the context of 
modern health care. This is not least because of the growing availability of increasingly 
efficient and effective computer based knowledge delivery systems (see below). One GP 
said: 
I think pharmacy is probably less well placed to do long-term conditions 
management. Because it’s an order of complexity and infrastructure, which is 
probably not as well suited to a pharmacy environment. [GP4]  
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Nevertheless, despite such questions and the role conflict related concerns discussed 
above, many of the pharmacists advocated the development of pharmaceutical services in 
the community.  
I think the pharmacist’s role in those services could expand, and should expand, 
really, because it’s a resource that is underutilized right now, in the community 
where people need it. [PH5]  
 
The findings offered here suggest that for many GPs (and probably other doctors) an 
extension of pharmacists’ roles in areas such as supporting self care and managing the drug 
treatment of long term conditions would, despite their relative security, be seen as 
threatening to their roles. Other studies have reported that pharmacists appear 
threatening to general practice ‘if they suggest too many (treatment) changes’ (Ortiz et al., 
1989).  
During this investigation a number of views were expressed about pharmacists’ 
subordinate positions to general practitioners in the health care hierarchy, not least by 
pharmacists themselves. 
One interpretation of the available data is that community pharmacists share a hierarchical 
view of the world with the medical profession but fear they lack the standing they believe 
they deserve relative to doctors. They may therefore tend to express relatively high levels 
of role related status anxiety, while also being on occasions judgementally critical of the 
abilities of others, including doctors, nurses, patients and the public (see, for instance, York 
Health Economics Consortium and School of Pharmacy University of London, 2010). 
Pharmacist respondents said their advice was not respected by patients ‘as much as it 
should be’. At the same time some interviewees with a general practice background also 
projected a hierarchical view, but with a greater tendency to suggest that pharmacists’ 
contributions could be optimised within general medical practitioner led environments:  
If you were being a bit more radical, you could say that if we truly want to integrate 
pharmacists into the GP team, you should make all practices dispensing. 
Pharmacists actually should become as part of that team. [GP2]  
 
There’s a control issue for GPs. So, in a perfect world, the GP would have a practice 
pharmacist and a practice nurse, and both would be working for him or her. [PH3] 
 
GPs expressed concerns about work place location issues, notwithstanding the possibility 
that modern approaches to sharing computer based knowledge might be used to facilitate 
easier working across physical site boundaries: 
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Perhaps I don’t think it (pharmacy support for improved medicines prescribing and 
use) should take place in the pharmacy, I think it should take place in the GP 
surgery, indeed in my last GP surgery we employed a pharmacist who did exactly 
that. She sat down with the patients and the medical record and went through their 
drugs. Because I think that advising on drugs without any knowledge of why there 
were prescribed is a strange thing to do.  [GP2] 
The tendency of pharmacists to believe that they are the only people capable of 
satisfactorily minimising the risks of medicines taking was also reflected in the view of 
support staff projected in some responses. Although it was suggested that future 
community supply models would ‘use’ support staff more along NHS hospital or say 
Scandinavian pharmacy model lines, there was a degree of reticence with regard to 
pharmacy technicians sharing ‘their’ (the pharmacists’) knowledge domain. This is 
indicative of a perceived role challenge, although there was also a desire to form more 
effective working relationships:  
(we) need to make sure that the team that is left back in the pharmacy is the right 
team, and not just some hotchpotch of employees brought in just to manage that 
day. [PH6]  
It was of note that non-pharmacist respondents tended to describe the value of community 
pharmacists in terms of their potential activities, rather than that of their current practices.  
It appeared that to a degree the easy access afforded by pharmacy ‘shops’ and the 
consequently reduced ‘social distance’ between ‘the pharmacist as shop keeper and the 
patient as customer’ may have undermined the standing of pharmacy in some 
respondents’ eyes. The desirability or otherwise of such a bias is of course questionable, 
but this does not negate such observations. 
It is open to debate as to whether or not community pharmacists are unfairly under-
utilised for what they presently do. However, the qualitative evidence presented here 
suggests that the current role of community pharmacists is perceived to be of relatively low 
utility by many GPs and other actors, and that this is a cause of concern to community 
pharmacists themselves. It may add to their sense of having ‘guilty secrets’ about their 
businesses (see below). Some policy makers seem optimistic about the opportunities for 
improved future collaboration between doctors and pharmacists working in primary care. 
However, there are significant barriers to change, and even positive medical expectations 
of community pharmacy often appear limited to a development of the ‘rule enforcing’ 
aspects of pharmaceutical care:  
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I can see pharmacists adding a lot of value around concordance and compliance. I 
tried unsuccessfully to get this working between my practice and my local 
pharmacy for a number of years.[GP4]  
 
On the ‘pharmacy side’ the majority of those interviewed talked of better collaboration 
with general practice. However, in conclusion to this section of this qualitative analysis it 
may be observed that even pharmacists themselves often appeared to be limited in their 
clinical role aspirations and reluctant to move beyond their established identities as risk 
managers, safe supply facilitators and improved compliance advocates. A key implication 
for the future is that community pharmacists appear to need to consider much more 
deeply questions about how in practice they can effectively enhance medicines prescribing 
and use through either working more closely with GPs and practice nurses, or offering new 
services in competition with other primary care providers. They also need to ask to what 
extent substantive progress on either front is achievable within the confines of the existing 
pharmacy practice business model. 
The Business Imperative 
Perceived or actual conflicts between business and health imperatives can present another 
challenge for community pharmacists. As noted earlier, GP and other critics of the 
profession may see its members as little more than ‘shop keepers with degrees’ (Hughes 
and McCann, 2003). As private (or indeed public sector) contractors to the NHS, pharmacy 
owners need to make an adequate income and return on investment. The same is of course 
true for medical partnerships and organisations like NHS Foundation Trusts (Foy et al., 
1998). However, several interviewees appeared to believe that reconciling commercial and 
professional incentives and priorities is especially challenging for community pharmacists.  
Some respondents suggested that pharmacists supply items in the interests of profit rather 
than patient care. This view has also been reported in other countries (Cavaco et al., 2005), 
although its expression may on occasions be used as a rhetorical device by interests 
concerned to limit pharmacy role extensions rather than as an evidence based statement 
of fact/belief.  
“Are they [pharmacy contractors] looking at it because they are really trying to 
make their pharmacies and pharmacists medicines experts or is it just a profit 
making scheme in the old supply model?”[PT2] 
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Respondents suggested that one reason for the fact perceived conflict between 
commercial imperatives in community pharmacy and health gain priorities is more acute 
than in the case of, say, medical partnerships is that people see pharmacies like those 
located in supermarkets as ‘business interest’ rather than professionally controlled. 
Another is that cash transactions between pharmacists and pharmacy service users are 
commonplace. Such factors were often assumed to have a negative effect: 
I have a very high regard for pharmacists who I think are underutilized. I’d come to 
this conclusion a while ago, this is why I am prejudiced in a way, that actually, the 
public - the NHS, the taxpayer - generally would get a better service from 
pharmacists if more were liberated from being in community pharmacy.[DH4] 
 
However, pharmacists themselves were typically more positive about the mixing of health 
care and other functions : 
It may prompt people to ask – even if they are in there for something very trivial, 
picking up some hair spray or a corn plaster, they ask something else because they 
feel that there is a healthcare environment there. That could spark an interaction 
that could then lead to an intervention. [PH6]  
 
Respondents discussed the extent to which respect for consumer sovereignty in the 
commercial setting means that ‘customers’ are not actively challenged about their 
behaviours or needs. Some seemed to believe that ‘consumerism’ would undermine the 
professional status and judgements of pharmacists. Others suggested that the dynamics of 
pharmacy business based relationships would encourage more equal discussions and 
(desirably) inhibit the development of paternalistic models of healthcare found in other 
parts of the health service.  
It was commented that employee pharmacists may be rewarded with promotion for 
increasing dispensing volumes, rather than improving health outcomes. It was also argued 
that corporate management approaches may serve to disrupt the development of long 
term trust based relationships between local health professionals: 
Our biggest issue, I think, for the multiples and their workforce, is that good 
pharmacists get moved to ever busier pharmacies, and that’s the career 
progression within the multiple sector.....that results in an inability for the good 
pharmacist to really leverage the opportunities of a good working relationship with 
their patients and with the local GP’s and other local healthcare professionals.[PH3] 
 
The apparently strained relationship between health and business imperatives at times 
made it appear that pharmacists might be at risk of developing a ‘guilty secret’ mentality. 
Their responses suggested that this normally stops them talking openly about tensions 
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between the financial incentives driving their business activities and the health interests of 
individuals and communities. However, in the interview setting individuals with a policy 
background appeared rather more hesitant to accept the validity of  ‘business’ priorities 
than pharmacist respondents, who seemed more secure in articulating the future in terms 
of a viable business model capable of delivering health related benefits.    
We’ve always had, in pharmacy, this sort of conflict between the businessman who 
wants just purely to pile it high, sell it cheap, make a profit, and if there’s a bit of 
professional acknowledgement around that ..... it’s a bit of a cache, really, that 
brings them on the pharmacist that only I can provide these medicines so there’s a 
protectionist almost attitude, alongside those who want to provide a clinical role. 
[DH3] 
 
General practice based participants in this research were, despite seeming to recognise the 
benefits that pharmacists can deliver in improving the public’s use of medicines, on 
occasions overtly critical of the retail activities that take place in community pharmacy, and 
seem to lack understanding of pharmacy premesis. 
To me, it’s been damaged by …..the fact that pharmacists almost always end up 
selling something. Whereas, quite often the right answer to ‘I’ve got a sore throat’ 
is…..have some hot drinks, hot Ribena. [GP3]  
 
It’s [clinical care in the pharmacy setting] messed up by practical issues around the 
design of pharmacies to have consulting space and confidentiality and so on. [GP3] 
 
The whole model of seeking that advice is a curious one. On the whole in most 
places, it’s a shop-counter. It’s not ‘can I have a word’ and then you go and sit down 
with the pharmacist. Are there many pharmacies that have a consulting room? 
[GP3] 
 
Underlying tensions between GPs and  community pharmacists have been reported 
elsewhere (Edmunds and Calnan, 2001a). They may yet prove a significant barrier to the 
implementation of community pharmacy policies in areas such as the management of 
repeat dispensing. The existence of corporate pharmacy chains has long been associated 
with such concerns (Shaw, 1972) and problems such as the lack of close personal 
relationships between GPs and pharmacists who may be expected regularly to move 
between localities. 
Sidhu (2003) has also described how being located within a corporate business 
environment may influence pharmacists’ professional roles. More recently some 
supermarket pharmacies have reportedly been reluctant to offer supervised administration 
of medicines and needle-exchange schemes to service users with drug abuse related care 
 
 
224 
needs (Bush et al., 2009). Such illustrations evidence the fact that business linked factors 
can impact upon the professional identities and role fulfilment of employed community 
pharmacists. 
Some GP respondents seemed to believe that the community pharmacy setting does not 
offer an appropriate location for the provision of clinical services, but that pharmacists 
might usefully be able to deliver them in a primary care practice environment. This may be 
a deeply held position. But it is also possible that GPs may tend to respond defensively to 
the possibility that other independent professionals might become able to review patients’ 
treatments more proactively than is presently possible. The idea that corporate bodies like 
those pioneered in community pharmacy could in future markedly change the balance of 
primary care practice ownership might also seem challenging and influence expressed 
attitudes. 
Interviewees from all groups described the current pharmacy business structure and the 
dominance of dispensing activities as one of the main barriers to the development of 
cognitive service based pharmacy roles. Community pharmacy evolution was described as 
being constrained by the current funding system: 
[Pharmacy] delivers what it’s supposed to deliver. Delivers what they get paid for. 
[PH2]   
If you choose to, you can invest in future patient services. But the current climate is 
such with Category M, that you’d be a brave man - and by brave, I mean stupid - to 
invest what profit you have, what cash reserves you have, in services when it might 
get clawed back in a few months time to leave you sort of minus equity. [PH5] 
There is evidence that pharmacists are today facing increasing financial pressures (see 
Chapters 3 and 6). Yet one possible interpretation of such remarks is that economic 
challenges may be being used as a ‘scapegoat’ for practitioner failures to embrace new 
services opportunities in a more proactive way. This research suggests that the most 
profound barriers to the latter lie deep in the community based profession’s role defined 
identity. However, the most important point to stress at this juncture is that community 
pharmacists are often (by themselves and others) seen as being caught between the 
altruistic values of professional practice and the realities of operating businesses in a 
competitive market.  
Such a view may in fact be too simplistic. But even so, the continuing existence of 
perceived serious conflicts between the commercial imperatives driving pharmacy owners 
and the requirements of high quality professional healthcare provision may significantly 
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damage community pharmacy’s development opportunities. Resolving related 
presentational and, to the extent they in fact exist, substantive business issues may prove 
essential for community pharmacists to extend significantly their clinical roles in the NHS 
primary care environment of the future. 
Technological developments 
All the interviewees taking part in the survey reported here said that technological progress 
will be central to future health care interactions, and play a vital role in defining the future 
of community pharmacy.  
...I think in all areas in which the citizens transact with professionals, there’s a 
dynamic at play as a result of modern technology and ways of living, which is a 
trend toward self-service, automation and not having to go to the physical 
embodiment of the service. Doing it online or by phone or whatever.  [PT1]  
Pharmacist respondents talked positively about technological changes allowing supply 
processes to be completed more efficiently. Yet as it currently exists community pharmacy 
is threatened by computer and robotic developments. 
Technological advance in any walk of life, profession or just public life is hugely 
threatening…..I understand that for a workforce that feels very pressured, they 
almost feel that a robot or whatever that maybe will take over my job.... is very 
threatening. [PH6]  
Improvements in supply chain technology, such as the electronic transfer of prescriptions 
and the automation of the dispensing process, were viewed as having a capacity to confer 
harm as well as benefit. In line with various policy statements, it was believed that 
automated dispensing will result in pharmacists spending less time fulfilling their supply 
role and so allow the development of more cognitive services.  
However, respondents also expressed concerns that increasingly sophisticated dispensing 
technologies could facilitate medicines supply being physically separated from community 
pharmacy. This may affect funding arrangements and ultimately undermine the 
pharmacist’s identity in the high street. 
The more you get supply not through a pharmacy, the more it will disassociate in 
the public’s eye the expertise and input of a pharmacist. If they get their stuff 
through the post, they probably won’t even know the pharmacist’s been involved in 
it. It will alter their perception of (a) pharmacist as someone embedded in the 
function of supply. [PH1] 
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In particular, access to patient records was (as already observed) seen as an important 
driver of future practice. However, pharmacist respondents, in line with their risk 
minimiser/manager role, said that such access should be governed by strict controls, with 
an emphasis on protecting patient confidentiality through rules and procedures. They also 
expressed concerns about the prospect of taking on greater risk and responsibility without 
additional funding:  
I think to enable us to have an extended role, more records should be accessible, 
but it’s got to be balanced. There’s got to be perspective put on that, so that it’s not 
extra responsibility for the sake of it, without remuneration for that responsibility. 
[PH5]  
Despite this evident caution, some interviewees with medical backgrounds challenged 
pharmacists’ abilities to use patient data responsibly and effectively. Whether the 
expression of such views was due to genuine concerns about pharmacists’ abilities and 
behaviours or to a protectionist desire to restrict access to what has previously been a 
medical domain is uncertain. It could be argued that medical assumptions about the 
commercial imperatives of pharmacists were partly validated by the response of the 
pharmacist who was unsure about the desirability of gaining access to records without 
additional payments. But there is evidence that GP behaviours are also driven by financial 
incentives (Foy et al., 1998). 
The main finding of this work is that while technological developments are universally seen 
as important drivers of future practice change, they are also perceived as being inherently 
threatening. It was through technological progress that the traditional ‘medicines maker’ 
role that represented ‘a potent symbol of the pharmacist’s status and value to the 
community’ (Harding and Taylor, 1999) was in the past replaced by that of being a 
‘medicines supplier’. This is in turn under threat from technical change (Varnish, 1998). The 
automatic dispensing of medicines has the potential to remove the existing human input 
into the technical supply process. The extent to which this will allow community 
pharmacists to adopt roles that serve to augment or parallel those of clinicians such as 
doctors is uncertain. But this research highlights the fact that to make best future use from 
a public (health) interest perspective of technological developments relevant to medicines 
supply and use optimisation the sectional sensitivities and interests of professional 
stakeholders such as GPs and pharmacists themselves will need to fully understood, and 
effectively addressed.  
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Discussion – Tiers of Conflict within the Community 
Pharmacy Role 
The approach adopted here helps to reveal how the members of different groups ‘socially 
construct’ the role of the community pharmacist. The thematic analysis of the interviews 
revealed the role(s) of community pharmacists as ‘business men’ and shopkeepers, 
medicines suppliers and risk managers, medicines makers and scientists, and 
clinicians/health professionals. It also identified tensions and conflicts that individuals may 
experience in seeking to fulfil the demands of such differing parts. 
Medicines supply is what today’s public predominately expects from community 
pharmacists, who continue to have legal responsibility for medicines provision. Even 
though up until the Second World War their role was much wider, medicines supply is 
arguably central to the modern community pharmacist’s ‘functional’ identity. As shown in 
chapter two it consumes a major proportion of their time.  
Community pharmacists now appear to be involved in a partially voluntary process of 
transition towards their playing a greater role in ‘managing’ the overall risk and benefits 
associated with the supply and use of medicines and/or providing care related services. 
Current policy statements suggest that their future roles are likely to revolve to a large 
extent around developing further their professional identities as pharmaco-therapeutic risk 
mangers and medicines use optimisers through changed relationships with both medical 
prescribers and patients.  Their current credentials for playing such a part rest to a 
significant degree on their training as ‘pharmaceutical scientists’. But there are important 
questions relating to whether or not this historic positioning is going to prove adequate. 
Their public acceptance as clinicians is at best limited, and it is of note that until the gradual 
evolution of NHS hospital clinical pharmacy between the 1960s and the 1980s pharmacists 
were nowhere in the world seen as prescribing advisers to doctors such as GPs. 
Harding and Taylor (1997) recognised that technology based advances had impacted on 
pharmacists work. They argued that the social objective of pharmacists is to transform 
drugs into medicines, and consequently that role developments that stopped medicines 
being at the profession’s focal point could well prove damaging to its status. They 
suggested that there would be a de-professionalising effect if ‘drugs lose their centrality to 
pharmacists’ activities’ and that pharmacists should therefore further consolidate and 
focus their knowledge and skills on areas related to medicines’ (in part socially defined) 
actions and interactions. 
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The ‘clinical’ role that pharmacists are evolving into from a policy perspective (see chapter 
1) may stand in contrast to this in as much as it involves pharmacists widening their 
therapeutic and allied competencies into areas outside medicines use per se and the 
traditional pharmaceutical sciences. While there are several definitions and interpretations 
of ‘clinical pharmacy’ in the community setting, it is generally understood to be services 
provided at the individual level, using the ‘skills of the practitioner’ (Department of Health, 
2008a) – knowledge and ‘professional judgement’ – to facilitate better personal care and 
outcomes.  
The commercial imperatives of community pharmacy were described as an important 
barrier to its further development and integration with the rest of the health service. This 
echoes findings reported elsewhere (Bush et al., 2009; Hughes and McCann, 2003). By 
comparison general practice  are less overtly commercial than pharmacy, not least in as 
much as they do not normally sell goods or services directly to the public (Foy et al., 1998). 
Structural and economic challenges, such as the growth of large chains and recent debates 
about issues such as parallel trading in pharmaceuticals and associated supply shortages, 
may also have fuelled perceptions of pharmacies as commercial entities rather than health 
care providers  (Davis et al., 2009). 
Tensions and disparities between the four community roles described above (‘business 
men’ and shopkeepers; medicines suppliers and risk managers/minimisers; medicines 
makers and scientists; and clinicians/health professionals) arguably place community 
pharmacists in a deeply conflicted position. The resulting internal contradictions (which to 
a degree reflect additional ambiguities about medicines as both treatments and poisons) 
are often recognised by observers external to the profession.  
In terms of ‘clinical’ role development such findings help to explain why pharmacists may in 
practice have failed to receive the positive support that political policy statements appear 
to suggest and why they have been relatively slow to take up relevant opportunities. There 
is additional evidence that community pharmacists’ conflicted images as shopkeepers 
‘versus’ health care providers have further impaired progress towards role extension 
(Hughes and McCann, 2003), despite pharmacy users’ beliefs that such concerns are 
exaggerated (Varnish, 1998). 
The health professions in England may to date be seen as having developed along relatively 
isolated or ‘separatist’ as opposed to integrated lines. Notwithstanding policies aimed at 
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promoting better co-ordinated working and enhanced inter-disciplinary collaboration, this 
still appears to characterise community pharmacy.  Alongside this, concerns have also been 
expressed about ‘role boundary’ encroachments (Edmunds and Calnan, 2001a; Eaton and 
Webb, 1979; Ritchey and Raney, 1981; Tully et al., 2000; Harding and Taylor, 1997; Weiss 
and Sutton, 2009), into the general practice domain. In this context GPs are reportedly 
most likely to be antagonistic towards activities that require independent judgement or 
autonomous action related to patient care on the part of the pharmacist (Adamcik et al., 
1986).  
Before the establishment of the NHS and the creation of regulatory arrangements that 
made most effective medicines ‘prescription only’ the de facto situation was that 
community pharmacists and general medical practitioners offered alternative gateways to 
care. Today this is not so much the case, but there remain areas of competition.  The recent 
opening by GP practices of integrated community pharmacies can to a degree be compared 
to pharmacists’ expansion into the clinical activities – such as, for instance, giving 
immunisation – that were once carried out exclusively in doctors’ surgeries or other 
medically controlled environments. An underlying desire to prevent such competition (and 
through it greater consumer choice) may in part explain the apparent preference within 
general practice for employing pharmacists in practice settings rather than developing 
alternative collaborative models.  
Such observations lead on to questions about whether or not the desired social functions 
of pharmacy are primarily delivered by pharmacies or by pharmacists independently of 
their settings. In this context it is of note that there is evidence that many pharmacy users 
cannot tell the difference between pharmacists and their support staff (Cavaco et al., 2005; 
Oparah and Iwuagwu, 2001). This may be especially so when pharmacists are out of sight in 
the back of the pharmacy.  
Such observations raise a variety of issues. But for the purposes of this analysis the most 
important are taken to relate to the future capacity of community pharmacy to adapt to its 
changing environment on ways that will permit it a continuing role, whether or not this 
involves concentrating on medicines use and outcomes optimisation or becoming a 
broader health care delivery oriented profession. In this context Tuner (1990) suggested 
that the successful implementation of new roles relies upon the extent to which current 
role incumbents are unified in their desire for role change and can be mobilised to achieve 
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it. He also, perhaps unsurprisingly, identified client demand for change as a critical success 
factor.  
The findings of this research indicate that at present community pharmacy is relatively 
poorly aligned in terms of its collective thinking on role change, and that different external 
stakeholder groups also have contrasting views on what future progress might or might not 
be desirable. The interpretation offered here is consequently that, despite the apparently 
clear policy prescription offered by documents such as ‘Pharmacy in England: building on 
strengths - delivering the future’ community pharmacy is in reality facing a crisis of identity. 
This suggests that if the profession is to survive and prosper in the medium to long term 
then it will be required to more effectively address these issues than currently appears to 
be the case. At the centre of the dilemma being faced are questions like: 
 ‘should pharmacists seeking a more clinical role be located more frequently in 
general medical practices, or does the future of community pharmacy as a 
contributor to improved and more cost effective primary health care lie more in 
offering treatments for an extended range common acute and chronic conditions in 
independently located pharmacy settings?’ and 
 
 ‘should medicines supply also be more frequently located in integrated primary 
care settings, or will it continue to be more safely and efficiently provided via 
physically separate community pharmacies that also offer self care support and 
allied preventive services, supplemented as appropriate by home delivery and 
other medicines supply services?’ 
Possible answers to such queries are considered later in this thesis. But at this point it is 
most relevant to emphasise that the evidence presented here indicates that from a public 
interest perspective the problems, challenges and conflicts underlying them will not be 
easily resolved by the community pharmacists and general medical practitioners most 
directly involved. It seems unlikely, for instance, in the light of the current NHS reform 
process that locally oriented Clinical Commissioning Groups will be able to look beyond 
short priorities and sectional medical concerns objectively to consider long term strategies 
for overall primary care development. It is more probable that leadership offered at the 
level of the NHS Commissioning Board could help provide an appropriate resolution, 
although this will in large part depend on the NHS CB’s interpretation of its role and the 
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development of a wider, more comprehensive, primary care development linked pharmacy 
policy vision than has in the past existed. 
Limitations 
This qualitative study was purposively conducted with a specific sample of policy leaders 
from across primary care. Care was taken in their selection. But it is possible that their 
views and opinions do not adequately reflect those of practitioners ‘at the coal face’. 
However, given that most of the interviewees continue to practice, and that some of the 
findings reported here are echoed by larger practitioner based studies, this is unlikely to be 
the case.  
Given the position of interviewees close to the centre of policy discussions it is also possible 
that they may during interviews have put forward positions for political or associated 
reasons, rather than to reflect their most deeply held personal views. Such possible 
distortions cannot be entirely avoided. But in the main the strength and consistency of the 
themes running across the interviews in relation to concepts such as the ‘under-utilisation’ 
of community pharmacy suggests that this was not a major problem.  
As with any qualitative method, the structure of the guide used and questioning style of 
the interviewer (who was identifiably a pharmacist) can also influence the nature of the 
responses (Pope et al., 2000). While every effort was made to maintain a neutral position it 
is again possible that respondents were to a degree influenced by such factors, and could 
as a result have been (for example) more positive about some aspects of community 
pharmacy than if the interviewer had been a doctor or a non-health professional. But it is 
observable that statements critical of pharmacy were made.  
Chapter Conclusions 
The roles that community pharmacists in England are in today’s conditions expected to play 
are in a number of respects conflicted. The evidence available indicates that many 
pharmacists and GPs wish to perpetuate their ‘traditional’ role as the suppliers of 
medicines, employing new technologies in relatively conservative ways to enable them to 
act as guardians of their safe and appropriate use. However, policy leaders within 
pharmacy and the NHS are more likely to want them to play an extended part in 
clinical/health care. This can be seen as an encroachment on the doctors’ professional 
domain which threatens medical practitioners and may expose established pharmacy 
businesses to retaliatory action.  
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Risk management involving risk elimination/minimisation wherever possible appears 
central to the role defined identities of many community pharmacists. But this may impair 
their ability to manage complex uncertainty and engage more fully than at present in 
clinical decision making. Further perceived and experienced conflicts around issues such as 
the ‘shopkeepers with a degree’ as opposed to ‘ethically motivated health professionals’ or 
clinicians add further tensions, and may contribute to community pharmacists feeling they 
have a ‘guilty secret’ about the reality of their work and its value to others.  
While such ambiguities remain unresolved they are likely to act as a substantive barrier to 
change. Directive leadership from outside general medical practice and community 
pharmacy itself may be required to open the way to more productive approaches to 
primary care development that will allow pharmacists to contribute as cost effectively as 
possible to the supply and use of medicines in the community, and so optimise health 
outcomes.  
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Chapter 6. Strategies for the Pharmacy 
Business 
 
Chapter Introduction 
Community pharmacy operates at the boundary between the retail and healthcare 
environment. To implement and support future roles, the attributes of the business and 
the market within which it operates must be considered.  
Developing a business model that supports a future ‘clinical’ role for pharmacists is 
challenging. A key part of future healthcare policy will relate to cost containment and 
management of patient expectations, pharmacies will be required to do more for less. 
Healthcare costs will continue to rise faster than taxation and insurance can meet them. In 
2004 the UK Treasury projected that if the proportion of healthy life remains constant then 
spending for health and long term care will need to increase from 7.9% of GDP to 11% by 
2053-54 (House of Lords, 2004). The Wanless report (2004) suggested only with a public 
who were ‘fully engaged’ in their own health could the NHS hope to meet the expectations 
of the aging population. Pharmacy businesses owners will be only too aware that as 
expectations and costs increase their margins of return on capital invested will be 
squeezed. Indeed, pharmacies, like many other sectors of the healthcare system will be 
required to deliver more for less.  
Defining the industry boundaries allows for analysis of the external factors and competitive 
forces that help to define future threats and opportunities. Like any business, community 
pharmacy will need to react to the market pressures that it is likely to face, and make its 
services, outputs and outcomes as profitable, sustainable and efficient as possible. At 
present the evidence suggests that the community pharmacy industry, taken as a whole, is 
profitable (Keynote Report, 2011b), but the future sustainability of these profit levels is 
being brought into question.  
There are some unique features of the community pharmacy market which change the 
market dynamics. A particular attribute is the above average degree of political 
intervention which seeks to regulate the market. This above-normal regulatory 
intervention alters the way the market operates and needs to be considered closely in this 
analysis.  
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Other internal aspects of the pharmacy market are exceptional. Due to the fact that prices 
for prescription medicines are fixed or non-existent for many consumers, there is no 
incentive to search for ‘low cost’ providers. Therefore internal rivalry for prescription 
medication supply is instead based on location, business hours and other factors that affect 
consumer access costs, the availability of additional pharmacy services, the breadth and 
depth of consumer goods, brand image, advertising, store attractiveness and other 
dimensions of quality, such as prescription dispensing time. All of these factors must be 
considered in the future alignment of the business and the profession.  
This chapter considers approaches to business strategy in the community pharmacy market 
in order to address the main research question of future models of business and 
professional practice in England. This is achieved by defining and quantifying the market 
within which community pharmacy operates using the Porters five forces framework. There 
is little evidence that the community pharmacy market has ever been publically explored in 
this way, with such depth.  
Using the evidence from the qualitative interviews in chapter 5, publications in the trade 
press and original thought, this chapter begins to address the different strategies that the 
community pharmacy market as a whole can take in the short term to maintain the 
business. 
Theoretical Framework 
This chapter uses a theoretical base of business strategy, known as the five forces 
framework defined by Michael Porter (Porter, 1980; Porter, 2008). This framework focuses 
on the risk of entry of potential competitors, the intensity of rivalry among established 
companies within the industry, the bargaining power of the buyers, the bargaining power 
of the suppliers, as well as the closeness of substitutes to an industry’s products (figure 
6.1).   
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Figure 6-1– The Five Forces that shape industry competition (adapted from Porter, 
2008) 
 
The strongest competitive force (or forces) determines the profitability of an industry and 
become the most important to strategy formulation. However, the most salient force is not 
always obvious. Understanding the competitive forces, and their underlying causes, reveals 
the roots of an industry’s current profitability while providing a framework for anticipating 
and influencing competition. Therefore understanding an industry structure is also 
essential to effective strategic positioning.  
Porters Five Forces 
Risk of Entry (Weak) 
A competitive market is characterised by free entry of firms into the marketplace. In such a 
market, firms enjoying above normal profits will soon find these profits being reduced by 
new entrants. The community pharmacy market in England differs from this free market 
approach through restrictions on NHS dispensing contracts.  
The Pharmacy Market 
On the 31st March 2011, there were 10,961 community pharmacies registered with an NHS 
contract. Across the sector about 1% of pharmacies operate without an NHS contract. 
These pharmacies tend to be located in airport terminals supplying P medicines, or in areas 
where the supply of private prescriptions supports their operation, such as private 
hospitals or locations close to Harley Street. Although the focus here is on England, it is 
worth noting that there were 707 pharmacies in Wales (Welsh Assembly Government, 
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2011), 1215 in Scotland (ISD Scotland, 2010) and 529 in Northern Ireland (Department of 
Health and Social Services and Public Saftey, 2012) in 2010. Therefore including private 
contractors and hospitals increases this to 13,930 registered pharmacies operating in Great 
Britain (General Pharmaceutical Council, 2011). 
Each of these pharmacies will operate in different ways and to a large extent this is driven 
by their ownership, geographic location, and business philosophy. The sector within which 
pharmacy operates is dominated by several large multiple providers. Boots is the clear 
market leader with approximately 2,000 stores in England (Boots UK, 2012). The closest 
competitor is Lloyds pharmacy which operates approximately 1,400 pharmacies in England 
(Office of Fair Trading, 2010). 
Figure 6-2– Community Pharmacy Market Composition in England by Ownership 
2011 
 
Blue: Large Multiples; Red: Supermarkets; Green: Small Multiples; Yellow: Independents. Left: CCA Members. Right: Non CCA 
Members. Source: Company Reports & Websites; Mintel Reports; NHS Information Centre; Trade Press; OFT Calculation in 
2009 and author estimations.  
The Company Chemists Association is a trade association that represents the large multiple 
providers, and therefore exerts significant influence on the delivery and structure of the 
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community pharmacy market. Together its members own in the region of half of all 
pharmacy contractors in England (left hand side of figure 6.2).  
The community pharmacy sector operates across several markets, and therefore on the 
fringes of the sector are other specialist health and beauty retailers. While across the 
specialist health and beauty market, Boots remains the market leader, other entities such 
as Wilkinson’s, Superdrug, Space.NK, Savers and Body Shop all compete for market share of 
health and beauty product sales.   
Patterns of Pharmacy Ownership 
One of the significant developments affecting the community pharmacy sector in England is 
the changing pattern of ownership. Historically, self-employed community pharmacists 
owned the majority of pharmacies in England and Wales. As predicted in the late nineties 
(Ottewill and Magirr, 1999), the last decade experienced a steady increase in the 
proportion of pharmacies in chains of five or more, increasing from about a third to over 
two-thirds (The NHS Information Centre, 2011). For the last four years, the proportion of 
pharmacies in a chain has remained at around 61.5%. This varies within geographical areas, 
with Milton Keynes PCT recording 88% of their pharmacies in multiples, compared to just 
16% in Islington PCT. 
Control of Entry 
The ability to gain an NHS dispensing contract is the biggest obstacle to community 
pharmacy market entry. Until 1989 pharmacy contractors were reimbursed on a cost-plus 
basis for drug ingredient costs. This system was introduced in the 1960s and 1970s to 
remedy the declining number of pharmacies. The resulting increase in pharmacy contracts 
led to increased costs and an inappropriate expansion of community pharmacies in some 
areas. The Department of Health sought to address the uncontrolled increase in numbers 
with control of entry regulations, introduced in 1987. These stated that any pharmacy 
wishing to obtain an NHS contract had to satisfy the relevant authority that it was either 
“necessary or desirable”. Effectively this created a closed market for pharmacy, resulting in 
fairly static numbers of community pharmacies throughout the UK network, until 2005. 
In 2001 the Office of Fair Trading (OFT) began a market investigation, under section 2 of the 
Fair Trading Act 1973, to examine if the community pharmacy market was working well for 
consumers. Two years later in January 2003 the OFT published a report into the control of 
entry of retail pharmacy services in the UK and had one key recommendation.   
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"We recommend that the control of entry regulations for community pharmacies in 
the UK should be ended. This would mean that all registered pharmacies with 
qualified staff may dispense NHS prescriptions." [Para 1.25](Office of Fair Trading, 
2003). 
The OFT believed that control of market entry increased costs, limited efficiency and 
reduced innovation in the pharmacy market. The threat of market de-regulation presented 
a significant risk to existing contractors, who could potentially lose their geographical 
monopolies. Within policy circles, the civil servants with a responsibility for pharmacy 
recognised that full deregulation of market entry would have detrimental consequences for 
local healthcare provision, and limit future investment in pharmaceutical services (Office of 
Fair Trading, 2003).  
Therefore the government response rejected complete de-regulation, instead putting 
forward proposals for a “balanced package of measures” to allow further market entry. 
After consultation, the government offered several exceptions to the control of entry of 
pharmacies, these being: 
 Pharmacies located in shopping centres over 15,000 square meters but only in 
out-of-town developments and not in town centres; 
 Pharmacies that intend to open more than 100 hours per week; 
 Pharmacies set up by consortia as part of new one-stop primary care centres. 
The centres must offer more than usual GP services serve a substantial 
population of around 18,000–20,000 patients and be part of the local PCT’s 
strategic service development plan; and 
 Pharmacies that are wholly mail order or internet-based. These pharmacies 
will be required to provide a fully professional service within the provisions of 
the new contract.  
It took until April 2005 for the majority of these reforms to be introduced by revising NHS 
regulations. The result was an increase in pharmacy numbers, with the majority of 
pharmacies opening under the 100 hours exemption (figure 6.3).  
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Figure 6-3- Number of Community Pharmacies in England by Year 
 
*Data collected on the 31st March of each year. Source: NHS Information Centre 
From an existing contractor perspective this increased market competition. The PSNC 
highlighted how the global sum for pharmacy has not increased to meet this demand. The 
result has meant that funding is now shared between a greater number of pharmacies, 
reducing the income that each individual pharmacy receives (PJ News, 2008) (Also see 
chapter 3).  
Due to the relaxation of opening restrictions in 2005, over 1200 new pharmacies opened, 
However, these new openings tended to be located in urban areas, as shown in figure 6.4.  
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Figure 6-4 – Map of Pharmacies in England, July 2009 
 
Source: OFT, NHS BSA, DotEcon analysis Annex VII. 
The increase in pharmacy numbers seen following the reforms has created little tangible 
increase in accessibility to the average consumer as the mean distance to a pharmacy from 
either home or a GP surgery has only decreased by 40 meters (Office of Fair Trading, 2010). 
Pharmacies continue to locate close to GP surgeries, with almost a third (32.5 per cent) of 
prescriptions written at a surgery where a pharmacy is co-located, and 93.1 per cent are 
written within 500m of a pharmacy (Office of Fair Trading, 2010). 
The main benefactors of these legislative changes have been the multiples and the 
supermarkets. The majority of the 100 hour and out-of-town applications for pharmacies 
have come from the retail driven multiples and the supermarkets, which are keen to 
increase their market share within the sector.  
Pharmaceutical Needs Assessments 
While the introduction of full market restrictions could be considered a major shift in 
community pharmacy policy, the tendency to revert to the status quo has prevailed. The 
government and the policy subsystem resisted the wholesale relaxation of the rules and 
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instead opted for a more considered and conservative set of adjustments to the market 
entry system.   
In the 2008 pharmacy White Paper, it was proposed that the current entry tests for 
community pharmacy should be replaced by ones based on the Pharmaceutical Needs 
Assessments prepared locally by Primary Care Trusts. The health act regulations governing 
this received royal assent in November 2009. This legislation requires primary care trusts to 
develop and publish pharmaceutical needs assessments (PNAs) and then use PNAs as the 
basis for determining market entry to NHS pharmaceutical services provision. There is 
uncertainty as to how these will be implemented due to the current flux in primary 
healthcare. This is complicated by the introduction of further revision of control of entry 
regulation later in 201255. 
The new regulations propose introducing additional quality requirements for contractors. 
This is another way of bringing pharmacy contractors within the governance framework of 
the NHS. It will allow the local primary care organisation to dictate entry to the market and 
to a large extent market exit.  
This development is incredibly important for community pharmacy as it will give the 
primary care organisations the power to withhold funds and close those pharmacies that 
are not reaching the required quality standards. Currently it is extremely difficult for 
primary care organisations to close pharmacies over quality concerns. Only with 
intervention from the regulator can this be made possible. In theory this new regulation 
should increase quality and drive up consumer experiences. However, it will also add to the 
bureaucracy that pharmacies will face.  
Pharmacies use their geographical location in order to maintain a local monopoly on 
prescription medication supply. Changes in market entry legislation therefore have a 
significant effect on the ability of pharmacies to maintain a local monopoly. In some, 
particularly urban areas the saturation of pharmacies has led to intense local competition. 
Distribution of pharmacies geographically 
The accessibility of community pharmacies is recognised as one of their key strengths. In 
2010 it was calculated that over 43% of the population lived within 500m of a community 
pharmacy (Office of Fair Trading, 2010). Research conducted by the Department of Health 
                                                          
55 In July 2012 the pharmacy minister Earl Howe announced that the 100hr exemption category would be scrapped.  
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(Continental Research and Solutions Research, 2008) suggests that 99% of the population 
are within 20 minutes of a community pharmacy by car, and 96% by walking or using public 
transport, when there were about 200 pharmacies per million population (Department of 
Health, 2008a).This figure has increased to over 210 pharmacies per million since the 
changes to market entry were introduced in 2005 (table 6.1).  
Table 6.1 - Distribution of Prescription Items and Pharmacies in contract with 
PCTs, by SHA at 31 March 2011 
 Community 
Pharmacies 
Multiple 
Contractors 
(percentage) 
Independent 
Contractors 
(percentage) 
Prescription 
items 
dispensed 
per month 
(000)s 2010-
11 
Population 
(000)s Mid 
2009 
 
Pharmacies 
per 100,000 
population 
2010-11 
 
England 10,951 6,730 (61) 4,221 (39) 70,889 51,810 
 
21 
 
North East 581 1,114 (65) 214 (37) 4,669 2,584 22 
North West 1,701 367 (63) 587 (35) 11,635 6,898 25 
Yorkshire and 
the Humber 
1,139 785 (69)  354 (31) 7,975 5,258 22 
East Midlands 873 566 (65)  307 (35) 6,009 4,451 20 
West 
Midlands 
1,203 737 (61) 466 (39) 7,692 5,431 22 
East Of 
England 
1,083 618 (57)  465 (43) 6,997 5,767 19 
London 1,810 683 (38) 1,127 (62) 8,985 7,754 23 
South East 
Coast 
835 572 (69)  263 (31) 5,404 4,340 19 
South Central 722 530 (73)  192 (27) 4,629 4,095 18 
South West 1,004 758 (75)  246 (25) 6,893 
 
5,231 
 
19 
Source: General Pharmaceutical Service, NHS Information Centre.  
Around England, pharmacies tend to coalesce in urban areas close to GP surgeries. Across 
the different parts of the country there are between 18 and 23 pharmacies per 100,000 of 
population, with London having the highest density of pharmacies.  
In the future there is a strong possibility that other healthcare providers will seek to enter 
the pharmacy market, particularly general practitioners or private healthcare firms to 
complement their current enterprises. It is highly likely that private companies will be 
established to deliver pharmaceutical care services at the bequest of local commissioning 
groups in direct competition with community pharmacies. Health clubs, particularly 
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Nuffield Health and Virgin Health are seeking to offer screening services in competition 
with community pharmacy providers. Synergistic alliances between private healthcare 
suppliers and community pharmacies are currently being explored, as are contract 
agreements with hospitals and secure facilities.  
Recently there has been an increase in the number of applications to open pharmacies 
from general practitioners. This has been driven by changes in their governance resulting 
from the new NHS framework and the perceived benefits of operating with community 
pharmacists. Close integration between a pharmacy and a GP surgery can limit the income 
to those operating further away from the surgery. This is likely to increase the competition 
within the prescription sector and lead to questions about the impartiality of GPs.  
Consumers report that they have a usual pharmacy and may therefore be unwilling to 
utilise new market entrants, especially as several established companies, such as Boots, 
have significant ‘brand loyalty’. However, the switching costs for the consumer are 
relatively low. In some localities new 100 hour pharmacies have managed to obtain a 
significant amount of dispensed prescriptions from the incumbents.  
For OTC medicines and health and beauty products the risk of new traditional high street 
entrants is limited as the market is currently saturated. Nevertheless, novel channels of 
supply, particularly Internet shopping could pose a future risk.  
Internal Rivalry (Strong) 
Rivalry is intense within the community pharmacy market. The limit in profitability available 
from the contract has only sought to intensify the competitive struggle between 
companies. In rural areas, pharmacies also compete with dispensing doctors to secure 
prescription income.  
Within certain geographical localities internal rivalry between pharmacies is mounting. 
Local pharmacies are being squeezed by the large grocers seeking to increase their market 
share in prescription supply, but also their health and beauty sales. In response 
independent pharmacies now open for longer hours, offer prescription collection services, 
dispense medicines in medication aide devices and contract with care homes to secure 
trade. 
Until 2001 there was little rivalry in OTC medicines due to re-sale price maintenance, 
however since this has ended, there has been intense competition. Pharmacies must now 
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compete on price for over the counter medicines as well as health and beauty products. 
The supermarkets, owned by some of largest companies in the world, have significant 
buying power that allows them to be extremely competitive on price. In times of economic 
recession consumers are drawn towards these savings. This has led to a decrease in the 
average cost of OTC medicines and has drawn custom away from traditional pharmacy 
suppliers  to cheaper outlets.  
One of the consequences of the reconfiguration of primary care has been an increase in 
private providers operating in traditionally public service roles. The efficiency of private 
sector operations in secondary care settings has provided patients with faster dispensing 
and shorter waiting times. The involvement of the community sector into secondary care is 
likely to increase because of further pressure to reduce costs through VAT savings56.  
Pharmacy services are negotiated at a local level by discussions between the local 
pharmaceutical committee and commissioners. In most cases contractors accept the 
negotiated LPC price for services. However, as competition increases some contractors 
have been undercutting the LPC price to gain market share for services in a locality, 
undermining the whole sectors negotiating platform. 
Externally there is rivalry between pharmacy contractors and general practitioners who are 
effectively negotiating over the same primary care budget to provide pharmaceutical 
services. Management of this interface will be key to future income because under the 
current proposals general practitioners will be responsible for an even greater proportion 
of the primary care budget.  
The development of electronic prescribing systems is likely to further increase internal 
rivalry. Consumers will need to nominate their chosen pharmacy, which will effectively lock 
the patient into this pharmacy and may increase the effort required for consumers to 
change pharmacy. This is one of several technology developments that are likely to affect 
future practice.  
Technology development and Electronic Prescription Service 
Several drivers within the market are pushing pharmacies towards more technology 
focused delivery mechanisms. The electronic prescription service is currently being 
                                                          
56 In simple terms primary care medications are VAT free, while secondary care prescriptions include VAT.  
 
 
245 
implemented across England. This allows prescriptions to be sent directly from a GP 
surgery to a community pharmacy in a near paperless way.  
The widespread implementation of this system encourages pharmacies to adopt more 
technology into the dispensary and change their work patterns to accommodate computer 
systems. On a market level, this also removes the geographical monopoly operated by 
some pharmacies. The electronic message can be sent instantly to any pharmacy in the 
country, opening the market to greater internal competition. This will devalue the location 
aspects of the community pharmacy that support its income. The ‘winners’ in this situation 
are likely to be the large multiples who can exploit their networks to embrace the 
electronic system.  
EU legislation designed to prevent counterfeiting will also increase the amount of 
technology in the dispensary. The Falsified Medicines Directive suggests that each product 
will require an authentication device, necessitating pharmacies to scan and process 
individual packs of medicines. The market will have to bear the costs and additional burden 
to the supply chain. However, this innovation in pack design will help to drive original pack 
dispensing. This in turn will help to facilitate the large scale automation of supply 
processes.  
In conjunction with electronic prescribing, original pack dispensing and automated 
scanning of products represents a drive towards a more technologically focused supply 
chain. Inevitably moves will be made to use technology to drive efficiency in the market. 
The winners in this case will be those who have large supply centres, especially the 
vertically integrated multiples, or the supermarkets who have efficient supply networks 
already in place.  
The changing nature of the geographic monopoly would suggest that there is a market for 
internet based supply of prescriptions.  These still represent a marginal minority of 
pharmacies but the trend of opening has increased. Technology advances and growing 
need for consumer convenience may drive an increase in their existence (as seen in other 
countries including Germany, Sweden and the Netherlands). The UK has embraced internet 
shopping. It represents the largest online retail market in Europe. The competition 
between these pharmacies in cyberspace will increase. Yet at present this still only 
represents a fraction of the market. The PAGB estimate that only 4% of OTC consumers in 
the UK use mail order and the internet to acquire self medication. 
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The extent to which internet pharmacies will develop should not be overstated. Internet 
sales in health and beauty products have been limited. This is chiefly because consumers 
need to smell toiletries and perfumes in order to make an informed decision. In addition, 
many of these discretionary product categories are impulse driven, which is difficult to 
recreate in an online environment. Secondly, pharmaceuticals are controlled substances. In 
the P medicines category, certain regulatory obligations concerning safe supply limit the 
ease at which these products can be sold. Some prescription medications require cooling 
and have specific regulations about their transport via postal services (e.g. Controlled 
Drugs). These represent a major barrier to entry for online retailers. Therefore the online 
market will undoubtedly continue to grow, but without regulatory change it is unlikely to 
have a significant impact on the rest of the sector in the short term.  
Strategic unrest within the Market  
For a relatively small professional group, over 100 different organisations represent the 
interests of those in the profession. This leads to internal conflict about the future 
development of the market. As a result politicians and policy leaders are challenged in 
every decision. Without strong leadership the sector is likely to remain weak in primary 
healthcare as it seeks to manage the stronghold of general practice. The internal priorities 
of the different parties need to be resolved if the conflict and challenges within the market 
are to be addressed. Yet, as rivalry continues achieving such consensus may prove 
extremely difficult.  
Buyers (Strong) 
Consumers are one of the key factors driving any market. In the case of pharmacy there are 
three main consumers, the Department of Health, the local commissioners (currently PCTs) 
and the general public. Each of these consumers in the pharmacy market has their own 
needs and desires.  
The Department of Health 
The Department of Health is one of the main generators of revenue in the community 
pharmacy market through NHS prescriptions. The national contractual framework 
represents the primary source of income for many pharmacy contractors. Effectively the 
Department of Health is a monopoly buyer of pharmaceutical services. Therefore in 
negotiations they wield significant power, demanding fast and efficient prescription 
medication supply at a viable cost.  
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The financial crisis of 2008 followed by the bailout of banks placed a severe strain on 
government finances. A series of budget cuts were outlined in the 2010 comprehensive 
spending review to address the structural deficit. While the NHS budget was spared 
significant cuts, pressure to increase productivity in all areas resulted in the need for the 
NHS to deliver efficiency savings worth £20bn by 2014. Therefore it is unlikely that new 
investment will enter into the contractual framework. At present the savings have been 
implemented through a concerted effort to reduce spend on drugs. For example the 
October 2011 negotiations led to a reduction of £39million in category M to March 2012. 
Although the Department used these drug budget savings to support the New Medicine 
Service, there is no guarantee that future savings will be invested back into the pharmacy 
sector. 
Against this economic backdrop healthcare outcomes need to improve, efficiency needs to 
increase, but without additional investment. Pharmacy has been described as key in 
achieving this by helping shift care from expensive secondary care settings to 
comparatively cheaper primary care settings in the community (Department of Health, 
2010).  
The role of community pharmacy in delivering this ambition has been described in several 
policy documents, most recently by the NHS Future Forum. An attempt at enacting this 
policy has been through the development of Healthy Living Pharmacies57. 
The fragmented nature of the retail pharmacy industry does not aide the contractors’ 
position within these negotiations. The Department of Health and the NHS are deeply 
political organizations, with all major decisions requiring ministerial sign off. Larger firms 
can afford to lobby at the parliamentary level, while smaller contractors need to rely on the 
PSNC. Therefore the PSNC has to manage the interests of a wide range of businesses which 
can undermine negotiations, further adding to the power of the Department of Health.  
As a consumer, the Department of Health will continue to seek efficiency improvements at 
the expense of community pharmacy contractors. The year-on-year growth in contract 
funding has failed to keep pace with the growth in prescription items (see chapter 3). It is 
unlikely that this will change, in fact, the Department of Health is likely to require even 
greater improvements in productivity.  
                                                          
57 As described in the appendix 
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Beyond supply, the Department of Health also demands a return on the investment made 
in nationally commissioned advanced services. In particular MURs have been criticised for 
not achieving sufficient improvements in healthcare (Cook, 2012). Reference costs for 
inpatient admission are £1,400 per patient(Payment by Results team, 2011). Therefore if 1 
in 50 MURs prevents a medication related admission then the service is cost neutral. 
However, as a consumer of this service the Department of Health requires evidence for its 
continued investment. For this reason a national evaluation of the most recent advanced 
service -the New Medicines Service- has been commissioned (see chapter 4). 
Primary Care Commissioners 
In 2010 the government White Paper “Liberating the NHS” represented the biggest 
fundamental restructure of primary healthcare services since the inception of the NHS. This 
set out a vision for placing power in the hands of local clinicians in GP led clinical 
commissioning groups. These groups will be responsible for the provision of health services 
and healthcare budget within a locality. Although the extent to which they will commission 
services from community pharmacy is currently unknown it is unlikely that pharmacy 
services will be a priority. In the short term local services will be GP commissioned, but 
without the links and support between general practice and pharmacy, this is unlikely to 
produce positive results. Indeed, community pharmacy will need to develop better 
relationships with the rest of the NHS if it is to capitalise on these developments.  
Under the new configuration, Public Health England (PHE) and Local Authorities (LAs) will 
use NHS pharmaceutical services for the delivery of public health services, which are 
subsequently recharged to the national commissioning board. However the national 
commissioning board and the local authorities will inevitably seek to limit their exposure to 
the costs of general pharmaceutical services. 
Beyond services, these primary care commissioning groups will also govern the nature of 
prescriptions dispensed. In doing so they can exert significant influence over the 
remuneration that pharmacy contractors receive by adjusting what and how much is 
prescribed. For example, if doctors are encouraged to prescribe three monthly 
prescriptions, then community pharmacy income from prescriptions will decrease. 
Creating the mind-set within the Department of Health, GPs and patients that pharmacy is 
a credible player within the primary care arena will require significant investment in 
building relationships outside of the current market. The profession needs to embrace 
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these services as part of their practice and drive them forward if success in these areas is to 
be achieved.  
The General Public 
The final ‘buyers’ are the patients who purchase healthcare products and present their 
prescriptions for dispensing. Patients can decide where to take their prescriptions and are 
free to move from one pharmacy to another. According to an OFT survey of 1,000 
households, 94% claimed to have a ‘usual chemist’ for their prescriptions (FDS 
international, 2003). These pharmacies offer social stability and support, especially for the 
more vulnerable in society (Continental Research and Solutions Research, 2008). In the 
same market research patients described locality, convenience and waiting time as the 
most important factors when deciding which pharmacy to patronate. 
The choice of pharmacy for a P medicine is driven mainly by convenience and locality (62 
per cent) but also by the availability of staff who can offer advice (23 per cent) (FDS 
international, 2003).  
Consumer behaviour in OTC medicines and health and beauty products reflects typical 
retail dimensions of cost, convenience and service quality. For some, convenience is 
important, for others, dimensions of product range or price take priority (table 6.2). There 
has been a strong growth in own label OTC products in categories previously dominated by 
well-known brands (Wood, 2009). This is because consumers are “feeling the pinch” and 
therefore willing to trade down from branded products. As such consumers are gravitating 
towards supermarkets, which offer convenience and lower prices, taking market share 
from pharmacies (Keynote, 2011).  
Compared to supermarkets, retail driven multiples are recognised as being more expensive 
for health and beauty products. They are attempting to maintain market share through 
customer loyalty, reward card schemes, depth of product selection and higher customer 
service standards. However the trend shows a shift in consumers from pharmacies to 
supermarkets.  
The older population are more empowered and demanding than their predecessors. They 
are less likely to be duped by promotion led tactics. Therefore the emphasis within the 
sector is likely to switch from promotional led tactics that drive impulse buying towards 
more everyday low pricing that supports large volume sales. Such strategies support those 
companies with sufficient buying power. 
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Despite the loss of market share, the overall sector is growing. Health and beauty sales 
remain resilient as these represent the main non-discretionary spending of consumers. 
Given the arguments presented above, the overall  growth for traditional pharmacies will 
most likely be  minimal as a result of market saturation and the increasing competition 
from supermarkets.  
Euromonitor data suggests that in 2011 health and beauty specialist retailers increased by 
4% in current value terms with a stable 1% growth in the number of outlets and sales area 
(Euromonitor, 2012). The sector is underpinned by the affluent female middle classes. But 
growth has been attributed to the expanding interest in personal health and well being and 
the aging population, that demand specialist health and beauty products (Euromonitor, 
2012). 
As shown in table 6.2, for pharmaceutical services consumers prefer expertise and quality 
and are willing to travel further to receive them. The attributes associated with services, 
such as obtaining a diagnosis, expert knowledge on medical conditions, ability to have an 
examination, and a professional who is able to access medical records all influence where 
patients go for advice (Hughes et al., 2008). Yet the challenge for pharmacists and 
pharmacy contractors is that these attributes typically sit in the general practice domain. 
Discrete choice experiments suggest that consumers currently have a strong preference for 
GP advice over pharmacy advice for both minor and more complicated medical problems 
(Porteous et al., 2006). If pharmacy contractors are seeking to provide more services then 
they will need to adopt qualities traditionally associated with general practice.  
 
Table 6.2– Dimensions of consumer choice for pharmacy goods and services 
(adapted from Office of Fair Trading, 2010) 
 Prescription 
medicines 
Pharmacy 
Medicines 
General 
Sales list 
medicines 
Clinical 
Services 
Proximity    x 
Opening Hours   x x 
Waiting Times  x x x 
Convenience/ one stop 
shop 
   x 
Range x   x 
Price x   x 
Advice/Expertise     
Quality of Service   x  
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Key:  important to many consumers;  important to some consumers; x important to few or not 
relevant.  
Consumers are uncertain about pharmacists’ training and knowledge (Department of 
Health, 2009a). Research suggests that there is a correlation between understanding of 
pharmacists’ expertise and patient willingness to ask for advice. However it is not solely 
consumer education that is required to change behaviour, but also adequate resources. For 
example consumers consider that poor privacy prevents pharmacies from providing blood 
pressure testing or diabetes services (Department of Health, 2009a). Further examples are 
listed in table 6.3. Consequently consumers believe that more serious tests would be less 
appropriate in a pharmacy. Although they are willing to accept the role that pharmacists 
play in common minor more manageable illnesses (Department of Health, 2009a). 
Table 6.3– Negative Consumer Views of Community Pharmacy  
Dimension Consumer Views 
Environment Perception of cluttered and busy environment, particularly independents 
Privacy Lack of appropriate environment in which to perform services 
Records Lack of access to a shared medication or healthcare record 
Training Lack of qualified staff to perform services and a basic lack of knowledge of 
pharmacists training 
Joined up 
Working 
Fears over the two-way communication between general practice and 
community pharmacy 
Feminisation Viewed as a very feminine environment, which is not ideal for most male 
consumers. 
Source: adapted and updated from Pharmacy Consumer Market Research, OFT, 2010, DH,2008.  
Across the different buyers, pharmacy contractors sit in a relatively weak position. The 
reliance on the Department of Health for the majority of income coupled to the challenging 
retail environment suggests that the market will face a tough time ahead.  The strategy put 
forward by government policy is to invest in clinical service delivery. But to meet these 
demands pharmacies will need to increase service awareness, invest in the pharmacy 
environment to improve privacy, develop integrated records and educate patients. The 
ease of implementing such changes when income streams are being squeezed should not 
be underestimated.  
Suppliers (Strong) 
There are several suppliers into this market. This is not only those suppliers associated with 
products such as the pharmaceutical industry and medicines wholesalers, but also those 
associated with the supply of labour. Indeed, the universities and government represent 
the main controllers of the adequate supply of trained labour.   
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Community Pharmacy Labour Market 
Pharmacists 
Pharmacies require a pharmacist who has undertaken five years of graduate training at an 
accredited university to be present in order to trade. There are currently over 45,4580 
registered pharmacists in the Great Britain58. Of these 71% of pharmacist are employed in 
the community sector, with just over a fifth in hospital practice (21.4%), and 7.2% working 
in primary care (Seston and Hassell, 2009a). With the exception of 200559, the number of 
pharmacists joining the register has grown steadily at about 2% each year since 1997. 
However, the number joining the register recently has increased dramatically, driven by 
both supply and demand. Figure 6.5 represents the different factors to be considered in the 
pharmacy labour market. 
 
Figure 6-5– Workforce Flow Model 
 
Source: Adapted and updated from Guest et al (2008).  
In 2010, 2,505 new trainees entered pharmacist pre-registration training, bring the total 
number of trainees that year to 3,071 (General Pharmaceutical Council, 2011). This is 
compared to a figure of around 1,000 a decade ago. This surge in numbers has been 
created by a swell in undergraduates studying pharmacy. New schools of pharmacy at the 
                                                          
58 Personal Communication with General Pharmaceutical Council 28th May 2012.  
59 In 2005 a new payment structure resulted in more pharmacists leaving the register.  
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University of East Anglia in 2003, Reading, Kingston and Medway in 2004, Hertfordshire in 
2005, Wolverhampton, Hudderfield and Keele Universities in 2006 and the University of 
Central Lancashire in 2007 have all contributed to the increase in the number of students 
studying pharmacy, and subsequently applying for the registration assessment (figure 6.6) 
and entering the pharmacy labour market. This has happened at a time where existing 
schools of pharmacy, under pressure from changes in higher education funding, have also 
sought to increase their numbers60. Further new pharmacy schools are planned.     
Figure 6-6– Number of Registration Assessments 
  
Historically there has been a slight undersupply of pharmacists for workforce requirements. 
This had led to pharmacists being classified as shortage occupations by the UK border 
agency Migration Advisory Committee. However it was recommended in November 2011 
that pharmacists be removed from the list61, reflecting the changing balance in pharmacy 
numbers driven by new entrants. Since 2006, the proportion of pharmacists who come 
from overseas has remained fairly static (figure 6.7), representing about 12% of the register 
(Seston and Hassell, 2011). The most popular route of entry for these pharmacists was via 
the European Route (44.6%) (Seston and Hassell, 2011). 
  
                                                          
60 Further details of this have been published by this author on behalf of the British Pharmaceutical Students Association. 
http://www.bpsa.co.uk/pressreleases/BPSA_Student_Numbers_Discussion_Paper_-_17th_July_2012.pdf 
61 http://www.ukba.homeoffice.gov.uk/sitecontent/newsarticles/2011/november/18-short-occup 
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Figure 6-7– Entrants to the Register 2006-2010  
 
Source: (Seston and Hassell, 2011) 
Those leaving the register have also remained fairly constant. However, the inactive 
workforce has grown slightly due to the increasing feminisation of the profession. New 
female entrants to the profession outnumber men by two to one (Seston and Hassell, 
2009b) a pattern being mirrored around the world (International Pharmaceutical 
Federation (FIP), 2009).  The pharmacy workforce census found an increased prevalence in 
portfolio working, part time working (Seston and Hassell, 2009a), which is driven by 
feminisation (figure 6.8). The tendency of the female workforce to work part time or to 
have career breaks can be attributed to the demands of child care.  
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Figure 6-8– Feminisation of the pharmacy profession 
 
Source: (Seston and Hassell, 2011) 
The full effect of the increase in numbers is yet to be felt. However the effect of more 
graduates entering the register will inevitably lead to greater competition for jobs. The new 
graduates may be considered to be a threat to those already employed as their training is 
more clinically orientated than their experienced colleagues. This may lead to ashift in the 
demographic profile of the profession and in turn result in  a loss of experienced staff.  
The pharmacy workforce census suggests that more than a third of pharmacists in the 
community sector work as locums (Seston and Hassell, 2009a).  The availability of locum 
positions is likely to decrease because of the swell in graduate numbers. As a result 
securing work will be harder and therefore those working as locums are likely to opt for the 
security of permanent contracts. Therefore the work-life balance and flexibility that locum 
work once offered  (Shann and Hassell, 2006) may decrease, forcing these workers out of 
the profession.  
It is likely that the position developing is England is likely to follow that of countries like 
Sudan, unless policies relating to recruitment of trainees in the higher education sector are 
reviewed. In Sudan, the number of pharmacists increased by 130% over twenty years as a 
result of government polices to expand higher education. The result was an oversupply of 
pharmacists, particularly in urban areas (International Pharmaceutical Federation (FIP), 
2009).  There is anecdotal evidence of this beginning to happen in urban areas of England.  
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Unless more jobs can be created to meet the current supply of pharmacists, it is likely that 
the overall effect will be a decrease in the average salary of pharmacists. On one hand it is 
argued that increased competition in the labour market will improve quality. On the other, 
the knowledge that a pharmacist can be easily replaced may prevent them from exercising 
professional autonomy that is in contradicts their employers wishes, even if it is in the 
interest of the patient. Therefore pharmacists are likely to have less autonomy and more 
likely to obey the demands of their employer. However, the recent creation of a 
pharmacist’s union may mitigate the extent of this in practice.  
Registration of Pharmacy Technicians 
Support staff are often the first point of contact for many customers and are integral to the 
running of a pharmacy. It is imperative that the values of this interest group are not 
underestimated. Measures introduced by the Government in response to the current 
economic climate include a commitment to making efficiency savings in the health service. 
In this context the development of pharmacy technicians is important strategically as this 
group are  increasingly being considered as a group for intra-professional role-substitution 
(Willis et al., 2011).  
In July 2009 statutory regulation of pharmacy technicians began on a two year voluntary 
basis, becoming mandatory in July 2011.  Currently there are 21,00062 registered pharmacy 
technicians in England. As with the pharmacist workforce, most technicians work in 
community settings. As many as 40% of community pharmacies operate without a 
technician, compared to the hospital setting where most pharmacists work with one 
(Schafheutle et al., 2008).  
Substituting labour to technicians is not a new proposition. It was first recommend in the 
Nuffield report that pharmacists should delegate activities to suitably trained staff (The 
Nuffield Foundation, 1986). In the hospital sector pharmacy technicians have successfully 
extended their roles in response to the long-standing shortage of pharmacists since the 
early 1980s (see chapter 1). In secondary care settings pharmacy technicians have 
successfully extended their roles to release pharmacists into more clinically orientated 
tasks. Yet this reconfiguration of roles has not been achieved in the community sector 
(Hassell et al., 2002), primarily due to liability issues associated with personal control and 
supervision. 
                                                          
62 20,998  registered pharmacy technicians 28th May 2012. 
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Current evidence of the effectiveness of labour substitution is positive, but based on small-
scale, descriptive studies where the research design prevents generalisation to other 
settings (Willis et al., 2011). There is little evidence that labour substitution in community 
pharmacy is cost effective. For example, Savage (1995) found that when comparing two 
pharmacies with and without a technician, an hour of pharmacist’s time could be released 
each day. However, this time was sporadic and not predictable in the working day, thus 
preventing the time being used for improving patient care (Savage, 1995). 
While the UK evidence remains weak, European experience suggests that this sector of the 
workforce could grow. Pharmaconomists in Denmark, prescriptionists in Sweden and 
pharmacist’s assistants in Holland are able to undertake pharmaceutical tasks with a 
greater level of responsibility when compared to their UK counterparts. However, 
compared to the UK, these ‘technicians’ have longer periods of training. Prescriptionists are 
trained to Bachelor degree level, similar to a UK BPharm, and are therefore able to 
complete technical tasks without supervision. As are Dutch pharmacist’s assistants, who 
are able to dispense prescriptions, counsel patients and undertake medication reviews 
without the direct supervision of pharmacist. However the current regulatory environment 
in community pharmacy practice and the training of UK technicians limits the further 
development of technicians’ roles.  
Pharmacies have medicines counter assistants and pharmacy (dispensing) assistants in 
addition to pharmacists and pharmacy technicians (Schafheutle et al., 2008). The 
consistency of support staff across the industry is hugely variable. There is little national 
data on this workforce, although NHS staffing survey reports that there are 3,569 FTE 
pharmacy assistant posts in NHS trusts in England (NHS Pharmacy Education and 
Development Committee, 2011). The average number of employees in the pharmacy any 
time varies across pharmacy type between 1.7 employees (for supermarkets) and 3.9 
employees (for smaller multiples) per hour that the pharmacy is open 
(PricewaterhouseCoopers LLP, 2011). This suggests that nationally there are in the region 
of 30,000 non-pharmacist full time equivalents employed in this sector. 
Workforce capabilities and education 
The reengineering of the pharmacy education in schools of pharmacy is creating 
practitioners who are more competent in clinical care roles and proactive care delivery. 
Those joining the profession should be able to embrace extended pharmaceutical roles 
with greater ease. However, if those opportunities to practice clinical skills do not exist, 
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then it is likely that they will be disillusioned and leave the labour market. Therefore 
creating a synergy between the activities of the sector and the education of pharmacists is 
important to keep the workforce motivated. 
Pharmacists already in practice will need to consolidate their knowledge and develop their 
skills to become ‘clinical practitioners’ if the profession is to embrace the ‘utilisation’ 
demanded by policy. This requires a payment structure and culture that supports the 
development of education in the workplace. However such a requirement is unlikely to be 
achieved in the short term future because incomes into community pharmacies are 
strained.  
Wholesalers 
The pharmaceutical industry is the main originator of prescribed pharmaceuticals in 
England. Their profits are governed by the pharmaceutical price regulatory scheme (PPRS). 
As a result of the 2009 negotiations the industry reduced prices by 3.9% in February 2009 
and 1.9% in January 2010. As pharmaceutical companies reduce prices they have sought to 
limit their exposure by introducing reduced wholesale or Direct to Pharmacy schemes. 
These schemes remove the discounts applied in the supply chain to help maintain the 
manufacturers’ margins. These distribution arrangements are significantly less lucrative for 
wholesalers, although for the time being do not financially impact pharmacies beyond the 
additional complexities of the supply arrangements (Office of Fair Trading, 2007).The 
justification for these arrangements is to prevent counterfeiting and to maintain the 
integrity of the supply chain, and currently the manufacturers have to demonstrate that 
pharmacy profitability is not impacted63. 
The UK wholesale market is separated between a handful of large full line wholesalers and 
numerous smaller short line ones. These groups can significantly influence the ability of a 
pharmacy to obtain a ‘purchase profit’ through the pricing structures and discounts that 
they offer. They are being squeezed by their suppliers in the pharmaceutical industry and 
are therefore passing this onto community pharmacies further down the supply chain. This 
reduces the margins for all of the actors involved.  
By contrast OTC products are traded like most other retail commodities. Consumers expect 
branded pharmaceuticals, such as Nurofen and Benadryl to be stocked in pharmacies.  In 
negotiations the grocers and large retail led multiples are able to obtain larger discounts 
                                                          
63 Further discussion of DTP schemes is described in chapter 3. 
 
 
259 
due to their buying power. As consumers trade towards own label products, those 
contractors with strong product ranges and internal suppliers are able to entice more 
custom. This leaves smaller pharmacies in a weaker position, and has led to the increase in 
the number of buying groups in an attempt to sustain margins. 
Virtual Chains 
In order to address the imbalance between the buying power of the large multiples, many 
independent contractors have opted to join buying groups. In the UK about a third of 
pharmacies are members of voluntary groups. The largest of these groups is Numark, with 
over 2,640 pharmacies as members, owned by the wholesale distribution company Phoenix 
who took charge in 2005. The group grew in 2008 following a merger with Nucare. In 
similarity with other major wholesalers, Numark offers a joint ownership scheme to enable 
pharmacists to open new premises. The debt equity scheme allows pharmacists to have a 
49% share and Numark a 51% share of the business. After five years the pharmacist can 
purchase Numark’s share  
Alliance Healthcare introduced Alphega, the leading network of pharmacies in Europe to 
the UK in 2009 and currently has 700 members in the UK. Other buying groups include 
Avicenna, CamRx, PharmaPlus and Cambrian Alliance.  
Avicenna is primarily a buying group with over a thousand members. Pharmaplus (formed 
after the merger of Pact group and Wisebuys) has a membership of over 200, and acts as 
an advocate for independent pharmacies. CamRx brand themselves as a pharmacy 
development group, and like Cambrian Alliance, work to represent independent pharmacy 
interests.  
Changing structure of Medicines supply 
The nature of the products supplied on prescription by community pharmacies is changing. 
The ‘blockbuster’ innovations of the previous decades have reached the end of their patent 
lives. The market, by volume,  is therefore predominately generic products, with little sight 
of significant innovation in solid dosage forms (Light and Lexchin, 2012). New 
pharmaceutical products tend to be focused on secondary care, and represent complex 
technologies that require increased monitoring and support for administration.  
The result of this in the medium to long term is that through whatever mechanism the 
discount and margins available to pharmacy contractors will decrease. As the genericisation 
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of medicines continues, the relative value of the products that pharmacies supply will 
decrease. At this point questions will be asked about the cost of the supply chain that in 
some cases is ten times the cost of the product being supplied. 
Substitute products (Weak) 
The above average degree of political and regulatory intervention in the pharmacy market 
makes substitutes a minimal threat. Firstly, the government has conferred in doctors, 
dentists and other suitably qualified healthcare providers the exclusive rights to prescribe 
medication for NHS patients. Pharmacists (and in some cases doctors) have been provided 
the exclusive rights to supply these prescribed medication to consumers. Secondly, the 
government pays for the cost of the medication supplied as well as additional fees 
associated with the supply process, such as the pharmacists’ professional dispensing fee. As 
the eventual payer of medications, the government seeks to use methods to control and 
balance the costs of drugs supplied in the NHS. Thirdly, the government limits who can 
supply those medications and in what locations, by adding controls upon the market. 
Therefore the only alternatives for medication supply are dispensing doctors or secondary 
care facilities, such as A&E. However, internally within the market substitute supply 
through internet pharmacies could create competition for traditional community 
pharmacies on the high street, as could the potential expansion of GP businesses into 
dispensing. For pharmaceuticals services general practices but also health and fitness 
centres are potential threats64. 
  
                                                          
64 These are both considered in the section that relates to market rivalry. 
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Summary 
The combination of the forces identified using the Porter’s framework represent eight 
market attributes that those within the sector need to be cognisant of in the future. These 
attributes, shown in table 6.4, represent variables that require consideration in any future 
models of practice.  
Table 6.4 – Main drivers of Community pharmacy 
 Summary Statement 
Economy 
 
Future investment in public services and health will remain limited for the foreseeable 
future. Government investment in pharmacy and other healthcare services will 
continue to be restricted. 
Consumerism 
 
The aging population will demand more a higher standard of care and be more 
demanding of future healthcare services. 
Technological Advancements 
 
Technology has the potential to dramatically change the supply model and alter the 
nature of rivalry between pharmacies. 
NHS Reconfigurations The buyers with the market are changing, which could shift the ability of pharmacy 
contractors to be commissioned. There are potential threats and opportunities for 
services to be commissioned from pharmacies. 
Market Entry and Consolidation 
 
The current framework of market entry is unsustainable and is therefore continues to 
intensify internal rivalry.  
Structure of Medicines Supply Prescription volumes are increasing and medication prices are lowering. The changing 
nature of medicines supply places increasing power in the hand of manufacturers and 
limits the power of pharmacy contractors in negotiations.  
Workforce Capabilities and 
Education 
The capabilities of the profession to deliver an altered model of practice is an essential 
component of change beyond the status quo. 
Organisational Unrest  The business rivalry internally has led to organisational distrust, which has negated a 
united strategic view for the profession. This is echoed by the lack of strong leadership 
within the professional body. 
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Chapter Conclusion 
Porter’s framework provides a suitable strategic basis on which to view the pharmacy 
market. There are several important conclusions to draw from this analysis. First is the 
unpredictable effect of marco-economic forces on community pharmacy businesses. The 
downturn of global markets has meant that significant ‘new’ investment into community 
pharmacy is unlikely. The NHS reorganisations may possibly present a window of 
opportunity for investment, but given the rivalry between GP and pharmacy in primary care 
this would, in the short term, appear unlikely.  
The buyers in the market are also affected by the wider economic downturn. Consumers, 
operating under restricted budgets, are more price conscious and demanding more for less. 
This squeezes the margins across the pharmacy business. The main buyers in pharmacy, the 
Department of Health, are also experiencing budgetary constraints. They are seeking to 
find ways of reducing spend on medicines, a trend that began before the economic crisis 
and one that looks set to continue. Community pharmacy businesses are finding that their 
revenues from the NHS are being reduced; a trend that is unlikely to reverse in its direction.  
The suppliers and other actors in the medicines supply chain are equally seeking to 
maintain their profit margins. In doing so the environment for pharmacy is becoming more 
competitive as a result of reduced ‘purchase profits’. The margin may be offset by a 
reduction in the largest cost to the business; labour. The increase in pharmacy graduates, 
unless controlled, will drive salaries for community pharmacists down across the sector. 
The workforce, uncertain about the security of their jobs, and suffering from the effects of 
increasing workloads are disillusioned about the future.  
Taken together these forces for change and threats in the current community pharmacy 
market are placing pressure on current profit levels. Strategically the pharmacy market will 
need to represent itself in such a way that allows it to continue to receive premium 
incomes and develop strategies that allow the business to be sustainable. If the trends 
observed within each of these domains continue to full effect, then the current viability of 
community pharmacy businesses will be brought into question. 
The purpose of the business in societal terms remains uncertain. To many people, 
particularly consumers and general practitioners, the purpose of the business is to supply 
prescription medicines together with health and beauty products. Yet, those in policy 
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circles continue to describe the purpose of the community pharmacy as being one of public 
health delivery that addresses inequalities in health. 
The payment for medicines does not purely represent the product supplied. It also 
understood to include a recompense that supports the ‘value’ of the community pharmacy 
business to health and social care (appendix C). Yet several disruptive technological 
developments have the potential to fundamentally change the nature of medicines supply 
and undermine the value currently added by the business.  
More recent investments in the sector have been based on a transparent fee per service 
model which remunerated pharmacy businesses for advice. Yet such models require 
evidence of outputs and healthcare gains if they are to continue to receive investment. As 
such businesses across the sector are likely to change their model from relying on supply 
towards reliance on advice and proving the ‘value added’ by the business.  
There are many different strategies that can be taken in the short term to develop the 
community pharmacy business. However, these rely to a large extent of the level of future 
funding provided by the government to support the development of community pharmacy. 
The range of service begins at a position of limited investment where the purpose of the 
service is purely to maintain the supply of prescription medicines at the lowest possible 
cost. The alternative end of the spectrum is a pharmacy service that has increased levels of 
investment and moves towards becoming a central part of the healthcare service, acting 
alongside and in conjunction with general practitioners. It is the development of these 
strategies and the alignment of the strategies with the professional models that forms the 
basis of the discussion in the final chapter. 
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Chapter 7. De-professionalising pharmacy 
and re-professionalising pharmacists? – 
Discussion 
Chapter Introduction 
This thesis has presented qualitative and quantitative research findings generated via a 
series of separate, although logically linked, studies. This final chapter provides a narrative 
synthesis of the total body of research and original thought offered. It addresses the 
fundamental research question at the heart of this body of work, namely How are business 
and professional practice models for community pharmacy in England likely to be 
structured in ten to twenty years time? 
Even within the relatively narrow parameters of the UK pharmaceutical sector there are 
many aspects of the future which cannot be accurately predicted. But for those seeking to 
safeguard and support the ongoing development of community pharmacy in a complex, 
evolving, world it would be wrong to ignore the potential value of rational forethought 
about major trends, and the ways in which demand for medicines and their effective use 
will alter as the next two decades unfold. Without open minded, critical, inquiry it will be 
impossible to determine what established aspects of the profession are most worth 
defending, and what new capabilities are most worth pursuing. 
This chapter begins by briefly reiterating the background to the development of modern 
community pharmacy practice. It re-examines material from the literature review 
contained in chapter 1 in the light of the additional findings presented in subsequent 
chapters. It then seeks to explore the perceived ‘problem’ that underlies the research 
question posited above before discussing the possible ‘solutions’ identified. This relates to 
changing expectations of, and needs for, pharmacists’ services and their capacity to adapt 
to meet existing and new needs at least as cost effectively as other potential service 
providers. Alternative future scenarios are considered, along with the views of different 
stakeholder groups with direct or indirect interests in pharmacy related business and/or 
professional activities (see chapter 5). Aspects of the power and dependency relationships 
within pharmacy and between pharmacists and other groupings, such as the medical 
profession and its members, are investigated.  
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The concluding sections of this chapter then return to the Freidsonian perspective on 
(health) professionalism as it applies to modern community pharmacy, before discussing 
some of the limitations of the research methods used and highlighting opportunities for 
future work. Freidson’s work on the sociology of professionalism was outlined at the 
beginning of this thesis. It is argued here that community pharmacy as a profession is only 
likely to enjoy a ‘strong’ future if its members understand the need to balance his ‘three 
logics’ of bureaucratic (typically politically led), market incentive driven and professional 
directed control in the work place, and follow a ‘re-professionalisation’ strategy that 
genuinely seeks to make substantive value-adding contributions to the public good, rather 
than pursuing sectional or merely rhetorical goals. 
Background 
In national settings like that of England a significant attrition of the ‘traditional’ 
pharmacist’s role took place in the first half of the twentieth century. This occurred as a 
result of the transfer of medicines manufacturing from the profession to the 
pharmaceutical industry. In the wake of that historic shift, the impact of the Second World 
War on British society led to the development of publically funded health and (at least to a 
degree) social care. The birth of the NHS in 1948 further eroded the compounding function 
of community pharmacists and coincided with the introduction of many more ‘prescription 
only’ medicines. Together, these developments led to a sustained increase in prescription 
numbers coupled with a shift away of many consultations about illness from pharmacy to 
the general practice setting.  
This was desirable in as much as it was a reflection of improved access for most of the 
population to primary healthcare services. Yet the impact on pharmacy was mixed. 
Increased dispensing volumes served financially to support community pharmacy 
businesses. But community pharmacists were to a degree marginalised as health care 
providers, not least because they in the main felt obliged to retreat to the ‘back of the 
shop’ to conduct and/or supervise dispensing and allied activities. 
Prior to the formation of the NHS pharmacists were recognised as practicing with a high 
level of autonomy. Their standing in the community and their knowledge of medicines 
allowed them to advise and treat people as they felt fit, even if the lotions and potions 
supplied were of questionable efficacy (Anderson, 2008). Community pharmacists often 
provided semi-formal health care to the less prosperous, whist doctors tended to focus 
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their attention on the wealthier classes. The asymmetry of knowledge underlying 
exchanges between professionals like pharmacists and the public tended to promote 
‘paternalistic’ practices and facilitated the development of a ‘social contract’ that allowed 
pharmacists to charge premium prices for the products they sold, balanced by the ‘free’ 
advice accompanying them. Knowledge asymmetries between consumers and service 
providers lie at centre of the social processes leading to ‘professional’ status (Freidson, 
1970).  
However, as suggested above, community pharmacists’ discretion to treat conditions was 
reduced by the creation of the NHS and allied mid 20th century developments. They were in 
effect forced to spend most of their time dispensing general medical practitioner written 
prescriptions for treatments. This benefited the standing of GPs as against community 
pharmacists, whose position was further challenged by growing public awareness that 
increasingly powerful medicines were being supplied in ‘patient ready’ dosage forms by the 
emergent pharmaceutical industry.  
In addition, the growth of prescription volumes aided the expansion of commercial 
pharmacy chains, which benefited from savings to scale and linked supply chain economies. 
This made pharmacists more likely to be employees than owners. In association with this 
trend, both the NHS and corporate management began to push for greater standardisation 
of behaviours and practices to promote efficiency and service quality as defined in their 
process and task oriented terms. This further impacted on the perceived standing of 
pharmacists as autonomous health professionals.  
Notwithstanding educational and allied reforms designed to offset such effects, the 
available evidence indicates that community pharmacists gradually became regarded as an 
‘under-utilised resource’ (chapter 1). Despite being busy, the content of their role has 
increasingly been seen as discordant with the substance and ambitions of their professional 
training. It can be argued that this in time helped to promote changes in the functions of 
the Royal Pharmaceutical Society. Yet since the 1990s reforms across the entire UK 
healthcare sector have gravitated towards a rebalancing of both internal and external 
professional power and dependency relationships.  
For pharmacy this led to the establishment of the General Pharmaceutical Council, which 
ultimately answers to the public for its governance of the profession. Managerialism and 
extended regulation have acted to control the work environment for pharmacy in a way 
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which serves to limit not only individual but also collective ‘autonomy’, and arguably to 
weaken further the ‘traditionally’ defined professional status of community (and other) 
pharmacists. Loss of ownership opportunities and falling incomes relative to both 
medicines supply work load and the medical profession’s earnings have further influenced 
the situation of pharmacists. So too may have the emergence of relatively assertive forms 
of ‘consumerism’ in the health arena.  
The ‘normalisation’ of some forms of medicines supply and use through increased access in 
non-pharmacy outlets such as supermarkets and petrol station forecourts, coupled with 
the greater ‘lay’ access to  knowledge about pharmaceuticals and their appropriate 
employment, have to an extent ‘de-mystified’ pharmacists’ – and to an apparently lesser 
degree doctors’ – roles.  The basic mechanism implied here is that exclusivity over access to 
and the ability to interpret the knowledge at the centre of the pharmacists’ professional 
‘territory’ has been undermined by technical and social progress. Hence the ‘power’ 
enjoyed by pharmacists by virtue of their ‘agency role’ has declined.  
The Problem 
NHS community pharmacy businesses rely heavily on NHS prescription dispensing and 
allied payments for their income. These typically account for over 80 per cent of revenues 
in independent pharmacies. But it is becoming increasingly possible to automate such 
‘semi-cognitive’ work. Just as in the past many factory and agricultural tasks have been 
mechanised, this challenge is now confronting pharmacists.  The genericisation of much 
medicines use, which is in many instances making it transparent that the current cost of 
dispensing is as much as (or more than) that of purchasing medicines from their 
manufacturers, is further destabilising the financial base of pharmacy businesses. Such 
trends are leaving the established community pharmacy business and its professional 
model increasingly exposed to fundamental questioning.  
The Department of Health and other sources have already suggested that further cost 
savings could be achieved via the ‘commoditisation’ of medicines supply, in contexts 
ranging from product purchasing to prescription assembly (Agwunobi and London, 2009). 
This will, all other things remaining constant, over time push down dispensing fees to the 
lowest possible level consistent with public interests in safety and sustainability. Such a 
trend could render the typical community pharmacy business of today commercially 
unviable, and in reducing the returns available to normal profitability remove the economic 
foundation that has (whether or not it has been cost effective from a public interest 
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standpoint) in the past underpinned the provision of professional services other than 
dispensing in community pharmacies. 
In line with this picture, service funders outside the DH have also questioned whether or 
not the premiums paid for the expertise of pharmacists in the supply of prescription 
medicines deliver value for money. It is increasing being argued that (with the exception 
perhaps of the clinical screen, although computerisation could eventually impact this area 
as well) dispensing can today – given the development of pharmacy technicians’ roles, as 
well as that of automated dispensing machines – be safely performed without the direct 
oversight of the pharmacist(Department of Health, 2008a).  
Outside the profession it is often recognised that pharmacists are relatively well educated, 
and have a set of skills and knowledge that could be used to fulfil a direct health 
care/improvement role beyond that of simple medicines management. Yet their knowledge 
is not presently seen as being used to full effect. As noted above, it is this situation which 
has led to the conclusion that pharmacists are ‘underutilised’ (as distinct from under-
occupied) and are ‘wasting’ their time on activities which they need not directly undertake.  
Pharmacy policy documents in the UK and similar nations like The Netherlands have, with 
varying degrees of clarity, expressed such thinking since the early 1980s. Community 
pharmacists in England are currently processing, checking and supplying nearly a billion 
prescription items a year. While income streams remain closely associated with 
prescription volumes, it is understandable that these factors have driven pharmacists  to 
the checking bench (chapter 2). Yet the commentary provided by the policy and practice 
research literature of the last three to four decades suggests that a more efficient, less 
wasteful, approach would almost certainly place pharmacists in a more direct health 
improvement role.  
The pharmacy policy cadre, defined here as an amorphous leadership group disseminated 
across a variety of settings, has attempted to respond to the challenge to their core 
professional base by developing a strategy that shifts from a ‘supply based product focus’ 
to a ‘patient based clinical therapeutics focus’, while at the same time seeking to minimise 
both current business risks and the dangers associated with overt conflict with the medical 
profession. Terms such as ‘medicines management’, ‘role extension’, ‘pharmaceutical care’, 
‘medicines optimisation’ and ‘public health pharmacy’ have filtered into policy documents. 
Their use implies that pharmacists should step beyond the logistical supply function and 
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embrace roles that support both patients and other health workers in their efforts to use 
medicines to best (or at least better) effect, in order to enhance health outcomes (chapter 
1).  
The new contractual framework introduced in 2005 represented an important step along 
this change pathway, by creating a tiered nationwide commissioning structure for 
pharmaceutical services. Yet barriers to increasing the supply of extended services (such as 
perceived inadequacies in funding, and in some instances a lack of individual expertise 
and/or confidence combined with a risk averse group culture) have persisted (chapter 4).  
The research reported here indicates that the single most important impediment on the 
business model ‘side’ of the community pharmacy equation has been the current system’s 
incapacity to incentivise incrementally sustained change. Evidence is emerging that 
pharmacists are able to perform wider health improvement roles in ‘public health’ areas 
such as smoking cessation (Blenkinsopp et al., 2003) and alcohol use moderation (Dhital et 
al., 2010), as well as in ‘medicines optimisation’ areas such as promoting greater adherence 
in medicines taking (Clifford et al., 2006). Yet pharmacists working in a business led 
environment presently tend to revert to the dispensing bench because it is not 
economically viable to re-allocate their skills to activities of this type. 
One implication of this is that pharmacy businesses will require substantive investments to 
be made in non-pharmacy staff and dispensing automation, if a permanent re-allocation of 
pharmacy labour use is to be achieved. At present there do not appear to be enough 
opportunities to allow an economically viable rebalancing to take place (chapter 6). 
Although the present contractual framework was intended to facilitate re-allocations of 
pharmacists’ activity, it has failed to do so (chapter 2). Unless new agencies such as the 
NHSCB decide pro-actively to promote such progress it may in future become even more 
difficult for community pharmacy owners to re-engineer their NHS and/or wider primary 
care role. 
Comparisons between the research findings presented here with those of previous UK 
based studies and the wider international literature underline the entrenched nature of 
early 21st century pharmacists’ supply roles. The situation has been further complicated by 
regulation and governance arrangements which have reportedly kept community 
pharmacists in fear of prosecution for making dispensing errors (chapter 3 and appendix A) 
and (as noted above) further limited their ‘professional autonomy’. The analysis presented 
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in this thesis suggests that many (especially younger) community pharmacists are eager to 
use their skills for health improvement but that in practice they are often prevented in 
having opportunities to do so (chapter 4). The resultant sense of frustration has added to 
the tensions associated with factors such as the commoditisation of dispensing services 
discussed in chapters 3 and 6.  
In looking forward it may be argued that there is presently still a potential for both ‘strong’ 
and ‘weak’ community pharmacy futures. The latter would be one where the profession 
continues to be pre-occupied by the medicines supply and a narrow management role, 
with other groups – such as medicine and nursing – incorporating the clinical aspects of 
pharmaceutical care and optimal medicines use support into their roles. At the extreme, 
pharmacists could become replaced by less expensive technicians who would take on the 
main elements of supplying medicines to the public. The overall cost and profitability of the 
process would be minimised. The pharmacists displaced may (in competition with the 
increasing number of new graduates entering the market) be able to find employment in 
GP practices or other medically led community settings. But their individual earnings may 
over time fall to the levels paid to other practice employees, like nurse practitioners. 
By contrast a ‘strong’ future scenario may be seen as one where pharmacists have a robust 
and well defined health improvement role, gained through the application of their current 
and as required extended future abilities in areas such as risk management, improved 
safety and health promotion (chapter 5). Such a future, based on demonstrably cost-
effective value-adding contributions to enhanced public health and wellbeing, could 
represent an effective ‘re-professionalisation’ strategy capable of bringing benefits to both 
service users and pharmacists themselves. It may be the case that any successful ‘re-
professionalisation’ strategy would at least in the short term need to be consistent with the 
commercial contexts within which pharmacists and pharmacies currently operate (chapter 
6). However, incremental evolution may in time lead to radical change. At the individual 
level it may also, at least in some circumstances, be possible for those willing to accept risk 
for the chance of future gain (and/or who presently have relatively little to lose) to ‘step 
out’ of existing pharmacy structures into new environments. 
Secure professional groups normally require clear boundaries that define their functionally 
relevant practices and identities (chapter 1). Yet within community pharmacy there is 
disagreement as to the best way to progress. The objectives and interests of, for instance, 
younger pharmacist employees as opposed to pharmacy contractors may often overlap, 
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but are not necessarily identical. Such realities can cause confusion, if not overt conflict, 
and lead different stakeholders to perceive the ‘problem’ that needs to be resolved in 
differing ways (chapter 5). Further, powerful external influences like that those linked to 
political expectations and expediencies may on occasions require pharmacy to go down 
paths that are not necessarily the most rational or beneficial from a health gain standpoint. 
Such realities cannot be ignored. However, neither should they be permitted to obscure 
public interests or conceal important long term opportunities. 
Possible Solutions 
There are several broad conclusions that can be drawn from the research evidence 
presented in this thesis, which offer insights relevant to developing solutions to the 
problem identified above. They include, first, the understanding that pharmacists must 
genuinely be willing to adapt and change, to use their existing and as necessary new skills 
to meet the evolving needs of societies they serve if they are to embrace a successful ‘re-
professionalisation’ strategy (chapter 4). The latter will need to incorporate the concept of 
cost effectiveness as central to the meaningful optimisation of medicines supply and use, if 
a continuing role for pharmacy is to be found acceptable by the community as a whole. 
Second, following on from the above, there is a need to re-specify the twenty first century 
role requirements of pharmaceutically qualified professionals working in the community 
setting. Current ambiguities relate to the balance between drug supply and clinical care 
delivery, and the extent to which community pharmacy based services could and should 
compete with and be able to substitute for, as opposed to complementing and enhancing, 
GP and allied services (chapter 3). Seeking radical primary care re-design as opposed to 
current system improvement may well involve higher risks and uncertainties for all the 
professions involved than would incremental modification of the status quo. But from a 
public interest viewpoint it may also offer greater potential advantages. 
Third, on the basis of the evidence gathered during the work undertaken for this thesis and 
presented in previous chapters, perceived and actual conflicts between the commercial 
imperatives underlying pharmacy as a business and the values that community 
pharmacists aspire to have as professionals represent a significant barrier to overall 
service improvement. They therefore need to be understood clearly so that effective 
action can be taken either to reconcile them, or dispel needless fears. One important issue 
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to consider in this context relates to the extent to which corporate cultures can internalise 
professional values. 
When seeking to identify ways forward in relation to the above it is of note that Freidson 
(1970, 1994) argued that professionals need both an ideology and a practical commitment 
that expresses a greater devotion to ‘doing good’ than to obtaining financial rewards. On 
this basis pharmacists and pharmacy related companies need to distance themselves from 
commercial imperatives that are perceived as being excessively dominant, and redefine 
their core mission in more altruistic and health gain focused terms. As with other 
professions, this is required to justify the market shelter under which they operate.  
It is argued here that if pharmacists remain in the community location and simply seek to 
hold onto their core supply role as it currently stands, then robotics and technology will in 
time very probably push them towards being relatively low paid technicians. To paraphrase 
Bill Scott, the Chief Pharmaceutical Officer for Scotland: “if supply is pharmacy’s sacred 
cow, then it is on its way to the abattoir”. 
If this view is accepted it follows that pharmacists would be well advised to focus on areas 
where they can demonstrably contribute the greatest possible health gains and net 
financial savings. These can broadly be divided into three main categories:  
 Advising and treating patients/customers with common (minor/uncomplicated) 
ailments, and reducing individual and community-wide disease risks. There is 
evidence that the largest area in which errors occur is medicines taking (Garfield et 
al., 2009). But looking initially beyond this, pharmacists and their community 
pharmacy teams already diagnose common ‘minor’ ailments and assist patients in 
the treatment of chronic diseases. Part of this role is reassurance (Harding and 
Taylor, 1997). But role extensions have in this context recently been supported by a 
strategy aimed at making effective medicines (ranging from chloramphenicol for 
conjunctivitis to tamsulosin for prostatic hyperplasia) more easily available to 
patients via pharmacies (Aronson, 2004). Historically, both self purchased and NHS 
funded pharmacy and GSL medicines have been supplied for acute self limiting 
‘minor’ conditions such as ‘athlete’s foot’, and for the relief of symptoms such as 
pain or nasal congestion. But they are also of potential relevance in common 
chronic disease or related risk management contexts, such as the prevention and 
control of vascular diseases via blood pressure reduction. 
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Problems such as smoking, obesity and excessive alcohol use will also continue to 
require interventions designed to influence behaviour, supported as and when 
possible by the supply of pharmaceutical products. Although there has been a 
degree of (medically led) controversy surrounding steps such as the licensing of 
chloramphenicol for sale as a Pharmacy medicine, the available evidence suggests 
that (even if sustained monitoring is required) public health has benefited as a 
result of improved community pharmacy facilitated access (Walker and Hinchcliffe, 
2010). 
 
 Supporting the prescribing and effective use of therapeutics by clinicians. As 
average life expectancy increases beyond eight decades, further (healthy) survival 
improvement is likely to demand the informed, early, use of effective medicines 
and an increasing use of targeted interventions based on genetically mediated 
health risks. The use of relevant technologies is likely to expand out from hospitals 
into primary care settings, and to create in the community setting more need for 
clinical pharmacy and allied services similar to those pioneered in UK hospitals 
(Aronson, 2006). Arguably, clinical pharmacologists could provide this service. Yet 
the capacity available in this speciality is limited.  
By contrast, community pharmacists appear to be relatively well placed to build on 
their existing roles in areas such as identifying drug contra-indications and potential 
interactions, and in future pro-actively supporting the development of more 
‘personalised’ patterns of pharmaceutical therapy. But questions remain as to the 
extent to which the co-location of pharmacy, medical and nursing labour will be 
required to facilitate optimal progress.  
 
 The oversight/‘quality management’ of broadly defined medicines supply, to 
ensure that patients have safe and reliable access to the treatments they need. 
This became regarded as the central role of pharmacy in ‘developed countries’ 
during the era after medicines manufacturing shifted to industry, and many 
medicines became ‘prescription only’. It is still central to pharmacy practice in 
countries like the UK. The findings reported in this thesis show that this is the role 
that currently dominates the time of community pharmacists (chapter 2). Through 
the use of automation, communications technology and dedicated staff, 
pharmacists may in future be able use their knowledge and skills to not only 
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provide better ‘oversight’ of drug supply and further minimise dispensing errors 
and unwanted events of all sorts, but to extend their role beyond medicines 
management into optimising patient support and therapeutic choices. It is 
reasonable to conclude that further (cost effective) improvements at this level of 
pharmaceutical care should be possible. However, against this it might be asked 
why significant problems in relation to medicines use appear to remain, and 
whether or not there is evidence that merely increasing ‘the treatment as 
previously administered’ (i.e. investing more rather than less in community 
pharmacy) will in fact enhance outcomes.  
To achieve desired progress, a variety of changes in current community pharmacy working 
practices and financial structures will be needed. The research presented here has 
identified the following possible ‘solutions’, the implementation of which will – as has been 
argued in previous chapters – depend on both external ‘political will’ and internal 
pharmacy commitment and willingness to both invest and accept risk. Potential measures 
include: 
 Reducing the prescription dispensing workload. Original research undertaken as 
part of the work reported earlier in this thesis indicates that reducing the volume 
of dispensing could open the way to the redistribution of pharmacists’ time 
towards other patient care activities. One way of achieving this would be to 
increase prescription durations, and give patients’ greater responsibility for storing 
their own medicines. Arguably, a significant number of ‘chronic disease’ 
prescriptions may in future only need to be dispensed every three months, rather 
than every month. This may entail a rise in the value of individual prescriptions, 
and risk increasing waste. Yet against this it should help to consolidate dispensing 
and allied workloads, not only in pharmacies but also in general practices. 
 
 Supervision regulations can at present be said to be ‘keeping pharmacists bound 
to the dispensing bench’.  There is some evidence that productivity gains could be 
achieved by changing responsibility requirements, de-criminalising dispensing 
errors and making a clearer distinction between the separate issues of personal 
liability and the liability of the pharmacy business.  
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 Making better overall use of the pharmacy team. The changes to regulations 
outlined above could allow pharmacies to utilise more effectively the skills of their 
staff teams. This has been a key theme in the recent Healthy Living Pharmacy (HLP) 
proposals. A re-definition of supervision should permit community pharmacists to 
embrace more effectively the role of leader of their pharmacy healthcare teams. 
Such an approach need not prevent pharmacists from continuing to provide 
dispensing oversight and patient care, but should allow them to play an extended 
part in facilitating and as appropriate managing enhanced pharmacy staff 
contributions to health improvement. 
 
 A managed community pharmacy market, that balances fairly the access and 
service quality demands of consumers against the level of business and allied risk 
to which pharmacy owners and their employees are exposed, is vital for 
maintaining the sustainability of community pharmacy. Deregulating the 
community pharmacy environment to permit free(r) competition is favoured by 
some authorities. But this could result in more pharmacies pursuing a limited 
quantum of public funding, and result in reduced access to pharmaceutical services 
amongst some community groups.  
Current data suggest that increased competition from providers such as 
supermarket pharmacies is undermining the levels of investment made by other 
types of contractor(Bush et al., 2009). Well directed market management 
interventions might check such trends. They could also enable action to ensure that 
pharmacy premises of poorer quality close. This may allow NHS funds to be re-
allocated between remaining (and any required new) pharmacies to improve 
services. Although the enhanced regulation of (NHS) pharmacy premises might be 
robustly opposed by some stakeholders, a planned market consolidation may in 
future represent the most viable way forward. This is especially likely to be so if in 
the longer term ‘austerity conditions’ prevail in the macro-economy. 
 
 Electronic record exchanges. Future healthcare systems will almost inevitably 
enjoy a greater degree of electronic connectivity. Trends in this direction ought to 
present many opportunities for community pharmacists to engage in aspects of 
healthcare provision previously possible only in the general medical practice 
domain. Yet to date progress in this direction has been slow, partly because of the 
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concerns of doctors as represented by stakeholder bodies such as the BMA. One 
possible way forward might be for community pharmacists to seek systematically 
to improve their relationships with local general practices. Closer integration may 
not only support better care across the interface, but will also help to create trust 
between the two professional groups.  
It might be argued that, in theory at least, an extended and better ‘linked in’ 
primary care role for community pharmacy in England could permit pharmacy 
businesses to access sums in excess of the current circa £2bn NHS budget for 
pharmacy services. However, in practice GP business interests are strongly placed 
to resist changes that they may regard as threatening. It is unlikely that ‘organised 
medicine’ could in future block the development of large scale, low cost, dispensing 
facilities capable of further reducing medicines supply outlays. Yet the medical 
profession and its representatives may have more power to promote the 
development of clinical pharmacy within medically controlled settings, rather than 
permitting its further development in community pharmacies. 
 
 Redesigned remuneration structures.   The need to promote better integrated 
working between community pharmacy and other parts of primary health and 
social care, together with a closer alignment of pharmacy business and professional 
incentives, will almost certainly result in a re-engineered payment system for 
contractors. Until recently the NHS rewarded pharmacy businesses for the advice 
and knowledge provided by their staff through permitting income (in part derived 
via discounts and allied mechanisms) acquired from supplying products to underpin 
such activities. There was no clear distinction between the price paid for the 
product and the price paid for the service.  
The new pharmacy contractual framework introduced in 2005 began to create a 
more discernable demarcation line, by establishing a more transparent payment 
matrix for pharmacy services. But as the returns from narrowly defined medicines 
supply are reduced it may well prove difficult for community pharmacists to obtain 
compensatory revenues from the provision of cognitive services, unless more 
positive evidence of their value can be generated (appendix C).  
This is challenging, because the ‘advice’ provided by pharmacists is not a tangible 
‘good’ that can be evaluated in the same way as can supplying a priced box of 
medicine. One of the possible reasons why pharmacists have to date been limited 
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in their ability to capture data relating to the value of their ‘extra-supply’ service 
offers is because of their being primarily concerned with dispensing. But looking 
beyond that there are also substantive questions about what is in fact being 
achieved, and how best contributions to health such as, say, giving the relatives of 
sick children or vulnerable adults the confidence not to go to their GP or local 
hospital A&E can be assessed. 
Future scenarios 
There are a variety of ways that new funding systems could be structured and the delivery 
of innovative forms of pharmaceutical care in the community achieved. In such a complex 
field it is not possible to identify a single most probable way forward.  However, building on 
the above discussion of potential solutions to the problems community pharmacists as 
both ‘businessmen’ and health professionals are now facing, the scenarios suggested below 
outline a range of alternative possibilities as to how progress may be realised.  
1. The list based system 
In this scenario, the current distinction between community pharmacy and general practice 
is maintained. However, pharmacies are remunerated in a similar way to general practice. 
Better functional integration of NHS services helps to ensure that patients are free to 
‘nominate’ their chosen pharmacy. Supply costs are covered in the list prices of medicines 
in ways which incentivise pharmacists to advise prescribers on the most cost effective 
therapies. Patients purchase advice, medicines and other goods and services in the 
pharmacy. But NHS pharmacists also have responsibilities and financial incentives to 
manage patients with long term conditions on their lists. Each community pharmacy acts as 
a coordinating centre for ‘their’ patients for hospital admissions and discharge and 
specialist outreach services. Pharmacists are mainly concerned with assuring optimum 
therapy for individual patients and are rewarded by ‘quality outcome’ payments. A 
significant part of their role in this scenario – the origins of which stem from reforms in 
Scotland and the establishment there of the Chronic Medication Scheme (Community 
Pharmacy Scotland, 2010) – is concerned with the delegated management of diseases 
diagnosed by doctors. This requires close collaboration with local surgeries, which have 
overlapping patient lists. However, a proportion of GPs have expressed concerns that 
pharmacists are undermining medical authority. Examples of substandard therapeutic 
management are on occasions used to try to prevent pharmacists from contributing further 
to ‘medical’ domains of work.  
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2. The healthcare hub  
In this model pharmacies serve as ‘walk-in’ health centres for NHS and private users. 
Funding is in large part based on item of service fees. Pharmacists are encouraged to 
provide support and care to patients on an ad hoc basis, most often in the context of 
treatments for acute ‘minor’ ailments. However, there are also case finding and risk 
management services. Such activities involve the whole pharmacy team. Pharmacists 
remain to a large extent focussed on supply but also use their skills and expertise in training 
staff and supporting them to carry out the majority of interventions. Through strengthened 
links with local authorities pharmacies run ‘disease/health’ awareness campaigns and are 
able to reach a significant proportion of the population due to the high footfall through 
their premises drawn in by their supply and retail services. The development of larger GP 
practices has reduced their accessibility, and helped pharmacies to become healthcare 
hubs within the community. In addition to item of service fees, pharmacies receive 
overhead and allied fixed cost contributions, alongside reduced dispensing incomes. The 
origins of this model can be seen in the ‘healthy living pharmacy’ concept. It is regarded as 
a limited success, although the more retail driven pharmacies struggle to balance a 
healthcare focus with that demanded by the sale of their commercial product lines. 
Further, many members of the public still consider pharmacists to be ‘lower tier’ or ‘partial’ 
professionals. 
3. Traditional model, reduced cost 
In this illustration the funding model for pharmacy businesses remains broadly unchanged, 
and pharmacists’ roles also remain fairly static. Each year the Department of Health 
squeezes the margins permitted to community pharmacies. This leads to an increased 
concentration on the supply side of the market, which is dominated by a few large 
‘vertically integrated’ multiple pharmacies. (This results in a decrease in pharmacists’ 
salaries as they compete for declining employment opportunities.) These large providers 
have adopted a central warehouse based supply model. A relaxation of supervision 
requirements has also allowed them to reduce costs via the creative use of registered 
pharmacy technicians. Small and medium size chains are being driven out of the market, 
although some ‘independents’ survive despite declines in NHS funding for pharmacy 
services. Pharmacies are seen by the public as places to collect medicines and to purchase 
other goods, and are often relatively hard to differentiate from other retail based entities. 
Patients are able to buy and access a wider range of pharmaceutical and diagnostic 
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products and services than was in the past available. But pharmacies are not in the main 
seen as having a ‘serious’ health care role. 
4. The separation of dispensing and primary pharmaceutical care 
In this framework many primary care pharmacists work directly for or with general 
practitioners, or in clinical commissioning groups and allied bodies, to advise on prescribing 
and care for GP referred cases. Dispensing, by contrast, remains located outside 
GP/primary care practices. It is in large part located in ‘very high volume’ community 
pharmacies or centralised dispending units run mainly by technicians, which deliver fully 
assembled prescriptions either directly to service users’ homes or intermediate locations. 
This transition has been aided by the electronic transfer of prescriptions and automated 
processes which allow prescriptions to be dispatched within a matter of minutes. A new 
tier of the workforce, similar to Scandinavian ‘prescriptionists’, has evolved to carry out the 
majority of medicines supply and oversee the sale of GSL medicines. They provide protocol 
based advice on minor ailments. Surviving pharmacy businesses remain profitable due to 
high volumes and low overheads. However, (as in the scenario above) many smaller chains 
and independent pharmacies have been driven out of the market.  
The pharmacist workforce in primary care as a whole has therefore decreased. The great 
majority of those that remain employed have, following in the footsteps of their hospital 
colleagues, adopted an almost entirely ‘clinical’ role. ‘High flying’ established and newly 
qualified pharmacists welcome opportunities to develop their therapeutic and patient 
protection roles, although a number of pharmacy schools have closed and graduates of the 
remainder have had increasingly to seek work outside the health sector. Many patients 
recognise that pharmacists are professionals who are equipped with a knowledge of 
medicine based therapeutics similar or superior to that of many doctors. Yet working in 
relatively large general practices has made them less available to the public than staff 
working in traditional community pharmacies. They normally operate on an appointment 
only or clinic basis. Some more enterprising pharmacists have formed their own ‘primary 
care groups’, and are commissioned to provide pharmaceutical care as a result of 
innovative agreements with local commissioners.  
 
It is envisaged that in all instances pharmacy role developments outlined above will be 
supported by technological developments, albeit that vested interests in primary care may 
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on occasions seek to inhibit their uptake. It is of note, for instance, that the ability of 
hospital pharmacists to innovate and expand their clinical role may paradoxically have been 
related to past shortages of hospital pharmacy manpower and resourcing. This led to the 
expansion of technician numbers that in turn opened the way to pharmacy labour 
reallocations. 
Embracing apparently ‘risky’ innovations might well be key to developing ‘stronger’ future 
practice models. Defining and adopting the latter, should they emerge, will require not only 
educational reform at the undergraduate level, but also educational support for those in 
practice. In this context relevant developments are being proposed by the Modernising 
Pharmacy Careers Programme Board, which aims to support and develop a workforce 
ready to apply its skills and knowledge in the pursuit of public and patient interests. Yet any 
recommendations that this group makes will inevitably take time to have practical effect. 
They are likely (given the duration of the MPharm course) to take at least six years to start 
to impact practice, and a further decade or so to have widespread effects (Smith and 
Darracott, 2011). Even then (failing sufficient political will and public demand to ensure 
that beneficial reforms are effectively implemented) stakeholders active in the pharmacy 
arena seek to moderate the systemic effects of changes in pharmacy education and service 
provision.  
Choosing the Future - Stakeholder Interests 
Many events lie outside the direct control of the populations and institutions that they 
affect. Environment disasters such as earthquakes and floods normally fall into this 
category. Similarly, non-catastrophic but nevertheless mould-breaking events such as new 
scientific discoveries or the introduction of innovative technologies ranging from novel 
medicines to high performance computers can act as exogenous forces, strong enough to 
alter economic and social orders. Hence the discovery and subsequent treatment of 
Helicobacter pylori as a causative agent in peptic ulcer disease markedly decreased the 
demand for gastric surgery, and the need for gastric surgeons. Events outside their control 
limited the need for this professional group. 
In the same way, pharmacists could not even if they had wished to turn back the tides that 
led to the introduction of the industrial pharmaceutical manufacturing processes that 
undermined their historic compounding function. In that sense the pharmacy profession is 
part of a complex social system that is driven by economic, social and technical forces that 
it cannot hope to control. Developments in the pharmaceutical and biomedical sciences, in 
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the diagnosis, prevention and treatment of illness, and in understanding the genetic and 
allied mechanisms pathways underpinning the aetiology of the complex diseases of later 
life, will all influence the future of health care delivery.  
For instance, near-patient monitoring, ‘personalisation’ and more specific targeting of 
medication might in time serve to revolutionise pharmacists’ therapeutic roles in both the 
community and hospital settings. Another example of an exogenous technical factor that is 
important in this context is the rapid and continued advancement in the power of 
automated computerised dispensing systems. These are leading to new ways of 
mechanising the supply of medications.  
However, having acknowledged the above realities, the potential for individual or group 
human agency to influence the course of events should not be ignored. The overall 
direction of travel for community pharmacy (from compounding and unregulated 
medicines supply through to regulated, higher volume, finished product supply in the first 
half century of the NHS’ existence and now towards commodity or near commodity price 
supply balanced by an extended clinical function) is almost certainly set. Yet those working 
in pharmaceutical sector should still be able to influence many specific facets of this 
transition. 
In this context some of the most difficult aspects of seeking to predict how in practice the 
future will unfold relate to balancing the different viewpoints and perspectives of those 
involved in the ongoing change process. This in a large part involves, as the analysis offered 
in chapter 5 indicates, understanding the capacity and willingness of pharmacists 
themselves, individually and collectively, to adapt to their evolving environment in a timely 
way. The summary overview of stakeholders’ perspectives provided below reflects this fact. 
Pharmacy Business Owners  
The community pharmacy business model has provided the financial framework within 
which community pharmacy as a profession has developed. As indicated above, it has 
throughout the lifetime of the NHS had medicines supply at its heart. Indeed, even in the 
days of manufacturing in chemist shops this was the case. The difference was that in the 
period up to World War II pharmacists were still relatively free to supply any medicine to 
any customer as they judged appropriate. Today, the current multi-billion pound 
contractual framework is built upon the supply of industrially manufactured medicines. 
Pharmacy business owners have consequently had an interest in keeping the margins to be 
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made via medicines supply as high as possibly. On the service purchasing side negotiators 
have had a corresponding interest in reducing dispensing costs, although given the political 
sensitivities surrounding health care they too may be described as ‘inherently risk averse’. 
The research undertaken for this thesis has found that, unsurprisingly, the pharmacy 
business community has been reluctant to move away from its medicines supply centred 
financial base without guarantees that a more ‘health service’ oriented approach would 
provide a similarly profitable and sustainable income stream. Pharmacy contractors, who 
have tended to dominate the profession’s representative bodies, have invested in the 
current community pharmacy infrastructure. Unless faced with the prospect of imminent 
losses, there will be little reason (whatever their size or structure) for them to accept 
greater perceived risk of any sort without a counter-balancing guarantee of a satisfactory 
return on capital invested.  
Given the need to maintain medicines supply continuity, the purchaser side response to 
this is likely to involve a gradual reduction of dispensing and allied fees. That is, a situation 
akin to scenario 3 (traditional model, reduced cost) above will develop, should the logic of 
traditional business interests prevail. This could mean that employee and ‘small owner’ 
community pharmacists who remain ‘in business’ will become trapped in a supply role 
close to that of a bureaucratically directed technician, rather than that of an autonomous 
health care professional. 
However, ‘enlightened’ pharmacy owners may also see long term advantages in moving 
towards scenarios 1 (the list based system) and 2 (healthcare hub), or relevant hybrids 
thereof. At the same time if actors outside pharmacy respond negatively to attempts to 
(even at reduced cost) preserve the traditional business model, this could result in an 
accelerated precipitation of scenario 4 (the separation of dispensing and primary 
pharmaceutical care). 
‘Pharmacist practitioners’ 
Many practicing community pharmacists currently report feeling burdened with the 
volume of dispensing they undertake (appendix C). Locum and other staff pharmacists 
value their employment. Yet both qualitative and quantitative analyses indicate that they 
typically believe that their profession has failed to achieve that status that it (and they) 
deserves, and that they do not have the opportunities required to use their professional 
skills to the full. They therefore accept the ‘under-utilised’ label. 
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There is also evidence that the ‘new breed’ of pharmacist whose mindsets are presently 
being formed in higher education institutions is more clinically orientated than their 
predecessors. Yet the academics responsible for their education tend to disagree between 
themselves as to whether or not pharmacy students are destined to become scientists, 
clinicians or both (Jesson et al., 2006). This is perhaps in part because many have too little 
insight into current health care demands and priorities of the wider NHS. Students 
recognise this contradiction, the deficient contextualisation of their knowledge, and the 
questions surrounding their future contributions (Jesson et al., 2006). This ‘inconsistent 
socialisation’ within schools of pharmacy has led to ‘disillusionment and disenchantment’, 
associated with a sense of role ambiguity (Chalmers et al., 1995).  
The conclusion drawn here is that many existing and potential new pharmacy practitioners 
desire a more fulfilling role, and are willing to accept a greater degree of collective risk than 
pharmacy business owners would find acceptable in order to achieve it. All other things 
remaining constant, their preferred direction of travel will be towards scenarios 1, 2 or 4. 
Doctors and other GP practice or health centre based primary health care providers  
In the community setting, pharmacists are in a sense reliant on the medical profession to 
prescribe. In power and dependency terms medical dominance has put pharmacy in a 
subordinate position, a situation which is at times positively reinforced by members of the 
profession themselves (Edmunds and Calnan, 2001b). Even with limited pharmacist 
involvement in CCGs, the NHS reforms due to be formally introduced in April 2013 appear 
unlikely to reduce the disparities in status between pharmacists and GPs, failing 
intervention by the NHS CB and/or the local authority based Health and Wellbeing Boards. 
The findings offered in chapter five indicate that any significant renegotiation of 
pharmacists’ roles within primary care will need support from other providers – most 
importantly GPs – in order to be successfully introduced. Yet in hospitals, the initial 
development of clinical pharmacist roles was not infrequently met with hostility by medical 
practitioners. The same appears often to be so in the community setting. Despite individual 
examples of constructive joint working pharmacists have historically had relatively weak 
relationships with the rest of the ‘primary healthcare team’ (Erwin et al., 1996; Eng, 1987; 
Ellis, 1992; March et al., 1999; Bond, 2000). Managing this interface will become even more 
important if pharmacists are to move towards a role such as that described above as 
scenario 1 (the list based community pharmacy practice system option), and there is a 
significant risk this will be seen as an encroachment on the economic interests and core 
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professional activities of the medical profession (Eaton and Webb, 1979; Freidson, 1970; 
Edmunds and Calnan, 2001b).  
Members of the medical profession working in primary care and elsewhere hold significant 
managerial, social and political power. As such they are able to exert considerable pressure 
on community pharmacy, and are in a position to strongly influence its future 
development. The available data suggests that GP interests may cause them to tend to 
favour a scenario 4 type (supply and clinical role separation) future.  However, even if this is 
not uniformly the case, pharmacists’ abilities to constructively shape their relationships 
with the medical profession will without question be important in relation to the 
continuing development of their profession and the extent to which they are genuinely 
able to contribute to enhanced public health. 
NHS planners and Department of Health officials 
NHS bureaucrats with responsibilities for managing pharmacy services and influencing their 
roles are required to locate pharmacy within the context of the health service as a whole 
and its users’ overall interests. However, the latter are not always easy to define. One 
conclusion offered here is that health sector officials’ views often appear to be influenced 
by the extent to which they personally identify with pharmacy or with other stakeholder 
groups.  
Attitudes may also be influenced by (as suggested above) the degree to which seeking 
change in any given area is (even if potentially beneficial (or damaging) in the long term) 
linked with immediate political costs and benefits. As such, the maintenance of a secure 
drug supply and the avoidance of conflict and/or embarrassment to Ministers may be 
particularly important to members of this community. Therefore they tend to favour a 
gradualist evolutionary approach across a range of alternative scenarios, until or unless 
they receive unequivocal political direction. That is, they will tend to be risk averse, which 
will increase the likelihood of ‘pathway dependence’ and exisiting trends towards scenario 
4. 
Politicians and the determinants of ‘political will’ 
Politicians should act to protect public interests in an informed and fair manner, although 
in electoral terms they need to be mindful of the prejudices and preferences of ‘their’ 
voters. The selection and timing of policy interventions is often therefore a matter of 
judgement, which needs to be consistent with not only temporal considerations (for 
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example, introducing higher charges or service withdrawals just before elections could well 
be ill-advised) but other, sometimes ‘softer’, perceptions.  For instance, in some 
communities investing new funds in private community pharmacy businesses may be 
regarded as inherently less desirable than placing resources in what may be seen as 
‘publicly owned’ GP practices or NHS hospitals.  
Politicians also need to balance competing legitimate interest issues, such as on the one 
hand supporting an innovative pharmaceutical industry and on the other minimising drug 
costs. In the case of community pharmacy it is unlikely that any political group would want 
to be seen as responsible for a sudden wave of closures of familiar community assets. 
Politicians might rather wish to be seen to be supporting self care and more convenient 
access to care, although at the same time few would want to risk being exposed to charges 
of undermining safety or confidentiality made by medical institutions.     
Public and patient interests  
The consumers of community pharmacy services are the public, including both healthy 
people and those prepared to accept the label of ‘patient’. The research reported here did 
not include a quantitative investigation of current perceptions of how members of either 
group wish to receive pharmaceutical care, or the extent to which – for instance – they 
would be happy for community pharmacists to (with appropriate permissions) to have 
greater access to electronic health records. Experience in, for example, areas such as 
smoking cessation suggests that attitudes towards issues such as whether or not it is 
acceptable for community pharmacists to offer clinical services are relatively plastic, and 
can be changed by positive or negative experiences. But the key point to emphasise here is 
that consumer sovereignty is arguably as important a concept in any professional arena as 
it is for democratic market economies as a whole. 
In normal contexts markets ‘work’ by permitting incremental change, and the step by step 
movement of funds in the direction of preferred options and away from those judged by 
customers to provide poorer value. Progress of this type is difficult to achieve in all 
professionally led, publicly funded, health care systems. But in looking to the future it may 
be suggested that wherever possible service users should be able to make choices between 
different types of primary care provider, as well as options to select alternative providers of 
the same type. Otherwise even if members of the public were potentially to desire 
developments such as those summarised as scenarios 1 or 2 above it may, despite modern 
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approaches to service commissioning, be very difficult for them to be dynamically involved 
in expressing their preference. 
The Future – Towards a ‘professional business’ model?  
The Kingdon model of the policy process (described in chapter 4), suggests that it is not 
simply the availability of a solution to a problem that results in political change. Political will 
and external support is required for any given policy intervention to succeed. Substantive 
change normally needs ‘policy entrepreneurs’ to couple the multiple streams of the model 
together. The view taken here is that the policy cadre in pharmacy would be well advised to 
seek to develop a stronger internal consensus as to which way forward is most desirable for 
the profession, while at the same time seeking to strengthen external support for 
pharmacy development. It is also important to remember that in any evolutionary process 
the changing environment will be the ultimate arbiter of what is fit for purpose, rather than 
the preferences of existing populations. 
At present the fractured discourse between pharmacy owners and pharmacist employees 
appears to be creating a real obstruction to delivering professional progress. This has been 
exacerbated by internal pharmacy business rivalries (most notably between ‘multiples’ and 
‘independents’, as well as pharmacist employers and pharmacist employees) that have 
further inhibited the creation of a united strategic view in ways that are quite different 
from the internal dynamics influencing the development of, for instance, the medical and 
nursing professions. For pharmacy itself to influence its future evolution more effectively 
than presently seems to be the case arguably necessitates a level of leadership and 
strategic thinking that at present seems lacking within the policy cadre of the profession.  
Wider political support for relevant policy proposals is also needed at both the macro level, 
from key decision makers, and the micro levels. Those most influential in the latter context 
include local general practitioners and other primary healthcare providers, managers and 
commissioners. In practice, it seems inevitable that support from the medical profession 
will be key to influencing the direction that community pharmacy takes. Aside from 
competitive concerns this will only be forthcoming in situations where there is substantive 
evidence that community pharmacy providers offer a comparable or better quality service 
than the available alternatives. This will require the demonstration of ‘true’ systematic  
health gains beyond just the avoidance of low-probability high-risk events that the current 
supply function may or may not deliver. Without such evidence it seems almost certain that 
current NHS community pharmacy income streams will continue be squeezed in England. If 
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all other things remaining broadly constant then this will promote trends like those 
suggested in scenario 3.  
Simplistic policies intended to promote financial savings might well, accidentally or 
otherwise, undermine the capacity of community pharmacy business to go on adapting to 
meet future health needs, and address the issues at the heart of what can be termed 
‘medicines optimisation’. If and where this proves to be the case it will not only damage the 
profession’s interests. It is also likely over time to generate added costs and lost health 
related opportunity for the community as a whole by blocking desirable lines of evolution. 
Likewise if short term business pressures are permitted to cause stagnation and prevent 
change similar outcomes will result. 
As already argued, there is in reality no certainty as to which one of the scenarios outlined 
above is most likely to dominate in 2020s and beyond. Yet having noted this there will 
almost certainly continue to be at the heart of the community pharmacy role a 
combination of assuring the availability of good quality (and good value) medicines and 
working with doctors, nurses and the public to apply knowledge about how to provide and 
use them to best effect. Against this broad understanding, a path dependency perspective 
(see chapter 1) suggests that the line of development indicated in scenario 4 can most 
reasonably be taken to represent the probable future model for community pharmacy at 
this point in time.  This ‘separation of dispensing (supply business) and primary 
pharmaceutical care (professional)’ scenario has an increased chance of becoming a reality 
as a result of the external support for such an approach from those outside the profession 
(chapter 5) and the weight of disruptive technological advances that may already be taken 
to be catalysing change in this direction. 
However, this likely endpoint may not in fact be the most desirable one to pursue, either 
from a professional or a public interest centred perspective. It is in this context worth 
noting that progress in all professional fields in part reflects the political and economic 
attempts of given groups of skilled individuals to attain and maintain control and autonomy 
in specific areas of activity, and to protect territory in the labour market in order to secure 
income and favourable working conditions. The future outcomes of such struggles have the 
potential to play a large part in defining the scale and nature of community pharmacy in 
the twenty first century, over and above past determinants. 
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It can be reasonably argued that the most desirable way forward would be for pharmacy 
and pharmacists to put (and be seen to put) the public’s (health) concerns and best 
interests at the top of their agenda. For some observers this is in essence what medical 
doctors like GPs have done in countries such as the UK, in ways which could be said to 
locate commercial aspects of their roles within a robust outer professional coating. It 
seems probable that if (community) pharmacy could move more in this direction it would 
as a group become better positioned to gain greater public and political support for policies 
that would enable it to make a significantly extended contribution to healthcare, and 
secondarily assure the income streams needed to sustain appropriate ‘business’ models.  
Freidson’s (2001) work and related studies suggest that there are three logics relating to 
the organisation of complex functions in society – bureaucratic (politically led) 
managerialism, consumerism (and market led ‘sectional managerialism’), and 
professionalism. The latter rests upon traditions of individual ‘virtue’ and autonomous 
decision making based upon the complex, scientifically supported knowledge. This is 
intended to deliver good quality services to clients in ways which put their needs first, in 
exchange for State granted protections.  
That is to say, professionals are legally provided with forms of market shelter that modify 
competitive forces and are in return required to put each of their client’s interests above 
their own financial and managerially directed concerns. However, in the modern world 
professionals are increasing required to work in complex managerially controlled settings, 
driven by ‘consumerism’ and political decisions.  
This has led to disputes and uncertainties in areas like health care that are difficult to 
resolve. But for the purposes of this thesis the ultimate judgment of Freidson’s approach is 
arguably that professionals can legitimately operate businesses with a commercial interest 
so long as the values of such an enterprise put the client’s interests over and above those 
of the business. This implies that ‘ideal type’ community pharmacies and pharmacists are 
right to be concerned with keeping the income streams and environmental business 
conditions required to maintain their viability provided that they in return deliver social 
‘good’. The challenge for all such businesses, whether corporately or individually owned, is 
to be able to show that they are governed in ways that ensure that professional values are 
not only respected but are genuinely central to their cultures and actions. 
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The current trends in community pharmacy practice seem to indicate a weakening of the 
‘professionalism logic’. To an extent the economic market shelter provided by 
professionalism and the existence of the NHS may have been abused for financial gain. 
Pharmacists themselves must accept responsibility for their own actions, albeit that such 
trends can also be linked to inadequate national policies that on occasions may have failed 
to acknowledge and support the role of professionalism in maintaining all aspects of health 
care quality, including the provision of pharmaceutical care, as services adapt to changing 
needs and circumstances. In this context sociologists have described the proletariasation of 
the profession, as pharmacists move away from the autonomy of self employment towards 
salaried labour (Hassell, 2004); the de-professionalisation of pharmacists as a result of loss 
of professional characteristics, in particular autonomous decision making (Harding and 
Taylor, 1997); and increasing corporatisation that has turned the pharmacy market from a 
healthcare providers into a profit maximising corporation (Bush et al., 2009).  
The conclusion drawn here is that rather than considering concepts such as the 
professional as opposed to the business aspects of community pharmacy as separate 
phenomena, as has in places been the case earlier in this thesis, the Freidsonian logics 
should instead be approached, understood and developed in an integrated manner in 
order to fundamentally understand the challenges facing community pharmacists, and the 
best way forward for community pharmacy as a whole.  
The maintenance of a credible and sustainable market shelter (that is, conditions in which 
fees are not driven down to a basic commodity level which precludes anything but the 
provision of minimal services in the community pharmacy setting) is heavily dependent on 
being able to demonstrate and  guarantee a level of quality that a market based approach 
could not support. At present the necessary evidence is lacking, and many of the findings 
contained in this thesis have disappointing implications. But if pharmacies and pharmacists 
could embrace a rigorously defined professional approach to their overall working practices 
and so become professional-value-driven businesses there remains reason to hope that the 
community pharmacy model of the future could reach more towards the ‘scenario 1 and 2’ 
end of the spectrum. This will entail going above and beyond basic legal frameworks, and 
creating corporate environments that expresses professionalism throughout all aspects of 
their activities. 
This thesis does not seek to provide a reply to the question ‘how can this be achieved in 
practice?’. But it does at least identify the fact that answering, successfully or otherwise, is 
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a task that will be central to the profession’s future. Taking the long view, practitioners of 
pharmacy and their antecedents have, despite the prophecies of professional demise 
outlined at the beginning of this thesis, continually adapted and transformed over the last 
millennium to keep pace with demographic, epidemiological, technical and social 
developments. The history of pharmacy tells of a profession that has acted with resilience 
to threats and embraced opportunities. But it will need to continue in this vein in order to 
resist the paths that point towards a ‘weak’ pharmacy model. Perhaps paradoxically, the 
view offered here is that in the final analysis (community) pharmacy’s continuing survival 
will ultimately depend on its practitioners’ abilities to recognise and demonstrate to other 
stakeholders in health that what matters most to them is not their own profession, or even 
the medicines at its centre. It is rather preserving the lives and optimising the wellbeing of 
the people and populations that professional status grants them the privilege to serve. 
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Limitations of this thesis 
In retrospect the biggest limitation of the thesis presented here is the broad and wide 
reaching nature of the core research question that this research has sought to address. In 
reality there is no single way in which the future can be accurately predicted. The advent of 
the supercomputer and endless databases has not made the dream of long term prediction 
any closer than that of our forbearers. However, this does not mean that one cannot think 
systematically about the future and try to make some sense of the trends, developing 
issues and emerging technologies. 
Early preparatory work for this program of research explored the benefits and limitations 
of futurology and foresight studies. However the relative methodological weakness of 
these approaches precipitated an alternative methodological approach. The end result of 
which has been a series of distinct research studies that have followed a theme to 
undercover the trends underlying community pharmacy and allied primary healthcare 
practice, and created original knowledge upon which further practice research can be built. 
The strength of the conclusion of any research is limited by the quality of the data that is 
analysed. In the case of policy analysis the target is constantly moving and evolving within 
the fluidity of social change and the dynamic relationships of the social world. For example 
much of the initial research presented here commenced during a period in which the 
coalition government were preparing unprecedented changes to the face of primary 
healthcare services in England. It could even be suggested that the role structure of 
community pharmacy in such turbulence represents a ‘wicked problem’, and therefore 
limits the applicability of the research beyond a particular point in time. 
For this reason the economic and strategic analyses provided in chapters 3 and 6 are 
probably the weakest part of the work presented here. The lack of robust and transparent 
data on which to build economic models of community practice prevented hard 
conclusions from being drawn about the cost effectiveness of the different scenarios of 
future practice presented earlier in this chapter. Therefore it is difficult to economically 
ascertain the relative advantages (and disadvantages) of the models of practice proposed 
above. However the qualitative research which has reported overarching sociologically 
trends and beliefs about practice provides a value insight into the potential of future 
practice, which in many respects may be of more value than narrowly defined economic 
analyses.  
 
 
292 
Elsewhere in the thesis the methods of research have been documented transparently 
alongside reasons that justify their use and appropriateness. No scientific method, 
especially when used in the ‘real world’ can be free from methodological weakness at some 
level, but efforts have been taken to limit these confounding factors. The background of 
the author as a pharmacist is one such factor that requires acknowledgement. However, 
where weaknesses exist they have been documented and efforts to reduce them recorded. 
The results presented here have focused on the English community pharmacy setting. 
While many of the challenges and trends observed and recorded here are likely to be 
experienced by pharmacies and pharmacists around the world, the generalisability of these 
findings beyond the English context should not be overstated. The findings of this thesis 
have helped contribute to a paper written for the International Pharmacy Federation (FIP) 
which sets out the global case for change in pharmacy practice (Thum-Bonanno et al., 
2012) as other actors across the world are likely to relate to the underlying trends observed 
here. 
Future Research 
The wide reaching nature of the work presented in this thesis, which covers the disciplines 
of social science, political science, economics and pharmacy practice exposes many 
possible avenues for future research. In many ways, this section offers a critique of the 
areas where the whole of pharmacy practice discipline requires further development.  
Economic Analysis of Pharmaceutical Care - In the literature review and its subsequent 
analysis it was evident that economically led data to support the development of the 
pharmacy profession is lacking. The policy process is increasingly driven by economic 
decisions and yet pharmacy lacks robust economic literature to support it services and 
outputs (see limitations section above). Therefore the creation of a credible economic basis 
for current community pharmacy activities would help decision makers to settle on future 
courses of action and will provide a counterfactual that can be used for the evaluation of 
any future interventions into primary care. For example, it is known anecdotally that 
pharmacies help to create social cohesion in a given locality, but the quantitative value of 
this cohesion to the local population is unknown (appendix C). 
Pharmacy Workforce - Understanding and interpreting the needs and the basis of the 
pharmacy workforce are integral to any future developments as these practitioners will be 
tasked with implementing political decision at the coal face. The maintenance of a census 
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that seeks to understand the needs of the community pharmacy workforce, both 
pharmacists and pharmacy staff is essential. In particular there is a lack of even basic 
descriptive data on the numbers, needs and desires of community pharmacy counter 
assistants that at present plays a key role in the delivery of pharmaceutical care. 
The management and processing of repeat prescribing systems - The repeat prescribing of 
medicines in system terms should theoretically be very simple. However in reality there are 
a vast number of processes that patients must follow in order to access their repeat 
medications. Understanding patients needs and reengineering this system to relieve 
general practice and pharmacy workloads, as well as improving patient experience is a key 
area in which future health service research should focus. The evidence presented in this 
thesis suggests that 28 day prescribing polices require review, but lacks enough data to 
form a solid conclusion. Embracing a system wide view of prescribing and repeat supply 
systems on all stakeholders across primary care is important if polices are to change.  
System Wide Modelling - Models are by their nature a simplification of reality and 
therefore they are subject to the flaws that simplification provides. The models of 
community pharmacy used throughout this thesis can be further strengthened and 
improved by adding further layers of complication that were not possible given the 
economic and time constraints of this thesis. Such data will be a useful base for the 
development of future funding models of community pharmacy practice.  
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Chapter and Thesis Conclusion 
“I claim not to have controlled events, but confess plainly that events have controlled 
me” 
Abraham Lincoln 
Most of the future lies outside the direct control of the populations and institutions they 
effect. Pharmacy as a business and as a profession is no different. Yet, the potential for 
groups to influence the course of history should not be ignored. This thesis has explored 
the question ‘how are business and professional practice models for community 
pharmacy in England in the ten to twenty years time likely to be structured?’ It has 
examined aspects of how community pharmacists and community pharmacy businesses 
might seek positively to influence their future direction of travel.  The research presented 
above has scrutinized how members of the professional group, known as community 
pharmacists, might seek to influence the advancement of public interest orientated 
healthcare models of the future. This has been achieved through understanding the 
perspectives, beliefs and agency positions of the different stakeholders that are involved in 
the ongoing process of change. To a large extent this has involved understanding the 
capacity and willingness of community pharmacists and community pharmacy businesses 
to individually and collectively adapt to their evolving environment.  
For community pharmacy, the transition from compounding and unregulated medicines 
supply at the beginning of the last century, through to the supply of regulated and 
automated high-volume finished product commodity supply, has destabilised their base 
and created a need for community pharmacy to adapt and change. Such transition has 
been accompanied by a changing societal relationship with professional groups, as the 
government and wider public begin to question the benefits of providing professions with 
State granted protections. These factors have undermined the pharmacy professions’ 
economic and social standing and created a need for further change. 
Policy makers have suggested that pharmacists are ‘underutilised’ (as distinct from 
‘underworked’) and should contribute more to health improvement than their role 
currently permits. Yet change has been slow. The fixed interval work sampling study carried 
out here established that community pharmacists’ continue to spend over half of their time 
on basic dispensing and supply activities.  
 
 
295 
One significant inhibitory factor has been the increase in prescription volumes seen since 
the 1950s, coupled with a payment structure that has incentivised pharmacy contractors to 
focus on dispensing. There are many factors that have led to the increase in prescription 
volume. But the research findings contained in this thesis indicates that shortening of 
prescription durations has been a contributing factor. The ostensible reason for this trend 
has been medicines waste reduction, but its overall cost may not always have been 
balanced by the benefits gained. Increasing prescription lengths may allow pharmacists to 
redistribute their time towards those patient care activities that are deemed to better 
‘utilise’ their skills. Further regulatory changes such as the relaxation of supervision 
regulations and making a clearer distinction between the separate issues of personal 
liability and the liability of the pharmacy business may also provide a further avenue down 
which practice change can be advanced. 
The path down which community pharmacy drives will be the result of a variety of political 
negotiations between different stakeholder groups. It is only when the problem, solution 
and political will of the policy system combine that politically expedient change can take 
place. The literature on the implementation of Medicine Use Reviews suggests that 
community pharmacist led service developments have been affected by seven factors, 
namely: the pharmacy environment; financial drivers; accreditation and training issues; 
patient recruitment problems; lack of external support; documentation/evidence 
deficiencies; and practitioner motivation. Using the Kingdon model of the policy process, 
qualitative interviews with ‘policy leaders’ provided insight into how these factors have 
influenced policy and its implementation in contexts like that of the New Medicines 
Service. The latter was, for instance, delayed by inconsistent external support and political 
will. 
Re-specifying the twenty first century role requirements of pharmaceutically qualified 
professionals working in the community setting is the first step in establishing change 
within the community pharmacy sector. However, pharmacists must genuinely be willing to 
adapt and change away from their current risk averse medicines supply management role 
bounded by standard protocols and procedures, to instead use their existing (and as 
necessary new) skills to meet the evolving needs of the societies they serve. In embracing 
this change the profession needs to consider the use of other members of the pharmacy 
team as well as their wider relationships with other actors in primary care.  
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No profession or business can safely regard its long term survival as assured.  Managing the 
interface between the professional priorities and the need for economic income is a 
challenge for all professional groups. The current remuneration structure in community 
pharmacy relies heavily on the supply of prescription medicines. Integrated working 
between community pharmacy and other parts of the healthcare (through for example the 
introduction of electronic record exchanges), together will closer alignment of pharmacy 
business and professional incentives, will almost certainly result in a re-engineered 
payment system for contractors. Yet any remuneration structure must be managed against 
the perceived and actual conflicts between the commercial imperatives underlying 
pharmacy as a business and the values that community pharmacists aspire to have as 
professionals. This latter represents a significant barrier to overall service improvement.  
Only the future will reveal the ‘true’ answer to the question that overarches this thesis. 
However, history indicates that to continue being relevant in the future and to ensure their 
long term survival, community pharmacists in England must offer timely and economic 
ways of solving contemporary health problems and go on attracting public and political 
support.  Future success will ultimately depend on the professions ability to recognise and 
publicly communicate that what matters most to them is preserving the lives and 
optimising the wellbeing of the people and populations they serve. 
If this professional grouping chooses to operate in the wider public interest then they have 
the potential to undergo a ‘re-professionalised’ strategy. Such a strategy would require 
them to reengineer their offering in such a way that they are seen to represent a key tier of 
easily accessible, public interest focused, primary healthcare where pharmacists’ role in 
society would be concerned with preserving the lives and optimising the well being of the 
population.  
The transition towards an integrated business model driven by professional values requires 
both stronger internal leadership and robust external stakeholder support. A path 
dependency approach to the current situation suggests that without these medicines 
supply will probably split from the provision of clinical pharmacy in the community setting, 
leaving community pharmacy as a weak ‘commodity cost’ service provider.  
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Appendix A - The Nature of Community 
Pharmacy Work 
 
It was shown in chapter 2 that the majority of pharmacists’ time was spent on ‘traditional’ 
dispensing activities, which have been described as an ‘underutilisation’ of pharmacists’ 
time (chapter 1). Yet, while the proportion of time spent on activities has not markedly 
changed, the productivity within each of the work categories has increased, most notably 
the increase in number of prescription items dispensed. 
In order to understand the changing nature of the community pharmacy workload, the 
processes within the community pharmacy require mapping against each of these work 
categories. Using the framework developed for the work sampling study, the work activities 
of pharmacies and pharmacists were narrowed down to discover the driving factors 
associated with workload (table 3.1) in each of these categories. This analysis provided 
workload groups in the community pharmacy setting, namely: safety workload; counselling 
workload; self care workload; services workload; administrative and regulatory workload; 
training workload; business workload; personal time; and prescription medicines supply 
workload 
Table A.1 – Workload Factors  
Activity Workload Classification 
1. Prescription monitoring and appropriateness  Safety Workload 
2 Assembly and labelling of products  Prescription Medicines Supply Workload 
3  Endorsing prescriptions and clerical health related work  Administrative & Regulatory Workload 
4 Counselling patients on prescribed medicines Counselling Workload 
5 Non-prescription medicines counselling/responding to 
symptoms 
Self Care Workload 
6  Professional encounter with non-patients Safety Workload 
7 Health Related Communication Safety Workload 
8 Provision of Advanced Services Services Workload 
9 Provision of Enhanced or other NHS Services Services Workload 
10 Provision of Private Enhanced Services Services Workload 
11  Provision of services to homes Services Workload 
12 Inventory and Stock Control Prescription Medicines Supply Workload 
13  Staff training and Education Training Workload 
14 Housekeeping Administrative & Regulatory Workload 
15 Sales Transactions Business Sales Workload 
16 Money and Managerial Administration Administrative Workload 
17  Rest Waiting and Personal time Personal Time 
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18 Non-professional encounters Self Care Workload  
 
Each of these workload categories is considered in turn to reveal how the nature of 
pharmacists’ workload has changed, and to reveal any anticipated trends in future 
workload.  
Prescription Safety workload 
Dispensing is a multistage process, where upon presentation of a prescription (which is 
effectively an invoice). Medicines are prepared and supplied to the patient. This includes 
checking the prescription for errors and assessing its suitability in terms of interactions, 
contraindications and possible adverse drug reactions; selecting the correct product; 
appropriately labelling and recording the prescription supply; checking the patients 
exemption status; providing appropriate advice on medication use to the patient; and 
when warranted discussing medication matters with prescribers. One of the key 
responsibilities of community pharmacists is to maintain safe supply of medicines by 
reducing medical errors. The development of computer printed prescriptions helped to 
reduce the number of typographical errors made by general practitioners, although others 
persist. Previous estimates suggest that around 7.5 per cent of prescriptions in general 
practice contain an error (Shah et al., 2001). However, more recently the PRACtICE study, 
which examined 6,048 unique prescription items for 1,777 patients, found that 1 in 20 
prescription items contained either a prescribing or monitoring error, affecting 1 in 8 
patients. Although the majority of errors were judged to be either of ‘mild’ or ‘moderate’ 
severity, 1 in 550 of all prescription items contained an error judged to be ‘severe’. 
Therefore despite efforts to reduce the burden of prescribing errors, pharmacists are 
required to remain vigilant.  
While prescribing errors remain a challenge, the onus on pharmacists to check and 
maintain the quality of medical products in the community pharmacy has reduced due to 
improved regulatory standards. Despite improvements in supply chain security, the MHRA 
continues to issue regular recalls of medicinal products. In the past five years there were at 
least three recalls due to suspected counterfeit medicines in the supply chain. The falsified 
medicines directive (2011/62/EU) introduces a mandatory pan European safety feature for 
medicines at risk of falsification to tackle this threat. While this legislation proposes a 
technology-based safety feature, which ideally will allow the pharmacist to automatically 
read the batch number, serial number and expiry date of a product, it will inevitably create 
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changes in the workload faced by pharmacists (Davies and Taylor, 2009).  The requirement 
to capture a unique code within the pharmacy will create an incentive to automate 
pharmacy processes. But until this happens, pharmacy staff will be burdened with 
additional processing steps. 
The personal regulatory responsibility for ensuring the safe supply of products by the 
pharmacist has also increased. In 2009, the pharmacist Elizabeth Lee was given a custodial 
sentence at the Old Bailey for a dispensing error under section 85.5 of the 1968 Medicines 
Act. Despite the court of appeal overturning the verdict, the media attention drove many 
pharmacists towards more defensive practice due to fears of imprisonment.  Regulatory 
reform of the Medicines Act is anticipated to address pharmacist concerns. However, until 
this is enacted, pharmacists will be overly risk averse and therefore less willing to delegate 
tasks to other staff. Indeed, they will have additional tasks in checking the activities of 
others in the pharmacy for which they are liable.   
Counselling workload 
The increase in prescription volume correlates with an increase in the number of patients 
requiring counselling and support to use of their medicines. Theoretically, pharmacists 
should provide advice to support all patients, seeking to ensure that medical directions are 
understood (Puspitasari et al., 2009).  
Since the nineties, a new paradigm of pharmacists’ advice has been to support patient 
adherence to medicines. This has been embodied most recently in the New Medicines 
Service (chapter 4) which allows pharmacists to spend time advising patients on newly 
prescribed medicines. As poor adherence has become increasingly recognised as a 
problem, on the back of arguments associated with waste (see later discussion), 
pharmacists will find themselves increasingly pre-occupied with adherence interventions.  
Yet, as shown in chapter 2, balancing the demands of supply and counselling can impose 
restrictions on pharmacists’ abilities to support medicines taking. Policy is seeking to shift 
more consumers towards self care advice from community pharmacies. Meanwhile the 
need for advice with prescription medications will continue to increase as new medicinal 
technologies, particularly bio pharmaceutics, are developed. Managing these conflicting 
demands is already proving difficult (chapter 2). 
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Self care workload 
Defined by the WHO as ‘what people do for themselves to establish and maintain health, 
prevent and deal with illness’(World Health Organisation (WHO), 1998), self care has 
become a cornerstone of recent health and social policy. The geographical accessibility of 
community pharmacies, coupled with convenient opening times, has resulted in 
pharmacies being championed as a provider of minor ailments advice (Paudyal et al., 2011; 
Cavaco et al., 2005; FIP Pfizer, 2010). Inevitably these polices will drive consumers into 
pharmacies. However, the availability of the pharmacist to address these consumer needs 
is limited by their other tasks (chapter 2).  
Services workload 
Additional workload was created by the 2005 contractual framework, which introduced 
new service-based income streams to community pharmacies by reallocation of funding 
from supply. Therefore pharmacy contractors needed to provide extended services in order 
to maintain the same level of income. As described later in chapter 4, the first of these 
advanced services, medicines use reviews (MUR) take about 55 minutes to complete, 
creating significant additional work for the pharmacists and their team. If the relative value 
of such services increases then workload will inevitably shift towards service delivery. 
Administrative and Regulatory workload 
On 1st October 2009 the Department of Health introduced the ‘responsible pharmacist’ 
regulations creating a legal duty for pharmacists to ensure the safe and effective running of 
the pharmacy at all times, even when absent. The intention of the legislation was to clarify 
the roles and responsibilities of pharmacists, as distinct from owners, as well as creating 
provisions in which pharmacists could be absent from the pharmacy in order to develop 
extended clinical roles. Yet recent research carried out by the RPSGB and PSNI found that 
many pharmacists felt disempowered to influence the running of the pharmacy and 
struggled to implement the regulations in practice (TNS UK Limited, 2011). By contrast, 
many complained that the additional record keeping burden and had concerns about 
personal liability, which prevented them delivering clinical services. Indeed, some believed 
that the legislation has driven behaviours which undermine patient safety and add to 
professional stress and tension in the workplace (TNS UK Limited, 2011). 
Governance regulations for community pharmacies have further added to the 
administrative burden, to such an extent that additional funding was made available in 
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contract negotiations. For example in 2008 increased payments were made in recognition 
of the extra time required to sort prescriptions and declare expenses, as well as the 
additional paperwork required due to controlled drug (CD) regulation changes. Further 
administrative tasks have followed as a result of NPSA alerts and changes in primary care 
information governance arrangements. These have been further compounded by the 
structured series of reforms that have been implemented by the General Pharmaceutical 
council, which have acted in the short term to distract pharmacists from direct patient 
care.  
Training workload 
A further regulatory encumberment has been the mandatory requirement for pharmacists 
to complete at least nine continuing professional development ‘cycles’ per year to maintain 
their place on the general pharmaceutical register.  While many pharmacists were already 
working in such a way as to improve their personal development, the addition of recording 
these cycles puts further strain on their time. 
Business workload 
The changing landscape of the retail sector in England has placed increasing pressure on 
small businesses, particularly those in high street locations (see next section). The 
economic recession, the development of out-of-town shopping malls, the expansion of 
supermarkets coupled with their changing consumer offer (over one third of supermarket 
floor space is dedicated to non-grocery items), have all acted to create a difficult economic 
environment for community pharmacy businesses.  As a result of the reductions in 
profitability caused by changes to the NHS contractual framework – for example Day Lewis, 
a chain of over 160 pharmacies, reported that despite a growth in prescription items of 
6.2%, this only represented a 4.7% increase in value (Day Lewis, 2011) - have meant that 
businesses are being forced to make difficult staffing choices to maintain operating 
margins.  
When staffing (as discussed later in chapter 6) represents the largest single outlay, it is 
understandable that under a difficult economic outlook working hours are reduced, further 
increasing the workload for those who remain in employment. These challenging business 
conditions not only increase the workload of individual pharmacists but also have 
repercussions on the safety and profitability of the pharmacy. 
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Personal time 
The increase in workload is having potentially negative effects on personal health and 
patient safety. In a survey by the Pharmacists’ Defence Association (the pharmacist union), 
many pharmacists felt unable to take rest breaks. This inability to take a break due has 
been attributed to understaffing and pressure to meet financial targets, particularly in the 
area of medicines use reviews. However, two thirds of pharmacists believed they were 
putting patient safety at risk by not taking a break. 
For a significant number of the profession the increased workload is leading to stress, 
dissatisfaction, anxiety and fatigue above the national average (Royal Pharmaceutical 
Society, 2010). Workforce studies from 2004 and 2008 found long hours and high levels of 
stress in pharmacy. This has been compounded by the community pharmacy contractual 
framework which has had a largely negative impact on job satisfaction (Bond et al., 2008) 
because it added new roles without removing those roles that were previously performed. 
Long hours can lead to health problems for the individual, but also safety risks for 
consumers. Working beyond the 48 hours of the European Working time directive 
significantly increases the likelihood of mistakes. The challenge of long hours and shift work 
is relevant for all pharmacists, but perhaps to locums in particular as they have long travel 
times and erratic work patterns. Yet despite this, one response to the burdening 
administrative workload experienced by pharmacists is to become locums.  
Prescription medicines supply workload 
Of all of the drivers of pharmacy workload, prescription volume is often described as the 
greatest. Over the course of the last decade the number of prescriptions dispensed outside 
hospitals in England has risen almost 70 per cent. While in 2000 there were 552 million 
items dispensed, that rose to 927 million in 2010, of which 850 million were supplied from 
community pharmacies (figure 3.1). This is not a population effect because the average 
number of prescription items dispensed per person has also risen sharply, from 11.2 in 
2000 to 17.8 in 2010 (The NHS Information Centre, 2011). 
Putting these figures in context, there were 10,951 community pharmacies in England in 
2010 (The NHS Information Centre, 2011). This suggests in the region of 77,680 
prescription items per pharmacy each year, or 6473 prescription items per month. This is 
approximately 1,500 prescription items per week. If the average pharmacy opens for 65 
hours per week (chapter 2), then 23 prescription items are dispensed every hour or one 
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every three minutes. The equivalent calculation for 2001 was 16 per hour. These 
calculations include several assumptions and averages. But they demonstrate that the 
pressure, in volume terms, to dispense prescriptions has markedly increased even though 
over one thousand extra pharmacies have opened over the last decade. 
Appendix Conclusion - The Overall Nature of Work Load 
Improvements in the regulation of pharmaceutical ingredients and controls have acted to 
reduce the time spent by pharmacists on assuring the quality of medicines. Yet this 
reduction has been countered by successive policies, which, coupled with a rising tide of 
prescriptions, have increased pharmacists’ workload in the management of minor ailments 
and delivery of extended pharmaceutical services. Further administrative and regulatory 
changes, as well as an increasingly competitive market, have all added to the workload 
pressures that pharmacists experience. The increase in workload has led to continued 
complaints by pharmacists about the pressure they are facing in their working lives, 
resulting in a Royal Pharmaceutical Society campaign (Royal Pharmaceutical Society, 2010), 
which tried to indentify the drivers and possible solutions. 
The key workload drivers identified all relate to the financial rewards that support the 
pharmacy business. Inevitably financial income will drive the behaviour of those working in 
any commercial enterprise and community pharmacies are no exception. With this in mind, 
the next section of this chapter goes on the analyse the various community pharmacy 
income streams and explores the wider market trends in order to identify how these are 
likely to affect future workloads and, therefore by proxy, future roles.    
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Appendix B  - Developing an Ideal Type of 
Community Pharmacy 
 
Community pharmacies are businesses. They operate in a commercial retail environment 
with an aim of making profit, without which, they would become economically unviable. 
This appendix seeks to present a simplified model of the community pharmacy business for 
the purposes of explaining how the functions of the business influence the activities of the 
pharmacist, and to provide a baseline for testing future projections of the business.  
It is important to acknowledge that all models, no matter how complicated, are subjective 
approximations of reality. No model can be a perfect description of reality. But the very 
process of constructing, testing, and revising models forces policymakers to tighten their 
views about how aspects of the economy work. 
The process of designing and developing a model of the ideal type community pharmacy is 
shown in figure B.1 below. The basis for the model is predicated on Albert Einstein’s maxim 
that ‘everything should be made as simple as possible, but not simpler’. Therefore 
simplifications have been made and assumptions to create the variables. These 
simplifications are described in the model below.  
 
Figure B.1 – Model Development Framework 
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Framework development and information gathering 
In order to develop the model, several literature sources relating to community pharmacy 
businesses were interrogated. In particular the PWC Cost of service inquiry, the PSNC 
website and the community pharmacy handbook(Waterfield, 2008). Certain aspects of the 
model required data not in the public domain. Where possible this was provided in 
confidence by pharmacy contractors or by the PSNC. The basic tenets and assumptions 
inherent to the model were confirmed with a group of community pharmacy contractors 
and superintendents in order to provide calibration. The basis of the model was one of the 
business logic models, where income goes in, costs go out, and outputs are created. These 
are described in table B.1 below. The construction of the model was aided by the use of 
Microsoft Excel.   
Table B.1 – Ideal Type Business Model 
Income Costs Outputs 
NHS Supply Income Staff costs Profit 
NHS Services Income Property Costs Prescriptions Supplied 
Non NHS Income Depreciation of Assets Services Delivered 
 Other Costs  
 Head office Costs  
 Cost of Capital  
 
Community Pharmacy Income 
For the purposes of the ideal type model, there are effectively three main income streams 
into a community pharmacy: Non NHS income (including health and Beauty sales, private 
income and OTC medicines); NHS Supply Income (including purchase profit); and NHS 
Services Income. Each of these income streams is analysed in turn.  
NHS Income – The National Contractual Framework 
As described in chapter three, a significant proportion of community pharmacy income is 
drawn from the national contractual framework, principally for the supply of prescription 
medicines, although the framework also accounts for advanced and enhanced service 
(table B.2). The advanced services are negotiated nationally as part of the overall 
contractual framework budget, whereas the enhanced services are commissioned locally, 
currently by local primary care organisations. 
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Table B.2 – The 2005 pharmacy contractual framework 
ESSENTIAL 
 
ADVANCED 
 
ENHANCED 
 
NATIONAL CONTRACT 
 
LOCALLY COMMISSIONED 
 
Dispensing of medicines 
Repeat dispensing 
Promotion of healthy lifestyles 
Signposting 
Support for self care 
Disposal of unwanted medicines 
Support for disabilities 
Clinical governance 
Medicines use review 
New Medicines Service 
Medicines management 
Minor Ailment Pilot 
Needle & syringe exchange 
Supervised to drug misuse 
Intermediate care service 
Care homes advice 
Rota-out of hours 
Smoking Cessation 
Palliative care 
Weight management 
Emergency Contraception 
Long term Conditions 
management 
Chlamydia screening 
 
Essential Services 
All community pharmacy contractors must provide the essential services in order to 
dispense NHS prescriptions. The most dominant of these is the dispensing of medicines. At 
present contractors are paid a 90p professional fee for each item supplied under the terms 
of the contractual framework(Department of Health and the Welsh Assembly Government, 
2012). In addition they also receive special fees and allowances in a range of instances 
where additional work is required such as record keeping for controlled drugs or where a 
formula must be prepared. On average this currently equates to about8.69p per 
item(Pharmaceutical Services Negotiating Committee, 2011d). To support overheads 
contractors who dispense over 2240 items per month receive a practice payment (77.1p 
per item)which is conditional on minimum staffing levels for the number of items 
dispensed. These contractors also receive establishment payments of just over two 
thousand pounds per month (£2,092) to support the provisions of other essential 
services(Department of Health and the Welsh Assembly Government, 2012). Separate 
arrangements exist for pharmacies that dispense below this number.Pharmacies providing 
the electronic transfer of prescriptions are also entitled to a monthly payment of £200 
(Department of Health and the Welsh Assembly Government, 2012).Table B.3 shows the 
indicative income per prescription supplied based on the October 2011 negotiations. This 
shows that the marginal income per prescription varies according to the number of items 
supplied. For the average pharmacy, dispensing in the region of 6000 items per month, this 
equates to just over two pounds per item dispensed (table B.3). 
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Table B.3 - Indicative Income from Prescriptions per month (October 2011) 
Items 
per 
month 
Item fee Establishment 
payment 
Special fees 
and 
allowances 
Repeat 
dispensing 
set up fee 
Practice 
payments 
(including 
contribution 
for DDA) 
Total income 
from fees 
and 
allowances 
pcm 
£ per 
item 
1,000 900 _ 87 125 50 1,162 1.16 
1,100 990 - 96 125 627 1,838 1.67 
1,600 1,440 - 139 125 878 2,582 1.61 
2,300 2,070 - 200 125 878 3,273 1.42 
2,600 2,340 1,940 226 125 1,911 6,542 2.52 
3,000 2,700 2,092 261 125 2,205 7,382 2.46 
4,000 3,600 2,092 348 125 2,940 9,104 2.28 
5,000 4,500 2,092 434 125 3,675 10,826 2.17 
6,000 5,400 2,092 521 125 4,410 12,548 2.09 
7,000 6,300 2,092 608 125 5,145 14,270 2.04 
8,000 7,200 2,092 695 125 5,880 15,992 2.00 
9,000 8,100 2,092 782 125 6,615 17,714 1.97 
10,000 9,000 2,092 869 125 7,350 19,436 1.94 
11,000 9,900 2,092 956 125 8,085 21,157 1.92 
12,000 10,800 2,092 1,043 125 8,820 22,879 1.91 
 
Regardless of the drug supplied pharmacists will receive the amounts listed in the table B.2.  
In addition pharmacies can obtain a retained margin on the medicines supplied.  
Retained Buying Income 
There is an assumed income that can be made on the medicines margin between the prices 
the pharmacy contractors are reimbursed by the NHS for each drug supplied and the actual 
cost the contactor pays for the medicine from the wholesaler. Across the contractual 
framework this is targeted to remain at £500m per annum. However, this is not evenly 
distributed across contractors. Although on average this equates to buying profit of 55.63 
pence per item. 
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Table B.4 – Estimated Average Buying Profit per month by Item volume  
Average Prescription Volume 
(per month) 
Estimated Average Buying Profit   
(per month) 
Estimated Average Buying 
Profit   
(per annum) 
3000  £ 1,669.00  £           20,028.00 
5000  £  2,781.00  £           33,372.00 
6000  £  3,338.00  £           40,056.00 
8000  £  4,450.00  £           53,400.00 
12000  £   6,675.00  £           80,100.00 
 
For the simplicity of the model the 55.63 pence per item is assumed. In reality some items 
have far greater buying margin than others. The national average cost per item of £9.04 is 
used for generating the total revenue. In total the additional fees, such as establishment 
payments, repeat dispensing fee and practice payments and well as prescription income 
are shown in table B.5 for pharmacies of varying prescription volumes.  
Table B.5- Indicative revenue and income from prescription supply 
Average Prescription 
Volume (per month) 
Total Income 
from fees  
(per annum) 
Total Income from 
Drugs costs  
(per annum) 
Total Revenue 
(Income + Drug 
Costs per annum) 
Estimated Average 
Income from 
prescriptions  
(per annum) 
3000 £  88,592.40 £ 325,440.00 £ 414,032.40 £  108,620.40 
5000 £  129,918.00 £ 542,400.00 £ 672,318.00 £  163,290.00 
6000 £  150,580.80 £ 650,880.00 £ 801,460.80 £  190,636.80 
8000 £  191,906.40 £ 867,840.00 £ 1,059,746.40 £  245,306.40 
12000 £  274,557.60 £ 1,301,760.00 £ 1,576,317.60 £  354,657.60 
 
Therefore NHS Supply income can be summarised as follows: 
f (NHSSupply) = Establishment Payment + Repeat Dispensing Fee + (Items * [Item Fee + 
Special Fee + Practice Payment + Retained Buying Profit]) 
For those prescribing over 3,000 items the model is  
f(NHS Supply_month) =  2092 + 125 + (Items * [0.9 + 0.0854 + 0.771 + 0.5563] 
f(NHSSupply_month) = 2217 +(Items*2.3127) 
f(NHSSupply_year)=12*[2217+(Items*2.3127) 
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NHS Services Income 
The other element of the contractual framework that forms part of the national 
negotiations are cognitive pharmaceutical services. The contractual framework was 
intended to improve access to pharmaceutical services in local communities(Department of 
Health, 2003d). Through two categories of service - advanced and enhanced.  
Advanced services, are negotiated nationally by the PSNC. Currently there are only four 
such services: The Medicines Use Review (MUR) and prescription intervention service; The 
New Medicines Service (NMS); Appliance Use review (AUR); and Stoma appliance 
customisation service (SAC).  
Medicines Use Review and Prescription Intervention - These interventions are paid on a fee-
per service basis, with each pharmacy contractor limited to 400 MURs per annum. 
Achieving the full allocation in means an additional income of £11,200 per year (table B.6). 
From the 1st October 2011, at least half of all MURsare conducted in three national target 
groups. These being: patients on high-risk medicines; patients recently discharged from 
hospital; and patients with respiratory disease.(The barriers and drivers to the 
implementation of MUR services is discussed in greater detail in chapter 4).  
Table B.6 – Medicines Use review Income 
MURs 
(per month) 
Value per annum 
5 £           1,680.00 
10 £           3,360.00 
20 £           6,720.00 
30 £         10,080.00 
(max allowance) 33.33 £         11,200.00 
 
New medicines service - This service was launched on the 1st October 2011. The policy 
developments that led to its introduction are analysed in chapter 4. The essence of the 
service is to offer patients advice and follow up with their medications that have been 
newly prescribed. Pharmacies are offered an initial set up payment for providing the 
service, (£750). The funding is then based upon a matrix related to their prescription 
volume that equates to approximately £25 per NMS completed.  
Table B.7 – Indicative Funding for NMS (October 2011) 
Volume of Number of NMS Number of NMS Number of  NMS Number of NMS 
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prescription items 
per month 
completions per 
month necessary 
to achieve 20% 
target payment 
completions per 
month necessary 
to achieve 40% 
target  payment 
completions per 
month necessary 
to achieve 60% 
target payment 
completions per 
month 
necessary to 
achieve 80% 
target payment 
0-1500 1 (£25) 2 (£50) 3 (£75) 4 (£100) 
1501-2500 2 (£50) 4 (£100) 6 (£150) 8 (£200) 
2501-3500 3 (£75) 6 (£150) 9 (£225) 12 (£300) 
3501-4500 4 (£100) 8 (£200) 12 (£300) 16 (£400) 
4501-5500 5 (£125) 10 (£250) 15 (£375) 20 (£500) 
5501-6500 6 (£150) 12 (£300) 18 (£450) 24 (£600) 
6501-7500 7 (£175) 14 (£350) 21 (£525) 28 (£700) 
7501-8500 8 (£200) 16 (£400) 24 (£600) 32 (£800) 
8501-9500 9 (£225) 18 (£450) 27 (£675) 36 (£900) 
9501-10500 10 (£250) 20 (£500) 30 (£750) 40 (£1000) 
+1000 (+1) (£25) (+2) (+£50) (+3) (+£75) (+4) (+£100) 
 
Table B.7 above shows the target payments for the first year. After the second year of the 
service the lower target tier will disappear.  
Appliance Use Review (AUR) and Stoma Appliance Customisation (SAC) - These services are 
less frequently undertaken. Contractors are paid £28 per AUR that takes place on a 
pharmacy premises or £54 if it takes place in a patients home65(Department of Health and 
the Welsh Assembly Government, 2012). Where the stoma appliance customisation service 
is provided, the contractor receives a payment of £4.32 for each item that qualifies for 
customisation. Qualifying items are listed in the drug tariff. The extent to which this adds a 
significant contribution to the income is limited by the number of applicable items and 
patients using these products.  
Of these four advanced services the Medicines Use review (MUR) is the most prevalent, 
with the new medicines service (NMS) second. Together these two services can add an 
additional £18,400 to the average community pharmacy each year. Although this income 
acts as a driver to provide these services, the income gained must be off set against a 
counterfactual of dispensing prescription medicines.  
                                                          
65
 The fees and conditions associated with this service are set out in Part VIE of the drug tariff 
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Enhanced Services 
According to the NHS Information Centre, 30,962 local enhanced services were provided by 
community pharmacies in England in 2010-11. Enhanced services have been developed to 
address a variety of healthcare problems, although the most frequently offered are Stop 
Smoking support, Supervised Administration, Minor Ailment Schemes and medicines supply 
via Patient Group Directions(The NHS Information Centre, 2011). The funding  structure 
allows these services to be contracted out to private pharmacy contractors (Pollock et al., 
2007), from local unified budgets, which are part of general primary care provision.  
The ability to provide locally commissioned enhanced services varies between primary care 
organisations across the country. Even when a service is offered in a locality, there is 
competition between the different pharmacy contractors. The variation is not limited to 
location, but also ownership(Bush et al., 2009). This is partly because delivery of services 
are disproportionably more costly to smaller pharmacies who have less capital to invest in 
adequate facilities (Department of Health, 2009b). This unpredictability of income from 
service delivery has resulted in many pharmacies shying away from providing them. It is 
difficult to generalise about the income associated with these services as the payment 
structures are dependent on the local service specifications and the type of service. 
Generally most offer some sort of initiation payment to cover overhead costs and 
equipment, followed by a fee per service model. Given this spectrum of services and fees, it 
is approximated that enhanced services represent only a small proportion of a community 
pharmacies income. There were 30,962 enhanced services provided by pharmacies in the 
England (table B.8). On average enhanced services are negotiated locally, and represent 
£4,977 per pharmacy per annum (Hall, 2012), with large national variation.  
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Table B.8 – Community Pharmacy Enhanced Services 
Services Number Provided 
Anticoagulant Monitoring  103  
Care Home  647  
Disease Specific Medicines Management  252  
Gluten Free Food Supply  474  
Home Delivery  960  
Language Access  492  
Medication Review  2,383  
Meds Assessment & Compliance Support  691  
Minor Ailment Scheme  3,686  
Needle and Syringe Exchange  2,283  
On Demand Availability of Specialist Drugs  1,102  
Out of Hours  1,032  
Patient Group Direction  3,552  
Prescriber Support  13  
Schools  0  
Screening  1,737  
Stop Smoking  6,104  
Supervised Administration  5,385  
Total services provided  30,962  
Source: General Pharmaceutical Service 2010-11. 
Estimating the services in the model is complicated by the wide range in the level of 
income that these provide to pharmacies. However £4,997 is the most reliable average 
estimate currently available(Hall, 2012). It was discussed with pharmacy contractors that 
on average services are worth about £25 per service delivered, comparable to the fees paid 
for advanced services and NMS.  
NHS Services Income 
Therefore services income is a function of the number of services performed. For simplicity, 
NMS fee, although on a sliding scale has been simplified to £25 per fee. Therefore NHS 
services income is  
f(NHSServices) = [(MUR Fee*Volume)+(NMS Fee*Volume)+(AUR 
Fee*Volume)+(SAC*Volume)+(Enhanced Services) 
f(NHS Services) = [(28*mur_volume)+(25*nms_volume)+ (Enhanced Services) 
Non NHS Income 
Private prescriptions are usually priced by applying a dispensing fee and the cost of the 
medicine plus a sufficient mark up. With the exception of pharmacies located close to 
private practices, this generally provides only a very marginal part of a pharmacies income. 
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According to the national prescribing centre, the proportion of prescriptions written for 
Controlled drugs privately is 0.45% of the NHS total, or about 50,000 private controlled 
drug items per year. Extrapolating this to the community pharmacy NHS total, would 
suggest that in the region of four million private prescriptions are issued in primary care 
each year, equivalent to 37 prescription per pharmacy per year, less than one a week 
(National Prescribing Centre, 2012). 
Private services for which all of the cost is borne by the patient are becoming increasingly 
popular in community pharmacy. While no national statistics currently exist for these 
services, the extent to which they are provided by the large multiple organisations suggests 
that they are widespread.  These services tend to address lifestyle challenges and include 
schemes such as hair retention clinics, weight loss clinics or cardiovascular risk 
assessments. The services are combined with patient group direction that allows the supply 
of a prescription medicine to patients with specific symptoms. While costs of these services 
vary, they are typically in the region of about £30 per consultation.  
For the purposes of this model, the each private prescription is valued at £7.40, which is 
the standard prescription charge, as this is representative of the income received above 
and beyond that of the drug cost. Therefore, when complete 37 prescriptions a month, this 
is equal to about £275 of additional income per month. Therefore , based on 37 
prescriptions per year, this represents £275 of private income per year.  
By comparison, for most community pharmacies the largest private income stream is the 
retail sale of drugs and medicines, healthcare products and supplements, toiletries, 
perfumes and cosmetics. Based on figures from National Statistics' Annual Business Inquiry, 
Key Note estimates that retail sales by chemists and drugstores in the UK were worth 
£13.47bn in 2009 (Keynote, 2010). For some pharmacies, particularly those in high foot fall 
retail locations, such as shopping centres, retail sales are a large part of their business. 
Gross margins in this area are typically still around the 10%, but vary depending on the 
pricing policy of an individual pharmacy and the products sold. 
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Table B.9 – Annual Non-NHS Revenue 
 
Average total NHS 
Revenues from PwC 
Survey  
Reported NHS 
Proportion of 
Revenue 
Non NHS Revenue per 
annum 
Income 
Value 
Independent  £   722,420.00  85% £108,363.00 £10,836.30 
Small Multiple (6-20 
branches)  £  827,833.00  90% £82,783.30 £8,278.33 
Small Multiple (>20 
branches)  £  1,086,992.00  90% £108,699.20 £10,869.92 
Non Retail Driven Large 
Multiple  £  910,222.00  88% £109,226.64 £10,922.66 
Retail Driven Large 
Multiple  £  863,214.00  23% £664,674.78 £66,467.48 
Supermarket  £  874,715.00  85% £131,207.25 £13,120.73 
Source: Estimations based on PwC survey and discussion with pharmacists. 
Incomes from health and beauty sales is highly variable, and is a function of the type of 
pharmacy. For the majority, the NHS sources represent between 80-90% of revenue, but 
for retail driven multiples, revenue from external sources represents a considerable 
proportion of income. 
This revenue includes the costs of: 
f(NonNHS Income) = [(Total Revenue -NHS Revenue)*0.1] 
where total revenue is a factor of pharmacy type. This represent and annual figure. 
This model assumes that pharmacies on average make a 10% margin on all non NHS sales. 
In reality this will have a wide variation, with some expensive perfumes sold at higher 
margins, and some medicinal products sold at a smaller margin.  
Incomes into Community Pharmacy 
For the purposes of modelling, the incomes into community pharmacy are from NHS 
Supply, NHS service or from Non NHS sources.  
f(Pharmacy_Income) = (NHSSupply_year) + (NHS Services) + (NonNHS Income)  
where 
f(NHSSupply_year)=12*[2217+(Items*2.3127) 
 f(NHS Services) = [(28*mur_volume)+(25*nms_volume)+ (Enhanced Services) 
f(NonNHS Income) = [(Total Revenue-NHS Revenue)*0.1]   
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The Nature of Community Pharmacy Costs 
The NHS income into community pharmacies does not discriminate between ownership or 
business model within the pharmacy. The national framework applies in the same way to 
all pharmacies dispensing over 2,300 prescriptions per month. However, the natures of the 
costs of running the pharmacy are variable based on a number of factors. For example, 
Retail driven large multiples tend to have higher costs due to their location in prime retail 
areas such as shopping centres and high streets (£577 per m2 for retail driven large 
multiples and £238 to £288 per m2 for all other pharmacy types)(PricewaterhouseCoopers 
LLP, 2011). 
There are a diverse range of providers that have each carved out their niche within the 
community pharmacy market in England. Using a nomenclature based on ownership, these 
providers can be defined as Large retail driven multiples; Non-retail driven multiples; 
Supermarkets; Independents; and Small multiples(PricewaterhouseCoopers LLP, 2011). 
Independents are considered to be those pharmacies in chains of less than six,small 
multiples are groups of six or more pharmacies, but not one of the six large entities (Boots, 
Lloyds, Rowlands, Co-op, Day Lewis and Superdrug). Retail Driven Multiples represent 
branches from the six big entities that focus on retail services, and Non-retail driven large 
multiples which focus on NHS services. Supermarkets are in-store pharmacies from 
Sainsburys, Morrisons, Asda and Tesco.  
The Department of Health modelling of services categorised pharmacies using a similar 
approach: local independent pharmacies; Specialist pharmacy chains; Pharmacy–led health 
and beauty retailers; and Supermarket pharmacies(Department of Health, 2009a). 
Local independent pharmacies are built on their strong community connections, often 
located in rural or deprived areas. They are perceived to be difficult to navigate, often 
being cluttered; missing a clean clinical environment; and lacking the privacy and 
anonymity afforded by other pharmacy types(Department of Health, 2009a).Specialist 
pharmacy chains offer a clinical, efficient environment. However the sterile environment 
inhibits the same continuity provided by local independent providers(Department of 
Health, 2009a). The pharmacy-led health and beauty retailers offer a large range of 
products to consumers building their business on retail. Although they lack the personal 
service and relationships provided by independent and specialist providers, they are 
perceived to offer appropriate levels of privacy and a clinical environment for 
services(Department of Health, 2009a). Supermarket pharmacies are located in-store and 
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offer anonymity and convenience, particularly appealing to men due to their non-feminised 
environment. Consumers felt that there was a long way to go for these pharmacies to 
develop the on-going personal relationships required or the clinical 
environment(Department of Health, 2009a). 
It is important to consider this nomenclature when considering the costs associated with 
running a community pharmacy. Broadly speaking the costs of running a community 
pharmacy can be separated into staff costs, property costs, depreciation of asset costs, 
other costs, value, office costs and value of asset costs. Managing the property cost which 
consist of rents, including utilities and business rates are important to the business 
profitability. Other costs include, professional fees, staff training, insurance, cleaning, 
postage and printing and bank charges (PricewaterhouseCoopers LLP, 2011). 
Breakdown of the Costs 
Staff Costs represents the largest element of cost incurred by a pharmacy business. The 
figures shown in table B.10 have been calculated based on the staff costing provided to the 
PwC cost of service inquiry. This includes all costs at the branch level including accountants, 
cleaners and delivery and distribution staff.  For non retail driven enterprises this 
constitutes an average cost of approximately £150,000 per annum on average.  
However, staff costs are related to the workload within the pharmacy, and the productivity 
of that labour source. For those pharmacies dispensing large volumes of prescriptions, or 
opening for extended hours, there is a requirement for more labour and therefore further 
costs. How pharmacies manage these costs is complex, but for the most part related to the 
work undertaken. The drug tariff sets out the number of staff that a pharmacy must have 
present for the full practice payment to be claimed based on volume (figure B.2).  
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Figure B.2 – Required dispensing staff hours per week for practice payment 
 
Beyond 11,000 items, 19 hours of dispensing staff are required for every extra 1,500 
prescriptions dispensed. Appropriate dispensing staff includes a pharmacist; a non-
practising pharmacist working as a dispenser; a pre-registration trainee (only half of the 
pre-registration trainees hours should be counted for this purpose) or an assistant trained 
to undertake the functions being performed.  
Behind the variable functions of staff costs, some remain static including the work of 
cleaners, accountant which remains constant across the different pharmacies.  
f(Staff Cost) = f(Volume of Prescriptions) + f(Non NHS Revenue) + f(Opening Hours) + 
f(overhead staff) 
Table B.10 – Average Staff Costs 
 Total Staff Costs 
Independent £       152,660.81 
Small Multiple £       153,813.79 
Non Retail Driven Large Multiple £       154,023.38 
Retail Driven Large Multiple £       428,214.29 
Supermarket  £       192,854.29 
Overall  £       189,333.33 
Source: PwC Cost of Service Inquiry 
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Property Costs 
The cost per square metre are similar for all pharmacy types; between £238 to £288 per 
m2. Retail driven large multiples are £577 per m2. These higher total property costs may in 
part be due to higher costs locations (table B.11). 
Table B.11 – Property Costs 
 
Mean rent 
(per sq metre) 
Mean floor area (sq 
metre) 
Mean Cost 
(per annum) 
Independent 258 101 £         26,058.00 
Small Multiple 197 109 £         21,473.00 
Non Retail Driven Large Multiple 228 105 £         23,940.00 
Retail Driven Large Multiple 370 619 £       229,030.00 
Supermarket 170 49 £           8,330.00 
Source: PwC Cost of Service Inquiry survey of contractors with DH/PSNC assumptions 
The main factor in the property costs is the type of pharmacy. For the purposes of the 
model, the main rent is averaged to £263 per sq metre, with an assumed average size of 
105 sq metres. This equates to an annual cost of £27,615.  
f(Property Costs) = f(mean rent) * f(floor area) 
f(Property Costs) = [263*floor area] 
Depreciation of Assets 
Depreciation of assets is the operating costs based on average refit costs of the pharmacy 
using estimates of refit/replacement provided by the PwC survey. This includes the shop, 
IT, consultation room shelving and other pharmacy assets. This is based on average 
depreciation per branch. Each asset was weighted based on likely time to require 
replacement66.  
Table B.12 – Depreciation of Assets 
 Average depreciation per branch per annum 
Independent  £                                   13,000.00 
Small Multiple  £                                   14,000.00 
Non Retail Driven Large Multiple  £                                   17,500.00 
Retail Driven Large Multiple  £                                   44,000.00 
Supermarket  £                                     8,000.00 
Source: PwC Cost of Service Inquiry 
                                                          
66
 This is based on the calculations used in the PwC cost of service inquiry. 
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This feature is a function of the type of pharmacy and the ownership. The larger size and 
organisation of the large multiples leads to additional refit costs.  
f(Depreciation of Assets) = f(pharmacy type) 
Other Costs  
There are other additional operating costs in the pharmacy. These include costs that the 
pharmacy may face, including delivery, professional fees, insurance, stationary, IT, mixed 
financials, Bank charges etc.  
Table B.13 – Other Costs 
 Other Costs 
Independent £                                   17,767.00 
Small Multiple £                                   14,498.00 
Non Retail Driven Large Multiple £                                   20,776.00 
Retail Driven Large Multiple £                                   43,547.00 
Supermarket £                                     7,265.00 
Source: PwC Cost of Service Inquiry survey of contractors with DH/PSNC assumptions 
These operating costs are again a function of pharmacy type and ownership. On average 
these were reported to the PwC to be about £20,909 per annum.  
f(OtherCosts) = f (Pharmacy Type) 
Head Office Costs  
The costs of the running and maintaining the head office need to be accounted for in the 
operating costs of the pharmacy. Head Office costs have been allocated on a per branch 
basis, distribution by revenue per pharmacy. Some head office costs are universal, some 
redistributed. Independents have very low head office costs, and represent a cost of less 
than £2,600 per branch per annum (table B.14).  
Table B.14 – Head Office Costs 
 Head Office Costs 
Independent  £                                     2,600.00  
Small Multiple  £                                   38,000.00  
Non Retail Driven Large Multiple  £                                   85,000.00  
Retail Driven Large Multiple  £                                 141,000.00  
Supermarket  £                                   68,000.00  
Source: PwC Cost of Service Inquiry survey of contractors with DH/PSNC assumptions 
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As with other costs, these remain to a large extent driven by the structure and nature of 
the pharmacy business.  
f(HeadOfficeCost) = f(Pharmacy Type) 
Value of Assets 
The return on assets represents the return that a company should earn on invested capital 
in order to provide sufficient return to the investors who are financing the business, 
categorised by tangible and intangible assets. This includes the tangible assets: working 
capital, fixtures and fittings, IT assets and stock holdings of the pharmacy; and the 
Intangible Assets, which have been calculated through the Greenfield Modelling approach. 
This is an estimate of intangible assets as a proportion of revenue, made by comparison of 
a hypothetical new pharmacy and an existing pharmacy. This provides an estimate of the 
value of the assets in a community pharmacy business (table B.15) 
Table B.15 - Value of Assets 
 Total Assets 
Cost of 
Capital  
Fair Return on 
Assets 
Independent  £                      254,671.00  15.7%  £         39,983.35  
Small Multiple (6-20 branches)  £                      270,732.00  17.2%  £         46,565.90  
Small Multiple (more than 20 branches)  £                      367,432.00  15.2%  £         55,849.66  
Non Retail Driven Large Multiple  £                      398,746.00  9.1%  £         36,285.89  
Retail Driven Large Multiple  £                      703,377.00  9.1%  £         64,007.31  
Supermarket  £                      326,284.00  9.1%  £         29,691.84  
Overall  £                      372,810.00  12.3%  £         45,855.63  
Source: PwC Cost of Service Inquiry survey of contractors with DH/PSNC assumptions 
A fair return on these assets was then calculated using the WACC methodology to 
demonstrate the value of the capital, in the PwC cost of service inquiry. The cost of equity 
has been calculated using a standard capital asset pricing model (CAPM). Based on various 
assumptions the PwC best estimate for average pre-tax real WACC is 12.3%.Therefore the 
calculated Fair return on investment is the WACC (12.3%) multiplied by (Tangible and 
intangible assets) minus the tax benefit.  
The fair rate of return represents the return that a company should earn on invested 
capital in order to provide sufficient return to investors who are financing the business. 
Essentially this is the cost of the capital invested in the business.  
In the model this is a factor of pharmacy type as larger business are able to access capital at 
comparable cheaper rate.  
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f(CostofCapital) = f(pharmacy type) 
Overall Costs 
In this the largest factor is the value of the total assets.  
f(Costs) =  [Staff Cost + Property Cost + Depreciation of Assets + OtherCosts + Head 
office Costs + Cost of Capital] 
where 
f(Staff Cost) = f(Volume of Prescriptions) + f(Non NHS Revenue) + f(Opening Hours) 
+ (overhead staff) 
f(Property Costs) = [263*floor area] 
f(Depreciation of Assets) = f(pharmacy type) 
f(OtherCosts) = f (Pharmacy Type) 
f(HeadOfficeCost) = f(Pharmacy Type) 
f(CostofCapital) = f(pharmacy type) 
 
The relative value of these overall costs is shown in table B.16.  
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 Staff Costs Property Costs Depreciation Other Costs Head Office Costs Return on Assets Total 
Independent £ 152,660.81 £ 26,058.00 £ 13,000.00 £  17,767.00 £  2,600.00 £   39,983.35 £252,069.16 
Small Multiple (6-20 branches) £ 153,813.79 £ 21,473.00 £ 14,000.00 £  14,498.00 £  38,000.00 £   46,565.90 £288,350.70 
Small Multiple (more than 20 branches) £ 153,813.79 £ 21,473.00 £ 14,000.00 £  14,498.00 £  38,000.00 £   55,849.66 £297,634.46 
Non Retail Driven Large Multiple £ 154,023.38 £ 23,940.00 £ 17,500.00 £  20,776.00 £  85,000.00 £   36,285.89 £337,525.26 
Retail Driven Large Multiple £ 428,214.29 £ 229,030.00 £ 44,000.00 £   43,547.00 £  141,000.00 £   64,007.31 £949,798.59 
Supermarket £192,854.29 £ 8,330.00 £ 8,000.00 £  7,265.00 £  68,000.00 £   29,691.84 £314,141.13 
The total costs are higher than those reported by PwC as there calculation include the value of total assets of the business, not just NHS business.  
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Appendix C - The ‘Value’ added by the 
Pharmacy Business 
 
A business model depicts an organisation’s value creation, proposition and capturing. It is a 
meaningful concept for explaining the relationship between strategy and the skills of the 
pharmacist. The same pharmacist ‘commercialised’ in different ways may result in a 
different commercial outcomes. Hence the business model can be understood as a 
medicating constant between the profession and its economic value.  
It is the profession’s social ‘value’ that has allowed pharmacy businesses to acquire 
premium incomes in excess of those observed in other sectors of the retail. Different 
aspects of the community pharmacy business operate different business models, but to a 
large extent pharmacy has provided an ‘advice based’ model, where the value creation has 
been as a result of the knowledge and skills of the pharmacist. Consumers utilise their 
‘clinical’ skills to provide them with a diagnosis, without a direct financial charge. This can, 
in some cases, provide early diagnosis and referral for more serious medical conditions. The 
‘value’ of the advice is recouped through the sales of a product to accompany that 
diagnosis.   
Such a model relies on people needing and requiring advice and then subsequently 
purchasing suitably priced products. However, as a model it is in threat. In the first 
instance, consumer perceptions of advice have changed. Customer service is something 
that is expected, even demanded. In pharmacies the boundary between good customer 
service and health advice is blurred. This leads to a perception of pharmacists’ counselling 
and diagnosis skills as being part of a customer service role, rather than a ‘clinical’ 
healthcare role. As such, it becomes harder to present a case for premium incomes as a 
result of this advice. Yet, evidence suggests that one in seven consultations results in advice 
without a sale (FIP Pfizer, 2010). Coupled to this, the value of each sale has decreased. The 
abolition of re-sale price maintenance in 2001 further reduced the margins on OTC 
medicines, exacerbated recently by tightened consumer spending.  
Pharmacies, in a similar way to post offices, create ‘value’ beyond those typically associated 
with retail activities. Central to developing a strategic future for community pharmacy is 
 
 
349 
understanding which of these ‘values’ and societal functions are considered worth 
preserving in future business models.  
Consumers ‘value’ the fact that pharmacists are the most accessible health care 
professional. This offers a large social support network for many people with long term 
conditions. Changing the structure of supply to ‘hub and spoke’ or ‘mail order’ models may 
threaten this ‘value’ and therefore reduce the premiums that are paid for medicines 
supply.  
The accessibility of ‘advice’ to a large population was central to the creation of the ‘healthy 
living pharmacy’ initiative. The ‘healthy living’ pharmacy concept, developed by NHS 
Portsmouth and the local pharmaceutical committee, aims to use pharmacies to promote 
good health and provide proactive health advice. It built upon the pharmacy White Paper 
call for pharmacies to become healthy living centres, promoting health and self care 
(Department of Health, 2008a). In contrast to previous pharmacy innovation, such ‘advice’ 
is not only provided by the pharmacist, but by the whole pharmacy team. Pharmacies 
receive income for providing this ‘advice’ rather than providing a specific product. The 
evidence base behind this initiative has been broadly positive, and their government is 
seeking to gather further evidence of the effectiveness of community pharmacies through 
pathfinder sites.  
Other schemes have shown potential to develop a system where the ‘value’ provided by 
the pharmacist is separated from supply of a product. Doncaster PCT developed a quality 
and outcomes framework (QOF) for community pharmacy in 2007. The scheme aimed to 
financially reward pharmacists based on outcomes, whereby pharmacies could earn 100 
points a year with an average pay of £90 per point, totalling £9,000 in potential annual 
earnings. Within its third year, the QOF had secured universal participation in the area and 
helped to achieve targets such as raising pharmacies' safety alert response rate from 40 to 
90 per cent. 
These two different examples both provide business models where the ‘value’ of the 
pharmacist is integral to the business. From a professional perspective this addresses the 
‘under-utilisation’ accusation that is described in policy. However, these models separate 
the remuneration for advice from the supply of a product.  
Developing business models for the future require an acknowledgement of where the 
funding streams for this value added by the pharmacists come from. A ‘weak’ future for 
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community pharmacy would be one where the profession continues to become consumed 
by supply, with other groups, such as medicine and nursing incorporating the clinical 
aspects of pharmaceutical care and medicines management into their roles. Indeed, less 
expensive (and experienced) technicians and assistants could assume the majority of the 
supply of medicines to the public. In such a scenario the ‘value’ that supports the business 
is a technical and logistical supply function as opposed to a ‘clinical’ knowledge and advice 
function. As such the economic rewards for the former are likely to be far less than those of 
the later.   
On this basis the challenge for both the business and the profession is to demonstrate that 
the current ‘value’ that community pharmacies apply to the supply chain is worthy of 
future investment and support. This begs the question of where is the ‘value added’ by 
community pharmacy, and where is likely to be in the future.  
The most obvious ‘value’ is the supply of nearly a billion prescription items to patients 
across England, and this should not be underestimated. Yet it represent as technical and 
logistical supply function, rather than a ‘clinical’ addition of value. Table C.1 describes the 
main areas where ‘value’ is added and therefore the main basis upon which future business 
model could develop. 
Table C.1– Value added by Community Pharmacy 
‘Value’ Model Evidence Base 
Supply of Medicines 
 
The supply of nearly a billion prescription items each year. This is the essence of the 
current supply based model. Funding model for community pharmacy currently supports 
the community pharmacy business (Pharmaceutical Services Negotiating Committee, 
2011d) 
Safety  1% of GP prescriptions have serious error on them (Shah et al., 2001). Pharmacists 
prevent serious harm being caused in a limited number of patients (Dornan et al., 2009). 
The Department of Health pays for this ‘risk management’ through the contractual 
framework. Future models could adopt a primary care based approach where pharmacists 
are located in the surgeries   
Advice on Prescription 
Medicines Taking 
Pharmacists can aide in the adherence of medicines to patients. This provides the basis for 
the models behind the New Medicines service (Clifford et al., 2006) and MURs 
Accessibility, Social Support, 
Self Care Management. 
1.6 million visit pharmacy daily; accessible to population (Department of Health, 2008a). 
Pharmacies provide reassurance to patients (Harding and Taylor, 1997). Over a billion 
packs of medicines were purchased in the UK (The Proprietary Association of Great 
Britain, 2010), at least half of which were purchased in community pharmacies. The social 
support and advice is recouped through the sale of OTC medicines. Yet one in seven 
consultations without a sale (FIP Pfizer, 2010) 
Early Diagnosis and Health 
Checks  
Early diagnosis during health checks (Department of Health, 2008b) and disease 
awareness programs are supported by direct payments from the health service. Under 
this model advice is directly remunerated   
Referral and Signposting, 
Lifestyle Support 
Pharmacists reassure and allow access to other providers  (Carroll et al., 2010). Examples 
of specific schemes include Alcohol reduction (Watson et al., 2011; Dhital et al., 2010)The 
Healthy Living pharmacies program aims to provide additional income for the advice 
provided in these circumstances. However traditionally this was included within the 
income for product supply  
Individual Pharmacy Services Evidence of beneficial outcomes in a variety of services (Burnham, 2011). In these cases 
the pharmacy is remunerated for advice directly   
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The ‘new’ incomes streams into community pharmacy represent a change in the way 
pharmacists are remunerated. Previously advice and supply cost were entangled in the 
physical object, the medicine, whereas these new services provide support and advice, but 
without the physical object. As such they are less tangible and therefore easier to discredit. 
To some extent this explains why pharmacists hold onto the tangible product of supply as 
being so important to their identity.   
Indeed the ‘value’ of capturing prescription errors is one of economic utility (Dornan et al., 
2009). Yet the payment for this ‘service’ is captured within the price paid for the supply of 
the medicine67. This is the same for other ‘intangible’ benefits that pharmacies provide. For 
example, patients often consult the pharmacist for reassurance to justify visiting the 
general practitioner (Harding and Taylor, 1997; Harding and Taylor, 1994) and for advice on 
accessing other parts of the healthcare service (Carroll et al., 2010), are also included in the 
payments for prescription supply. 
Extrapolation of the ‘value’ of local pharmacies can be taken from the social support 
provided by other retail outlets, in particular Post Offices. For example, the post office 
network of approximately 14,000 outlets is believed to offer wider social benefits in terms 
of social cohesion in the region of between  £1.232 billion and £5.344 billion out of an 
overall estimated total social value of between £2.3 billion and £10.2 billion (NERA 
Economic Consulting, 2009). In the case of post offices there was a large difference 
observed between the social values for the network as a whole, and the values associated 
with the specific services provided by post offices, which was interpreted to represent the 
value that consumers to the wider social role of post offices. It is hypothesized here that 
community pharmacy would reflect a similar pattern. Particularly as pharmacies operate in 
contrast to the inverse care law (Hart, 1971; Hart, 2000) showing a greater density of 
pharmacies in areas of deprivation. 
The same ‘value’ principle applies in the supply of OTC medicines, where the cost of advice 
is recouped through supply. Overall an estimated 1.6 million people visit a pharmacy every 
day (Department of Health, 2008a). Most patients with long-term conditions regularly visit 
the same pharmacy to seek healthcare advice (Continental Research and Solutions 
Research, 2008). One in seven pharmacy consultations fails to result in a sale (FIP Pfizer, 
                                                          
67 The safety role that pharmacists play should not be overstated. They, in turn also introduce errors as the dispensing error 
rate in community pharmacy is 3.3%, although only one error in a hundred was found to be severe  - Dean Franklin B and 
O'Grady, K. 2007: Dispensing errors in community pharmacy: frequency, clinical significance and potential impact of 
authentication at the point of dispensing. International Journal of Pharmacy Practice 15: 273-281. 
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2010). For example, £23.8 million was spent in the UK in 2010 on head lice and worm 
treatments (The Proprietary Association of Great Britain, 2010). Using a counterfactual of 
GP care (£36 per consultation before prescribing costs) (PSSRU, 2011), then a conservative 
estimate of £10 per treatment from a pharmacy suggests £72 million in savings by using 
community pharmacy. Although a crude estimate, this demonstrates how the advice of 
pharmacists is comparatively cheaper than GPs.  
By contrast the more recent developments for community pharmacy have adopted a ‘fee 
per service’ approach, where the ‘value’ of the pharmacist’s advice and support is paid for 
directly. Medicines Use Reviews and NMS are two examples. In some cases these have 
been shown to be economically viable. For example the NHS health checks delivered 
through community pharmacy, are designed to diagnose conditions such as diabetes, heart 
disease and chronic kidney disease early. The impact assessment showed that the NHS 
health check program would cost around £3,500 per QALY gained (Department of Health, 
2008b).  
The Healthy living pharmacy program adopts an approach where advice is remunerated. 
Early positive results from the Healthy Living Pharmacy program suggest that advice 
provided by health trainers is beneficial (Watson et al., 2011; Dhital et al., 2010).  
In the future the amount that health care planner pay for the ‘value’ of the pharmacy 
business will likely move towards a transparent advice based model. Making the payment 
structure more transparent will require better evidence of outcomes in order to support 
the continued investment. At present the economic evidence to support such transparency 
is in the main weak. Creating this political and social justification for the payments will have 
large impact on the future path that community pharmacy takes. 
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